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CHAPTER I 
AIM AND SCOPE OF THIS THESIS 
In which the reader learns something about what to find in this thesis and about 
what not to find. 

CONTENTS of CHAPTER I 
1-1 Introduction 5 
1-2 What will be found in this thesis 5 
1-3 What will not be found in this thesis 6 
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1-1 Introduction 
As more and more people become older and 
older, in part, as a consequence of our highly 
qualified medical care, the real number of 
people becoming demented will also inevita­
bly grow. The frequency of dementia 
increases with age: from 2% at 65 years to 
20% at 80 years (De Wilde et al, 1986). 
Figure 1-1 shows some of the expected 
І 
! 
Figure 1-1: Percentage of the population over 
65 (panel A) or 75 (panel B) years in 1980 
(black bars) and 2 0 0 0 (white bars); in panel 
С the prevalence of Alzheimer's disease (AD) 
is given (after Amaducci and Lippi, 1990). 
increases in the percentages of people 
becoming older than 65 and 75 years in the 
year 2 0 0 0 in some western countries (figure 
1-1, panels A and B). Furthermore it shows 
the prevalence of Alzheimer's disease, which 
accounts for more than 50% of the cases of 
dementia (Schulte, 1989; De Wilde et al, 
1986). It is clear that the number of sufferers 
from Alzheimer's disease will increase. 
Similar figures may be expected in the 
Netherlands (cf. Van Wielink and Van 
Dongen, 1986; see also Schulte, 1989). 
Apart from the devastating effects for the 
sufferers themselves, dementia is considered 
to be a threat for the economy of our 
western world. The amount of money which 
will be spent on taking care of them in 
nursery homes will be tremendous. In Holland 
this amount has been calculated to be 1.2 
milliard guilders per year (see Tanja and 
Hofman, 1985). This has, in part, intensified 
the research into the underlying processes as 
well as management of dementias, especially 
that associated with Alzheimer's disease. One 
example of this intensification is the large 
scale program which started in 1986 at the 
Catholic University of Nijmegen with grants 
from the 'Janivo' foundation. The intention of 
this program is to find an answer for a 
number of fundamental and practical ques­
tions on dementias. Without going into all the 
details of the different aspects of the projects 
of this program, it can be said that it covers 
nearly all major areas of neuroscientific 
research e.g. neuro-anatomy, neurochemistry, 
clinical research, and neuropharmacology. 
Within the last area, the work that will be 
presented in this thesis, moves. 
1-2 What will be found in this thesis 
The original title of the project on which 
this thesis is based, was: "Analysis of the 
relationship between Parkinson's disease and 
Alzheimer's disease; animal research". This 
title contains the two main elements of this 
thesis. First, it refere to two different diseases 
which are presumed to be related and second, 
it refers to animal research (see below). With 
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respect to the former the following can be 
mentioned. As pointed out above Alzheimer's 
disease accounts for most of the cases of 
dementia in the elderly. In several other 
diseases however dementia is developed in 
subgroups of patients, among them patients 
suffering from Parkinson's disease (De Wilde 
et al, 1986). Since the emphasis within the 
research unit, in which the research presented 
in this thesis was carried out, has been on 
Parkinson's disease in the past, this disease 
serves as the starting point for the research 
into dementia. 
In the first part of this thesis (chapter 2) the 
literature on Parkinson's disease and dementia 
will be reviewed. First, it will be explored 
whether Parkinson patients have a higher 
chance of developing dementia than normal 
elderly controls. From the literature it will be 
concluded this is the case and that a subpo-
pulation exists which suffers from dementia; 
a dementia, which may be, in part, inherent 
to Parkinson's disease. Furthermore it will be 
concluded that certain structures are involved 
in this type of dementia; structures which are, 
in part, also involved in the dementia 
associated with Alzheimer's disease. It will be 
shown that the mesolimbic system -in 
particular the nucleus accumbens and its 
output station the subpallidal areas, i.e. the 
ventral pallidum and substantia innominata- is 
of interest in this respect. Striving through 
literature it will be tentatively hypothesized 
that a continuum might exist from purely 
Parkinson's disease to purely Alzheimer's 
disease as far as it concerns certain aspects of 
cognitive and motor functioning in these 
diseases. 
In the second part of this thesis (chapters 3 
and 4), the animal research will be dealt with, 
which was limited for purely practical reasons 
to studies conducted in rats. Chapter 3 will 
deal with the role of the nucleus accumbens 
in behaviour; chapter 4 with the role of the 
subpallidal areas. In chapter 3, an hypothesis 
on the role of the nucleus accumbens in 
behaviour will be developed based upon the 
experimental findings presented in this thesis 
and existing experimental findings in the 
literature. Chapter 4 focusses mainly upon 
how information is transmitted from the 
nucleus accumbens via the subpallidal areas. 
It will be shown that these areas are highly 
heterogeneous in this respect. No specific 
studies into their own specific role in 
behaviour will be presented. 
In the last part of this thesis (chapter 5) the 
experimental findings will be integrated into 
the existing literature on the clinical picture of 
the dementia associated with Parkinson's 
disease. These findings will be finally briefly 
combined with the dementia associated with 
Alzheimer's disease. Some directions for 
future research will also be given. 
1-3 What will not be found in this thesis 
Having said to some extent what will be 
found in this thesis in the foregoing section, 
it might also be good to tell what will not be 
found. First, it will be no textbook on 
Parkinson's disease (or Alzheimer's disease). 
The review of the literature in chapter 2 will 
take only those areas into account that serve 
to underline the general stream of thoughts. 
Any area deviating too much from this is 
only considered briefly or not at all. For 
instance the enormous amount of literature on 
the biochemistry of senile plaques and 
neurofibrillary tangles will not be touched 
upon. Second, this thesis it will not offer a 
solution to the treatment of dementia in 
general and that associated with Parkinson's 
disease (or Alzheimer's disease) in particular. 
In principle it is a study in which at a 
fundamental level it is investigated what the 
roles of the nucleus accumbens and 
subpallidal areas in behaviour are. Having 
determined this, it might be better understood 
what the disturbances in Parkinson's disease 
(and Alzheimer's disease) are. This 
fundamental knowledge could then serve to 
detect these diseases in an early stage, and to 
develop early diagnostic tools. Furthermore it 
could tell something about how these diseases 
progress in time. Finally it could offer non 
pharmacological ways of treating the diseases. 
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With respect to the latter, it is a pity that the 
focus in neuroscience at the level of human 
function under pathological conditions or at 
the level of animal behaviour under 
experimental conditions is still more upon the 
fact what humans or animals can not do 
instead of what they still can do, or how they 
still manage to do it, yet, in another way (see 
e.g. Sacks, 1987). 
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PART I 
PARKINSON AND DEMENTIA 

CHAPTER II 
PARKINSON'S DISEASE AND DEMENTIA: 
PREVALENCE, PATHOLOGY 
AND RELATIONSHIP TO ALZHEIMER'S DISEASE 
In which the literature on Parkinson's disease with respect to dementia is reviewed. 
Furthermore its connection to Alzheimer's disease is explored. Finally an hypothesis 
is put forward, which links some findings together. 

CONTENTS Of CHAPTER II 
2-1 Introduction 
2-2 Dementia: some considerations 
2.2.1 Definition 
2.2.2 Some classifications 
2-3 Prevalence of dementia in Paridnson's disease 
2.3.1 Introduction 
2.3.2 Studies using DSM-III criteria 
2.3.3 Studies using MMS criteria 
2.3.4 Studies using other criteria 
2.3.5 Conclusions 
2-4 Factors associated with the occurrence of dementia In 
Parkinson's disease 
2-5 Pathology underlying the occurrence of dementia 
In Parkinson's disease 
2.5.1 Introduction 
2.5.2 Neurotransmitter systems 
2.5.2.1 Dopamine 
2.5.2.1.1 Introduction 
2.5.2.1.2 Experimental findings 
2.5.2.1.3 Discussion 
2.5.2.2 Noradrenaline 
2.5.2.2.1 Introduction 
2.5.2.2.2 Experimental findings 
2.5.2.2.3 Discussion 
2.5.2.3 Serotonin 
2.5.2.4 Acetylcholine 
2.5.2.4.1 Introduction 
2.5.2.4.2 Experimental findings 
2.5.2.4.3 Discussion 
2.5.2.5 Amino acids 
2.5.2.6 Peptides 
2.5.3 Conclusions 
2-6 Alzheimer's disease: involvement of the (meso)llmblc 
system and relationship to Parkinson's disease: do 
Alzheimer and Parkinson meet? 
2.6.1 Alzheimer's disease 
2.6.1.1 Introduction 
2.6.1.2 Some neuropathological findings 
2.6.1.3 Conclusions 
2.6.2 Relationship between Alzheimer's and Parkinson's 
disease 
2-7 An hypothesis on the role of the mesollmbic system In 
dementia 
"Involuntary tremulous motion, with lessened muscular power, in parts not in action 
and even when supported; with a propensity to bend the trunk forward, and to pass 
from a walking to a running pace; the senses and intellects being uninjured." 
James Parkinson, 1817 
2-1 Introduction 
In his historic essay "An essay on the 
shaking palsy" published in 1817 James 
Parkinson described the disease, that would 
finally bear his name, as indicated above 
(Parkinson, 1817). Although a number of 
symptoms characteristic for the disease were 
added to this description during the nineteenth 
century by a number of French neurologists, 
like Charcot, (Tyler, 1987) it is still valid as 
a general description. Yet, the last remarie 
"the intellects being uninjured" was already 
questioned shortly after the essay of Parkinson 
appeared (see Tyler, 1987). In fact numerous 
studies have been devoted to this issue (for 
some recent reviews see Brown and Marsden, 
1984, 1988a; Ruberg and Agid, 1988). Most 
of these studies used neuropsychological tests 
to unravel the presumed nature of the 
cognitive deficit inherent to Parkinson's 
disease. These studies can in fact be divided 
into two subcategories with different though 
not mutually exclusive basic questions. One 
subgroup attempts to find specific, isolated, 
cognitive deficits. An example of this is the 
question whether Parkinson patients have 
deficits in visuospatial orientation; patients, 
which are otherwise intellectually normal as 
measured by standard tests for general 
intelligence. In the other group it is tried to 
answer the question whether a subgroup of 
Parkinson patients can be recognized, which 
suffers from a general cognitive decline; a 
decline, generally indicated with the overall 
term 'dementia'. In this chapter the literature 
on the last matter will be reviewed. After 
going into the problems of defining dementia 
it will be explored to what extent such a 
general phenomenon as dementia is present in 
Parkinson's disease. After concluding that 
evidence exists that this might be the case, it 
will be subsequently explored whether it is 
connected with e.g. the motor symptoms 
inherent to Parkinson's disease and whether 
it is associated with a specific pathology. 
Moreover it will be related to the dementia 
inherent to Alzheimer's disease. Finally an 
hypothesis will be developed concerning the 
involvement of the mesolimbic system in 
dementia. 
2-2 Dementia: some considerations 
2.2.1 Definition 
As in all areas of psychiatry and neurology, 
defining the boundaries of a disease, i.e. 
'dementia', is one of the most difficult tasks. 
It raises the fundamental question whether our 
will to classify patients into categories ac-
cording to well (??) defined criteria in fact 
even helps us to understand the nature of 
human diseases. When reducing such often 
complex phenomena occurring in man to 
certain necessarily oversimplified categories, 
and then even further to numbers, much 
information will inevitably be lost (see e.g. 
Sacks, 1987). Despite this however for 
research purposes it still seems to be the only 
way to analyse human diseases as such and to 
analyse some fundamental processes involved. 
'Dementia' is a broad term used to indicate 
general cognitive decline or general mental 
detonation. Dementia is not a unitary disease 
but a clinical syndrome consisting of a 
number of symptoms (van Crevel, 1987; 
Foley et al, 1987; Schulte, 1989). In the 
report of the consensus meeting of the 
National Institute of Health of the United 
States held in 1987 this is stated as follows: 
'Dementia is a clinical state with many 
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different causes characterized by a decline 
from a previously attained intellectual level' 
(Foley et al, 1987, p3412). Others add that it 
'leads to an incapacity for reasonable 
independent activity' (Alexander and 
Geschwind, 1984). 
In clinical practice it is assessed in man by 
the use of several sets of criteria. One 
important set is given in the third edition of 
the Diagnostic and Statistical Manual (DSM-
Ш) of the American Psychiatric Association 
(Table 2-1). In fact this set of DSM-Ш 
criteria fits in with the above given 
description. A number of comments may be 
made here. First, the description of dementia 
is not limited to such a common criterion as 
a memory deficit. Thus, accordingly an 
isolated memory deficit alone does not 
warrant the clinical diagnosis of dementia. 
During the above cited consensus meeting this 
was stated as: 'the term dementia is not 
applied to isolated focal loss of function such 
as occurs in amnesia, aphasia, agnosia or 
apraxia' (Foley et al, 1987, p3412). This in 
return means that drugs that alleviate only 
single aspects of cognitive functioning are not 
considered as 'anti-dementia' drugs following 
DSM-Ш criteria. Second, as a result of the 
presence of a number of inclusion criteria the 
prevalence of 'cognitive disturbances' can be 
underestimated within a certain population; 
for, often not all areas are affected (see e.g. 
Alexander and Geschwind, 1984). In fact, as 
a result of these inclusion criteria people 
suffering from the 'subtle' cognitive effects 
associated with a number of diseases are not 
classified as 'demented'. This limits research 
into the characteristics of patients suffering 
from cognitive disturbances as such since only 
very overt cases are included; cases, which 
might be at the end of the disease process. 
Accordingly this classification might reveal 
little about the disturbances which might be 
present early in the disease process. It can 
thus be questioned whether this classification 
helps us to unravel the specific cognitive 
decline that is associated with a number of 
diseases, since patients suffering from minor 
disturbances will never be chosen in groups 
under investigation (see above). Third, 
'dementia' is differentiated from delirium by 
the fourth criterium: an alert state of 
consciousness precluding 'false positives'. 
Several quantitative scales are used in 
dementia research. Among them the Blessed 
Dementia Scale (Blessed et al, 1968), the 
Sandoz Clinical Assessment Geriatric Scale 
(SCAG; see McDonald, 1982 and references 
therein) and the Mini-Mental State (MMS) 
examination developed by Folstein and cowor­
kers (Cockrell and Folstein, 1988; Folstein et 
al, 1975). Since the latter is frequently used 
in dementia research in general this test will 
be expanded upon somewhat more here. The 
maximum score that can be obtained with this 
scale is 30 points. The test is divided into 
two sections; the first section requires focal 
responses only and covers orientation, 
memory and attention (maximum score 21 
points). In the second section the ability to 
name, follow verbal and written commands, to 
write a sentence and to copy two overlapping 
pentagons is tested (maximum score 9 points; 
Cockrell and Folstein, 1988; Folstein et al 
1975). A score between 28 and 30 is 
considered to indicate normal cognitive 
function. This scale is used to assess the 
severity of dementia, to correlate 'cognitive' 
scores with all sorts of scores on biochemical 
or pathological data, or to assess the effects 
of drug treatments. One general major 
problem with this kind of quantitative scaling 
is that it is not clear which of these 
individual testscores contributed to the overall 
effects found; be it an improvement upon 
treatment or a significant correlation with a 
certain parameter. 
It should be finally clearly stated here that 
the diagnosis of dementia is in general not 
made solely on the basis of a single test or 
single test scores but also by a clear 
anamnesis of the patient obtained from the 
patient itself as well as from relatives of the 
patient (Foley et al, 1987). Moreover the 
deterioration of test scores on repeated visits 
is an important indicator whether dementia is 
developing (Foley et al, 1987; see above). 
2.2.2 Some classifications 
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Table 2-1: Diagnostic criteria for dementia 
according to DSM-Ш (from Mayeux, 1984). 
1. Losa of intellect 
sufficient to impair social or 
occupational function; 
2. Memory impairment; 
3. One of the following: 
a. impaired abstraction 
b. impaired judgement 
c. aphasia 
d. apraxia 
e. agnosia 
f. constructional 
difficulty 
g. personality change 
4. Alert state of 
consciousness 
The term 'dementia' is used in connection 
with a number of diseases. Among them the 
so called primary dementia's like Alzheimer's 
disease, Multi-Infarct dementia (arteriosclero­
tic dementia), and dementias associated with 
such diverse diseases as Parkinson's disease, 
Huntington's disease and Pick's disease, and 
secondary dementia's like normal pressure 
hydrocephalus, metabolic diseases or 
alcoholism (Vecht-Van den Bergh, 1982). This 
classification into primary and secondary 
dementias is based upon the primary focus of 
the underlying pathological process. In 
primary dementias the pathology is primarily 
within the brain, in secondary dementias the 
brain is affected secondarily due to e.g. 
peripheral disturbances, like disturbances in 
the metabolism. Since the fundamental disease 
processes in the primary dementias are still 
largely unknown, this differentiation may not 
be valid throughout, or appear not to be 
useful in time. A classifìcatìon proposed 
during the consensus conference (see 
paragraph 2.2.1) is that of progressive versus 
arrestable or reversible dementias (Foley et, 
1987), which is closely related to the above 
given classifìcatìon: most primary dementia's 
are progressive whereas most secondary 
dementias are arrestable or reversible. This 
classifìcatìon may be, like the above given 
classification, only useful from a clinical point 
of view, and may need to be revised in time. 
A differentiation in dementia which is often 
encountered in the literature is that between 
'cortical' and 'subcortical' dementia; a 
concept launched by Albert et al in 1974 
(Albeit et al, 1974). It emerged from the 
study of the cognitive and personality changes 
in patients suffering from supranuclear palsy. 
Albert et al found the following symptoms to 
be characteristic for these patients: (i) for-
getfulness (ii) slowing of thought processes 
(iii) emotional or personality changes (apathy 
or depression with occasional outbursts of 
irritability) and (iv) impaired ability to 
manipulate acquired knowledge (Albert et al, 
1974; Albert, 1978). No, so caUed 'cortical 
deficits' like aphasia, apraxia or agnosia, were 
found (Albert et al, 1974; Albert 1978). Next 
to supranuclear palsy also other diseases were 
included; first, Parkinson's disease and 
Korsakoff's syndrome (Albert et al, 1974), 
subsequently Huntington's disease (Albert, 
1978). This group of diseases appeared to 
have the above given features in common, 
labelled 'sub-cortical dementia'. Furthermore 
it was argued that these diseases had 
predominantly pathological changes in 
subcortical areas, like changes in the 
caudatoputamen (Albert et al, 1974; Albert, 
1978). Strangely, when Albert was asked 
whether he knew of any disease which could 
be labelled as 'cortical dementia', he 
answered that he knew of no such disease 
(discussion following Albert's lecture in 
1978). For instance, he considered 
Alzheimer's disease as a mixed type of 
dementia since both cortical and subcortical 
phenomena are present in the disease process 
(Albert, 1978). Interestingly others have 
considered Alzheimer's disease as a 'cortical 
dementia' however by stating that the hallma-
rks of the cognitive deficits in Alzheimer's 
disease are more cortical in nature (Cummings 
and Benson, 1984; see also Benson, 1984). 
Furthermore they considered a discussion on 
the pathology irrelevant, since the whole 
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concept is in principal based on clinical 
observations; thus, regardless of whether the 
pathological changes are cortical or subcor­
tical (Cummings and Benson, 1984). Already 
in the first paper, Albert confuses matteis by 
mentioning that the symptoms of 'subcortical 
dementias' are in fact indicative of 
frontocortical dysfunctioning (Albert et al, 
1974) and suggests that it would be probably 
better to use the term 'frontosubcortical 
dementia' (Albeit, 1978). In fact the 
differences between the two subgroups would 
be the extent to which 'non fron to-cortical' 
areas are involved. A number of reviews have 
been devoted to this concept and questions 
regarding the usefulness and validity of this 
concept have been raised (see e.g. Brown and 
Marsden, 1988a; Cummings and Benson, 
1984; Mayeux et al, 1983; Whitehouse, 1986). 
Basic questions which have been raised are: 
(i) how valid are the diagnostic criteria, (ii) 
should the differences between the diseases be 
considered at an anatomical or a clinical 
level, and (iii) what should be done with 
differences between diseases which fall into 
the same category. In fact all reviews but one 
(Cummings and Benson, 1984) end with the 
conclusion that the evidence is far from 
conclusive to accept this differentiation as 
such (Brown and Marsden, 1988a; Mayeux et 
al, 1983; Whitehouse, 1986). Although this 
differentiation might be useful from a clinical 
point of view (see Van Domburg, 1990) it 
would appear from these reviews, that it is 
more rewarding for research purposes to 
analyse the deficits found in the different 
diseases in themselves in detail, and 
subsequently to try to relate these deficits to 
the differential pathology of structures in the 
different diseases. In this thesis this concept 
will therefore not be dealt with any further. 
2-3 Prevalence of dementia in Parkinson's 
disease 
2.3.1 Introduction 
From the foregoing discussion on the 
definition of dementia it will be clear that 
estimating the prevalence of dementia in 
Parkinson's disease is a difficult task, since it 
relies heavily on the criteria used to define 
dementia. In this paragraph a number of 
studies will be reviewed which have looked at 
the prevalence of dementia in Parkinson's 
disease. 
2.3.2 Studies using DSM-Ш criteria 
Only very few studies have explicitly used 
the criteria set out in the DSM-Ш. In a 
retrospective population study of 339 patients 
suffering from idiopathic Parkinson's disease 
Mayeux et al reported a prevalence of 10.9 
% ; thus, 37 patients met the criteria of 
DSM-Ш (Mayeux et al, 1988). Fuitheimore 
they observed that dementia occurred 3.84 
times more often in Parkinson patients older 
than 60 years than in a normal population of 
this age (Mayeux et al, 1988). In an earlier 
study conducted by the same authors a nearly 
fourfold higher prevalence of demented 
patients was found in a population of 57 
patients over 60 years (38.6%; Mayeux et al, 
1983). A somewhat lower prevalence was 
found in a population over 60 years in a 
study conducted by Hietanen and Teravainen, 
who found 25 % of the patients to meet the 
criteria of DSM-Ш in a group of 59 patients; 
only 2 % met these criteria under the age of 
60 (Hietanen and Teravainen, 1988). Only 8 
% of their control group of people over 60 
years met the criteria of DSM-Ш. Thus also 
in their study dementia occurred about a 
factor three more often in patients suffering 
from Parkinson's disease than in normal 
elderly , which is comparable to the 
data of Mayeux et al cited above. In a 
population of 48 elderly patients with 
idiopathic Parkinson's disease, Lees found a 
prevalence of 15% according to DSM-Ш 
criteria (7 out of 48; Lees, 1985). Jolkkonen 
et al finally found 19.4% of their patients to 
meet DSM-Ш criteria in a population with a 
mean age over 60 years (Jolkkonen et al, 
1986). 
2.3.3 Studies using MMS criteria 
A number of studies have used the scoring 
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Table 2-2: Prevalence of dementia according to a number of studies. Naturally this is only a 
selection. 
% Demented 
93.0 
81.0 
66.1 
62.4 
N 
60 
lOO 
56 
96 
Tests Authors 
WAIS, WMS etc. Pirozollo et al, 
1962 
memory, attention Martin et al, 1973 
etc 
not indicated Yoshimura, 1988 
short questionaire Korczyn, 1986 
attention, memory 
etc 
56.0 34 not indicated Hakim and Mathieson, 
1979 
53.6 28 Dementia Rating Freedman and Oscar-
Scale Herman, 1986 
40.4 57 Mental Detoriation Caltagirone et al, 
Battery 1985 
40.0 40 General Practice Mindham et al, 1982 
Research Unit In-
terview Schedule 
WAIS Loranger et al, 1972 
Memory function De Smet et al, 1982 
HIF 
Mini mental test Mildworf et al, 1986 
(Jacobs) 
several tests in- Lieberman et al, 
eluding recent and 1979 
remote memory, and 
orientation etc. 
(HIF) 
29.0 203 Orientation, me- Elizan et al, 1986 
mory, general in-
formation (HIF) 
29.0* 421 Method Celesia Martilla and Rinne, 
and Wanamaker 197 6 
36.5 
36.0 
34.0 
32.0 
63 
75 
96 
520 
1 
system set out by Folstein and coworkers 
known as the MMS examination (see section 
2-2). Huber et al using the cut-off point of 28 
points found 11 of 31 patients with 
Parkinson's disease (35.5 %) to be demented 
(score under 28) in a population with a mean 
age over 60 years (Huber et al, 1986). 
Applying these criteria to another study of the 
same group, it can be calculated that 23 of 
50 (46.0 %) patients were demented (Huber 
et al, 1988). Interestingly they explicitly stated 
that none of these patients met the criteria of 
DSM-in (Huber et al, 1988). A similar 
finding was done by Lichter et al, who found 
33.3 % of patients under the score of 28 in a 
population of 39 patients while none of these 
patients met DSM-Ш criteria (Lichter et al, 
1988). In this study they found 17% to be 
'mildly demented' (mean score 26.1) and 16 
% to be 'moderately demented' (mean score 
20.5; Lichter et al, 1988). 
Mayeux et al used a modified MMS for 
which the maximum score was 57 points and 
for which the mean for an elderly population 
was 52.3+1.7 (see e.g. Mayeux et al, 1988). 
Using this scale they found 33 of 37 patients 
with idiopathic Parkinson's disease to be non 
demented (mean 51.0) and 4 to be demented 
(10.8%; mean 24.5; Mayeux et al, 1988). 
These data correspond to the prevalence, 
which they found using the DSM-III criteria 
(10.9%) as outlined above (Mayeux et al, 
1988). Applying the criteria of this study to 
a study conducted earlier by them, the 
prevalence can be estimated to fall in between 
22.8% and 56.1% (Mayeux et al, 1983) which 
roughly corresponds to their DSM-Ш data on 
this population (38.6%; Mayeux et al, 1983). 
2.3.4 Studies using other criteria 
There is a host of studies that have rated 
the prevalence of dementia by sometimes less 
well defined and less clearly described 
criteria. In table 2-2 a number of these studies 
is summarized. Prevalences ranging from 5.9 
% to as high as 93.0% can be found. 
Especially with those studies that do not 
explicitly state which criteria are used to 
estimate the prevalence of dementia it is 
difficult to assess the actual value of the data 
found. Fortunately a number of studies have 
included age-matched control groups which 
allows to assess the extra risk of developing 
dementia in patients suffering from 
Parkinson's disease. Factors ranging from 1.29 
(40 % vs 31 %; Mindham et al, 1982) to as 
high as 9.4 (32 % vs 3.4 %; Lieberman et al, 
1979) are found. Other values like those 
found by Rajput et al (3.24: 9.4% vs 2.9%, 
Rajput et al, 1984; 1.96: 5.9 % vs 3.0 %, 
Rajput et al, 1987) fall in between these 
extremes, and are comparable to values given 
in the foregoing paragraphs. 
2.3.5. Conclusions 
From the studies mentioned in this section 
the following conclusions can be drawn. First, 
patients suffering from Parkinson's disease 
appear to be at a higher risk of developing 
dementia than normal -elderly- people 
although the exact prevalence is hard to 
estimate. The latter is partly due to the 
differences in the groups studied, and to the 
methods used to assess dementia. In fact 
Pirozollo et al suggest that a continuum of 
cognitive deficits in Parkinson's disease exists 
which makes it difficult to determine the 
prevalence of dementia per se (Pirozollo et 
al, 1982). Despite this, some authors favour a 
prevalence as high as 35-40 percent 
(Cummings, 1988; Mayeux, 1984; Mayeux, 
1987). Others however suggest after careful 
analysis of the studies that have estimated the 
prevalence of dementia, that this figure is 
only 15-20% in idiopathic Parkinson's disease 
(Brown and Marsden, 1984; see also Gibb, 
1989; Haan et al, 1988). Some authors even 
state that the prevalence of dementia in 
Parkinson's disease does not differ from that 
of a normal control population (Taylor et al, 
1988). In their review of the literature Brown 
and Marsden explicitly excluded (i) all 
patients possibly having other forms of 
Parkinson's disease than the idiopathic one, 
(ii) patients with mild dementia in studies in 
which the methods to assess dementia were 
questionable, and (iii) patients with signs of 
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arteriosclerosis (see e.g. Martilla and Rinne, 
1976: table 2-2; Brown and Marsden, 1984). 
Interestingly they end their discussion with 
the notion that still 10-15% more patients 
with idiopathic Parkinson's disease develop 
dementia than normal elderly people (of 
whom 5% develop (severe) dementia; Brown 
and Marsden, 1984). Thus, this would imply 
that patients with Parkinson's disease are still 
more susceptible (factor three) to develop 
dementia which is in line with the fore-going 
paragraphs (see e.g Hietanen and Teravainen, 
1988; Mayeux et al, 1988; Rajput, 1984; 
Rajput et al, 1984, 1987). A number of 
factors associated with the occurrence of 
dementia will be investigated in the next 
section. 
It should finally be noted that from the 
available studies using the DSM-Ш or MMS 
it appears that certain discrepancies exist as 
far as it concerns the number of demented 
patients assessed by the two methods. The 
MMS seems to lead to higher incidences than 
the DSM-Ш in a number of studies, although 
the modification in the MMS by Mayeux et 
al seems to correct for this (Mayeux et al, 
1988). 
2-4 Factors associated with the occurrence 
of dementia in Parkinson's disease 
Table 2-2: continued 
% Demented 
28.0 
18.6 
9.4 
8.0 
7.0 
5.9 
N 
125 
72 
138 
100 
40 
118 
Tests 
not indicated 
memory, attention 
etc. 
not indicated 
WAIS, WMS etc 
CAPE I/Q scale 
not indicated 
Authors 
Rajput and Roz-
dilsky, 1975 
Sacks et al, 
1972 
Rajput et al, 
1984; Rajput, 
1984 
Taylor et al, 
1985 
Oyebode et al, 
1986 
Rajput et al, 
1987 
WAIS: W e c h s l e r A d u l t I n t e l l i g e n c e S c a l e 
HIF : H i g h e r I n t e l l e c t u a l F u n c t i o n 
WMS : W e c h s l e r Memory S c a l e 
CAPE: Clifton Assessment Procedures for the Elderly 
Within the total population N=124 patients had evidence of clinical 
arteriosclerosis; without these patients the prevalence was 18.2 
% (N-319) 
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As outlined in the previous section (section 
2-3) Parkinson patients appear to be at a 
higher risk for developing dementia than 
normal elderly people. A number of studies 
have investigated which factors might be 
associated with the development of dementia. 
In this paragraph these studies will be 
reviewed. 
Parkinson's disease is known to occur at 
later stages in life (Morgan et al, 1987). Since 
it is known that with increasing age the risk 
of developing dementia is generally increasing 
(chapter 1, section 1-1) some effect of age in 
developing dementia in Parkinson's disease 
and hence in the prevalence of dementia in 
Parkinson's disease might be expected. Gibb, 
while reviewing the literature on the 
prevalence of dementia in patients with a 
disease onset between the age of 21 and the 
age of 46 and with a median disease duration 
between 12 and 19 years found, that only a 
very low percentage actually developed 
dementia (0.8%, N=123; Gibb, 1989). In fact, 
the age of Parkinson patients with dementia is 
higher than that of the patients without 
dementia (De Smet et al, 1983; Guillard et al, 
1986; Huber et al, 1988; Lichter et al, 1988; 
Lieberman et al, 1979; Martilla and Rinne, 
1976; Mayeux et al, 1988). Moreover the 
occurrence of dementia seems to be associated 
with a late onset of the motor symptoms 
(usually above 60 years; Elizan et al, 1986; 
Hietanen and Teravainen, 1988; Lieberman et 
al, 1979; Martilla and Rinne, 1976; Mayeux 
et al, 1988, PUlon et al, 1989; Wilson and 
Smith, 1987; see however Lichter et al, 
1988). One could thus conclude from these 
studies that age-dependent phenomena solely 
account for the occurrence of dementia. 
Fortunately as outlined in the previous 
paragraphs a number of studies have used 
age-matched controls. These studies have 
shown that still an extra risk for developing 
dementia exists in Parkinson patients. In this 
respect the studies conducted by Rajput and 
coworkers are illustrative, since these authors 
have determined the incidence of dementia 
occurring in Parkinson's disease in time in 
comparison with a control group (Rajput et al, 
1984, 1987; Rajput, 1984). They took the date 
that Parkinson's disease was diagnosed in a 
patient, and selected from the population of 
Rochester (USA) for every patient two 
controls of the same age and sex that visited 
the hospital during the same time. The so 
formed triplet was studied for the occurrence 
of dementia in time. The date of diagnosis 
and control selection was called the index 
date. It appeared that significantly more 
Parkinson patients developed dementia (about 
a factor three) within five years from the 
index date than controls (Rajput, 1984; Rajput 
et al, 1984, 1987). Accordingly it appears that 
other factors are also involved (see also Gibb, 
1989; Pillon et al, 1989). 
Another obvious factor which has been 
investigated is the duration of the disease 
itself. A number of studies indicate that the 
duration of the disease-process is positively 
correlated with the occurrence of dementia 
(Caltagirone et al, 1985; Lichter et al, 1988; 
Rajput, 1984; Rajput et al, 1987), although 
other studies do not seem to confirm this 
(Huber et al, 1988; Lieberman et al, 1979; 
Loranger et al, 1972; Martilla and Rinne, 
1976; Mayeux et al, 1988; Pillon et al, 1989). 
Especially from the data of Rajput it might be 
concluded that duration of the disease is a 
predisposing factor for developing dementia 
(Rajput, 1984; Rajput et al, 1984, 1987). It is 
conceivable therefore that the duration of the 
disease contributes in those patients which are 
vulnarable for developing dementia (see 
below; see section 2-5). 
A third factor which has been investigated 
is generally indicated as 'motor disability'. In 
general, the severity of the motor disability 
and the occurrence of dementia are positively 
correlated. Thus, the severer the motor 
symptoms the worser the intellectual 
functioning (Huber et al, 1988; Lichter et al, 
1988; Loranger et al, 1972; Martilla and 
Rinne, 1976; Mayeux et al, 1988; Oyebode et 
al, 1986). The same seems to apply to the 
Hoehn-Yahr scale, which measures functional 
disability and classifies patients along a five-
point scale. A number of studies have found 
22 
Figure 2-1: Correlation between the occurrence of dementia (Y-axis; percentage of patients) and 
the stage of the disease (X-axis; Hoehn-Yahr scale). Number of patients per group: І:33;П:191;Ш: 
65;IV:18; V:12 (after Martilla and Rinne, 1976). 
a positive correlation between the stage of the 
disease measured with the Hoehn-Yahr scale 
and the occurrence of dementia (figure 2-1; 
Agid, 1985; Elizan et al, 1986; Martilla and 
Rinne, 1976; Martin et al, 1973). 
It is interesting to note in this context that 
especially akinesia and rigidity are positively 
correlated with the severity of overall (motor) 
disability, whereas tremor seems to correlate 
negatively (Ransmayr et al, 1986). Similarly 
a negative correlation between the stage of 
the disease measured with the Hoehn-Yahr 
scale and tremor was found, whereas rigidity 
and especially akinesia correlated positively 
with the stage of the disease (Ransmayr et al, 
1986). Thus from these data one might 
predict that akinesia also correlates positively 
with the occurrence of dementia. Indeed, a 
number of studies have found that akinesia 
(bradykinesia or hypokinesia; and rigidity) 
correlated positively with mental impairment 
(figure 2-2; Elizan et al, 1986; Guillard et al, 
1986; Huber et al, 1988; see also Garron et 
al, 1972; Mayeux and Stern, 1983; Mortimer 
et al, 1982; Pillon et al, 1989; Zetusky et al, 
1985). Interestingly tremor correlated either 
slightly positive (Martilla and Rinne, 1976) or 
totally negative (Huber et al, 1988; see also 
Mortimer et al, 1982; Pillon et al, 1989; 
Zetusky et al, 1985) with mental impairment 
(figure 2-2). 
A factor which might confound the clinical 
diagnosis of dementia is depression: 
depression might erroneously lead to the 
diagnosis of dementia, so called 
'pseudodementia' (Alexander and Geschwind, 
1984). Although the prevalence of depression 
in Parkinson's disease might be as high as 
30-40 percent (major depression and 
dysthymic disorder, Mayeux, 1984; Santamaria 
et al, 1986) it does not seem to account for 
the occurrence of dementia as shown by 
several studies (Huber et al, 1988; Loranger 
et al, 1972). Furthermore in most cases the 
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Symptoms of depression preceeded the motor 
symptoms of Parkinson's disease (Santamaria 
et al, 1986). 
The data presented in this section show that 
next to age other factors contribute to the 
occurrence of dementia in Parkinson's disease. 
From the available data it appears that 
especially the occurrence of akinesia seems to 
predict the development of poor mental status, 
whereas the occumence of tremor seems to 
predict (a relative) preservement of mental 
D-D:TREMOR 
0-0 : RIGIDITY 
· - · : HYPOKINESIA 
Figure 2-2: Relationship between the severity of motor symptoms (Y-axis, arbitrary units; 
mean+sem) and the severity of dementia (X-axis; arbitrary units). Number of patients: 0:316; 1: 
67; 2: 37; 3: 24 (after ManiUa and Rinne, 1976). 
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status. It is tempting to speculate that these 
phenomena are in some way functionally 
linked. In fact these data appear to fit in with 
the two types of evolution-patterns of 
Parkinson's disease as described by Barbeau 
and Roy: one, which starts with akinesia and 
progresses rapidly with more severe akinesia 
and rigidity, and one, with a more benign 
couise which starts with tremor and in which 
rigidity and akinesia develop in a much later 
stage (Barbeau and Roy, 1984). Thus one 
could speculate that the occurrence of 
dementia is more associated with the former 
type of Parkinson's disease. It is therefore 
interesting to note that Lieberman et al found 
that the group of patients with dementia 
had a more fulminant course of motor 
symptoms than the group without dementia 
(Lieberman et al, 1979; see also Wilson and 
Smith, 1987). This issue will be dealt with 
further after considering the pathology 
possibly underlying the occurrence of 
dementia in section 2-5. 
2-5 Pathology underlying the occurrence of 
dementia in Parkinson's disease 
2.5.1 Introduction 
The pathology underlying Parkinson's 
disease has been subject of research ever 
since Brissaud 's observation in 1895 that the 
substantia nigra could be the anatomical 
substrate of Parkinson's disease (Tyler, 1987). 
Early investigations have shown that so called 
Lewy bodies are present in this nucleus. 
Moreover it has been shown that dopamine 
deficiency in the nigrostriatal system is a key 
feature of the disease; a feature, on which 
finally the therapy of using a precursor of 
dopamine, L-3,4-dihydroxy-phenylalanine (1-
dopa), was founded (see e.g. Marsden, 1990). 
This deficiency in the nigrostriatal system has 
ever since been firmly established by 
numerous studies. Of the classical triad of 
motor symptoms i.e. akinesia, rigidity and 
tremor, only akinesia and rigidity correlate 
with the loss of dopaminergic activity within 
the nigrostriatal system (see e.g Bemheimer et 
al, 1973; Fahn et al, 1971; Leendere et al, 
1986). This suggests that the occurrence of 
tremor may be related to the involvement of 
other systems in Parkinson's disease (see 
below). It has become more and more clear 
that a number of other structures is also 
affected in Parkinson's disease; among them, 
the noradrenergic locus coeruleus, the 
serotonergic raphe nuclei and the cholinergic 
nucleus basalis of Meynert (see below). In the 
following paragraphs a number of different 
neurotransmitter systems will be analysed with 
respect to dementia. 
2.5.2 Neurotransmitter systems 
2.5.2.1 Dopamine 
2.5.2.1.1 Introduction 
The main two dopaminergic systems arise 
from the cell-groups located in the ventral 
mesencephalic region: the substantia nigra, 
pars compacta (SNpC) and the ventral 
tegmental area of Tsai (VTA) (Bjorklund and 
Lindvall, 1984). According to the 
nomenclature of Dahlstrom and Fuxe these 
cell-groups compromise the so called cell-
groups A9 and АЮ respectively (Dahlstrom 
and Fuxe, 1964). The A9 cell-group projects 
to the dorsal striatum (caudate nucleus and 
putamen), whereas the AIO group projects to 
the ventral striatum (including the nucleus 
accumbens and olfactory tubercle) as well as 
to widespread areas of the cortex, including 
the entorhinal cortex, hippocampus and frontal 
cortex, and to the amygdala (figure 3-1 
chapter 3, section 3-2; Bjorklund and 
Lindvall, 1984; Oades and Halliday, 1987). 
2.5.2.1.2 Experimental findings 
As indicated in the introduction to this 
section the nigrostriatal system is clearly 
involved in Parkinson's disease. After more 
than 80% of the cells are lost, the motor-
symptoms become manifest (see e.g. 
Bemheimer et al, 1973; Morgan et al, 1987). 
With reference to dementia no differences 
have been found in cell loss in the SNpC 
(Gaspar and Gray, 1984) or in DA-
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concentration in the caudate nucleus (Ruberg 
and Agid, 1988) between non-demented and 
demented Parkinson patients. The latter 
authors however found a slightly increased 
concentration of the dopamine metabolite 
homovanillic acid (HVA) in the caudate 
nucleus of demented patients in comparison 
with non-demented patients (Ruberg and Agid, 
1988), indicating a somewhat higher turnover 
rate in demented patients. Interestingly 
however a closer examination of the SNpc in 
a recent study revealed that the cell loss in 
the most medial pans of this nucleus was 
positively correlated with the severity of 
dementia: the lower the number of neurons 
the higher the degree of dementia (Rinne et 
al, 1989a). The cell loss in the lateral parts of 
the SNpc was more closely related with the 
motor symptoms, such as rigidity and tremor 
(see section 2-7). From the medial parts of 
the SNpc the projections to inter alia the 
caudate nucleus arise (see e.g. Fallon, 1988), 
indicating that the increased dopamine 
turnover observed by Ruberg and Agid (see 
above; Ruberg and Agid, 1988) might be a 
compensatory phenomenon. Furthermore this 
area shares the projections to the mesolimbic 
and mesocortica] areas with the VTA (see 
further below). 
It has been found that the number of 
(pigmented) VTA cells was lower in non-
demented Parkinson patients than in controls 
(Bogerts et al, 1983; Van Domburg, 1990; 
Hirsch et al, 1988; Javoy-Agid et al, 1984; 
Uhi et al, 1985; see however Yoshimura, 
1988). Furthermore the tyrosine hydroxylase 
activity (Javoy-Agid and Agid, 1980) as well 
as the DA content (Javoy-Agid et al, 1981) 
were decreased compared to controls. Some 
authors observed large decreases in the 
dopamine content in the projection areas of 
the VTA-system, like the nucleus accumbens 
and para-olfactory gyrus, in non-demented 
Parkinson patients (see e.g. Homykiewicz, 
1980), whereas others found only slight 
decreases (Ruberg and Agid, 1988; after 
Scanon et al, 1983). These latter authors 
furthermore observed that only in the 
hippocampus the dopamine content differed 
between non-demented patients and normal 
controls (Ruberg and Agid, 1988). 
Interestingly, no changes in the dopamine 
turnover or the number of dopamine D2 
(spiperone) binding sites have been found in 
the nucleus accumbens in (non- demented) 
Parkinson patients compared to controls; both 
measures were clearly enhanced in the 
striatum (Javoy-Agid et al, 1984). Thus, 
despite more or less similar decreases in the 
number of cells in the A9 and АЮ, these 
structures have different profiles with respect 
to these parameters, suggesting that the АЮ-
system might lack the ability to compensate 
for changes in DA-activity (Javoy-Agid et al, 
1984), making it vulnerable to cell loss. It 
should be finally noted that no changes in 
dopamine Dl (flupenthixol) binding sites have 
been found in the striatum and the nucleus 
accumbens of non-demented Parkinson 
patients with respect to controls (Rinne et al, 
1985a). 
With respect to dementia differences have 
been found in the frontal cortex and cingulate 
cortex as far as it concerned DA-content i.e. 
the demented Parkinson patients had a lower 
content than the non-demented Parkinson 
patients (Ruberg and Agid, 1988). No 
differences were found in the entorhinal 
cortex and hippocampus. Furthermore no 
differences were found in any of these regions 
in concentrations of HVA (Ruberg and Agid, 
1988). In line with these findings Yoshimura 
found cell loss in the nucleus paranigralis (i.e. 
the ventral part of the VTA) in Parkinson 
patients with dementia (-25% vs control) 
which in his group of Parkinson patients was 
most prominent in those patients that had also 
Alzheimer (AD)-like pathology (see section 2-
6; -17% without AD vs -34% with AD; 
Yoshimura, 1988). No differences were found 
between non-demented Parkinson patients and 
controls (Yoshimura, 1988). As pointed out 
above the cell loss in the medial nigra 
correlated with the severity of dementia 
(Rinne et al, 1989a). 
2.5.2.1.3 Discussion 
It would overall appear from these data that 
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despite cell-loss in the VTA in non-demented 
patients the cortical activity may be retained 
in some cases in non-demented patients, 
whereas this activity is decreased in demented 
patients. It might be concluded from the data 
presented here that the dopaminergic VTA 
(AIO) system as well as the adjacent medial 
nigra are involved in the development and 
occurrence of dementia. 
2.5.2.2 Noradrenaline 
2.5.2.2.1 Introduction 
The main noradrenergic (NA;NE) cell 
groups within the brain are situated within the 
brainstem (see Nieuwenhuys, 1985; 
Nieuwenhuys et al, 1988) and are 
conventionally labelled A1-A7 after the 
nomenclature introduced by Dahlstrom and 
Fuxe (Dahlstrom and Fuxe, 1964). The locus 
coemleus (LC) is the most important area 
from which projections towards the forebrain 
emerge (Nieuwenhuys, 1985). The cortical 
projection areas are inter alia the amygdala, 
the hippocampus and the frontal cortex; 
subcortical projection areas are inter alia the 
hypothalamus and the nucleus accumbens 
(chapter 3; section 3-2). 
2.5.2.2.2 Experimental findings 
The number of neurons in the LC seems to 
be decreased in patients with Parkinson's 
disease compared with age-matched controls 
(Chan-Palay and Asan, 1989; Mann and 
Yates, 1983). The largest cell loss was found 
in the group of patients that developed 
dementia (Gaspar and Gray, 1984; Chui et al, 
1986; Mann and Yates, 1983). In the study 
of Chan-Palay and Asan it appeared that in 
demented Parkinson patients the largest cell 
loss occurred in the more rostral areas of the 
LC, i.e. the areas that project towards the 
above mentioned cortical and subcortical areas 
(Chan-Palay and Asan, 1989). As far as it 
concerns the NA-content in this nucleus, it 
has been found that non-demented Parkinson 
patients have a lower albeit non-significant 
NA-content than age-matched controls (Cash 
et al, 1987; Homykiewicz, 1980). It has 
moreover been found that demented patients 
have a lower NA-content as well as NA 
turnover than non-demented patients (Cash et 
al, 1987). Unfortunately the demented 
Parkinson patients in the latter study had 
Alzheimer-like characteristics (plaques.tangles), 
which makes it difficult to conclude whether 
this decrease was due to a process inherent to 
Parkinson's disease or whether it was due to 
concomittant Alzheimer's disease, since the 
LC has been found to degenerate in the latter 
disease (Mann, 1988). 
The NA-content is lower in non-demented 
Parkinson patients in a number of cortical 
areas (e.g. frontal cortex, cingulate cortex and 
hippocampus; Ruberg and Agid, 1988; Scatton 
et al, 1983), as well as in a number of 
subcortical areas (nucleus accumbens; 
posterior hypothalamus; Homykiewicz, 1980) 
than in controls. Only in the cingulate cortex 
a correlation between the occurrence of 
dementia and NA-content exists, since in this 
area demented Parkinson patients have a 
lower NA-content than non-demented 
Parkinson patients; demented and non-
demented Parkinson patients have equally low 
values in the other areas (Ruberg and Agid, 
1988). In fact, Scatton et al explicitly state 
that no correlation was found between NA-
content and intellectual detonation in any of 
the areas they investigated, like inter alia the 
frontal cortex (Scatton et al, 1983). 
Within the frontal cortex changes have been 
found in the number of binding sites for 
noradrenergic agents. Thus, in non-demented 
patients a decrease in the number of binding 
sites for the tritium labelled alphal-antagonist 
(3H)-prazosine was found compared to 
controls (Cash et al, 1984). However the 
number of alpha2 binding sites ([3H]-
clonidine), and the number of betal or beta2 
binding sites ([3H] dihydroalprenolol; DHA) 
were not different from the controls (Cash et 
al, 1984). These authors also studied whether 
differences existed between demented and 
non-demented Parkinson patients. It was found 
that the number of alphal binding sites in 
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demented Parkinson patients was not different 
from that of the controls, but -as expected 
(see above)- enhanced compared to non-
demented Parkinson patients (Cash et al, 
1984). Moreover the number of alpha2 
binding sites was lower than that in controls, 
but not different from that in non-demented 
patients; the number of betal but not beta2 
binding sites was increased in demented 
patients compared to controls, but not 
compared to non-demented patients (Cash et 
al, 1984). Since these demented patients had 
Alzheimer-like characteristics it is difficult 
however to assess the actual value of these 
data (see above). 
2.5.2.2.3 Discussion 
From these data it appears that in non-
demented Parkinson patients the coeruleo-
cortical system is hypoactive. The 
decrease in alphal-antagonist binding sites 
might indicate a compensatory phenomenon: 
a low noradrenergic activity and accordingly 
a low number of antagonist binding sites (cf 
Cools et al, 1987, 1990a and references cited 
therein). Furthermore the coeruleo-cortical 
system seems to be affected in patients 
suffering from dementia, although the effects 
are difficult to evaluate exactly due to co-
existent Alzheimer's disease. It is anyhow 
striking that the changes in receptor binding 
sites in these patients are completely different 
from those in the non-demented patients. 
Some clues to these differences might be 
obtained from the following experimental 
findings. In rats it has been shown that a 
decrease in NA-content in the cortex in time 
is accompanied by an enhanced number of 
beta (antagonist) binding sites in time (Spom 
et al, 1977), as well as by an en-hanced 
production of cyclic adenosine mono 
phosphate in time (cAMP; Spom et al, 1977; 
see also Spom et al, 1976). Minneman et al 
furthermore showed that only the number of 
betal binding sites was in-creased; no changes 
were found in the number of beta2 binding 
sites (Minneman et al, 1979). Moreover 
changes in the number of beta (antagonist) 
binding sites were accompanied by inverse 
changes in the number of alpha2 (agonist) 
binding sites (Maggi et al, 1980). These data 
might explain the findings in the demented 
Parkinson patients (increase in betal,no 
change in beta2 and a decrease in alpha2 
binding sites),and fit in with the notion that 
the noradrenergic system is indeed hypoactive 
in these patients (see Chan-Palay and Asan, 
1989). The fact that similar changes were not 
found in the non-demented patients despite 
equally low levels of NA-content appears to 
contrast with this. Although this may be due 
to the Alzheimer-like pathology (see above) 
another explanation might be that the 
functional activity in the non-demented 
patients is still somewhat higher. The data 
might then be explained as follows. It has 
been found that the increased beta-receptor 
mediated cAMP production (coupled to an 
increased number of beta binding sites; see 
above) is dependent on the relationship 
between noradrenaline and dopamine (Herve 
et al, 1990). It was shown that in the 
presence of a decreased dopamine content, the 
extent of the noradrenergic lesion determines 
whether the beta-receptor is activated or not: 
a low NA-content in this set up leads to 
hyper-sensitivity, a somewhat higher content 
to hyposensitivity (Herve et al, 1990). The 
latter phenomenon is not observed in the 
absence of a dopamine lesion. It would thus 
appear that dopamine plays a role in the 
regulation of the sensitivity of the nor-
adrenergic system (see also Rossetti et al, 
1989). Since in the demented and non-
demented patients the dopaminergic activity is 
lowered (albeit to a different extent), the 
extent of the noradrenergic lesion determines 
the changes in receptor densities. Hence it 
might be reasoned that the (functional) 
noradrenergic activity in the non-demented 
Parkinson patients is somewhat higher than in 
the demented Parkinson patients. Overall these 
data thus suggest that the coeruleo-cortical 
system is differentially affected in non-
demented and demented Parkinson patients. 
2.5.2.3 Serotonin 
The main origin of the serotonergic 
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projections is situated in the basal 
mesencephalon (Nieuwenhuys, 1985; 
Nieuwenhuys et al, 1988). It has been shown 
that cell loss occurs in the dorsal raphe nuclei 
in non demented (-35%) and demented (-
47%) Parkinson patients (Jellinger, 1987b). 
Decreases in serotonin content have been 
found in the frontal and cingulate cortex as 
well as in the hippocampus and caudate 
nucleus of non-demented patients (Ruberg and 
Agid, 1988). With respect to dementia no 
differences have been found between 
demented and non-demented patients in these 
areas (Ruberg and Agid, 1988). 
2.5.2.4 Acetylcholine 
2.5.2.4.1 Introduction 
Within the brain several cholinergic systems 
exist (see Nieuwenhuys, 1985; Nieuwenhuys 
et al, 1988). A number of different cell 
groups can be recognized which give rise to 
a wide variety of projections throughout the 
brain; these cell-groups are now 
conventionally labelled CH1-CH6; a 
nomenclature proposed by Mesulam and 
coworkers in 1983 (Mesulam et al, 1983a). 
With respect to dementia the CH4 cell-group 
(nucleus basalis of Meynert (NBM)) is the 
most intensively studied cell-group, which is 
largely due to the putative involvement in 
the dementia inherent to Alzheimer's disease 
(Perry, 1984; Mann , 1988; see section 2-6). 
This NBM is situated within the so-called 
substantia innominata at the ventral surface of 
the brain in man (Репу et al, 1984; Saper 
and Chelimsky, 1984; Ulfig, 1989). It gives 
rise to cholinergic projections to the entire 
cortex (Mesulam et al, 1983a, 1983b). 
2.5.2.4.2 Experimental findings 
Lewy bodies have been found in the NBM 
of non-demented Parkinson patients (Gaspar 
and Gray, 1984; see also Nakano and Hirano, 
1984). No difference has been found with 
respect to demented patients (Gaspar and 
Gray, 1984). As far it concerns the occurrence 
of neuro-fibrillary tangles (NFT) in the NBM, 
it has been found that no differences exist 
between non-demented and demented patients 
(46.2% (N=14) vs 50.0 % (N=6); Gaspar and 
Gray, 1984). Interestingly, the occurrence of 
NFT in the NBM of demented patients with 
Alzheimer-like characteristics in the cortex 
was much higher (91.7%(N=12); Gaspar and 
Gray, 1984). 
In table 2-3 a number of studies is 
summarized which have determined the extent 
of cholinergic cell loss within the NBM in 
Parkinson's disease. From this table it 
emerges that in non-demented Parkinson 
patients cell loss is found; in fact the cell loss 
can be as high as 60% (see also Nakano and 
Hirano, 1984; Candy et al, 1983). Furthermore 
it appears that demented patients have a larger 
cell loss than non-demented patients regardless 
of whether Alzheimer-like characteristics are 
present or not. In fact, it would appear that 
the cell loss is even larger in the absence of 
Alzheimer-like characteristics (Gaspar and 
Gray, 1984; Yoshimura, 1988). Others have 
finally found that the nuclear volume and 
RNA-content of NBM-neurons are lower in 
demented Parkinson patients compared to 
controls and non-demented Parkinson patients; 
the latter groups differed only slightly from 
each other (Mann and Yates, 1983). 
The activity of the acetylcholine 
synthesizing enzyme cholineacetyltransferase 
(CHAT) in the NBM is slightly reduced in 
non-demented Parkinson patients compared to 
controls (Gaspar and Gray, 1984; see also 
Dubois et al, 1983; Perry et al, 1989). In 
demented patients, the CHAT-activity was 
lower than in non-demented patients (Gaspar 
and Gray, 1984). 
The frontal cortex, as a prominent 
projection area of the NBM, shows a reduced 
CHAT-activity in Parkinson patients without 
dementia compared to controls (Dubois et al, 
1983; Gaspar and Gray, 1984; Репу et al, 
1983; Perry et al, 1985; Ruberg et al, 1982, 
1986). Furthermore it has been found that 
demented patients have even lower CHAT-
activities (Gaspar and Gray, 1984; Репу et al, 
1983; Perry et al, 1985; Ruberg et al, 1982, 
1986). In fact a tendency for a negative 
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correlation has been found to exist between 
the degree of dementia and the CHAT-activity 
in the frontal cortex (Rinne et al, 1989b). 
Others observed a more profound negative 
correlation between the degree of dementia 
and the CHAT-activity (Dubois et al, 1983). 
Since these latter authors included however 
demented patients with Alzheimer-like 
characteristics, it is not clear whether this 
correlation was due to a process inherent to 
Table 2-3: Number of cells and density of cells within the NBM region in Parkinson patients 
without and with dementia. The values of the patient-groups are expressed as percentage of controls 
(=100% by definition). 
Control PD-dementia PD+dementia Authors 
lOO (29) 
100 ( 8) 
lOO (12) 
lOO ( 5) 
100 ( 5) 
lOO ( 7) 
51.1 (18) 
82.7 ( 4) 
68.0+(14) 
8.2 
99.9 ( 5) 
NUMBER OF CELLS 
41.1 (32) 
27.8 ( 3) 
27.2+( 6) 
8.5 
48.0-l-(12) 
4.1 
81.1 ( 5) 
60.9 ( 5) 
39.8+7.3 (3) # 
66.6 ( 3) 22.9 ( 2)$ 
29.0 ( 2)$$ 
Jellinger,1987b 
Perry et al, 1985 
Gaspar and Gray, 
1984** 
Yoshimura,1988** 
Tagliavini et al, 
1984 
Whitehouse et al, 
1983 
DENSITY 
lOO (29) 
100 (12) 
100 ( 5) 
100 ( 5) 
100 (22) 
60.0 (18) 
66.9+(14) 
7.7 
99.3 ( 5) 
85.7 ( 3) 
38.7 (32) 
27.0+( 6) 
8.3 
53.2+(12) 
6.1 
75.6 ( 5) 
64.8 ( 5) 
34.0 ( 3) 
50.0 ( 4) 
Jellinger, 1987b 
Gaspar and Gray, 
1984** 
Yoshimura,1988** 
Chui et al, 1986 
Chan-Palay, 1988b 
In brackets the number of patients is given 
** for the demented patients the first number refers to patients without 
Alzheimer-like characteristics, the second number to patients with 
Alzheimer-like characteristics; 
# mild cognitive deficits (not clear whether they are demented or 
$ not clear whether these patients have Alzheimer-like characteristics; 
$$ with Alzheimer-like characteristics; 
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Parkinson's disease or to a process inherent to 
Alzheimer's disease. It should be noted 
however that they did not observe a 
correlation between the CHAT-activity and the 
Alzheimer-like pathology, whereas they 
observed a correlation between the degree of 
dementia and the Alzheimer-like pathology 
(Dubois et al, 1983). This strongly suggests 
thus that the negative correlation between the 
degree of dementia and the CHAT-activity 
might reflect a pathological process inherent 
to Parkinson's disease. 
The activity of the metabolising enzyme 
acetyl-cholinesterase (ACHE) was decreased in 
the frontal cortex of non-demented Parkinson 
patients compared to controls (Ruberg et al, 
1986; see also Perry et al, 1985). Demented 
Parkinson patients had even lower activities 
(Perry et al, 1985; Ruberg et al, 1986). It 
should be noted that especially the IOS form 
of this enzyme was decreased; no differences 
were found for the 4S and 16S form (Perry et 
al, 1985; Ruberg et al, 1986). It should 
furthermore be noted that a positive 
correlation existed between the CHAT- and 
ACHE-activities (Ruberg et al, 1986). 
The number of binding sites for tritiated 
quinuclidinyl benzilate (3H-QNB), a M1/M2 
muscarinic antagonist (see e.g. Watson et al, 
1986), was enhanced in the frontal cortex of 
non-demented Parkinson patients compared to 
controls (Dubois et al, 1983; Ruberg et al, 
1982). Moreover Parkinson patients with 
dementia had even higher numbers of binding 
sites (Dubois et al, 1983). However, since 
these latter patients had also Alzheimer-like 
characteristics it could be argued that this 
effect was not due to a process inherent to 
Parkinson's disease but inherent to the 
Alzheimer-like pathology (see above). Still, 
others observed a positive correlation between 
the degree of dementia and the number of 
muscarinic binding sites in patients without 
Alzheimer-like characteristics (Rinne et al, 
1989b) showing that this increase in 
muscarinic binding sites is due to a process 
inherent to Parkinson's disease. This appears 
to be even more true since these latter authors 
observed no changes in binding sites in the 
frontal cortex of patients suffering from 
Alzheimer's disease (Rinne et al, 1989b). 
Finally they showed that especially the 
number of M2-binding sites was altered in 
Parkinson's disease (Rinne et al, 1989b). The 
number of binding sites is negatively 
correlated with the CHAT-activity in the 
frontal cortex (Rinne et al, 1989b; Ruberg et 
al, 1982). It should finally be noted that the 
degree of tremor correlated negatively with 
the number of QNB binding sites (Dubois et 
al, 1983). Together with the data reported 
above one might come to the tentative 
suggestion that tremor and dementia were also 
negatively correlated (see section 2-4). The 
authors did not observe such a correlation 
however (Dubois et al, 1983). 
Other cortical areas (occipital, parietal, 
temporal and entorhinal cortex) also showed 
a decrease in CHAT-activity in Parkinson 
patients; again the effect was most apparent in 
the demented patients (Cross et al, 1987; 
Perry et al, 1985, 1989; Perry et al, 1983; 
Rinne et al, 1989b; Ruberg et al, 1982, 
1990). A similar pattern seems to exist for 
ACHE-activity (Perry et al, 1985). Within the 
parietal cortex the number of nicotinic binding 
sites was decreased in Parkinson patients; the 
effect was most apparent in the demented 
Parkinson patients (Perry et al, 1989). A 
positive correlation appeared to exist between 
the number of nicotinic binding sites and the 
CHAT activity (Perry et al, 1989; cf. 
Whitehouse, 1989 for the frontal, occipital 
and temporal cortex). 
The cholinergic system arising from the 
medial septal area has been less intensively 
studied with reference to dementia in 
Parkinson's disease. A reduction in CHAT-
activity has been noted in the hippocampus of 
non-demented Parkinson patients compared to 
controls (Ruberg et al, 1982; Perry et al, 
1987, 1989). No differences were found 
between demented and non-demented 
Parkinson patients (Perry et al, 1987, 1989). 
No changes were observed in the number of 
muscarinic binding sites in non demented or 
demented Parkinson patients (Rinne et al, 
1989b; Ruberg et al, 1982). The number of 
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nicotinic binding sites was however equally 
low in non-demented and demented Parkinson 
patients compared to controls (Репу et al, 
1987, 1989). This latter decrease was 
positively correlated with the decrease in 
CHAT activity within this area (Perry et al, 
1987, 1989). 
The cholinergic system arising from the 
nuclei tegmenti pedunculopontinis, pars 
compacta (CH5) has also been reported to be 
affected in Parkinson's disease (Jellinger, 
1987 b). From the data of Jellinger it is not 
clear whether the patients, which he studied, 
were demented or not (Jellinger, 1987b). 
2.5.2.4.3 Discussion 
These data overall clearly indicate that both 
in clinically non-demented and demented 
Parkinson patients the cholinergic NBM-
cortical system is affected. If this system is 
involved in the development of dementia, it 
implies that also in this area a threshold 
phenomenon like in the nigrostnatal system 
might exist (see Homykdewicz and Kish, 
1984). Moreover these findings may explain 
the continuüm of deficits found by Pirozoilo 
et al (Pirozollo et al, 1982). Furthermore these 
data lend support for the suggestion that the 
mental impairment (i.e. 'dementia') in 
Parkinson's disease is due to non-
dopaminergic lesions (see Pillon et al, 1989; 
see paragraph 2.5.3). It is finally noteworthy 
that Dubois et al observed that clinically non-
demented Parkinson patients showed a 
reduced memory performance when treated 
with a subthreshold dose of the cholinergic 
antagonist scopolamine (Dubois et al, 1987). 
The inverse relationship between the number 
of muscarinic M2 (antagonist) binding sites 
and the CHAT- activity might be explained 
either as postsynaptic denervation 
supersensitivity or as presynaptic 
subsensitivity. In the latter case one has to 
assume that the M2-receptors are located 
presynaptically, which has been suggested to 
be the case (Timmermans and Thoolen, 1987), 
and that the increase in antagonist binding 
sites reflects a decrease in the autoreceptor 
sensitivity (cf Cools et al, 1990a and 
references cited therein). In this respect it is 
interesting that a positive correlation was 
found between the CHAT activity and the 
number of nicotinic (antagonist) binding sites. 
Together with the foregoing considerations 
this might suggest then that this latter finding 
reflects supersensitivity at the postsynaptic site 
due to a low CHAT-activity, i.e. a decrease 
in antagonist binding sites, and possibly an 
increase in agonist binding sites. It would 
thus appear that the cholinergic system tries 
to compensate for a lowered cholinergic 
activity. 
2.5.2.5 Amino acids 
It has been shown that the sodium 
dependent D-[3H]-aspartate binding in the 
parietal cortex was not changed in patients 
suffering from Parkinson's disease; in fact 
neither demented nor non- demented patients 
showed any difference versus the controls , 
although the CHAT-activity was clearly 
decreased in the former patients (Cross et al, 
1987). 
2.5.2.6 Peptides 
The immunoreactivity for the tachykinin 
substance Ρ (SP) was lower in 7 out of 22 
cortical areas in demented Parkinson patients; 
among them frontal and temporal areas 
(Clevens and Beai, 1989). However since 
these patients had also Alzheimer-like 
characteristics the actual value of these data 
is difficult to assess. 
The immunoreactivity for the neuropeptide 
somatostatin (ST; Bloom and Polak, 1987) 
has been found to be decreased in the 
cerebrospinal fluid of Parkinson patients; a 
clear tendency existed for demented patients 
to have lower ST-like immunoreactivity 
(Jolkkonen et al, 1986). In line with these 
findings it was observed that the ST-like 
immunoreactivity in the hippocampus of 
demented patients was lower than that in the 
hippocampus of non-demented patients 
(Epelbaum et al, 1983). In none of the 
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cortical ateas (e.g. hippocampus, frontal 
cortex, temporal cortex and entoihinal cortex) 
differences were found between non-demented 
Parkinson patients and controls. However in 
the frontal cortex a nice negative correlation 
was found between the degree of dementia 
and the levels of somatostatin (Epelbaum et 
al, 1983). Since these demented patients also 
showed Alzheimer-like characteristics it can 
not be concluded that the observed effects 
were due to processes inherent to Parkinson's 
disease per se; for, it has been shown that 
somatostatin is also decreased in patients 
suffering from Alzheimer's disease (Bloom 
and Polak, 1987). 
Galanin is a 29 amino acid peptide 
originally isolated from the porcine intestine 
(Tatemoto et al, 1983). It has been shown to 
exist in several areas in the human brain 
including the basal nucleus, i.e. the NBM 
(Chan-Palay, 1988a; see Crawley et al, 1989 
for a review). In the latter it is localized in 
intemeurons that innervate the cholinergic 
NBM-neurons, and co-localized with 
acetylcholine in the NBM-neurons themselves 
(Chan-Palay, 1988a). It has been shown that 
in demented Parkinson patients, in which the 
number of cholinergic neurons is decreased 
(table 2-3), a galanin hypertrophy exists, i.e. 
the remaining cholinergic neurons are 
hyperinnervated by galanin containing 
terminals (Chan-Palay, 1988b; 1990). In non-
demented patients, in which the decrease in 
cholinergic neurons is less, this hardly 
occuired (Chan-Palay, 1988b, 1990). Since 
galanin has been found to suppress 
cholinergic activity (Crawley et al, 1989), 
these findings imply that the remaining -
lower- cholinergic activity in demented 
patients is even further suppressed, which 
probably leads to more severe cognitive 
dysfunction. 
2.5.3 Conclusions 
From the present review of the literature it 
is clear that in Parkinson's disease 
disturbances are found in a number of 
transmitter systems, next to the classical 
pathology in the nigrostriatal system. In fact, 
it appears that a continuum exists from a 
small pathology in these systems with a 
relatively spared mental functioning to a 
severe pathology with an impaired mental 
functioning, warranting the diagnosis of 
'dementia'. In figure 2-3 some of the 
structures mentioned in this section are 
depicted together with the pathological 
changes that have been observed. From this 
figure it is clear that the (meso)limbic system 
is involved in the occurrence of dementia in 
Parkinson's disease (cf. Cools, 1990). With 
respect to the hypothesis presented in section 
2-4 it is interesting to recall that Rinne et al 
observed that rigidity (and akinesia) correlated 
negatively with the number of neurons in the 
lateral nigra -confirming the observation that 
the degree of these symptoms correlate with 
the decrease in dopamine in the caudato-
putamen complex (see paragraph 2.5.1)-
whereas the degree of dementia correlated 
negatively with the number of neurons in the 
medial areas (Rinne et al, 1989a). The latter 
findings seem to agree with the fact that also 
the adjacent VTA is damaged in patients 
suffering from dementia in Parkinson's 
disease. In further support of this it has 
recently been shown that histopathological 
changes in the medial nigra/VTA and their 
projection areas lead to a 'dementia' 
syndrome (Torack and Morris, 1986; 1988; 
Verity et al, 1990; see also Neary et al, 
1990). Together with the data presented in 
the previous section this suggests that these 
two findings, (i) dementia due to a pathology 
in the VTA/medial nigra and (ii) rigidity 
(akinesia) due to a pathology in the lateral 
nigra, may be related to each other. In fact it 
might be speculated that the pathology 
spreads from the lateral to medial areas (or 
vice versa) or that the pathology co-occurs in 
these areas. In this respect it is interesting 
that tremor correlated positively with the 
number of cells in the lateral nigra (Rinne et 
al, 1989a) suggesting that the degree of 
pathology in the lateral nigra is less in these 
patients. According to the above given 
considerations, one might speculate that the 
degree of pathology in the medial nigra/VTA 
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Figure 2-3: Summary drawing of some neurochemical changes in Parkinson's disease without (A) 
and with (B) dementia. The evidence for the connections between the structures is given in chapter 
3 (section 3-2) and chapter 4 (section 4-2). 
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is also less, leading to a rather preserved 
mental functioning. It should be clearly stated 
in this stage that the cholinergic system 
arising from the NBM is also clearly affected 
in demented patients, which may be related 
to the finding that the VTA is damaged; an 
issue that will be dealt further with in section 
2-7. It should furthermore be clearly stated 
that non-demented and demented Parkinson 
patients suffer from cognitive deficits (chapter 
S) which have been shown to be related to 
the pathology in the nigrostriatal system (i.e. 
caudate nucleus; see Cools et al 1984a, 
1989c; Cools 1990 for reviews). 
The question arises now whether the VTA 
and its projection areas are also involved in 
other forms of mental dysfunctioning, i.e. 
dementia. In the next paragraph evidence will 
be presented that these structures are also 
affected in the dementia of the Alzheimer 
type. 
2-6 Alzheimer's disease: involvement of the 
(meso)limbic system and relationship to 
Parkinson's disease: do Alzheimer and 
Parkinson meet? 
2.6.1 Alzheimer's disease 
2.6.1.1 Introduction 
In 1907 the German neuropathologist Alois 
Alzheimer described specific cortical 
neuropathological changes in a woman with 
dementia (see Thomas and Isaac, 1987). This 
disease i.e. this specific form of dementia 
would bear his name ever since: Alzheimer's 
disease. Nowadays, this disease is recognized 
as one of the major forms of dementia (Mas 
et al, 1987; Schoenberg et al, 1987; chapter 
1, section 1-1). Several authors have 
suggested and shown that two forms can be 
recognized: a presenile form starting before 
the age of 65, and a senile form starting after 
the age of 65: the former is generally called 
Alzheimer's disease (AD), the latter senile 
dementia of the Alzheimer type (SDAT) (see 
e.g. Gottfries, 1980; Iversen, 1987, Iversen, 
1988). It is believed that these forms differ in 
the extent of cortical pathology and in certain 
neurochemical parameters (Iversen, 1987; 
Iversen, 1988). Despite these differences they 
are both characterized by the same type of 
histopathological hallmarks: abundant senile 
plaques and neurofibrillary tangles in several 
cortical areas (Mann, 1988). It is not intended 
here to review the vast amount of literature in 
this respect, since comprehensive reviews 
exist (see e.g. Kemper, 1984; Perry, 1984; 
Mann, 1988). Instead, it will be explored 
whether the circuitry depicted in figure 2-3 is 
involved in AD/SDAT. Unless otherwise 
stated the term AD will be used throughout 
the text. 
2.6.1.2 Some neuropathological findings 
Numerous studies have shown that the 
cholinergic cellcontinuum in the substantia 
innominata, i.e. the NBM (see paragraph 
2.5.2.4) is affected in AD (see e.g. Collerton, 
1986; Mann, 1988; Vogels, 1990, for 
reviews). In line with this, disturbances have 
been found in cortical areas to which these 
cells project (Mann, 1988). It would appear 
that the pathology in the mediodorsal 
temporal cortex is the most severe with 
increasingly smaller pathologies in the 
secondary and primary association areas 
(Kemper, 1984; Pearson and Powell, 1987). 
Furthermore the amygdala is heavily involved 
in the disease process (see e.g. Brady and 
Mufson, 1990). It would however appear that 
the frontal cortical areas are less severily 
damaged; a finding which is especially related 
to older patients (>79 years; Rossor et al, 
1981; WUcock et al, 1982; see also 
Rossor, 1982). In fact it might differentiate AD 
from SDAT (Rossor et al, 1981; Rossor, 
1982). 
It has been suggested that the lesions in the 
NBM are due to retrograde degeneration 
(Pearson and Powell, 1987; Vogels, 1990). 
This suggestion seems to be supported by the 
observation that other cortical projection 
systems degenerate in this disease. Thus it has 
been shown that both the noradrenergic locus 
coeruleus (see Van Domburg 1990 for a 
review) as well as the dopaminergic VTA 
show pathological changes (Van Domburg, 
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1990; German et al;, 1987; Gibb et al, 
1989a; Hamill et al, 1988; Mann et al, 
1987). 
The above mentioned cortical areas project 
towards the ventral striatum, i.e. the 
ventromedial part of the striatum, the nucleus 
accumbens and the olfactory tubercle (figure 
2-3; chapter 3, section 3-2). It has been 
shown that in AD the number of dopamine 
D2 (spiperone) binding sites is decreased in 
the nucleus accumbens and caudato-putamen 
in comparison with controls (Rinne et al, 
1986). Only the number of binding sites 
within the nucleus accumbens however 
correlated -significantly- positively with the 
degree of Alzheimer pathology in the cortex, 
hippocampus and amygdala (Rinne et al, 
1986). These data nicely correspond with the 
observation in rats that the number of D2-
receptors was increased in the above 
mentioned subcortical areas after lesions in 
the frontal cortex (see Pycock et al, 1980; 
chapter 3; section 3-5). Furthermore the 
number of muscarinic QNB binding sites was 
decreased in the nucleus accumbens (Rinne et 
al, 1985b), which correlated positively with 
the decrease in the number of D2-bmding 
sites (Rinne et al, 1986). Moreover the 
number of cholinergic neurons within the 
ventral striatum has been found to be 
decreased; interestingly, no changes were 
found within the dorsal striatum (Lehericy et 
al, 1989; cf Geula et al, 1990). With respect 
to the latter finding it should be mentioned 
that others observed a decrease in the large 
neurons in the caudato-putamen complex of 
Alzheimer patients (Oyanagi et al, 1987, 
1989). These authors suggested that these 
neurons might be cholinergic intemeurons or 
non-GABA projection neurons (Oyanagi et al, 
1987). A striking finding by them was, that 
the decrease in large neurons in the caudato-
putamen complex correlated positively with 
the decrease in large neurons in the NBM 
(Oyanagi et al, 1989). The relevance of these 
findings is at present however not clear. 
2.6.1.3 Conclusions 
It would appear from the foregoing 
paragraph that the structures depicted in figure 
2-3 are also involved in Alzheimer's disease 
to some extent. Furthermore it appears that 
the pathology might spread from the cortical 
(hippocampus, amygdala and frontal cortex) to 
subcortical (nucleus accumbens, NBM) areas. 
These data overall suggest that the limbic 
system including the VTA may be involved in 
aspects of the dementia associated with 
Alzheimer's disease. 
2.6.2 Relationship between Alzheimer's and 
Parkinson's disease 
As already indicated briefly in the previous 
section, section 2-5, Parkinson's disease seems 
to be accompanied sometimes by Alzheimer-
like pathology in cortical and subcortical areas 
(see also Boiler et al, 1980; Gaspar and 
Gray, 1984; Hakim and Mathieson, 1978; 
1979). Conversely Alzheimer's disease has 
been found to be associated with a Parkinson-
like pathology (Ditter and Mirra, 1987; 
Joachim et al, 1988). Thus, Lewy bodies have 
been found to exist in the substantia nigra of 
patients suffering from Alzheimer's disease 
(Ditter and Mirra, 1987; Gibb et al, 1989a; 
Joachim et al, 1988), with a prevalence higher 
than that of a control population (Joachim et 
al, 1988). In fact, Ditter and Mirra observed 
that 55% of their cases (11 out of 20 
patients) had Parkinson-like changes in 
pigmented nuclei (Lewy bodies; neuronal loss 
and gliosis; Ditter and Mirra, 1987). 
Furthermore varying degrees of cell-loss have 
been found in the substantia nigra: from no or 
slight changes compared to controls (Van 
Domburg, 1990; Hamill et al, 1988; Mann et 
al, 1980; 1984, 1987) to severe changes 
(Ditter and Mirra, 1987; Gibb et al, 1989a). 
One might predict from the foregoing that 
Alzheimer patients have Parkinson-like motor 
symptoms, like e.g. rigidity. Indeed this has 
been found to be the case. The most 
frequently observed Parkinson-like symptoms 
(60-80% of the patients) were rigidity, 
hypokinesia, hypomimia, and shuffling gate 
(Ditter and Mirra, 1987; Molsa et al, 1987; 
Sulkava, 1982). Tremor occurred only in a 
minor subpopulation (0-10%; Ditter and 
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Мііта, 1987; Moka et al, 1984; Sulkava, 
1982). The prevalence of the former set of 
symptoms was higher in the Alzheimer group 
than in a respective control group (see Molsa 
et al, 1984), suggesting that it may be 
intrinsic to the disease process. The 
occurrence of Parkinson-like symptoms 
seemed to be linked to lower levels of 
dopamine in the caudate nucleus (Reinikainen 
et al, 1988; see also Mann et al, 1980) and 
cerebrospinal fluid (Kaye et al, 1988) of 
Alzheimer patients. 
Interestingly, it was moreover found that the 
occurrence of the symptoms rigidity, 
hypokinesia and hypomimia was positively 
correlated with the severity of dementia, 
whereas this was not the case for tremor 
(Molsa et al, 1984; see also Huff and 
Growdon, 1986). It should however be noted 
that some authors state that these symptoms, 
which were found in the Alzheimer patients, 
are not similar to those found in Parkinson 
patients (Tyrrell and Rossor, 1989). 
According to the hypothesis outlined in 
section 2-5 the foregoing suggests that the 
pathology either spreads from the VTA to the 
substantia nigra or co-develops in these areas. 
Following Quinn et al's review on the co­
occurrence of Alzheimer's and Parkinson's 
disease, these diseases may co-occur to 
varying degrees, leading to a spectrum 
consisting of pure Parkinson's disease to pure 
Alzheimer's disease via the intermediates: the 
demented parkinsonian and the parkinsonian 
dement (Quinn et al, 1986; see also Jellinger, 
1987a; Jellinger and Riederer, 1984). Within 
this range the atypical Parkinson or the 
atypical Alzheimer patient may thus be 
situated (see Gibb et al, 1989b; Perry et al, 
1990). In fact, as Quinn et al suggest the 
subthreshold phenomena of the disease 
processes inherent to Parkinson's and 
Alzheimer's disease may be summed to give 
the full clinical picture of dementia (Quinn et 
al, 1986). 
2-7 An hypothesis on the role of the 
mesolimbic system in dementia. 
The review of the literature presented in 
this chapter would lead to the hypothesis that 
the AIO and A9 dopaminergic cell-groups are 
differentially involved in Parkinson's (and 
Alzheimer's) disease (cf. Cools, 1990). 
The A9-cells appear to be involved in at 
least the motor symptoms i.e. akinesia and 
rigidity. Animal experiments have moreover 
shown that subtle neurochemical changes 
within the caudate nucleus of rats (Cools, 
1980; Vrijmoed-de Vries and Cools, 1986), 
cats (Jaspers et al, 1984) and monkeys (Van 
den Bereken and Cools, 1982) change the 
ability to arbitrarily shift behaviour (see 
chapter 3, section 3-3 and chapter 5, sections 
5-2 and 5-3 for elaboration of this point; see 
Cools et al, 1984a, 1989c; Cools, 1990 for 
reviews), whereas larger neurochemical 
changes induce increases in tonic 
electromyographic activity in the 
gastrocnemius soleus muscle of the hindlimb 
in rats (Ellenbroek et al, 1985a). The 
experimental designs used in these studies 
might be good animal models for the inability 
to switch behaviour without the help of 
external stimuli observed in Parkinson's 
disease (chapter 5, section 5-2 and 5-3), and 
the rigidity observed in these patients. In fact, 
the former might in part underlie the akinesia 
observed in Parkinson patients. 
From the present review it is clear that the 
pathology in the A9 system cannot solely 
account for the tremor occurring in Parkinson 
patients. Together with the data on dementia, 
it might be speculated that a dysbalance 
between the A9 and AIO system might lead 
to tremor: a hypoactive A9 system and a 
normo- or hyperactive dopamine AIO system 
(cf. Cools, 1990). Although no hard data 
exist to support this, it is noteworthy that in 
rats it has been shown that lesions of the 
dopaminergic terminals in the nucleus 
accumbens decrease the amplitude of the 
tremor induced by the cholinergic agent 
tremorine (Dickinson and Slater, 1981). As 
will be pointed out in chapter 3, section 3-2 
and chapter 4, sections 4-2 and 4-3, an 
increase in the dopaminergic activity in the 
nucleus accumbens is accompanied by an 
increase in the cholinergic NBM-coitical 
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activity (cf. Cools et al, 1989b). Accordingly 
an enhanced cholinergic activity might be 
expected to be associated with tremor. At this 
stage it is good to recall the following data of 
Dubois et al presented in paragraph 2.5.2.4: 
the inverse relationship between the number 
of muscarinic binding sites in the frontal 
cortex and the severity of tremor (Dubois et 
al, 1983), Since the former is inversely related 
to the CHAT-activity in the frontal cortex 
(Ruberg et al, 1982; Rinne et al, 1989b), one 
might speculate that the CHAT-activity and 
the severity of tremor are positively 
correlated. If so, this would support the above 
given notion. The authors however did not 
mention whether this correlation existed or 
not (Dubois et al, 1983). 
The AlO-system seems to be involved in 
the dementia associated with Parkinson's 
disease: a decreased activity in this system 
appears to be associated with the development 
of dementia (cf. Cools et al, 1989b; Cools, 
1990). Following the reasoning above, the 
cortical cholinergic activity might be expected 
to be lowered in Parkinson's disease with 
dementia. As outlined in section 2-5 this is 
indeed the case in the dementia associated 
with Parkinson's disease and moreover as 
pointed out in section 2-6 with the dementia 
associated with Alzheimer's disease. In table 
2-4 the general hypothesis of this chapter and 
thesis is shown. From this table it is clear 
that studying the dopaminergic AlO-system 
might reveal aspects of the dementia 
associated with Parkinson's and Alzheimer's 
disease (Cools et al, 1989b; Cools, 1990). In 
fact, it has recently been suggested that 
lesions of the AlO-system in rats might be a 
good animal model for -some aspects of-
dementia in the human (Scamati et al, 1980). 
A number of remarks should however be 
made here. First, this hypothesis does not 
mean to imply that the pathology within the 
Table 2-4: An hypothesis on the role of the A9 and AIO dopaminergic cellgroups in Parkinson's 
and Alzheimer's disease (see Cools et al, 1989b, 1989c; Cools, 1990). 
___ .__. _ __ ._ 
A9 H H H I / " 
dementia - + ++ ++ 
Motor symptoms tremor rig./ak. rig./ak. 
Clinical picture Parkinson Parkinson demented demented 
dement parkinsonian (Alzheimer) 
\: decrease in activity; \ : increase in activity; -=: normal activity; 
number of arrows indicates severity of the effect 
+: present; -: absent; number of +'s indicates severity 
rig.: rigidity; ak.: akinesia 
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AlO-system follows the same pattern in these Alzheimer's) disease. 
diseases. Several authors have indeed 
suggested that the cellular pathology 
underlying Parkinson's and Alzheimer's 
disease is different (Price et al, 1986). 
Furthermore, the cortical areas seem to be 
primarily affected in Alzheimer's disease, 
leading to secondary changes in the 
subcortical areas, whereas the pathology in 
Parkinson's disease might be primarily 
subcortical in nature with a subsequent 
disruption of the function of the cortical 
structures (Candy et al, 1985; 1986; Jellinger, 
1987a; see also Pearson and Powell, 1987). 
The latter might be achieved through a 
dysfunctioning AIO- system, that disrupts the 
activity of a series of structures (like the 
nucleus accumbens and NBM; Cools et al, 
1989b; Cools, 1990). Despite these different 
patterns however, these diseases may have 
behavioural disturbances in common. It should 
thus therefore be clearly stated here that the 
hypothesis does not take into account the 
pathology as such, like e.g. the development 
of Lewy bodies in Parkinson's disease and 
plaques and tangles in Alzheimer's disease, 
but solely tries to set up a framework in 
which some of the behavioural disturbances 
within these dementias may be understood. 
Moreover the flow of behavioural disturbances 
may be related to the possible successive 
involvement of the structures that are affected 
in these diseases (Cools et al, 1989b, 1989c; 
Cools, 1990). Second, the AlO-system is a 
highly complex system. It consists of a wide 
series of dopamine projections as indicated, in 
part, in figure 2-3 (see further chapter 3 
figure 3-1). From this figure it is clear that 
especially the nucleus accumbens-substantia 
innominata (NBM) axis occupies a central 
role, since this axis receives projections from, 
and sends projections to the areas that are 
affected in Parkinson's (and Alzheimer's) 
disease. Therefore, in the following chapters 
the nucleus accumbens (chapter 3) and the 
substantia innominata (chapter 4) will be 
studied to unravel the role of these structures 
in behaviour. In chapter 5 the findings of 
these experiments will be related to the 
clinical picture of Parkinson's (and 
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CHAPTER III 
STUDIES ON THE ROLE OF 
THE NUCLEUS ACCUMBENS 
IN BEHAVIOUR 
In which rats have been forced to swim in order to allow the author of this thesis 
to investigate the role of the nucleus accumbens in behaviour. Be sure, none of the 
rats drowned. A general hypothesis on the role of this nucleus is put forward. 
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3-1 Introduction 
As outlined in chapter 2 the mesolimbic 
system seems to be involved in the dementia 
associated with Parkinson's and Alzheimer's 
disease. This chapter focusses upon the 
nucleus accumbens in an attempt to delineate 
its role in behaviour. First, a brief survey of 
the anatomy of this structure i.e. its afferent 
and its efferent projections, will be given. 
Subsequently, a working hypothesis for a role 
of the nucleus accumbens in behaviour will 
be developed on the basis of existing 
literature. Next, experiments will be described 
which were aimed at testing this hypothesis. 
Finally, the conclusions drawn from these 
experiments will be integrated into the 
existing literature and a new concept on the 
role of the nucleus accumbens in behaviour is 
developed. The chapter ends with a pilot 
study on the role of the nucleus accumbens in 
tremor. 
3-2 A brief survey of the anatomy of the 
nucleus accumbens 
3.2.1 Some general remarks 
Together with the ventromedial part of the 
striatum and the olfactory tubercle, the 
nucleus accumbens constitutes the ventral 
striatum (Heimer and Wilson, 1975; see also 
Heimer, 1978; Heimer et al, 1982). On the 
basis of Golgi impregnations two main groups 
of neurons can be discriminated within this 
nucleus, that share features with those from 
the overlying striatum: spiny neurons and 
spiny poor neurons (rat: Rueda et al, 1986; 
rabbit: DeFrance et al, 1985a; man: White, 
1981). Within the former category the small 
to medium sized neurons are the most 
abundant type of neurons. These may in part 
constitute intemeurons containing gamma-
amino-butyric acid (GABA; see Pickel et al, 
1988). Within the category of sparsely spined 
neurons the large spine poor neurons are the 
predominant type, which may constitute 
cholinergic intemeurons (see e.g. Phelps and 
Vaughn, 1986; see also DeFrance et al, 1981; 
1985a). 
The nucleus accumbens contains a wealth of 
acknowledged neurotransmitters and 
neuromodulators as well as a large number of 
putative transmitters and modulators (for a 
review see Fonnum and Walaas, 1981). Since 
this chapter is mainly concerned with the 
dopaminergic, noradrenergic and 
glutamatergic/aspartatergic innervations 
(section 3-4) features of these projections will 
be highlighted in the following paragraphs. 
3.2.2 Some selected afferent pathways 
3.2.2.1 Dopaminergic innervation 
Ever since the original studies of Ungerstedt 
in 1971 (Ungerstedt, 1971) the dopaminergic 
projections arising from the mesencephalic 
substantia nigra (SN) and ventral tegmental 
area (VTA) to the telencephalic striatal 
structures have been studied over and over 
(see e.g. Beckstead et al, 1979; Chronister et 
al, 1980; Nauta et al, 1978). It is not 
intended here to go through this vast amount 
of literature for extensive and solid reviews 
on this topic exist (Bjorklund and Lindvall, 
1984; Oades and Halliday, 1987; see also Van 
Domburg, 1990). Instead, the state of the art 
is given in figure 3-1, which depicts an 
overview of the dopaminergic projections to 
the striatal areas in rats i.e the animal of 
interest in this thesis. It may be clear from 
this figure that the projections from the 
mesencephalic dopaminergic cell groups give 
rise to a rather complex pattern of projections 
in which some overlap exists (Fallon, 1988). 
The AIO innervates the ventromedial parts of 
the striatum as well as the nucleus accumbens 
and the olfactory tubercle; the A9 mainly the 
dorsolateral parts of the striatum (Gerfen et 
al, 1987). 
As in the dorsal striatum (Gerfen et al, 
1987) a compartmentation of transmitters also 
exists in the ventral striatum: areas which 
stain heavily for e.g. leu-enkephalin or choline 
acetyltransferase have been found to exist, 
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Figure 3-1: Summary drawing of the projections from the A9- and the AlO-cell groups to striatal 
areas in the rat; note that the mesencephalic area is depicted in a vertical plane (drawing kindly 
provided by Dr. Ρ van Domburg). 
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which are accompanied by a heavy 
immunostaining for dopamine or not (see 
Groenewegen et al, 1990 for a review). In 
the rat the content of dopamine seems to 
increase towards more caudal areas of the 
nucleus accumbens (Allin et al, 1988); an 
observation, which has not been confirmed in 
the rabbit (DeFrance et al, 1983). In 
agreement with the former however, a more 
dense immunostaining for dopamine was 
found in caudal areas (Voom et al, 1986; 
Groenewegen et al, 1990). A more or less 
similar picture is obtained from a study of 
Chronister et al in which the terminal pattern 
in the nucleus accumbens arising from the 
VTA was studied (Chronister et al, 1980). 
Interestingly the distribution of the dopamine 
Dl-receptor (see paragraph 3.4.3) seems to 
follow the same pattern (Allin et al, 1989). 
Although the functional aspects of this 
dopamine pattern is as yet not known it may 
be related to the different inputs from 
cortical areas in the nucleus accumbens 
(Groenewegen et al, 1990). 
3.2.2.2 Noradrenergic innervation 
Appreciable quantities of noradrenaline can 
be shown to exist within the nucleus 
accumbens (rat: Allin et al, 1988; Debonnel 
and Montigny, 1988; Fonnum and Walaas, 
1981; Versteeg et al, 1976; rabbit: DeFrance 
et al, 1983; human: Farley and Homykiewicz, 
1977). These quantities are however much 
lower than those of dopamine, with ratios 
varying from 3.9 to 40 depending on the 
region within the nucleus accumbens (see e.g. 
Allin et al, 1988). These latter authors have 
furthermore shown that noradrenaline is 
heterogeneously distributed in the nucleus 
accumbens. The highest concentrations were 
found in the more caudal areas (rat: Allin et 
al, 1988; rabbit: DeFrance et al, 1983). 
In line with the fore-mentioned observations 
noradrenergic terminals have been found to 
exist in the nucleus accumbens employing 
immunohistochemical techniques (Cools et al, 
1990a; Johansson and Hokfelt, 1981; Lindvall 
and Stenevi, 1978; Swanson and Hartman, 
1975). Although in some of these studies the 
distribution of terminals was rather diffuse, 
the study conducted by Cools and coworkers 
showed a clear and appreciable innervation of 
the nucleus accumbens with noradrenergic 
terminals (Cools et al, 1990a). Finally in 
further support of these findings high affinity 
uptake sites for noradrenaline have been 
found within the nucleus accumbens (Hetey 
and Zimmerman, 1986). 
Although a number of studies point to an 
innervation from the noradrenergic locus 
coeruleus (Chronister et al, 1981; Swanson 
and Hartman, 1975), this is not a generally 
accepted idea (Jones and Moore, 1977; Pickel 
et al, 1974). In fact, it is even suggested that 
the medulla oblongata (nucleus solitarius) 
might be the source of this projection 
(Chronister et al, 1981; Lindvall and Stenevi, 
1978). In line with the latter suggestion it was 
found that lesions of the ventral noradrenergic 
bundle altered the noradrenaline content in the 
nucleus accumbens (O'Donohue et al, 1979). 
Future studies must be awaited however 
before it can be decided whether two 
innervations (CooLs et al, 1990b) or only one 
innervation exist (see section 3-5). 
3.2.2.3 Excitatory amino acid innervation 
The nucleus accumbens receives afférents 
from a number of limbic areas like the 
amygdala (Kelley et al, 1982; Russchen and 
Price, 1984), the hippocampus (Groenewegen 
et al, 1987; Jayaraman, 1985; Newman and 
Winans, 1980) and the prefrontal cortex 
(Beckstead, 1979; McGeorge and Faull, 1989). 
Electrophysiological (DeFrance and Yoshihara, 
1975; DeFrance et al, 1980; DeFrance et al, 
1985a; Yang and Mogenson, 1984; Yim and 
Mogenson, 1982), anatomical (Christie et al, 
1987; Fuller et al, 1987) and biochemical 
(Walaas, 1981) studies have suggested that 
these afférents may use the excitatory amino 
acids (EAA) 1-glutamate and/or 1-aspartate as 
neuro-transmitter. 
The innervation from the hippocampus 
seems to originate mainly from the subiculum 
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(e.g Groenewegen et al, 1987). According to 
Groenewegen et al a ventral-dorsal axis in the 
subiculum is parallelled by a caudomedial to 
rostrolateral axis in the nucleus accumbens: 
"the fibres from the ventral subiculum 
terminate throughout the rostrocaudal extent of 
the medial part of the nucleus accumbens and 
terminals predominate in the caudomedial part 
of the nucleus. In contrast the dorsal 
subiculum projects throughout the lateral part 
of the nucleus accumbens with a 
predominance for the rostral part" 
(Groenewegen et al, 1987 pi 17). Other 
studies have more or less confirmed these 
observations (Fuller et al, 1987; McGeorge 
and Faull, 1989; Newman and Winans, 1980; 
Phillipson and Griffiths, 1985). It has 
furthermore been shown that these afférents 
innervate two types of cells within the 
nucleus accumbens: the larger aspiny neurons 
and the medium-sized spiny neurons 
(DeFrance et al, 1985a; Totterdell and Smith, 
1989; see also Groenewegen et al, 1990; 
DeFrance et al, 1981a; Meredith et al, 1990 
and references cited therein). Totterdell and 
Smith showed that the dopaminergic and the 
hippocampal input may converge on both 
types of neurons (Totterdell and Smith, 1989), 
suggesting thus that dopamine may modulate 
the incoming signals from the hippocampus 
(cf. Yang and Mogenson, 1984; see section 3-
5). 
The projections from the amygdala arise 
primarily from the basolateral part of this 
nucleus (Fuller et al, 1987; Jayaraman, 1985; 
McGeorge and Faull, 1989; Newman and 
Winans, 1980; Russchen and Price, 1984; 
Phillipson and Griffiths, 1985). They 
terminate predominantly in the more rostral 
areas (Phillipson and Griffiths, 1985). It is at 
present not known on which neurons these 
afférents from the amygdala impinge, although 
electrophysiological data suggest that they 
may directly influence the GABA-output 
neurons (Yim and Mogenson, 1983). 
Interestingly some data suggest that amygdala 
and hippocampus inputs may converge upon 
the same neurons in the nucleus accumbens 
(DeFrance et al, 1980). 
The projections from the prefrontal cortex 
arise from e.g the anterior cingulate area, the 
prehmbic area and the infralimbic area 
(McGeorge and Faull, 1989; see Kolb, 1984 
for review). They terminate in the rostro-
medial parts of the nucleus accumbens 
(Phillipson and Griffiths, 1985). It has not 
been studied yet on which neurons in the 
nucleus accumbens these projections terminate. 
Next to these cortical EAA pathways, 
afférents from the midline nuclei of the 
thalamus, e.g. the parafascicular-intralaminar 
nuclei (Jayaraman, 1985; Newman and 
Winans, 1980; Phillipson and Griffiths, 1985) 
also appear to use EAA as neurotransmitter 
(Christie et al, 1987; Fuller et al, 1987). It 
has been suggested that these EAA afférents 
terminate on cholinergic intemeurons as well 
as on GABAergic (output) neurons 
(Groenewegen et al, 1990; section 3-5) 
3.2.3 Efferent pathways 
The efferents from the nucleus accumbens 
reach widespread areas of the brain, ranging 
from areas as proximal as the ventral 
pallidum/substantia innominata to areas as 
distal as the central grey (see Domesick, 1981 
for review). In chapter 4 the former projection 
will be extensively discussed (section 4-2). In 
this paragraph the focus will be upon the 
projection to the mesencephalic substantia 
nigra since this projection may play a role in 
the experiments described in this chapter. 
Autoradiographic (Conrad and Pfaff, 1976; 
Groenewegen and Russchen, 1984; Nauta et 
al, 1978) and lesion studies (Somogyi et al, 
1981; Williams et al, 1977) have shown that 
the medial substantia nigra pars compacta and 
pars reticulata receive afférents from the 
nucleus accumbens (see also Groenewegen et 
al, 1990). These projections have been 
confirmed using injections of horse radish 
peroxidase into the nucleus accumbens 
(Newman and Winans, 1980). Interestingly, 
the data of Somogyi and coworkers suggest 
that efferents from the nucleus accumbens 
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may actually terminate upon nigral cells that 
project to the dorsal striatum (Somogyi et al, 
1981). Electrophysiological experiments have 
furthermore shown that electrical stimulation 
of the nucleus accumbens inhibits the firing 
rate of cells within the substantia nigra (rat: 
Scamati et al, 1983; cat: Strahlendorf and 
Barnes, 1983). Since this effect could be 
attenuated by systemic injections of the 
GABA-antagonist bicuculline (Strahlendorf 
and Barnes, 1983), this suggests that G AB A 
may act as neurotransmitter in this pathway. 
Support for this notion comes from 
biochemical experiments in which it has been 
shown that lesions of the nucleus accumbens 
decrease the activity of the GABA-
synthezising enzyme glutamate decarboxylase 
within the rostromedial parts of the substantia 
nigra (Walaas and Fonnum, 1980). These 
studies thus overall suggest that manipulation 
with the nucleus accumbens may have 
profound effects on the function of the dorsal 
striatal circuitry (section 3-4). 
3-3 The role of the nucleus accumbens in 
behaviour; a working hypothesis 
In recent years it has been put forward that 
dopamine is involved in allowing animals to 
switch behaviour (Oades, 1985). Until now 
however it has only been partly investigated 
to which categories of behaviour this swit-
ching extends and how it is mediated via the 
two main dopaminergic systems in the brain, 
i.e. the mesolimbic and nigrostriatal system 
(see section 3-2). Recently a number of 
studies have shown that the dorsal striatum, 
which is innervated by the A9-ceU group 
(section 3-2) is involved in allowing animals 
to switch arbitrarily behaviour at all levels of 
behavioural functioning; it allows to switch 
ongoing behaviour without the help of cur-
rently available sensory information or 
external stimuli (chapter 2, section 2-7; see 
for reviews: Cools et al, 1984a; Cools, 1985). 
A dysfunction of this structure disrupted this 
ability (e.g. Cools, 1980; Jaspers et al, 1984). 
An interesting observation however was, that 
the ability to switch behaviour with the help 
of stimuli from the environment remained 
intact (Cools, 1980) or, even, was enhanced 
(Jaspers et al, 1984; see also Bury and 
Schmidt, 1987; Wegener et al, 1988). Similar 
results have been obtained in rats trained in a 
Y-maze. Mitchell and Hall observed in a 
learning paradigm in which rats were trained 
to tum to one side (either to the right or to 
the left) in a Y-maze in order to obtain food-
reward in a stimulus-neutral environment, that 
rats were unable to perform this task when 
the striatum was lesioned ((Mitchell and Hall, 
1988a; 1988b). When the baited arms were 
marked by a clear stimulus (e.g. by black or 
white inserts) the lesioned animals were able 
to perform the task, and, even, appeared to do 
this better than control rats. This suggests that 
these rats performed the tasks described above 
basically by two strategies: one in which an 
internal frame of reference was used, and one 
in which an external frame of reference was 
used. It appears that the former may depend 
on an intact dorsal striatum. In fact this 
distinction refers to the distinction in 
egocentric and allocentric (task) learning. 
Data have been published which show that 
the former might be mediated by the dorsal 
striatum (Cook and Kesner, 1988; Potegal, 
1969). Jaspers et al derived from their experi-
ments the hypothesis that the capacity to use 
external stimuli to guide behaviour might 
reside outside the striatum (Jaspers et al, 
1984). In this respect it is interesting that 
allocentric task learning seems to be 
dependent on an intact hippocampus (Morris 
et al, 1986). Since the nucleus accumbens 
receives a dense innervation from the latter 
structure (section 3-2) and since it has been 
recently recognized that dopamine in the 
nucleus accumbens is involved in allowing 
organisms to switch behaviour (Robbins and 
Everitt, 1982; Swerdlow and Koob, 1987a), 
dopamine in the nucleus accumbens might 
play an important role in the ability of rats to 
switch behaviour with the help of external 
information; an hypothesis, which can also be 
derived from a series of other studies which 
have looked at different aspects of the role of 
the nucleus accumbens in behaviour (see e.g. 
Koob et al, 1978; Louilot et al, 1986; 
Makanjuola et al, 1980; Robbins and Koob, 
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1980; Solomon and Staton, 1982; Swerdlow 
et al, 1986a; see further section 3-5). In fact, 
in this respect the data from Louilot et al are 
instructive: an aggressive male intruder 
induced a prolonged increase in the 
concentration of the dopamine metabolite 3,4-
dihydroxy phenylacetic acid (DOPAC) in the 
nucleus accumbens, that outlasted the actual 
confrontation, whereas a non aggressive male 
only transient-ly enhanced it, i.e during its 
actual presence; a female intruder induced 
only a slight increase (Louilot et al, 1986). 
The authors concluded from these data that 
"mesencephalic DA neurons, at least those 
innervating the nucleus accumbens are 
activated by environmental stimuli, and that 
the extent of the activation is dependent on 
stimulus characteristics" (Louilot et al, 1986 
p399) and that "the maintenance of increased 
DA-activity might enable adaptation when 
faced with novel stimuli after the behavioural 
testing period" (Louilot et al, 1986 p399). 
Finally, in 1926 С Judson Herrick already 
stated in his book "Brains of Rats and Men" 
that "This region [olfacto-striatum, i.e the 
nucleus accumbens (Heimer et al 1982)] 
probably serves for the correlation of 
olfactory and other exteroceptive stimuli..." 
(Herrick, 1926, ρ 114). 
On the basis of the foregoing conside­
rations it is hypothesized that dopamine in 
the nucleus accumbens plays a role in the 
ability to switch behaviour with the help 
of currently available external stimuli. 
Since the swimming test used in previous 
experiments (Cools, 1980; Vrijmoed-de Vries, 
1985; Vrijmoed-de Vries and Cools, 1986) 
allowed the delineation of the function of the 
dorsal striatum in terms of switching to 
behaviours which are directed by stimuli from 
the environment, and behaviours which are 
not directed by stimuli from the environment, 
it was decided to use this test to provide, 
specific, evidence for the hypothesis outlined 
above. Inherent to this choice is the use of 
rats as experimental animals (see section 3-
4). 
3-4 The swimming test as a tool to study 
the role of the nucleus accumbens in 
behaviour 
3.4.1 Introduction 
In order to obtain evidence for the 
hypothesis outlined in section 3-3 the role of 
dopamine will be considered first in the 
swimming test (paragraph 3.4.3). Since it has 
been shown that noradrenaline interacts with 
dopamine in the nucleus accumbens (Nurse 
et al, 1984, 1985; Russell et al, 1987; see 
also Cools et al, 1978), the role of 
noradrenaline in the nucleus accumbens will 
be studied next (paragraph 3.4.4). Finally, 
since dopamine has been found to modulate 
inputs (Yang and Mogenson, 1984; Yim and 
Mogenson, 1982), which use excitatory amino 
acids (EAA) as neurotransmitter (Christie et 
al, 1987; Fuller et al, 1987), and since 
changes in these cortical areas have been 
shown to affect dopamine in the nucleus 
accumbens in return (Louilot et al, 1985; 
Pycock et al, 1980; Springer and Isaacson, 
1982) the behavioural effects of agents 
selective for EAA-receptors will be studied 
(paragraph 3.4.5). 
3.4.2. Materials and methods 
General 
Male Wistar rats (Central Animal 
Laboratory, Catholic University Nijmegen) 
weighing 180-210 grams were anaesthetized 
with an intraperitoneal injection of 
pentobarbital (60 mg/kg; Narcovet(R)) and 
equipped with cannulae (length: 5.0 mm; 
inner diameter: 0.2 mm; outer diameter: 0.65 
mm ) aimed at the nucleus accumbens with a 
stereotaxic apparatus according to standard 
procedures (Pijnenburg et al, 1976; stereotaxic 
coordinates A 9.8, L+/-1.2 and Η 2.7 mm 
determined after the atlas of König and 
Klippel, 1963; Ι,ΙΙ,ΙΠ). The cannulae were 
inserted under a lateral angle of 10 degrees 
and were fixed onto the skull with dental 
acrylic cement (Paladur(R)) and stainless steel 
retaining screws. After surgery the animals 
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Figure 3-2: Experimental paradigm for the swimming test: (a): observation in an open field (Ο­
ΙΟ min); (b): swimming without escape (10-16 min); (cl): swimming with escape (16-18 min); 
(c2): swimming with escape, rope offered (18-21 min). 
were individually housed in a temperature 
controlled room (Τ: 21+/-1 degrees 
Centigrade) on a standard day-night cycle 
(06:00-18:00 hrs lights on). Food and water 
were available as required. The rats were 
given at least one week of recovery from the 
operation before being tested. Injections were 
given by means of a 5.0 ul Hamilton(R)-
syringe extending 1.4 mm under the tip of the 
cannulae. The volume was 0.5 ul which was 
delivered by hand over a period of 5 se­
conds; hereafter the needle was kept in place 
for 10 seconds. Animals were used only 
once. Experiments were performed between 
09:00 and 17:00 hrs i.e. during the light 
phase of the day-night cycle. After completi-
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on of the experiments the rats were sacrificed 
by an overdose of pentobarbital after which 
the brains were removed. These were stored 
on 4% formalin until sectioning. The brains 
were sectioned into 20-30 urn slices by 
means of a freezing microtome (Bright, UK) 
and subsequently stained with cresyl violet. 
Hereafter the injection sites were precisely 
determined with the help of a binocular. Only 
animals with their injection sites within the 
boundaries of the nucleus accumbens were 
included in the statistical analysis (Ι,ΙΙ,ΙΠ). 
Procedure 
In principle the earlier described paradigm 
A : NON CUE-DIRECTED 
S w l M l n « f r e e S F Planing Ρ Tr«a41ne waier T W SlnKln* S 
В : CUE-DIRECTED 
Vanning bolloi Scanning « a l l SW 
Figure 3-3: Behaviours scored in the swimming (without escape) test: panel A: non cue-directed 
behaviours, panel B: cue-directed behaviours; behaviours as well as abbreviations are given (from 
Cools, 1980; Vrijmoed-de Vries and Cools, 1986). 
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for the swimming test was used (figure 3-2; 
cf. Cools, 1980; Vrijmoed-de Vries and 
Cools, 1986). In brief, rats were injected with 
the appropriate agent, and observed in a small 
open field (38*26*28 cm) for a period of 10 
minutes (IJIjn). The occurrence of abnormal 
motor-patterns was recorded (see for a 
description of these motor-patterns: Cools, 
1980; Vrijmoed-de Vries and Cools, 1986), 
as well as the number of rearings, which is 
an easily quantifiable, albeit rather rough, 
measure for general activity of rats (IV). 
Subsequently the rats were subjected to the 
actual swimming test (Ι,ΙΙ,ΙΠ). The rats were 
kept by their tail with their snout 30 cm 
above the water-level and dropped into a 
circular watertank (height 47 cm; diameter: 
34 cm) filled with water with a temperature 
of 35+/-1 degrees Centigrade. For a period of 
6 minutes the animals were forced to swim. 
Their behaviour was videotaped and 
subsequently analysed according to strict 
criteria (Ι,Π,ΙΠ). 
After this period a rope was lowered into 
the middle of the watertank to allow the ani­
mals to detect the rope and to escape by 
climbing it (free escape; see for details about 
the rope: Vrijmoed-de Vries and Cools, 1986; 
ІДІДП). In case the animals did not find the 
rope by themselves within two minutes, the 
rope was offered to them for a period of 
three minutes. The rope was kept in front of 
them and the animals were allowed to grasp 
it (forced escape; ІД,Ш). If the animals were 
not able to grasp or climb the rope within 
three minutes the test was ended. 
Behavioural analysis 
In figure 3-3 and table 3-1 the behaviours 
are shown which were scored in the 
swimming (without escape) test (Cools, 1980; 
Vrijmoed-de Vries and Cools, 1986). The 
behaviours were divided into two categories: 
a category which encompassed the behaviours 
which were not directed by stimuli in the 
environment, and a category which 
encompassed the behaviours which were 
directed by stimuli in the environment (wall 
and bottom of the tank) These behaviours 
were therefore labelled non cue-directed and 
cue-directed behavioure respectively (І,П,Ш; 
section 3-5). 
The swimming behaviour of the rats treated 
with the different drugs or distilled water 
(AD), which was used as control throughout 
the experiments, was analysed according to 
the following procedures. 
The number of different behaviours per 
category (cue-directed or non cue-directed) 
was scored per 2 minutes per rat (ІДДІ). 
Thus two scores per rat were obtained per 
two minutes: one reflecting the total number 
of different cue-directed behaviours 
(maximum=4) and one reflecting the total 
number of different non cue-directed 
behaviours (maximum=4). The latter score is 
related to 'variability' which has been used 
before as a parameter to unravel the role of 
the dorsal striatum (Cools, 1980; Vrijmoed-
de Vries, 1985; Vrijmoed-de Vries and Cools, 
1986). Scores per treatment group were 
obtained by calculating means+sem's per 
block of 2 minutes, which are presented in 
the graphs. 
In a number of cases the full sequence of 
behaviours was denoted (Ι,ΙΙ,ΙΠ). 
Subsequently, the actual frequency and 
duration of the individual behaviours were 
determined per 2 minutes per rat. The thus 
obtained data were pooled to obtain overall 
scores for frequency and duration per category 
of behaviours per 2 minutes. Means+sem's 
per block of 2 minutes were subsequently 
calculated, which are shown in the graphs. 
Furthermore the total number of switches to 
cue-directed or non cue-directed behaviours 
was determined, which is the total number of 
actual frequencies minus one (first behaviour). 
These switches were subdivided into switches 
from cue-directed to cue-directed or non cue-
directed behaviours, and from non cue-
directed to non cue-directed or cue-directed 
behaviours (Π,ΙΠ). 
In some cases the latencies (of appearance) 
of individual behaviours were calculated. 
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Table 3-1: Descriptions of the different behaviours scored in the swimming (without escape) test 
(compare with figure 3-3). 
NON CUE-DIRECTED BEHAVIOURS 
Swimming Free (SF): swimming in (circles in) the (middle of the) tank without making 
contact with the wall; 
Planing (P): keeping the head above the water surface by filling the lungs with air and 
floating through the tank (nearly no movements by hind- or forelimbs); 
Treading Water (TW): staying at one point in the tank by making movements of the 
hindlimbs with nearly no movements of the forelimbs; 
Sinking (S): sinking motionless to the bottom of the tank; 
CUE-DIRECTED BEHAVIOURS 
Crossing (C): swimming from one part of the wall to another without interruption (by 
another behaviour); 
Diving (D): movement directed to the bottom of the tank (forelimbs beneath hindlimbs); 
Scanning Bottom (SB): exploring the bottom of the tank by frequently poking the nose 
to the bottom and walking over the bottom of the tank; 
Scanning Wall (SW): swimming against the wall and trying to cling to the wall with 
the nails of the forelimbs; 
The following parameters were scored in 
the 'swimming with escape' test: the number 
of rats that detected the rope, the number of 
rats that escaped by themselves following 
visual and/or tactile detection of the rope (free 
escape) and the number of animals that 
escaped following forced tactile contact with 
the rope (forced escape; IJIJII). The animals 
were considered to have escaped successful-
ly when the hindlimbs were clearly visible 
above the water surface (Cools, 1980). 
Drugs 
All drugs were commercially obtained. 
Raclopride.tartrate (paragraph 3.4.3) was a gift 
from Dr. S-0 Ogren. Astra Research Centre, 
Sodertalje, Sweden. dl-Alpha-amino-3-
hydroxy-5-methyl-isoxazole-4-propionic acid 
(AMPA; paragraph 3.4.5) was a gift from Dr. 
Krogsgaard-Lareen, Lundbeck Copenhagen 
Denmark. 
Statistical analysis 
The parametric data from the swimming 
test, e.g. the number of different cue-directed 
and non cue-directed behaviours as well as 
the frequency and duration of cue-directed 
and non cue-directed behaviours, were 
analysed with a two-way analysis of variance 
(ANOVA) followed by a Student-Newman-
Keuls (SNK) test when appropriate (Ferguson, 
1981). Scores per rat were used as cell-entries 
with time and drug or doses as factors. 
Occasionally simple t-tests were used 
(Ferguson, 1981). In case of non parametric 
data i.e. detection of the rope, free escape 
and free+forced escape, a X-square was used 
(Ferguson, 1981; Siegel, 1956). 
Final remarks 
As indicated in the previous section (section 
3-3) inherent to the choice of the swimming 
test, which follows from the reasoning in 
section 3-3, rats have been used in the present 
experiments. To minimize any discomfort 
possibly experienced by the rats during the 
experiments the following measures were 
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taken. First, the rats were accustomed to the 
injection-procedure on the day preceeding the 
actual experiments, i.e. the stylets were 
removed from the cannulae and insetted 
again. It was moreover checked whether they 
were capable of taking part in the experiments 
on the following day by judging their overall 
physical health e.g. their weight and the 
outlook of their fur. Second, the temperature 
of the water in the swimming tank was kept 
at 35 degrees Centigrade, which closely 
matches the body temperature of the rats. In 
combination with the relatively short duration 
of the experiments (at most 11 minutes of 
swimming) this minimized the chance of 
severe hypothermia. In any case in which a 
rat was being at a risk of drowning the test 
was immediately ended. Third, after the 
experiments the rats were dried with a towel 
to avoid severe hypothermia and any 
discomfort of saw dust which might clot to 
their ñus. It should finally be noted that the 
rats which were used in the present 
experiments are relatives of the brown rats 
which are perfect swimmers. 
3.4.3 Dopamine 
3.4.3.1 Introduction 
Numerous studies have shown that d-
amphetamine affects behaviour upon injection 
in the nucleus accumbens (see e.g. Cador et 
al, 1989; Carr and White, 1983; Pijnenburg et 
al, 1976; Solomon and Staton, 1982; Staton 
and Solomon, 1984; Taylor and Robbins, 
1984, 1986; IV). Since this drug produces 
robust behavioural effects d-amphetamine was 
used in first instance to study the effect of 
manipulation with the nucleus accumbens in 
the swimming test. Although d-amphetamine 
releases predominantly dopamine, 
contributions of noradrenaline and serotonin in 
its behavioural effects can not be ruled out 
(see Parada et al, 1988). Therefore to obtain 
more conclusive evidence on the role of 
dopamine within the nucleus accumbens drugs 
selective for dopaminergic receptors were 
studied. 
Within the field of dopamine two concepts 
on dopamine receptors exist which have 
emerged from different backgrounds, yet, are 
not entirely mutually exclusive. 
While studying the electrophysiology of 
neurons of the snail Helix Aspersa Struijker-
Boudier and coworkers observed that two 
types of responses for dopamine appeared to 
exist, which indicated the existence of two 
types of receptors; one mediating excitation 
of neuronal activity (DAe-receptors), and one 
mediating inhibition of neuronal activity (DAi-
receptors; Straijker-Boudier et al, 1974). 
These types of receptors seemed to have their 
own specific pharmacological profile: 
apomorphine and haloperidol acted as an 
agonist and antagonist respectively at the 
D A e - r e с e ρ t о r, w h i l e ( 3 , 4 -
dihydroxyphenylamino)-2-imidazolme (DPI) 
and ergometrine acted as an agonist and 
antagonist respectively at the DAi-receptor 
(see Cools and Van Rossum, 1976, 1980 for 
reviews). When these agents were injected in 
the caudate nucleus of cats it was observed 
that a certain regional selectivity existed: 
DAe- receptors appeared to exist in an area 
of the caudate nucleus ('caput nuclei caudati, 
rostromedial part' (CRM), which was different 
from the area in which DAi-receptors were 
found ('caput nuclei caudati, anterodorsal part: 
r-CRM; Cools et al, 1976). The latter area is 
innervated mainly by the A8- (and A10-)cell 
group (Spooren et al, 1990), and is 
considered to be a limbic part of the caudate 
nucleus, whereas the former area is innervated 
by the A9-cell group and is considered to 
represent a 'classical' striatal area (Cools and 
Van Rossum, 1976, 1980; Spooren et al, 
1990). In rats, DAi-receptors seemed to be 
confined to the accumbens whereas the 
striatum seemed to be endowed with DAe-
receptors (Cools and Van Rossum, 1976, 
1980). In line with this piribedil, a DAi-
antagonist, has been shown to antagonize the 
dopamine induced production of cAMP in the 
nucleus accumbens (see Offermeyer and Van 
Rooijen, 1982). This would accordingly link 
the DAi-receptor to a well known second 
messenger system. 
The second concept on dopamine receptors 
emerged from an entirely different 
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background. In the 1970's it became clear 
that certain responses, like the release of 
prolactin from the pituitary gland, were 
regulated by another type of dopamine 
receptor than the dopamine receptor that was 
found to be coupled to a cAMP generating 
system (Kebabian and Calne, 1979; Stoof and 
Kebabian, 1984). Thus, some compounds 
decreased the release of prolactin, and hence 
appeared to mimic the effect of dopamine, 
whereas they were ineffective in stimulating 
cAMP production. From these and other data 
the existence of two types of dopamine 
receptors was hypothesized: a Dl-receptor 
which is positively coupled to а с AM Ρ 
generating system, and a D2-receptor which is 
negatively or not coupled to a cAMP 
generating system (Kebabian and Calne, 1979; 
Stoof and Kebabian, 1984). Subsequently 
selective ligands were developed for these 
receptors. Nowadays the following compounds 
are at hand: the Dl-antagonist SCH 23390 
(Iorio et al, 1983), the Dl-agonist SKF 38393 
(Pendleton et al, 1978; Setler et al, 1978), the 
D2-antagonist raclopride (Ogren et al, 1986), 
and the D2-agonist LY 171 555 (Titus et al, 
1983). 
Within the nucleus accumbens the existence 
of Dl binding sites has been shown by the 
use of tritiated SCH 23390 (rat: Allin et al, 
1989; Savasta et al, 1986; Schulz et al, 1985; 
monkey: Graham and Grossman, 1987) and 
tritiated SKF 38393 (rat: Scatton and Dubois, 
1985; mouse: Juhasz et al, 1987). Furthermore 
the existence of D2 binding sites has been 
shown (Allin et al, 1989; Bouthenet et al, 
1987; Nock et al, 1986). Behavioural (Bréese 
et al, 1987; Fletcher and Starr, 1988; IV), 
electrophysiological (White and Wang, 1986) 
and biochemical (Stoof and Verheyden, 1986; 
Stoof et al, 1987a, 1987b) experiments have 
furthermore underlined the existence of these 
receptor types in the nucleus accumbens. 
It not is intended here to bridge the gap 
between the two concepts since this would 
reach far beyond the aim and scope of this 
thesis. It has however been suggested that 
DAi-receptors share some features with Dl-
receptors - both appear to be linked to a 
cAMP generating system-, while DAe-
receptors and D2-receptors might also share 
some features (Offermeyer and Van Rooijen, 
1982). Whatever the precise similarities and 
dissimilarities however may be, the discussion 
will be left with the notion that at this stage 
both concepts have merits on their own, and 
stand in their own right. Future experiments 
might perhaps reveal more on their precise 
relationships. 
On basis of the foregoing it was decided to 
inject the following dopaminergic drugs in the 
nucleus accumbens in the swimming test: the 
general stimulant -indirect dopamine agonist-
d-amphetamine, the D2-agonist LY 171 555, 
the D2-antagonist(s) raclopride (dl-sulpiride, 
haloperidol), the Dl-agonist SKF 38393, the 
Dl-antagonist SCH 23390 and the DAi-
agonist DPI. It was moreover decided to 
study the effects of systemic injections of d-
amphetamine in order to study the relation 
between intra-accumbens and systemic effects 
of d-amphetamine. 
The materials and methods have been 
described in section 3.4.2. The results 
presented in this part are found in papers I, 
II and IV. 347 Rats were included in these 
experiments. 
3.4.3.2 Results 
Histology 
Histological verification revealed that the 
injection sites were confined to the dorso-
medial part of the nucleus accumbens (figure 
3-4). 
d-amphetamine 
As expected d-amphetamine (10 ug/0.5 ul) 
enhanced general activity, reflected by an 
increase in the number of rearings in the open 
field (AD vs d-amphetamine (mean+sem): 
49.5+3.2 (N=10) vs 76.7+5.1 (N=9), t=4.484 
df=17 p<0.01 two-tailed t-test; cf IV). 
This dose of d-amphetamine enhanced the 
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Figure 3-4: Representative series of injection sites within the nucleus accumbens Planes were 
taken from the atlas of König and Klippel, 1963, distances are in um from the interaural line. 
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Figure 3-5: Effects of d-amphetamine 10 ug/O.5 ul (black bars; N=9) and AD (white bare; N=10) 
on the number of different cue-directed (panel A) and non cue-directed (panel B) behaviours (Y-
axes). X-axes:time; values: group effects (two-way ANOVA's). 
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number of different cue-directed behaviours 
without an effect on the number of different 
non cue-directed behaviours as can be seen 
in figure 3-5 (I). Moreover a nearly 
significant interaction term was found for the 
cue-directed behaviours (F(2,51)=2.80, 
p<0.07). Also the number of rats that 
showed free escape was enhanced (table 3-2; 
I). The latter data indicate that the rats were 
able to change their behaviour according to a 
new stimulus which they visually and/or 
tactually spotted. In order to investigate 
whether also lower doses of d-amphetamine 
were effective, doses of 1 and 5 ug/0.5 ul 
were investigated. It appeared that also these 
lower doses of d-amphetamine were able to 
enhance the number of different cue-directed 
behaviours without an effect on the number 
of different non cue-directed behaviours; no 
dose-dependent effects were however found 
(not shown; I). A dose-dependent relationship 
was however obtained for free escape (table 
3-2). 
The results of the more elaborate analysis 
of the swimming behaviour of the rats treated 
with d-amphetamine or AD are shown in 
Table 3-2: Detection, free escape and 
free+forced escape after different doses of d-
amphetamine (I). Shown are percentages. 
DOSE DET. FREE FREE N 
+FORCED 
(AD) 50.0 30.0 60.0 10 
1 37.5 37.5 75.0 8 
5 62.5 62.5 62.5 8 
10 88.9 88.9*100.0* 9 
DET.rdetection; N: number of 
r a t s ; dose: ug/0.5 ul 
*: p<0.05 X-square two-ta i led 
figure 3-6. This figure clearly shows that the 
rats treated with d-amphetamine had a lower 
mean duration of non cue-directed behaviours 
(F(l,51)=17.96, p<0.01) and a higher mean 
duration of cue-directed behaviours 
(F( 1,51)= 16.56, p<0.01) than the rats treated 
with AD (I). Furthermore it appeared that the 
rats treated with d-amphetamine had the same 
frequency of non cue-directed behaviours as 
the rats treated with AD (F(l,51)=0.70, 
p<0.40), whereas they had a higher frequen­
cy of cue-directed behaviours than the 
controls (F(l,51)=11.45, p<0.01; I)· No 
significant interaction-terms were found in the 
above mentioned two-way ANO VA' s. The 
increases in frequency and duration of cue-
directed behaviours were primarily due to an 
increase in frequency and duration of 
'crossing' (p<0.02 and p<0.01 respectively 
two-tailed t-test) 
It is interesting to note that the mean bout-
length of cue-directed behaviours was not 
affected by d-amphetamine (d-amphetamine 
vs AD (mean+sem): 5.24+0.68 vs 5.36-Ю.49, 
t=0.143 df=17 p>0.05 two-tailed t-test), 
Table 3-4: Effect of d-amphetamine on cue-
directed behaviours. Frequency and duration 
are expressed as percentages as indicated in 
the text. Shown are means+sem's. 
f r e q u e n c y d u r a t i o n 
0-2 AD 7 3 . 4 + 3 . 3 8 3 . 9 + 4 . 2 
AMP 8 3 . 1 + 3 . 7 9 0 . 4 + 3 . 0 
2-4 AD 4 9 . 6 + 3 . 5 6 0 . 0 + 6 . 0 
AMP 6 1 . 3 + 1 . 7 7 8 . 3 + 3 . 6 
4-6 AD 4 8 . 8 + 0 . 9 5 1 . 2 + 5 . 9 
AMP 6 0 . 6 + 4 . 3 7 6 . 2 + 4 . 8 
AMP : d-amphetamine 
0 - 2 , 2 - 4 , 4 - 6 : t ime b l o c k s 
although the mean bout-length of 'scanning 
bottom' was decreased (table 3-3). A 
significant decrease in the mean bout-length 
of non cue-directed behaviours (2.48+0.43 vs 
3.76+-0.37, t=2.256 df=17 p<0.05 t-tailed t-
test) was however found, which was probably 
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Figure 3-6: Effects of 10 ug/0.5 ul d-amphetamine (amp; N=9) and 0.5 ul AD (N=10) on the 
duration and frequency of non cue-directed and cue-directed behaviours (Y-axes). X-axes: time-
blocks. Shown are means+sem's. 
due to a decrease in the mean bout-length of 
'sinking' (table 3-3). 
The frequency and duration of cue-directed 
and non cue-directed behaviours are not 
independent variables, for a rat can do only 
one behaviour at a time. Therefore a three 
way-ANOVA would have been a more proper 
statistical procedure, since it takes the two 
classes of behaviours as an extra factor into 
account. A more or less alternative way to 
this procedure is to express the frequency and 
duration of cue-directed behaviours as 
percentage of the total frequency and duration 
of behaviours (=cue-directed + non cue-
directed behaviours). These data are shown in 
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Table 3-3: Effect of d-amphetamine on mean bout-length of cue-directed and non cue-directed 
behaviours. Shown are means+sem's. 
AD 
AMP 
SW 
CUE-DIRECTED BEHAVIOURS 
С D SB 
6 . 6 8 + 0 . 8 2 
(10) 
7 . 7 8 + 1 . 1 3 
(9) 
2 . 2 4 + 0 . 2 4 
(10) 
2 . 6 1 + 0 . 2 8 
(9) 
1 . 9 9 + 0 . 2 4 
(10) 
1 . 6 5 + 0 . 2 3 
(9) 
4 . 2 9 + 0 . 5 0 
(9) 
2 . 1 8 + 0 . 2 1 * 
(8) 
NON CUE-DIRECTED BEHAVIOURS 
SF TW 
AD 3 . 7 3 + 0 . 3 8 
(10) 
AMP 2 . 0 9 + 0 . 1 7 * 
(9) 
3 . 9 1 + 0 . 3 7 
(4) 
3 . 6 7 + 0 . 8 5 
(8) 
4 . 7 2 + 1 . 1 4 
(3) 
4 . 5 0 
(1) 
2 . 6 8 + 0 . 6 9 
(3) 
4 . 5 0 
(1) 
For abbreviations of the respective behaviours see paragraph 3.4.2. AMP: d-
amphetamine; Mean bout-lengths were calculated over the total 6 min period. 
Values between brackets indicate the number of rats that showed a particular 
behaviour. 
*: p<0.01 two-tailed t-test 
table 3-4. From this table the same conclusion 
can be drawn as from the previous analysis: 
d-amphetamine enhanced the frequency and 
duration of cue-directed behaviours. 
When the actual number of switches to non 
cue-directed behaviours respectively to cue-
directed behaviours were analysed, the same 
picture emerged as for the frequency data: no 
change in the number of switches to non cue-
Table 3-5: Effect of d-amphetamine 10 ug/0.5 ul on the ability to switch behaviours. The 
different possibilities for switching between behavioural categories are explained in paragraph 3.4.2. 
Shown are means+sem's. 
CUE 
CUE 
CUE 
NON CUE 
NON CUE 
CUE 
NON CUE 
NON CUE 
AD 
AMP 
15. 
31 . 
.0+2. 
.4+3 
.8 
. 7 * 
27. 
28 . 
. 9 + 1 . 
.3+5, 
.8 
.3 
27, 
28. 
. 5 + 1 , 
.3+5. 
.8 
.3 
6, 
2. 
.9+3, 
.2+1 
.7 
.0 
AMP: d-amphetamine; values are scores over the total 6 min period 
*:p<0.01 two-tailed t-test 
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cue-directed non cue-directed 
number/2 mm 
LY 1 7 1 5 5 5 + RACLOPRIDE 
FREQUENCY 
LY 1 7 1 5 5 5 + RACLOPRIDE 
FREQUENCY 
• AD 18) 
^ RAC 25(8) 
• LYSOiei 
• LY 50.RAC 25(81 
г-Ш^ (M rti 
seconds/2 mm 
LY 1 7 1 5 5 5 + RACLOPRIDE 
DURATION 
LY 1 7 1 5 5 5 * RACLOPRIDE 
DURATION 
0-2 
Vi 
JUL 2-4 ¿-6 
time (mm) 
Figure 3-8: Effects of D2-selective drugs on the frequency and duration of cue-directed and non 
cue-directed behaviours (Y-axes). X-axes: time-blocks; shown are means+sem's; between brackets: 
number of rats. 
directed behaviours (F(l,51)=0.83, p<0.37) in 
comparison with AD, and an enhancement of 
the number of switches to cue-directed 
behaviours (F(l,51)=11.90, p<0.01; I). No 
significant interaction-terms were found in the 
two-way ANOVA's. When these switches 
were further subdivided according to their 
origin (cue-directed or non cue-directed) and 
according to their destination (cue-directed or 
non cue-directed), revealing thus four separate 
categories (see paragraph 3.4.2), it was found 
that d-amphetamine 10 ug/0.5 ul enhanced 
specifically the number of switches from cue-
directed to cue-directed behaviours (table 3-
5). 
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cue-directed 
number/2min 
non cue-directed 
L 
3 
2-
1-
LY 171555 
F (2 63) = 9.12, («001 
|: 
LY 171555 
F (263) = 027, NS. 
• AD (8) 
Ш LY25(8) 
LY50(8) 
RACLOPHtOE 
F(2.63) = 7 00.p<0.01 
RACLOPMDE 
F (2ß3) = 0.5Θ, N.S. 
• Α0(β) 
Ж RAC25ie) 
RAC 50(8] 
4H 
3 
2 
1 
LY 171555 + RACLOPRIDE 
_ F (1.42)= 1303.pi001 
І 
I 
ï 
LY 171555 * RACLOPmOE 
_ F (1 42) = 007. N S. 
• ίΥ50|β) 
Ш LY50.RAC25I8) 
0-2 2-U Í-& 0-2 2-4 ¿-6 
Figure 3-7: Effects of D2-selective drugs on the number of different cue-directed and non cue-
directed behaviours (Y-axes). X-axes: time-blocks; values: group effects two-way ANOVA's; shown 
are means+sem's; between brackets: number of rats. 
When the latencies (of appearance) of the 
individual behaviours were finally determined 
it turned out that d-amphetamine had no 
effect on any of the latencies of the different 
behaviours (not shown). 
dopamine D2 
In table 3-6 the effects of the different D2-
and Dl -agonists and antagonists on rearing 
in the IO min open field are shown. It is 
clear from this table that only the highest 
dose of SKF 38393 employed here, i.e. 400 
ng/O.5 ul had an effect on rearing per se: a 
decrease which was attenuated by SCH 
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23390 (400 ng). 
The selective D2-agonist LY 171 555 (IS­
SO ng/0.5 ul) significantly enhanced the 
number of different cue-directed behaviours 
without an effect on the number of different 
non cue-directed behaviours (figure 3-7, 
panels A and В; Π). The effect was most 
notable in the second two min period. A post 
hoc comparison for the cue-directed 
behaviours showed that the highest dose, i.e. 
50 ng/0.5 ul was significantly different from 
the control (p<0.05 SNK-test). Furthermore 
a small but significant interaction term was 
found (F(4,63)=2.69, p<0.05). Conversely the 
selective D2-antagorüst raclopride (25-50 
ng/0.5 ul) decreased the number of different 
cue-directed behaviours; again no effect was 
found on the number of different non cue-
directed behaviours (figure 3-7, panels С and 
D; II). A post hoc comparison for the cue-
directed behaviours showed that the highest 
dose, i.e. 50 ng/0.5 ul, was significantly 
different from the control (p<0.05, SNK-
test). Again a small but significant interaction 
term was found (F(4,63)=2.73, p<0.05). The 
ineffective dose of raclopride (25 ng) 
attenuated the increase in the number of 
different cue-directed behaviours induced by 
LY 171 555 (figure 3-7, panel Ε; П). This 
treatment had no effect on the number of non 
cue-directed behaviours (figure 3-7; panel F). 
It should be noted here that the selective D2-
antagonist dl-sulpiride induced a similar effect 
Table 3-6: Effects of dopaminergic drugs on the number of rearings in the open field preceeding 
the swimming test. Shown are means+sem's. 
DRUG DOSE SCORE 
AD 
RAC 
RAC 
LY 
LY 
LY+RAC 
SCH 
SCH 
SCH 
SKF 
SKF 
SKF 
SCH+SKF 
SCH+SKF 
SCH+SKF 
-
25 
50 
25 
50 
50+25 
100 
250 
400 
50 
200 
400 
400+ 50 
400+200 
400+400 
42.4+8.2 
35.0+6.9 
42.9+7.1 
41.8+7.9 
34.3+5.6 
25.8+6.9 
31.6+5.5 
36.0+4.2 
34.1+4.8 
44.6+2.6 
51.1+4.2 
12.6+4.0* 
14.3+4.0# 
10.8+3.9# 
32.8+8.66 
8 
8 
8 
8 
8 
8 
9 
9 
9 
10 
7 
8 
9 
8 
9 
RAC: raclopride; LY: LY 171 555; SCH: SCH 23390; 
SKF: SKF 38393 
dose: ng/0.5 ul 
*p<0.01 vs AD; # p<0.01 vs SCH 23390; 
@ p<0.05 vs SKF 400 (two-tailed t-tests) 
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Table 3-7: Effects of D2- and Dl-selective drugs on the frequency and duration of the remainder 
of cue-directed behaviours i.e. 'crossing', 'diving' and 'scanning bottom' (see text). Shown are 
means+sem's. 
DRUG DOSE FREQUENCY DURATION 
AD 
LY 
RAC 
LY+RAC 
SCH 
SKF 
SCH+SKF 
-
50 
25 
50+25 
400 
400 
400+400 
14. 
20, 
14. 
14, 
11, 
8, 
9, 
.1+1.4 
.6+2.2* 
.5+1.9 
.5+2.4# 
.8+2.0 
.8+1.5* 
.8+1.9 
25, 
36, 
21. 
27. 
20. 
11, 
17, 
.8+2. 
.8+5. 
.0+2. 
.3+5. 
.6+4. 
.9+1, 
.3+3, 
.3 
.9 
.5 
.0 
.5 
.9* 
.7 
8 
8 
8 
8 
9 
8 
9 
for the drugs see table 3-6; 
*: p<0.05 vs AD; #:p<0.05 vs LY (see text) 
frequency: number/6 minutes; duration: seconds/6 
minutes 
dose : ng/0.5 ul; N: number of rats 
as raclopride. Doses as low as S and 10 
ng/0.5 ul decreased the number of different 
cue-directed behaviours (F(2,69)=3.33, 
p<0.05), without an effect on the number of 
поп cue-directed behaviours (F(2,69)=2.38, 
p<0.10; not shown). The Dl- and D2-
antagonist haloperidol (250 ng/0.5 ul) finally 
decreased the number of different cue-directed 
behaviours (F(l,45)=7.39, p<0.01). This drug 
-surprisingly- also decreased the number of 
different non cue-directed behaviours 
(F(l,45)=11.08, p<0.01; not shown). 
The dose of 50 ng LY 171 555 had no 
effect on either frequency (F(l,42)=2.84, 
p<0.10) or duration (F(l,42)=0.66, p<0.43) 
of cue-directed behaviours (figure 3-8). 
Moreover no effects were found for the non 
cue-directed behaviours (frequency: 
F( l ,42)=0.48, p < 0 . 5 0 ; duration: 
F(l,42)=0.86, p<0.36). On the level of 
individual behaviours no significant effects 
were found although tendencies existed for an 
increase in the frequency of 'crossing' 
(p<0.10; two-tailed t-test) in the cue-directed 
behaviours and 'swimming free' (p<0.10); 
two-tailed t-test) in the non cue-directed 
behaviours. In the latter category also 
tendencies for decreases in the frequency and 
duration of 'sinking' (p<0.10; two-tailed t-
test) were found. 
No effects were found on the mean bout-
lengths of cue-directed (LY vs AD 
(mean+sem): 7.25+1.28 vs 8.45+1.06; 
t=0.722, df=14, p>0.05) or non cue-directed 
(LY vs AD: 5.05+O.96 vs 7.73+2.87; 
t=0.886, df=14, p>0.05) behaviours. 
Moreover no effects were found for the mean 
bout-lengths of individual behaviours (not 
shown). 
These results appear to be at variance with 
the results presented in figure 3-7. The 
possibility exists however that this may be 
due to the differences in the analyses 
employed. The analysis presen-ted in figure 
3-7 solely looks at the number of different 
behaviours per se, irrespective of the actual 
frequency of the different behaviours. Since 
the major bulk of the cue-directed behaviours 
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consists of 'scanning wall' (>70%) any subtle 
changes in the remainder of them ('diving, 
crossing and scanning bottom') may have 
been masked. Therefore, it was decided to 
reanalyse the data omitting 'scanning wall' 
from the data-files. Following this procedure 
it turned out that the dose of 50 ng LY 171 
555 enhanced the frequency of the remainder 
of cue-directed behaviours, i.e. 'crossing', 
'diving' and 'scanning bottom' (F(l,42)=5.35, 
p<0.05, SNK; table 3-7; Π); still, no 
significant effects were found for the duration 
F(l,42)=2.58, p<0.12; table 3-7; Π). 
Using the analysis including 'scanning wall' 
it turned out that the ineffective dose of 
raclopnde i.e. 25 ng remained ineffective 
(frequency: (F(l,42)=0.88, p<0.36; duration 
(F(l,42)=1.10, p<0.30 of cue-directed 
behaviours; figure 3-8; Π). The same was 
found when the data were reanalysed leaving 
out 'scanning wall': frequency: F(l,42)=0.03, 
p<0.85); duration: F(l,42)=1.39, p<0.25; 
table 3-7; Π). In the latter case however a 
significant interaction term was found 
(F(2,42)=3.52, p<0.05). 
When the combination of this ineffective 
dose of raclopnde and the effective dose of 
LY 171 555 i.e. 50 ng was studied, the 
analysis did not show any significant effects 
of this combination versus LY 171 555 for 
frequency (F( 1,42)= 1.65, p<0.21) or duration 
(F(l,42)=0.18, P<0.68) of cue-directed 
behaviours (figure 3-8; Π). When the data 
were reanalysed as described above it turned 
out that the combination was significantly 
different from LY 171 555 alone as far as it 
concerned the frequency (F(l,42)=3.99, 
p<0.052) of the remainder of the cue-
directed behaviours; no effect was found for 
the duration (F(l,42)=1.43, p<0.23; table 3-
7; Π). This confirms the data presented in 
figure 3-7. 
In table 3-8 the above presented data 
(frequency and duration) are expressed as 
percentages of the total number of behaviours 
(cue-directed and non cue-directed 
behaviours). These were calculated including 
Table 3-8: Effects of D2-selective drugs on 
cue-directed behaviours. Frequency and 
duration are expressed as percentages as 
indicated in the text. Shown are means+sem's. 
frequency duration 
AD 
LY 
RA 
LYRA 
AD 
LY 
RA 
LYRA 
AD 
LY 
RA 
LYRA 
94. 
91. 
89. 
90. 
5Θ. 
78, 
69. 
68 
58 
58 
55 
52 
.1+2, 
.7+2, 
.5+1. 
.4+3. 
.7+3, 
.3+3 
.0+5 
.0+4 
.2+3 
.9+6 
.2+2 
.1+2 
.1 
.3 
.7 
.2 
.6 
.5 
.6 
.3 
.0 
.9 
.7 
.9 
96. 
92. 
90. 
95. 
80. 
84, 
86, 
74, 
54 
68 
71 
66 
.8+1.4 
.4+3.0 
.8+2.4 
.1+2.4 
.7+4.3 
.9+6.3 
.3+3.6 
.9+8.8 
.2+10.7 
.9+8.1 
.7+8.7 
.7+9.9 
AD : d i s t i l l e d water 
LY : LY 171 555 50 ng 
RA : r a c l o p r i d e 25 ng 
LYRA: LY 171 555 50 ng + 
r a c l o p r i d e 25 ng 
0-2, 2-4, 4-6 : t ime Ы о с к з 
'scanning wall'. Analysing the 
data with a two-way ANOVA revealed that 
only significant effects were found for the 
frequencies. LY 171 555 tended to enhance 
the percentage of the frequency of cue-
directed behaviours (F(l,42)=3.46, p<0.07). 
Moreover a significant interaction term was 
found (F(2,42)=4.55, p<0.02). The dose of 
raclopride i.e. 25 ng was ineffective 
(F(l,42)=0.11, p<0.74) although a nearly 
significant interaction term was found 
(F(2,42)=2.89, p<0.07). This ineffective dose 
of raclopride tended to attenuate the effect of 
LY 171 555 (F(l,42)=3.34, p<0.08). 
The number of switches to cue-directed or 
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non cue-directed behaviours was not 
separately calculated, for, they are nearly equal 
to the frequency of cue-directed or non cue-
directed behaviours (see paragraph 3.4.2). The 
number of switches between cue-directed 
behaviours was significantly enhanced by LY 
171 555 (from 22.1+2.5 to 33.0+3.4, t=2.583 
df=14 p<0.05 two-tailed t-test; Π); no effects 
were found for the other categories. This 
increase tended to be attenuated by the 
ineffective dose of raclopride (from 33.0+3.4 
to 24.8+3.7) although this effect did not reach 
significance (t=1.632, p<0.20 t-tailed t-test). 
It finally appeared that both LY 171 555 
and raclopride tended to decrease the latency 
of 'swimming free': in both cases 'swimming 
free' appeared rather early in the sequence of 
behaviours (table 3-9). Interestingly no effect 
was found in the combination of the drugs 
showing that they were able to antagonize 
each others effect. 
In figure 3-9 the effect of LY 171 555 and 
raclopride on detection, free escape and 
free+forced escape is shown. It is clear that 
LY 171 555 enhanced the number of rats that 
showed free escape; an effect that could be 
attenuated by an ineffective dose of raclopride 
(II). The latter drug tended to decrease it by 
itself. Although the effects of the doses used 
here (25-50 ng) did not yet reach significance 
a somewhat higher dose (250 ng/0.5 ul) 
clearly decreased (p<0.05 X-square two-
tailed) the number of rats that detected the 
rope (0%; N=8 rats; Π). Moreover the latter 
dose tended to decrease the number of rats 
that showed free escape (0%, p<0.10; 11). 
Similar results were obtained for dl-sulpiride 
and haloperidol (not shown). 
dopamine Dl 
The selective Dl-antagonist SCH 23390 
decreased the number of different cue-
directed behaviours, without an effect on the 
number of non cue-directed behaviours (figure 
3-10; panels A and Β; Π). A post hoc 
comparison revealed that the highest dose, i.e. 
400 ng/0.5 ul was significantly different 
(p<0.05 SNK-test) from the control. The 
selective Dl-agonist SKF 38393 decreased -
if anything- the number of different cue-
directed behaviours (figure 3-10, panel C; II). 
None of the separate doses was however 
significantly different from the control. 
Furthermore these doses were unable to block 
the effect induced by SCH 23390 (figure 3-
10, panel Ε; Π). It should finally be noted 
that none of these latter treatments had any 
effect on the number of different non cue-
directed behaviours (figure 3-10, panels D 
Figure 3-9: Effects of D2-selective drugs on 
detection of the rope (A), free escape (B) and 
free+forced escape (C). Shown are 
percentages. The number of rats is indicated 
in the bars in panel С *: p<0.05 X-square 
two-tailed. 
and F; Π). 
Analysing the data for the effective dose of 
SCH 23390, i.e. 400 ng, in terms of 
frequency and duration revealed only changes 
in the duration of cue-directed and non cue-
directed behaviours: a slight 
increase in the duration of cue-directed 
behaviours (F(l,45)=3.62, p<0.06) and a 
decrease in the duration of non cue-directed 
behaviours (F(l,45)=4.08, p<0.05; figure 3-
11; Π). The increase in the duration of cue-
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Table 3-9: Effects of D2-selective drugs on the latencies of the different behaviours. Shown are 
median values (seconds). 
sw 
с 
D 
SB 
SF 
S 
Ρ 
TW 
AD 
4.5 
22.5 
28.5 
58.0 
360.0 
111.5 
360.0 
360.0 
LY 50 
cue-
4.0 
24.0 
31. Ь 
66.0 
non 
23.5 
166.5 
360.0 
360.0 
RA 25 LY 
-directed behaviours 
cue-
4.0 
15.5 
35.0 
54.0 
-directed 
59.0 
145.5 
360.0 
360.0 
beha 
SO + RA 25 
1 
4.0 
20.0 
45.5 
50.0 
viours 
141.5 
132.0 
360.0 
360.0 
For t h e a b b r e v i a t i o n s of t h e behaviours see paragraph 3 . 4 . 2 ; 
LY: LY 171 555; RA: r a c l o p r i d e ; N=8 r a t s per group; v a l u e s i n d i c a t e doses 
in ng/0.5 u l 
directed behaviours was primarily due to an 
increase in the duration of 'scanning wall' in 
the last time-block, i.e. 4-6 min (SCH 23390 
vs AD (mean+sem): 92.0+7.3 vs 62.4+12.8, 
t=2.009, df=15 J X O . I O two-tailed t-test). 
On the level of individual behaviours a 
decrease was found for the frequency (SCH 
23390 vs AD (mean+sem): 2.2+0.5 vs 
4.5+0.6, t=2.945 df=15 p<0.O2; two-tailed 
t-test) and duration (2.7+0.7 vs 6.0+O.9, 
t=2.894 df=15 p<0.02; two tailed t-test) of 
'diving' in the category of cue-directed 
behaviours. This effect was not antagonized 
by SKF 38393. No effects were found in the 
category of non cue-directed behaviours. 
Moreover no effects were found for the 
overall mean bout-length of cue-directed 
behaviours (SCH 23390 vs AD (mean+sem): 
10.15+1.09 vs 8.45+1.06, t=1.118 df=15 
p>0.05; two tailed t-test), or any 
individual behaviour. Furthermore no effects 
were found for the overall mean bout-length 
of non cue-directed behaviours (2.95+0.50 
vs 7.73+2.87, t=1.641 df=15 p>0.05; two-
tailed t-test) or any individual behaviour. 
Since the data presented in figure 3-11 are 
at variance with the data presented in figure 
3-10 the data were reanalysed omitting 
'scanning wall' from the data files as 
described above. No significant effects were 
found for the frequency (F(l,45)=0.85, 
p<0.37) or the duration (F(l(45)=1.20, 
p<0.28) of the remainder of cue-directed 
behaviours (table 3-7; П). 
With respect to SKF 38393, i.e. 400 ng 
(figure 3-11), no significant effects were 
found for the frequency or duration of cue-
directed or non cue-directed behaviours, 
although a slight increase in the duration of 
cue-directed (F(l,42)=2.75, p<0.11) and a 
slight decrease in the duration of non cue-
directed (F(l,42)=2.73, p<0.11) were found. 
On the level of the individual behaviours a 
nearly significant decrease for the frequency 
of 'crossing' (p<0.10; two tailed t-test) was 
found in the category of cue-directed 
behaviours. Furthermore significant decreases 
for the duration of 'diving' (SKF 38393 vs 
AD (mean+sem): 3.1+0.8 vs 6.0+0.9, 
t=2.408 df=14 p<0.05; two tailed t-test) as 
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Figure 3-10: Effects of Dl-selective drugs on the number of different cue-directed and non cue-
directed behaviours (Y-axes). X-axes: time-blocks; values: group-effects two-way ANOVA's; shown 
are means+sem's; between brackets: number of rats. 
well as 'scanning bottom' (4.0+1.2 vs 
8.9+1.3, t=2.770 df=14 p<0.02; two tailed 
t-test) were found. These effects were not 
antagonized by SCH 23390. Finally in this 
category a nearly significant increase 
(p<0.10; two tailed t-test) in the duration of 
'scanning wall' existed. No significant effects 
were found in the category of non cue-
directed behaviours, although the duration of 
'sinking' tended to be decreased (p<0.10 
two-tailed t-test). 
No statistical differences were found for the 
overall mean bout-lengths of cue-directed 
(SKF 38393 vs AD (mean+sem): 12.35+1.99 
vs 8.45+1.06, t=1.730 df=14 p>0.05; two 
tailed t-test) or non cue-directed (3.01+0.57 
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Figure 3-11: Effect of Dl-selective drugs on the frequency and duration of cue-directed and non 
cue-directed behaviours (Y-axes). X-axes: time-blocks; shown are means+sem's; between brackets: 
number of rats. 
vs 7.73+2.8, t=l,652 df=14 p>0.05; two 
tailed t-test) behaviours. In this case however 
both the mean bout-length of 'diving' and 
'scanning bottom' were significantly (p<0.05; 
two-tailed t-test) decreased. Furthermore a 
decrease in the mean bout-length of 
'swimming free' (p<0.05 two-tailed t-test) 
was found. These effects were not 
antagonized by SCH 23390. 
Reanalysing the data without 'scanning 
wall' as described above revealed a significant 
decrease of both the frequency (F(l,42)=4.12, 
p<0.05) and duration (F( 1,42)= 13.01, 
p<0.01) of the remainder of cue-directed 
behaviours (table 3-7). In the latter case a 
significant interaction term was found 
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(F(2,42)=5.58, p<0.01). 
With respect to the combination of SKF 
38393 4 0 0 ng and SCH 23390 4 0 0 ng no 
significant effects were found when this 
combination was compared with either SCH 
23390 400 ng alone (frequency: 
F(l,48)=1.39, p<0.24; duration: F(l,48)=0.72, 
p<0.40) or SKF 38393 400 ng alone 
(frequency: F(l,45)=0.0, p<0.95; duration 
F(l,45)=0.53, p<0.47) for the cue-directed 
behaviours (Π). Reanalysing the data without 
'scanning wall' did not change this picture. 
Moreover no significant effects were found 
when this combination was compared with 
AD (frequency: F(l,45)=1.96, p<0.17; 
duration: F(l,45)=0.75, p<0.38). In this case 
Table 3-10: Effects of SCH 23390, SKF 
38393 and the combination of these drugs on 
cue-directed behaviours. Frequency and 
duration are expressed as percentages as 
indicated in the text. Shown are means+sem's. 
0-2 
2-4 
4-6 
frequency 
AD 
SCH 
SKF 
SF 
AD 
SCH 
SKF 
SF 
AD 
SCH 
SKF 
SF 
94.1+2.1 
86.6+2.9 
Θ3.1+4.9 
83.6+3.6 
58.7+3.6 
60.9+3.3 
63.6+6.2 
61.2+4.7 
58.2+3.0 
55.8+2.5 
51.8+3.4 
57.7+4.1 
duration 
96.8+1.4 
93.3+2.1 
92.6+3.8 
93.2+2.3 
80.7+4.3 
86.5+5.1 
82.9+7.7 
84.3+5.2 
54.2+10, 
79.4+5.0 
81.4+4.6 
68.7+9.8 
AD : distilled water (N=8) 
SCH: SCH 23390 400 ng (N=9) 
SKF: SKF 38393 400 ng (N=8) 
SF : SCH 23390 + SKF 38393 
400 + 400 ng (N=9) 
0-2, 2-4 and 4-6: time blocks 
reanalysing the data leaving out 'scanning 
wall' revealed a slight decrease of the 
remainder of cue-directed behaviours 
(frequency: F(l,45)=2.83, p<0.10; duration: 
F(l)45)=3.25, p<0.08). 
In table 3-10 the effects of SCH 23390 
400 ng, SKF 38393 400 ng and their 
combination on cue-directed behaviours are 
presented as percentages of the total number 
of behaviours (cue-directed and non cue-
directed behaviours). From this table it can 
be seen SCH 23390 enhanced the duration 
of cue-directed behaviours (F(l,45)=4.04, 
p<0.05; F(2,45)=3.54, p<0.05) in line with 
the data presented above. Again no effect was 
found for the frequency of cue-directed 
behaviours (F(l,45)=l.ll, p<0.29). SKF 
38393 tended to enhance the duration of cue-
directed behaviours (F(l,42)=2.69, p<0.10; 
F(2,42)=3.60, p<0.04) in line with above 
presented data. None of the other 
combinations i.e AD vs SCH 23390 +SKF 
38393, SCH 23390 vs SCH 23390 +SKF 
38393 or SKF 38393 vs SCH 23390 + SKF 
38393 led to any significant effects. 
SCH 23390 4 0 0 ng tended to decrease the 
number of switches between cue-directed 
behaviours (from 22.1+2.5 to 19.1+3.6; Π). 
SKF 38393 400 ng on the other hand clearly 
decreased the number of switches between 
cue-directed behaviours (from 22.1+2.5 to 
14.1+2.6, t=2.218 df=14 p<0.05; two tailed 
t-test; Π). In none of these cases effects were 
found in the other categories. Furthermore the 
combination of SCH 23390 and SKF 38393 
was not significantly different from either the 
control or any of the drugs separately. 
Table 3-11 shows the effects of the 
different drugs selective for the Dl-receptor 
on the latencies of the different behaviours. 
From this table it appears that SCH 23390 
decreased the latency of 'swimming free', 
whereas SKF 400 had no effect. 
SCH 23390 (100-400 ng/0.5 ul) 
decreased the total number of rats 
(free+forced escape) that escaped (Π). The 
SCH 23390 induced effect was attenuated by 
SKF 38393 (Π). SKF 38393 (50-400 ng/0.5 
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Table 3-11: Effects of Dl-selective drugs on the latencies of the different cue-directed and non 
cue-directed behaviours in the swimming test. Shown are median values (seconds). 
sw 
с 
D 
SB 
SF 
S 
Ρ 
TW 
AD 
4.5 
22.5 
28.5 
58.0 
360.0 
111.5 
360.0 
360.о 
SCH 400 SKF 400 
cue-directed behaviours 
6.0 4.0 
16.0 25.0 
36.0 46.0 
103.0 93.5 
non cue-directed behaviours 
13.О 217.0 
105.0 111.5 
360.0 360.0 
360.0 360.0 
SCH 400 + SKF 400 
5.5 
19.0 
20.0 
45.0 
I 
46.0 
137.0 
360.0 
360.0 
For the abbreviations of the behaviours see paragraph 3.4.2 
SCH: SCH 23390; SKF: SKF 38393; values indicate doses in ng/0.5 ul; AD and 
SKF: N=8 rats, SCH and SCH+SKF: N-=9 rats 
ul) did not show a consistent effect upon 
detection and/or escape. The highest dose 
tended to decrease the number of rats that 
showed free escape (p<0.10 X-square test 
two-tailed). 
d-amphetamine 
and 
dopamine Dl and D2. 
Raclopride enhanced the number of rearings 
induced by d-amphetamine (figure 3-13, panel 
A). In fact, an inverted U-curve appeared to 
exist with the doses employed in this study 
(25-250 ng). 
The ineffective dose of raclopride (25 ng) 
did not attenuate the increase in the number 
of different cue-directed behaviours or the 
increase in free escape induced by d-
amphetamine (IO ug/0.5 ul) as can be seen 
in figure 3-13 (panels Bl and C2). Only the 
higher doses (50 and 250 ng), which were 
effective by themselves (figure 3-7), were able 
to attenuate this effect of d-amphetamine 
(F(3,87)=5.55, p<0.01; 50 and 250 ng vs 
AMP p<0.05 post-hoc SNK-test). The 
antagonism was most apparent in the second 
2 min period i.e. 2-4 min. Although a 
significant effect was found for the non cue-
directed behaviours (F(3,87)=2.69, p<0.051) 
none of the doses was significantly different 
from the control, i.e. d-amphetamine (not 
shown). 
An ineffective dose of SCH 23390 i.e. 250 
ng (figure 3-10; figure 3-12; table 3-6) 
attenuated the effects induced by d-
amphetamine; both the increase in rearing 
(figure 3-13, panel A), the number of 
different cue-directed behaviours 
(F(l,45)=5.74, p<0.02; figure 3-13, panel B2) 
as well as the number of rats that showed 
free escape (figure 3-13, panel C2). No effect 
was found on the number of different non 
cue-directed behaviours. 
dopamine DAi 
DPI (500 (N=9) and 1000 (N=9) ng/0.5 
ul) had no effect upon the number of 
different cue-directed behaviours (p<0.70) or 
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the number of different 
non cue-directed 
behaviours (p<0.90), 
nor were there any 
significant effects upon 
the number of rats that 
escaped (not shown). 
The highest dose i.e. 
1000 ng/0.5 ul tended 
to decrease the number 
of rearings in the open 
field (DPI vs AD 
(mean+sem): 24.3+6.3 
(N=9) vs 42.4+8.2 
(N=8)). 
systemic injections of 
d-amphetamine 
•I. rais 
100· 
80 · 
60 
¿0 
20 
ΗΤΊ Г. JZL 
FREE ESCAPE 
Π 
FREE-f FORCED ESCAPE 
® 
In order to study the 
effects of systemic 
injections of d-
amphetamine the 
paradigm was slightly 
changed. First, it was 
determined when the 
effect of systemic d-
amphetamine was 
maximal i.e. the time 
curve was determined of 
motor activity induced 
by d-amphetamine. To 
this end, rats were 
injected intraperitoneally 
with AD (1X) mlAg) or 
d-amphetamine (1.5 mg/kg; a behaviourally 
effective dose in rats: see e.g. Sharp et al, 
1987). Motor activity was subsequently 
measured for 80 minutes in motor cages, 
which are described in chapter 4, section 4-
3. The rats were habituated to the motor 
cages for 60 minutes. Figure 3-14 shows the 
time-curve of the effect of d-amphetamine. d-
Amphetamine clearly enhanced motor activity 
(bloody obvious test; Kitchen, 1987). As can 
be seen in this figure the maximal motor 
enhancing effect was reached in the period 
40-50 minutes, which is comparable to data 
reported in the literature (Sharp et al, 1987). 
Since the swimming test lasts at most 11 
® l * - | 
50 200 ¿00 
SKF 
50 200 400 SKF 
400 400 400 SCH 
Figure 3-12: Effects of Dl- selective drags 
on detection (A), free escape (B) and 
free+forced escape (Q. Shown are 
percentages. The number of rats is indicated 
in the bars in panel С *: p<0.05 X-square 
two-tailed. 
minutes, it was decided 
to subject the rats to the 
swimming test 30 
minutes after injection 
i.e. in the periods 30-
40 and 4O-50 minutes 
(figure 3-14, arrows). 
The rats were kept in 
their home cage after 
injection instead of 
being put in a novel 
open field (see 
discussion; paragraph 
3.4.3.3 and paragraph 
3.5.1). Finally the rats 
were isolated two days 
before the experiments 
were performed, d-
Amphetamine (0.25-1.5 
mg/kg) or distilled 
water (AD) was injected 
intraperitoneally (1 
ml/kg). In order to 
compare the effects in 
the swimming test with 
those reported for motor 
activity parallel groups 
of rats were injected 
with the appropriate 
d o s e s o f d -
amphetamine (0.25-1.5 
mg/kg) or AD and put 
into the above 
mentioned motor cages 
30 minutes after 
injection. Their activity was subsequently 
measured for 30 minutes. 
Figure 3-15 shows the effects of several 
doses of d-amphetamine (0.25-1.5 mg/kg) in 
the swimming test (panels A and B) and in 
the motor cages (panels С and D). From 
panel A it is clear that d-amphetamine had a 
dual effect: the lowest dose did not affect the 
number of different cue-directed behaviours, 
whereas the higher doses shifted the pattern: 
an increase in time in the number of different 
cue-directed behaviours . This latter was 
reflected by the significant interaction term 
which emerged from the two-way ANOVA: 
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Figure 3-13: Effect of a D2- and a Dl-antagonist on the effects induced by d-amphetamine (10 
ug/0.5 ul): rearing (A), number of different cue-directed behaviours (B1-B2) and detection of the 
rope, free escape and free+forced escape (C1-C3). 
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F(6,81)=4.77, p<0.01. It should be stressed 
that no significant group effect was found: 
F(3,81)=1.05, p<0.37. The shift in the pattern 
was due to the fact that 'diving' and 
'scanning bottom' appeared later in the 
sequence or .even, disappeared, which was 
reflected by their significantly increased 
latencies (figure 3-16): p<0.05 for 0.5 and 
1.5 mg/kg (Dunn's test) following significant 
overall effects (Kmskal-Wallis): H(tie-
conected)= 18.28 df=3, p<0.05 and H(tie-
corrected)=18.89 df=3, p<0.05 respectively 
(Blaker, 1987). 
Whereas the highest dose, i.e. 1.5 mg/kg 
had no effect on the number of different non 
cue-directed behaviours, the lower two doses 
Table 3-12: Effects of d-amphetamine on 
detection, free escape, and free+forced escape. 
Shown are percentages. 
DOSE DET. FREE FREE+FORCED 
(AD) 75.0 50.0 62.5 
0.25 37.5 37.5 75.О 
0.50 75.0 50.0 87.5 
1.50 100.0 100.0* 100.0 
dose: mg/kg; N=8 rats per group 
*: p<0.05 X-square two-tailed 
decreased it as can be seen in figure 3-15 
panel B. Statistical evaluation of the data 
showed that a significant group effect 
(F(3,81)=5.40, p<0.01) existed. It turned out 
that the doses of 0.25 and 0.50 mg/kg were 
significantly different from the control 
(p<0.05 SNK-test). It finally turned out that 
the latency of 'sinking' was significantly 
enhanced with the doses of 0.5 and 1.5 
mg/kg (p<0.05 (Dunn's test) following a 
significant overall effect (Kruskal-Wallis) 
H(tie-corrected)=14.94 df=3, p<0.05; figure 
3-16). There was a non significant tendency 
for the latency of 'treading water' to be 
decreased with the highest dose. 
Both detection, free, and free and forced 
escape were enhanced with the highest dose 
of d-amphetamine i.e. 1.5 mg/kg; the lowest 
dose 0.25 mg/kg tended to decrease detection 
(table 3-12). 
The effects on motor activity are shown in 
figure 3-15 (panels С and D). It is clear from 
these panels that no differences existed in the 
first 10 minutes (F(3,30)=0.93, p<0.44) i.e. 
during the period in which the behavioural 
changes in the swimming test were observed 
(figure 3-15, panels A and B). However, it 
appeared that motor activity was dose-
dependently enhanced (F(3,90)=3.46, p<0.05) 
after this period (figure 3-15, panel D). The 
doses of 0.5 and 1.5 mg/kg were significantly 
different from the control (p<0.05 SNK-
test). It should be 
noted that also a significant interaction term 
was found (F(6,90)=2.35, p<0.05). 
3.4.3.3 Discussion 
intra-accumbens injections 
The main finding of these studies was that 
the number of different cue-directed 
behaviours was affected by manipulation with 
the nucleus accumbens without an effect on 
the number of different non cue-directed 
behaviours (Ι, Π). Moreover it appeared that 
the effects on горе-directed behaviour did not 
always parallel those effects which were 
found on the cue-directed behaviours. 
Furthermore the effects found cannot simply 
be ascribed to motor changes per se (II). 
As expected d-amphetamine enhanced motor 
activity in the open field preceeding the 
swimming test (cf. Costali et al, 1980; 
Pijnenburg et al, 1976; IV). The effect on the 
number of different cue-directed behaviours as 
well as on the actual switches to cue-directed 
behaviours might therefore be ascribed to 
this phenomenon. It was however therefore 
interesting to note that similar effects were 
obtained in the swimming test for LY 171 
555, whereas no effects were found on motor 
activity in the open field. This latter finding 
seems to be in agreement with reports from 
78 
500-
300-
IOD­
I— 
Ν 
IO 
• ^ 
ч
^ 
> 
^ 
20 30 40 
t 
β — о AD 1ml/kg N = 8 
• . d-AMP 15 mg/kg Ν = β 
>—J 
^ 
î 5 
50 60 70 0 
i time (mm) 
Figure 3-14: Motor activity induced by d-amphetamine 1.5 mg/kg and AD 1 ml/kg. Y-axis: 
counts/10 min; X-axis: time after injection; shown are means+sem's; the number of rats is indicated 
in the figure. 
the literature (Bréese et al, 1987; Cools, 1989; 
Plaznik et al, 1989). The same applies to 
raclopride and SCH 23390 (Cools, 1989; 
Plaznik et al, 1989; IV). These data thus 
show that the swimming test may be a very 
sensitive test for detecting subtle changes in 
ongoing behaviour, changes which are not 
easily detected in the open field (Π). 
A summary of the results of the present 
experiments is given in table 3-13. d-
Amphetamine enhanced the number of 
different (figure 3-5) as well as the frequency 
and duration (figure 3-6) of cue-directed 
behaviours. A number of observations 
preclude the possibility that the behavioural 
changes induced by d-amphetamine were due 
to perseveration of a single behavioural item 
(I). First, by definition such a series of 
identical behaviours was scored as a single 
event. A drug-induced increase in 
perseveration would thus lead to a sharp drop 
in the frequency of behaviours without 
concomitant changes in the duration of 
behaviours. No decreases in the frequency 
were however found (figure 3-6). Moreover 
no increases in the bout-length of single 
behavioural items were found (table 3-3). 
Furthermore the number of different 
behaviours was increased by d-amphetamine 
(figure 3-5), whereas a decrease in this 
number would have been expected in the case 
of perseveration. It should furthermore be 
noted that the d-amphetamine treated rats 
were able to detect the rope and change their 
behaviour according to this stimulus by 
climbing it (table 3-2). This indicates that 
their behaviour was not stereotyped. 
With respect to the question whether the 
effects of d-amphetamine were mediated via 
dopamine -it is known that d-amphetamine 
releases noradrenaline as well as serotonin 
next to dopamine (Parada et al, 1988)- it was 
interesting that the D2-agonist LY 171 155 
(Titus et al, 1983) appeared to mimic the 
79 
Figure 3-15: Effects of d-amphetamine (0.25-1.5 mg/kg) on the number of different cue-directed 
(A) and non cue-direaed behaviours (B) and motor activity (CD); panels A 3 and C: means+sem's; 
panel D: means; panels С and D: time after injection. 
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effect of d-amphetamine (Π)- In fact, the 
behavioural changes in the swimming 
behaviour seemed to be nearly identical: an 
increase in the number of different cue-
direaed behaviours (figure 3-7). Although no 
increase was found in the frequency of cue-
directed behaviours (figure 3-8), it turned out 
that LY 171 555 yet enhanced the frequency 
of cue-directed behaviours when 'scanning 
wall', which accounts for more than 70% of 
these behaviours, was omitted from the 
analyis (table 3-7). The latter suggests that 
AD 18) 0 2S(7) 0 50 IB) 150(8)mg/l<g 
' "¡TAMP 
Figure 3-16: Effects of d-amphetamine (d-amp) on the latencies of the different cue-directed and 
non cue-directed behaviours (Y-axes). *:p<0.05 vs AD (see text); X-axes: behaviours; shown are 
median values; between brackets: number of rats. 
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the behavioural changes were rather subtle. It 
should however be noted that LY 171 555 in 
contrast to d-amphetamine seemed to have 
some effect on the frequency of 'swimming 
free' and 'sinking'. The major difference 
between these drugs however was the fact 
that LY 171 555, unlike d-amphetamine, had 
no effect on the number of rearings (or motor 
activity) in the open field. These findings are 
in agreement with data from the literature (see 
above; see further section 3-5). 
The role of the D2-receptor was further 
underlined by the finding that the specific D2-
antagonist raclopride (Ogren et al, 1986) was 
able to attenuate the effect of LY 171 555, in 
a dose that was otherwise ineffective, and to 
decrease the number of different cue-directed 
behaviours in a somewhat higher dose (figure 
3-7). Finally LY 171 555 enhanced the 
number of rats that detected the rope i.e. a 
visual and/or tactile stimulus, and escaped; an 
effect that was also attenuated by the 
ineffective dose of raclopride (figure 3-9; Π). 
Finally it was in fact found that LY 171 55 
actually selectively enhanced the real number 
of switches between cue-directed behaviours. 
These data overall thus allow for the 
conclusion that dopamine D2-receptois are 
involved in the ability to switch to cue-
directed behaviours (Π)· 
The effect of d-amphetamine or LY 171 
555 on switching to cue-directed behaviours 
can be interpreted either as a drug-induced 
lack of decrease in time in switching to cue-
directed behaviours or as a true overall 
enhancement of switching to cue-directed 
behaviours. Two observations bear evidence 
for the latter interpretation. First, the effect 
was equally distributed over the different 
time-periods (figures 3-6 and 3-8). As pointed 
out no significant interaction terms were 
found in the two-way ANOVA's. In fact in 
both cases, i.e. d-amphetamine and LY 171 
555, the rats showed a decrease of the 
number of switches to cue-directed behaviours 
in time. Second, the rats showed an enhanced 
ability to change their behaviour with the help 
of a stimulus, which was introduced into the 
swimming tank i.e. the rope (table 3-2, figure 
3-9). Thus it appears that both d-amphetamine 
and LY 171 555 truly enhanced the ongoing 
behaviour of the rats (see section 3-5; chapter 
5, section 5-2). 
The finding that the selective Dl-agonist 
SKF 38393 (Pendleton et al, 1978; Setler et 
al, 1978) was unable to mimic the effect of 
d-amphetamine was unexpected, since the 
selective Dl-antagonist SCH 23390 (Iorio et 
al, 1983) not only blocked the increase in the 
number of different cue-directed behaviours 
and the number of rats showing free escape 
induced by d-amphetamine in a dose that was 
ineffective by itself (figure 3-13), but also had 
an effect of its own on these parameters in 
higher doses (figures 3-10 and 3-12; Π). This 
observation however stands not alone for it 
has been found that SCH 23390 was e.g. 
able to block d-amphetamine drug 
discrimination, whereas SKF 38393 was 
unable to substitute for d-amphetamine 
(Nielsen et al, 1989). The precise role of Dl-
receptors in the ability to switch to cue-
directed behaviours can therefore not 
unequivocally be derived from the present 
data (II). 
Although the specific Dl-antagonist SCH 
23390 (Iorio et al, 1983) decreased the 
number of different cue-directed behaviours, 
this effect could not be attenuated by the 
specific Dl-antagonist SKF 38393 (figure 3-
10; Pendleton et al, 1978; Setler et al, 1978). 
Conversely SKF 38393 also decreased the 
number of different cue-directed behaviours; 
an effect that could not be blocked by SCH 
23390 (figure 3-10). This suggests thus that 
both effects were not dopamine Dl-specific. 
On the other hand SCH 23390 decreased the 
total number of rats that escaped, which was 
attenuated by ineffective doses of SKF 38393 
(figure 3-12). It would thus appear that this 
latter effect is Dl-specific. These latter data 
show that Dl-receptors in the nucleus 
accumbens are behaviourally active in the 
swimming test. Several possibilities might be 
considered to explain the present data (Π). 
First, since SCH 23390 binds potently to 
serotonin (5-HT) 2 receptors (Bischoff et al, 
1986; McQuade et al, 1988) and is able to 
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Table 3-13: Summaiy of the results of the experiments presented in this part of this thesis. 
DRUG REC CDB CUE NCUE CUE ESCAPE 
different frequency CUE CUE NCUE 
AMP 
LY 
RAC 
SKF 
SCH 
D1/D2 
D2 
D2 
Dl 
Dl 
intra-accumbens 
[ t 
te 
n.d. 
<e 
~ 
inject 
t 
t 
n.d. 
1 
-= 
ІОПЭ 
-= 
— 
n.d. 
— 
~ 
=_ 
.. 
n.d. 
_. 
== 
t free 
t free 
(jfree) 
(jfree) 
\ free 
+forced 
DPI DAi n.d. n.d. n.d. n.d. 
AMP D1/D2 
systemic injections 
n.d. n.d. n.d. n.d. t fi 
REC: r e c e p t o r ; CDB, CUE: c u e - d i r e c t e d behav iour ; NCUE: non c u e -
d i r e c t e d behav iour ; 
AMP: d-amphetamine; LY: LY 171 555; RAC: r a c l o p r i d e ; SKF: SKF 38393; 
SCH: SCH 23390; a l l drugs but r a c l o p r i d e and SCH 23390 a r e a g o n i s t s ; 
1,1: i n c r e a s e r e s p e c t i v e l y decrease in t h e p a r a m e t e r ; 0: e f f e c t 
appears only in t h e remainder of c u e - d i r e c t e d b e h a v i o u r s , i . e 
' d i v i n g ' , ' c r o s s i n g ' and ' s c a n n i n g b o t t o m ' ; n . d . : not determined; 
#: change in p a t t e r n ; ==: no e f f e c t 
between b r a c k e t s : n e a r l y s i g n i f i c a n t e f f e c t 
block behaviour induced by 5-HT agonists 
(Bijak and Smialowski, 1989) its effects may 
be mediated via 5-HT receptors. Available 
data on the S-HT system in the nucleus 
accumbens however suggest that it acts 
rather in the opposite direction of dopamine 
(Jones et al, 1981; Pycock et al, 1978). 
Accordingly an enhancement (see above) 
rather than a decrease would have been 
expected. Since a decrease was found, it 
makes a 5-HT2 contribution to the effect of 
SCH 23390 rather unlikely (П). Second, the 
effect of SCH 23390 during the 0-6 min 
swimming period may still be mediated via 
the dopamine Dl-receptor if one accepts the 
following reasoning (Π). SKF 38393 is known 
to be only a partial agonist with a relative 
efficacy of only about 50% of that of 
dopamine (Nielsen et al, 1989; Setler et al, 
1978). Therefore, it is possible that dynamic 
changes in Dl-receptor activity in the course 
of the experiments might underlie the 
observed effects: a strong Dl-activation in the 
beginning, whereupon SKF 38393 acts as a 
Dl-antagonist, and a gradually lower Dl-
activation towards the end, whereupon SKF 
38393 acts as a Dl-agonist. Since until now 
no hard evidence exists for such a dynamic 
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Dl-activity, this possibility remains highly 
speculative (see section 3-5). In other words, 
the involvement of Dl-receptors in the ability 
to switch to cue-directed behaviours remains 
to be proven (Π). 
The fact that d-amphetamine LY 171 555, 
raclopride, SCH 23390 and SKF 38393 only 
affected the number of different cue-directed 
behaviours with no effect on the number of 
different non cue-directed behaviours indicates 
that the function of the striatum was not 
affected; neither directly via leakage nor 
indirectly via accumbens-nigrostriatal 
connections (see paragraph 3.2.3). 
Previously it has been found that raclopride 
has a dual effect on the motor activity 
induced by d-amphetamine (figure 3-17; see 
also figure 3-13; IV). As can be seen in 
figure 3-17 two things were basically 
observed: first, all doses of raclopride (0.05-
5.0 ug/0.5 ul) attenuated the d-amphetamine 
(10 ug/0.5 ul) induced activity; second, the 
lower doses (0.05-0.25 ug/0.5 ul) shifted the 
d-amphetamine induced activity curve to the 
right as well as enhanced the overall 
response; an effect, which was most apparent 
with the rearing activity (IV). The doses 
studied here (0.025-0.25 ug/0.5 ul) 
confirmed these initial findings to some extent 
(figure 3-13). Although they enhanced the 
number of rearings, no blockade was however 
found. In the experiments described in this 
chapter d-amphetamine and raclopride were 
injected simultaneously, whereas in the 
previous study (IV) d-amphetamine was 
injected 5 minutes after raclopride. 
Accordingly in the former an immediate 
competition between these drugs exists, which 
may in part explain the observed effect. 
The forementioned data (figure 3-17; IV) 
were interpreted via the assumption that 
raclopride had a higher affinity for pre- than 
for postsynaptic receptors (IV). Thus, as long 
as the doses were high enough the effect was 
predominantly dominated by the postsynaptic 
blockade. In time however, the effect of the 
presynaptic blockade would become clearly 
manifest, which would appear most clearly 
with the lowest doses (IV). An alternative 
explanation for these data might be given by 
assuming that raclopride binds to a site other 
than the D2-receptor in the nucleus 
accumbens. Although raclopride is highly 
selective for the dopamine D2-receptor (Ogren 
et al, 1986) some data in favour of such a 
possibility exist. Recently a binding site in the 
nucleus accumbens was found to which 
benzamide drugs like sulpiride and tiapride -
relatives of raclopride- bind with extreme high 
affinity (Csemansky et al, 1985). Interestingly 
d- and 1-sulpiride showed an equal affinity 
for this site, which indicates that the chiral 
centre in this drug is not important for the 
binding. Since raclopride is a relative 
(benzamide drug) of sulpiride one might 
expect that it has an affinity for this binding 
site. If so, it would be of interest then to see 
whether (+)- and (-)-raclopride bind with 
similar affinities; only (-)-raclopride binds 
with high affinity to the D2-receptor (Ogren 
et al, 1986). Preliminary results have already 
indicated that (+)-raclopride is not devoid of 
intrinsic activity in the accumbens, for it is 
able to enhance the motor activity induced by 
d-amphetamine (Van den Bos and Ogren, 
unpublished data). The effect appeared to be 
similar to the effect of the lower doses of (-
)-raclopride on d-amphetamine induced 
activity. More experiments are needed to 
investigate the possibility that the stimulating 
effects of raclopride on d-amphetamine were 
due to its interaction with this type of binding 
site. It should be noted that these findings 
may have implications for the use of ((-)-
)raclopride as therapeutic drug in schizoprenia 
(see Ellenbroek, 1988 pl45-146). 
As expected, raclopride 50 ng enhanced the 
amphetamine induced rearing in the open field 
(figure 3-13; IV). Yet, it attenuated the 
increase in the number of different cue-
directed behaviours in the swimming test 
(figure 3-13). These latter data could be 
explained by assuming that the decrease in 
the number of different cue-directed 
behaviours was due to hyperstimulation or, 
even, overstimulation of the dopaminergic 
system, which may lead to a disruption of the 
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Figure 3-17: Effect of raclopride on d-amphetamine induced motor activity (A, B, C) ; saline 
- 0.05 - 0.25 - 1.0 - 5.0 ug raclopride/0.5 ul, and d-amphetamine IO ug/0.5 ul; shown are 
means+sem's; N=9 rats per group (IV). 
function of the nucleus accumbens. According 
to the Lyon and Robbins hypothesis on 
central stimulant actions this hyperstimulation 
would lead to shortening of the behavioural 
sequence by the subsequent disappearance of 
certain behaviours (Lyon and Robbins, 1975). 
One would predict then that certain 
behaviours were lost from the sequence of 
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cue-directed behaviours in the swimming 
behaviour of the rats. Inspection of the data 
however does not allow for such a 
conclusion. Moreover this could not explain 
then why a nice dose-response curve was 
obtained for attenuating the increase in the 
number of different cue-directed behaviours 
induced by d-amphetamine: the higher dose of 
raclopride did not appear to enhance rearing, 
and hence did not appear to lead to 
hyperstimulation of the dopaminergic system, 
while it attenuated the d-amphetamine 
induced increase in the number of different 
cue-directed behaviours. At this stage it is 
thus not clear why only effective doses of 
raclopride attenuated the d-amphetamine 
induced increase in the number of different 
cue-directed behaviours. One possibility might 
be that this is partly due to the effect of 
raclopride on the sulpiride binding sites in 
the nucleus accumbens (Csemansky et al, 
1985; see above). These data overall 
furthermore underline the above given notion 
that rearing is not related to the swimming 
behaviour of the rat per se. 
The selective DAi-agonist DPI (Cools and 
Van Rossum, 1976, 1980) was ineffective in 
producing behavioural changes in the 
swimming test in doses that have been shown 
to be effective in other paradigms (Ploeger et 
al, 1989, 1990). The sensitivity of the DAi-
receptor to agonists has been found to be 
regulated by alphal-noradrenaline (Cools et al, 
1978). In fact, the sensitivities of the 
(postsynaptic) DAi-receptor and alphal-
noradrenergic receptor to their respective 
agonists are opposed to each other. The latter 
sensitivity is inversely related to the ongoing 
noradrenergic activity (Cools et al, 1987; 
Cools et al, 1990a). Since DPI was 
ineffective (DAi-receptor unreceptive to an 
agonist) it follows that in the swimming test 
the noradrenergic activity is low (see 
paragraph 3.4.4 and section 3-5). Moreover 
since the noradrenergic activity may be 
suggested to be test-dependent (cf. Cools et 
al, 1990a) it explains why DPI is 
differentially effective in different set-ups. 
systemic injections 
The data clearly showed that the swimming 
behaviour of the rats was affected upon 
systemic injections of d-amphetamine without 
concomitant effects on the motor activity of 
these rats. In fact, the data showed that the 
increase in motor activity appeared after the 
period in which the changes in the swimming 
test were observed. These data thus strongly 
underline the above given notions on this 
issue. It should be noted that it remains to be 
established whether the changes in the 
swimming test are predictive for or related to 
the changes in motor activity, which occurred 
after the period in which the swimming test 
was performed. 
A striking finding in these experiments was 
the observation that systemic injections of d-
amphetamine did not mimic the effects of 
intra-accumbens d-amphetamine. In contrast 
to the latter, systemic injections of d-
amphetamine changed the pattern of the 
number of different cue-directed behaviours, 
and appeared to have a dual effect on the 
number of different non cue-directed 
behaviours. It moreover enhanced the latencies 
of some behaviours. In fact, the only common 
feature was the increase in free escape. This 
parameter is however not specific for the 
nucleus accumbens, for it can be affected 
from both the nucleus accumbens (this thesis) 
and the striatum (Cools, 1980; Cools and 
Peelers, 1987; Vrijmoed-de Vries and Cools, 
1986). In line with the foregoing, others have 
also observed that differences exist between 
the intra-accumbens and systemic injections of 
d-amphetamine (see Neill and Justice, 1981). 
It has been shown that d-amphetamine in 
the dose range (0.25-1.5 mg/kg) employed in 
this study enhanced the release of dopamine 
in the nucleus accumbens and striatum (Sharp 
et al, 1987; Dichiara and Imperato, 1988). 
The nucleus accumbens is involved in the 
ability to switch to cue-directed behaviours 
(see above), whereas the (dorsal) striatum is 
involved in the ability to switch to non cue-
behaviours (see section 3-3). The effects of 
the different doses of d-amphetamine on the 
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number of different cue-directed and non cue-
directed behaviours may reflect a differential 
effe« of this drug on the function of the 
nucleus accumbens and (dorsal) striatum 
respectively. The pattern of the overall 
swimming behaviour appeared to change 
under increasing doses of d-amphetamine as 
shown by the increased latencies of 'diving', 
'scanning bottom' and 'sinking'. Thus the 
normal sequence (taking the median values of 
the latencies of the different behaviours) Sw-
C4D,SB)-SF-S-(P,TW) appeared to change to 
SW-C-SF-TW-O-(SB,P,S) (1.5 mg/kg) via 
SW-C-SF-(D,SB)4S,P,TW) (0.5 mg/kg). With 
respect to the cue-directed behaviours it 
appears that those behaviours which appear 
late in the sequence, i.e. 'diving' and 
'scanning bottom', disappear. This would 
imply that with increasing doses of d-
amphetamine the function of the nucleus 
accumbens is disrupted. Some data to support 
this latter notion appear to exist in the 
literature. Recent experiments have shown that 
d-amphetamine in a dose-range (0.5-1.0 
mg/kg) similar to that used here shifted the 
forelimb stepping pattern of rats from normal 
'closing steps' to 'crossing steps' (Cools et al, 
1989a). No effects were found on the 
hindlimb stepping pattern. Since the regulation 
of movements of the forelimb appears to be 
mediated specifically via the nucleus 
accumbens (see e.g. Ellenbroek et al, 1988), 
it was suggested by the authors: "it opens the 
perspective that (+)-amphetamine can be used 
as tool to study behavioural deficits typical 
for a programming dysfunction of the output 
stations of mesolimbic neurons" (Cools et al, 
1989a pll4). These latter data thus underline 
the abovementioned possibility. The present 
data might in return support the remarks made 
by Cools et al (Cools et al, 1989a; see 
above). The present data might furthermore 
lend support to the Lyon and Robbins 
hypothesis on the action of d-amphetamine 
(Lyon and Robbins, 1975). One would 
however predict from this latter hypothesis 
that the frequencies or duration of 'scanning 
wall' or 'crossing' would increase (repetition 
of behaviour). Although no attempt was made 
to quantify this, a qualitative analysis showed 
that this was not the case. With respect to 
the non cue-directed behaviours it would 
appear that d-amphetamine also affected the 
behaviours which appeared later in the 
sequence i.e. 'sinking'. It should however be 
noted that with the highest dose of d-
amphetamine, 'treading water' appeared 
earlier. In fact this accounted for the 
observation that the number of different non 
cue-directed behaviours was not changed with 
this dose of d-amphetamine (see above). At 
present no good explanation can be given for 
this however. 
Although the effects on cue-directed and 
non cue-directed behaviours were separately 
discussed, the possibility should not be 
dismissed that the effects of increasing doses 
of d-amphetamine were due to a change in 
the balance between the nucleus accumbens 
and the striatum. It remains finally to be 
studied to what extent the changes in the 
sequences which were found in this study are 
related to the changes in behavioural 
sequences observed by others (Ljungberg and 
Enquist, 1987) 
In sum these data showed that systemic 
injections of d-amphetamine affected the 
swimming behaviour of the rat, albeit in a 
way different from that of intra-accumbens 
injections. 
Overall conclusion 
In conclusion the results showed that intra-
accumbens d-amphetamine, which enhances 
among others the dopaminergic activity, 
increased the ability to switch to cue-directed 
behaviours (I). Moreover it appeared that 
these effects were at least mediated via the 
D2-receptor, the role of the Dl-receptor 
remains to be proven (Π). Furthermore it 
appeared that the role of the nucleus accum­
bens is the counterpart of that of the neostria­
tum, which is involved in allowing rats to 
switch to non cue-directed behaviours (Van 
den Bereken and Cools, 1982; Cools, 1980; 
Jaspers et al, 1984; Vrijmoed-De Vries and 
Cools, 1986). Finally systemic injections of d-
amphetamine changed the pattern of cue-
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directed behaviours with increasing doses, 
which may have been due to a disruption of 
the function of the nucleus accumbens. 
Overall the results specify and extend the 
general notion that dopamine is involved in 
switching behaviours (Oades, 1985; Matthysse, 
1981; Robbins and Everitt, 1982). 
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3.4.4 Noradrenaline 
3.4.4.1 Introduction 
As outlined in section 3-2 the nucleus 
accumbens contains an appreciable 
noradrenergic innervation (see e.g. Cools et al, 
1990a). Within the field of noradrenaline two 
main classes of noradrenergic receptors exist: 
alpha- and beta-noradrenergic receptors, which 
both can be further subdivided into two 
subclasses: alphal- and alpha2-receptors, and 
betal- and beta2-receptors respectively (e.g. 
Exton, 1985; Timmermans and van Zwieten 
1982). Within the nucleus accumbens these 
types of receptors have been shown to exist. 
Thus, the existence of alphal-((3H)-prazosin: 
Rainbow and Biegon, 1983; Cools, 1988; 
(125I)-HEAT: Jones et al, 1985), alpha2-
((3H)-clonidine: Unnerstal et al, 1984), and 
betal- and beta2-((3H)dihydro-alprenolol; 
Rainbow et al, 1984) binding sites was 
demonstrated. 
Several studies have investigated the role of 
noradrenaline in the nucleus accumbens in 
behaviour. Thus, it has been shown to 
enhance motor activity after intra-accumbens 
injections in (habituated) rats pretreated with 
nialamide (Pijnenburg and Van Rossum, 1973; 
Pijnenburg et al, 1975) or nialamide and 
reserpine (Jackson et al, 1975). Moreover it 
has been found to enhance motor activity 
after intra-accumbens injections in rats with 6-
hydroxy-dopamine (6-OHDA) lesions of the 
nucleus accumbens (Swerdlow and Koob, 
1989). At least one study showed however 
that noradrenaline was ineffective in 
enhancing motor activity in pretreated rats 
(Makanjuola et al, 1980). Jackson et al 
furthermore observed in their study that rats 
displayed crouching-like behaviour after intra-
accumbens injection of noradrenaline instead 
of displaying the coordinated running, which 
was observed after intra-accumbens dopamine 
injections (Jackson et al, 1975). From these 
experiments it can not be unequivocally 
concluded that noradrenaline in the nucleus 
accumbens is involved in enhancing normal 
motor activity. In fact, subsequent experiments 
have shown that intra-accumbens injections of 
noradrenaline decreased motor activity in non 
pretreated habituated (Pijnenburg et al, 1976) 
and non habituated rats (Plaznik, 1984; 
Svensson and Ahlenius, 1982; 1983). As far 
as it concerns the involvement of the different 
types of receptors it appeared that the alpha2-
agonist Clonidine (Timmermans and Van 
Zwieten, 1982) was able to suppress motor 
activity both in habituated (Pijnenburg et al, 
1976) and non habituated (Plaznik et al, 
1985) rats. In contrast the alphal-agonist 
phenylephrine was either without effect in 
habituated rats (Cools et al, 1990b) or 
decreased motor activity only slightly after a 
delay of 30-45 minutes (Pijnenburg et al, 
1976). In non habituated rats phenylephrine 
was ineffective in affecting motor activity 
(Plaznik et al, 1985). Furthermore the beta-
agonists isoprenaline (habituated rats; 
(Pijnenburg et al, 1976) and isoproterenol 
(non habituated rats; Plaznik et al, 1985) were 
ineffective. 
These data thus show that noradrenaline 
decreases motor activity in non pretreated 
rats; an effect which is the opposite of that of 
dopamine. Furthermore this effect might be 
mediated via the alpha2-receptor. Finally 
pretreating the rats as reported above might 
change the basal noradrenaline level to such 
an extent that noradrenaline induces opposite 
effects. 
More recent experiments have shown that 
noradrenaline in the nucleus accumbens may 
be involved in displaying active behaviour in 
the forced swimming test (Plaznik et al, 
1985), the regulation of tonic 
electromyographic (EMG) activity of the 
triceps muscle of the forelimb of the rat 
(EUenbroek et al, 1988), and in eliciting 
'explosive motor behaviour' (Cools et al, 
1987). Moreover it has been shown to play a 
prominent role in the inter-individual 
differences in rats of one strain (Cools et al, 
1990a). 
Since it has been shown that an interaction 
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exists between noradrenaline and dopamine in 
the nucleus accumbens of the rat (Nurse et al, 
1984 , 1985; RusseU et al, 1987; see also 
Cools et al, 1978), and since the role of 
dopamine has been studied with respect to the 
ability to switch behaviour (see paragraph 
3.4.3), it was decided to study the effects of 
drugs selective for the alpha-type of receptor 
in the swimming test in an attempt to further 
delineate the role of noradrenaline in the 
nucleus accumbens in behaviour. 
The materials and methods used in these 
experiments have been described in section 
3.4.2. 97 Rats were included in the present 
experiments. 
3.4.4.2 Results 
The alphal -agonist phenyl-ephrine 
(Timmermans and Van Zwieten, 1982; 750 
ng/0.5 ul) decreased the number of different 
cue-directed behaviours (F(l,45)=6.15, 
p<0.02), without an effect on the number of 
non cue-directed behaviours (F(l,45)=0.04, 
p<0.85; figure 3-18, panels A and B). It also 
decreased the number of rats that escaped 
(table 3-14). No effects were found on the 
number of rearings in the open field (phenyl-
ephrine vs AD (mean+sem): 36.4+7.5 vs 
42.4+8.2, t=0.540 àf=15 p>0.05 two-tailed 
t-test). A lower dose (500 ng) was not 
effective (not shown). 
The alpha2-agonist Clonidine (Exton, 1985; 
Timmermans and Van Zwieten, 1982; 750 
ng/0.5 ul) tended to decrease the number of 
different cue-directed behaviours 
(F(l,42)=3.21, p<0.08), and surprisingly 
enhanced the number of different non cue-
directed behaviours (F(l,42)=11.95, p<0.01; 
figure 3-18, panels С and D). It furthermore 
enhanced the number of rats that escaped 
(table 3-14). The number of rearings tended 
to be decreased but was not significantly 
different from the control (Clonidine vs AD 
(mean+sem): 27.3+6.7 vs 42.2+8.2, t=1.407 
df=14 p>0.05 two-tailed t-test). A lower dose 
(500 ng) was ineffective in inducing 
behavioural changes. 
The alpha2-antagonist rauwolscine 
(Timmermans and Van Zwieten, 1982; 750 
ng/0.5 ul) decreased the number of different 
cue-directed behaviours (F(l,42)=9.40, 
p<0.01), without an effect on the number of 
different non cue-directed behaviours 
((F(l,42)=1.88, p<0.17; figure 3-18, panels E 
and F). No effects were found on escape 
(table 3-14) or rearing (rauwolscine vs AD 
(mean+sem): 31.3+6.5 vs 42.2+8.2, t=1.042 
df=l4 p>0.05). A lower dose (500 ng) was 
ineffective in inducing behavioural changes. 
The nonselective alpha-antagonist 
phentolamine (Timmermans and Van Zwieten, 
1982; 250, 500 and 750 ng/0.5 ul; 7-8 rats 
per group) decreased the number of different 
cue-directed behaviours (F(3,81)=2,78, 
p<0.05); no effect was found on the number 
of different non cue-directed behaviours 
(F(3,81)=0.99, p<0.40; not shown). 
Moreover the number of rats that escaped was 
not affected (not shown). 
An ineffective dose of phentolamine (250 
ng/0.5 ul) was unable to attenuate the 
decrease in the number of different cue-
directed behaviours induced by phenylephrine 
(F(l,48)=0.73, p<0.40). This combination of 
drugs was however not different from AD 
(F(l,45)=3.09, p<0.20). This dose of 
phentolamine was however able to normalize 
the escape behaviour i.e. it attenuated the 
decrease in free escape induced by 
phenylephrine (250 ng phentolamine: 25%, 
N=8 rats (not significantly different from 
AD); 250 ng phentolamine + 750 ng 
phenylephrine: 44.4%, N=9 rats, p<0.05 X-
square versus phenylephrine (table 3-14)). 
3.4.4.3 Discussion 
The results of this study showed that 
noradrenergic drugs were able to affect the 
ongoing swimming behaviour of rats. The 
alphal-agonist phenylephrine (Timmermans 
and Van Zwieten, 1982) and the alphas-
antagonist rauwolscine (Timmermans and Van 
Zwieten, 1982) induced functionally similar 
effects: a decrease in the number of different 
90 
CUE-DIRECTED NON CUE-DIRECTED 
• AD • РНЕ 
rill 
0-2 mn 2-4 uw* Û-2 riwv 2-4 г 
• AD •CLO 
I h . Jriri 
0 - 2 т л 2 - 4 nwi 4 fi i m 0-7 nwi 2 - 4 ÌTWV 4 - 6 ™л 
•AD • RAU 
Ьь вгігі 
О 2 т л ? 4 г о - г «»ι г 4 f 
TIME (ГГІІЛ) 
Figure 3-18: Effects of noradrenergic drugs on the number of different cue-directed and non cue-
directed behaviours (Y-axes). X-axes: time-blocks. For abbreviations see table 3-14; N=8-9 rats per 
group. 
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cue-directed behaviours without an effect on 
the number of different non cue-directed 
behaviours (figure 3-18). Moreover the 
alpha2-agonist Clonidine (Exton, 1985; 
Timmermans and Van Zwieten, 1982) induced 
an effect: no change in the number of 
different cue-directed behaviours and an 
increase in the number of different non cue-
directed behaviours (figure 3-18). The 
nonselective alpha-antagonist phentolamine 
(Tmimermans and Van Zwieten, 1982) did not 
attenuate the effect of phenylephrine. It should 
be noted however that the number of different 
cue-directed behaviours under the combination 
of the drugs was not significantly different 
from the control values suggesting some 
blockade of the effect of phenylephrine; a 
notion, which is supported by the fact that 
phentolamine attenuated the decrease in free 
escape induced by phenylephrine. The fact 
that phentolamine is a nonselective antagonist 
for the alpha-receptors (see above) might 
account for the weak blockade. 
These data thus showed (i) that alpha-
noradrenergic drugs were behaviourally active 
after injection into the nucleus accumbens of 
rats and (ii) that alphal- and alpha2-selective 
drugs elicited different effects after injection 
into the nucleus accumbens on swimming 
behaviour of rats. 
It has been shown that the ability to switch 
to non cue-directed behaviours is mediated 
via the striatum (Cools, 1980; Vrijmoed-de 
Vries and Cools, 1986), whereas the ability to 
switch to cue-directed is mediated via the 
nucleus accumbens (see paragraph 
3.4.3). The fact that phenylephrine and 
rauwolscine did not affect the number of 
different non cue-directed behaviours shows 
that these drugs did not affect the function of 
the striatum. Instead they clearly affected the 
function of the nucleus accumbens. 
Conversely the fact that Clonidine enhanced 
the number of non cue-directed behaviours, 
while it did not affect the number of different 
cue-directed behaviours, suggests that this 
drug did directly or indirectly affect the 
function of the striatum, while it had no 
effect on the function of the nucleus 
accumbens. The following experimental 
findings may shed light upon this notion. As 
pointed out in section 3-2 the accumbens 
sends efferents to the substantia nigra pais 
reticulata. The latter in nun projects to the 
deeper layers of the colliculus superior (see 
Gelissen, 1987 for review). Moreover the 
nucleus accumbens projects to the neurons of 
the dopaminergic nigrostriatal pathway 
(section 3-2). The output neurons of the 
nucleus accumbens have been suggested to 
contain GABA as neuro-transmitter (section 3-
Table 3-14: Effect of noradrenergic drugs on detection, free escape, and free+forced escape. Shown 
are percentages. 
DRUGS DOSE DETECTION FREE FREE+FORCED 
AD 
PHE 
CLO 
RAU 
-
750 
750 
750 
50.0 
0.0* 
75.0 
37.5 
33.3 
0.0* 
75.0* 
37.5 
66.7 
44.4 
100.0 
87.5 
18 
9 
8 
8 
PHE: phenylephrine; CLO: Clonidine; RAU: rauwolscine; 
* p<0.05 X-square two-tailed 
dose: ng/0.5 ul 
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2). The effect induced by Clonidine on the 
number of non cue-directed behaviours 
resembled that of apomorphine in the 
neostriatum (Cools, 1980; Vrijmoed-de Vries 
and Cools, 1986). The latter drug has been 
shown to enhance the GABA-output to the 
substantia nigra pars reticulata, which in tum 
lowered the GABA-activity in the nigra-
collicular pathway (Cools et al, 1984b; 
Ellenbroek et al, 1985b; Gelissen, 1987). 
Accordingly Clonidine might have either 
enhanced the accumbens GABA-output to the 
substantia nigra pars reticulata or decreased 
the accumbens GABA-output to the 
nigrostriatal neurons. Since it has been shown 
that the ability to switch to non cue-directed 
behaviours is specific for the striatum (see 
e.g. Cools, 1985) it follows that the last 
possibility is the most likely one. 
In chapter 4 section 4-3 it will be shown 
that the ability to switch to cue-directed 
behaviours is transmitted from the nucleus 
accumbens to the subpallidal areas i.e. an 
increase in the number of different cue-
directed behaviours elicited by intra-
accumbens d-amphetamine was attenuated by 
the GABAa-agonist muscimol in the 
subpallidal areas. This shows that the ability 
to display different cue-directed behavioure 
requires at least a lowered GABA-output from 
the nucleus accumbens to the subpallidal 
areas. The alphal-agonist phenylephrine and 
the alpha2-antagonist rauwolscine decreased 
the ability to display different cue-directed 
behaviours. It follows accordingly that the 
accumbens-subpallidal GABA-activity might 
have been enhanced by these drugs. 
Although the present data do not allow to 
draw a firm conclusion on the involvement of 
alpha 1- or alpha2-receptors per se, for 
essential pharmacological experiments are 
lacking in this respect, the following might be 
speculated however. The fact that the alpha 1 -
agonist phenylephrine and the alpha2-
antagonist rauwolscine decreased the number 
of different cue-directed behaviours, whereas 
the alphal-agonist Clonidine was ineffective in 
this respect, suggests that in the accumbens-
subpallidal channel alphal- and alpha2-
receptors were in functionally opposite states: 
alphal-receptors were in a functionally 
receptive state for agonists, whereas alpha2-
receptors were in a functionally unreceptíve 
state for agonists, but in a functionally 
receptive state for antagonists (Cools et al, 
1987; 1990a and references cited therein). If 
it is assumed that alphal-receptors are 
predominantly located at the postsynaptic site 
of the synaps (Timmermans and Van Zwieten, 
1982), it might be derived from the present 
data and the foregoing considerations that a 
low noradrenaline activity existed in the 
accumbens-subpallidal channel (cf Cools et al, 
1987). The alpha2-receptor might be located 
either postsynaptically or presynaptically 
(Exton, 1985; Timmermans and Van Zwieten, 
1982). In the latter case alpha2-receptors 
might have been in a functionally opposite 
state to alphal-receptors since presynaptic 
alpha2-receptors regulate noradrenaline release 
(Exton, 1985; Timmermans and Van Zwieten, 
1982; cf Cools et al, 1987). If so, it might be 
derived then that in the swimming test the 
alpha2-agents acted at the presynaptic site. 
Similarly the inability of phenylephrine to 
affect the number of different non cue-
directed behaviours in contrast to the ability 
of Clonidine to do this, suggests that in the 
nucleus accumbens-nigra channel the alpha-
noradrenergic receptors, if present, were in 
functionally opposite states: alphal-receptors 
were in a functionally unreceptive state for 
agonists, whereas alphal-receptors were in a 
functionally receptive state (Cools et al, 1987; 
1990a and references cited therein). 
Following the reasoning above thus leads to 
the suggestion that the noradrenaline activity 
was high in this channel. If so, it would 
explain why haloperidol decreased the number 
of different non cue-directed behaviours as 
shown in the previous paragraph (paragraph 
3.4.3 ). Due to the fact that the alpha-1 
receptors in the accumbens-nigra channel were 
in a receptive state for alphal-antagonists, 
haloperidol, which has an affinity for the 
alphal-receptor (Christensen, 1985) may 
interact with the alphal-receptor. Hence, it 
may decrease the activity in the striatal 
system (see above) and accordingly decrease 
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the number of different non cue-directed 
behaviours. 
In conclusion the present data showed that 
alpha-noradrenergic drugs were functionally 
active in the nucleus accumbens. They may 
subserve functionally different roles in the 
regulation of the different aspects of the 
swimming behaviour of rats i.e. the ability to 
switch to cue-directed or non cue-directed 
behaviours. This notion is in agreement with 
data reported in the literature (Plaznik et al, 
1985; Pijnenburg et al, 1976). These data 
moreover indicate that more than one 
noradrenergic system exists in the nucleus 
accumbens. Whether the ability to affect the 
different cue-directed behaviours is mediated 
via dopamine or not will be discussed in 
section 3-5. It remains finally to be 
determined how and to what extent beta-
receptors are involved in the ability to switch 
to cue-directed or non cue-directed behaviours 
in rats. 
3.4.5 Excitatory amino acids 
3.4.5.1 Introduction 
As shown in section 3-2 the efferents from 
cortical (prefrontal cortex, hippocampus) and 
a number of subcortical (basolateral amygdala 
and midline thalamic nuclei) areas to the 
nucleus accumbens use excitatory amino acids 
(EAA) as neurotrans-mitter. EAA exert their 
effect via at least three types of receptors: a 
quisqualate (QA) type, a N-methyl-d-aspartate 
(NMDA) type and a kainate (KA) type 
(Collingridge and Lester, 1989; Cotman and 
Iversen, 1987). All these types are present in 
the nucleus accumbens of the rat (see e.g. 
Cotman et al, 1987). Until now the effects of 
these EAA in the nucleus accumbens have 
been mainly studied using motor activity as 
the dependent variable (Amt, 1981; Boldry 
and Uretsky, 1988; Donzanti and Uretsky, 
1983; Hamilton et al, 1986; Shreve and 
Uretsky, 1988a). In general these studies have 
shown that stimulation of EAA-receptois 
enhance motor activity. Recently some studies 
have also indicated that EAA in the nucleus 
accumbens might be involved in learning 
(Klimek et al, 1989; Scheel-Kruger et al, 
1989), and the acute (Pulvirenti et al, 1989) 
and chronic (Pulvirenti and Koob, 1989) 
effects of cocaine. 
Since EAA and dopamine in the nucleus 
accumbens may interact in several ways 
(Louilot et al, 1985; Pycock et al, 1980; 
Springer and Isaacson, 1982; Reinstein et al, 
1982; Yang and Mogenson, 1984; Yim and 
Mogenson, 1982; paragraph 3.4.1, section 3-
5) it was decided to study the behavioural 
effects of intra-accumbens injections of agents 
selective for EAA-receptors in the 
swimmming test in an attempt to further 
delineate the role of these EAA in the 
nucleus accumbens. 
Intra-accumbens injections of the following 
glutamatergic drugs were used: the QA-
agonist dl-alpha-amino-3-hydroxy-5-methyl-
isoxazole-4-propionic acid (AMPA), the 
Table 3-15: Effects of glutamatergic drugs on 
the number of rearings Shown are 
means+sem's. 
DRUG 
AD 
AMPA 
AMPA 
AMPA 
AMPA 
AP-7 
AP-7 
NMA 
NMA 
NMA 
KYN 
KYN 
DOSE 
-
10 
100 
250 
500 
100 
500 
250 
750 
1500 
250 
500 
SCORE 
42.2+5. 
39.2+4. 
37.5+4. 
30.8+7. 
31.3+5, 
45.2+7. 
54.9+4. 
48.2+4. 
46.0+6. 
24.9+3 
39.1+5 
48.4+4 
.7 
.0 
.8 
.8 
.9 
.0 
.4 
.9 
.5 
.0« 
.6 
.3 
N 
8 
9 
12 
9 
11 
9 
9 
9 
8 
' 9 
8 
9 
For abbreviations of the drugs 
see tex t ; N: number of r a t s ; 
dose: ng/0.5 ul 
* p<0.05 t - t e s t two-tailed 
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Figure 3-19: Effects of glutamatergic drugs on the number of different cue-directed (CDB) and non 
cue-directed behaviours (NCDB; Y-axes). X-axes: time-blocks; values: group effects and inter-
action-terms of two-way ANOVA's; N.S: not significant. 
NMDA-agonist N-methyl-dl-aspartic acid 
(NMA), and the selective NMDA-antagonist 
d-2-aniino-7-phosphonoheptanoic acid (AP-7; 
Collingridge and Lester, 1989; Cotman and 
Iversen, 1987). Furthermore the nonselective 
antagonist kynurenic acid (KYN; Collingridge 
and Lester, 1989) was used. 
The materials and methods have been 
described in section 3.4.2. The results 
presented in this part of the thesis can in part 
be found in paper Ш. 110 Rats were 
included in the present experiments. In all 
graphs means+sem's are shown, except for 
figure 3-21 in which only means are shown 
(from SNK-tests). 
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3.4.5.2 Results 
In the open field preceeding the swimming 
test, only the highest dose of NMA had an 
effect on the number of rearings (table 3-15; 
Ш). This dose i.e. 1500 ng/0.5 ul 
significantly decreased the number of rea­
rings. The highest dose of AMPA (500 
ng/0.5 ul) induced disturbances in motor 
behaviours i.e. forelimb tremors and 
tonic/clonic convulsions. This dose was 
therefore discarded from the subsequent 
analyses. 
As can be seen in figure 3-19 (panel A) 
AMPA (10-250 ng/0.5 ul) enhanced the 
number of different cue-directed behaviours 
(Ш). A post hoc SNK test showed that the 
dose of 250 ng was significantly different 
from the control (p<0.05). Moreover its 
profile differed from that of the AD-treated 
rats, which was reflected by the significant 
interaction-term. The effect was most clear in 
the last time period, i.e. 4-6 min. In figure 3-
19, panel C, it can be seen that AP-7 (lOO-
500 ng/0.5 ul) tended to enhance the 
number of cue-directed behaviours, an effect 
which appeared to be most clear in the last 2 
min period, i.e 4-6 min. Although no 
significant group effect was found, a 
significant interaction term existed. No effect 
was found with NMA (250-1500 ng/0.5 ul), 
or KYN (250-500 ng/0.5 ul) on the number 
of different cue-directed behaviours (figure 3-
19, panels E and G respectively). From figure 
3-19 it is clear that none of the drugs affected 
the number of different non cue-directed 
behaviours (panels B,D,F,H; III). 
Both AMPA, NMA and KYN were 
ineffective in inducing changes in the 
frequency of cue-directed behaviours (figure 
3-20, panels A, E and G respectively; Ш). In 
the case of AMPA this seemed to be in 
disagreement with the data presented in figure 
3-19, panel A. As pointed out in paragraph 
3.4.3 'scanning wall' may mask subtle 
changes in the remainer of cue-directed 
behaviours, i.e. 'crossing', 'diving' and 
'scanning bottom'. The data were therefore 
reanalysed omitting 'scanning wall' from the 
data-files. It turned out that AMPA 
significantly enhanced the frequency of the 
remainder of cue-directed behaviours i.e. 
'diving', 'scanning wall' and 'crossing' 
(AMPA vs AD (mean+sem): 12.44+1.61 vs 
6.75+1.36, t=2.700 dÊ=15 p<0.02 two-tailed 
t-test; Ш). AP-7 dose-dependently enhanced 
the frequency of cue-directed behaviours 
(figure 3-20 panel С; Ш). A post hoc SNK-
test revealed that both doses, i.e. 100 and 
500 ng/0.5 ul were significantly different 
from AD (p<0.05). Furthermore, the dose of 
500 ng was significantly different (p<0.05) 
from the dose of 100 ng. The frequency of 
non cue-directed behaviouis was not affected 
by any of the drugs (figure 3-20, panels 
B,D,F and H; Ш). 
Since no consistent effects were found on 
the frequency of non cue-directed behaviours 
the switchings between non cue-directed 
behaviours were not analysed separately. The 
other three categories (paragraph 3.4.2) are 
depicted in figure 3-21 (ΠΙ). From this figure 
it is clear that AMPA enhanced both the 
actual switches between cue-directed 
behaviours (panel A), as well as the actual 
switches between non cue-directed and cue-
directed behaviours (panels В and С; Ш), 
although with different profiles. Thus, whereas 
the lowest dose (10 ng/0.5 ul) enhanced the 
number of switches from non cue-directed to 
cue-directed behaviours and vice versa the 
highest dose (250 ng/0.5 ul) solely enhanced 
the number of switches between cue-directed 
behaviours. In the former case the switches 
were predominantly between 'scanning wall' 
and 'sinking', whereas in the latter case the 
switches between 'scanning wall' and 
'crossing' became dominant. It should be 
noted that the rats became more stereotyped 
with increasing doses: they kept repeating 
'crossing' without interruptions by other 
behaviours. NMA (250 ng/0.5 ul) enhanced 
only the number of switches from non cue-
directed to cue-directed behaviours and vice 
versa (figure 3-21, panels D, E and F; Ш). 
Again this was due to an enhanced switching 
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Figure 3-20: Effects of glutamatergic drags on the frequency of cue-directed (CDB) and non cue-
directed behaviours (NCDB; Y-axes). X-axes: time-blocks; values: group-effects and interaction-
terms of two-way ANOVA's; N.S.: not signiñcant. 
between 'sinking' and 'scanning wall'. AP-7 
(ЮО-500 ng/0.5 ul) dose-dependently 
enhanced the number of switches from cue-
directed to cue-directed behaviours (figure 3-
21, panel J). These increases were 
predominantly due to increases between 
'scanning wall' and 'crossing'. KYN finally 
appeared to be ineffective in inducing changes 
in any of the categories. A significant 
interaction-term was found in the case of 
switches between cue-directed behaviours 
(F(4,66)=4.07, p<0.05). 
In table 3-16 it can be seen that none of 
the drugs showed a consistent effect upon 
detection of the rope; only AMPA at the dose 
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of 10 ng/0.5 ul decreased it (Ш). None of 
the drugs consistently increased or decreased 
escape, although AP-7 tended to enhance it 
decreased the total number of rats that 
escaped. 
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Figure 3-21: Effects of glutamatergic drugs on the number of switches between cue-directed (top 
row), from non cue-directed to cue-directed behaviours (middle row) and vice versa (bottom 
row). Values: group effects; *:p<0.05 vs AD. 
(from 25.0% to 55.6%). The only consistent 
effects were found for the total number of 
rats that escaped. Both AMPA and NMDA 
3.4.5.3 Discussion 
The main finding of this study was that, 
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apart from KYN, all glutamatergic drugs 
affected the ability to switch to cue-directed 
behaviours in the swimming test upon 
injection in the nucleus accumbens (Ш). 
These data confirm that EAA-receptors in the 
nucleus accumbens are indeed functionally 
active (Amt, 1981; Boldry and Uretsky, 1988; 
Donzanti and Uretsky, 1983; Hamilton et al, 
1986; Shreve and Uretsky, 1988a). Since it 
turned out that each drug produced its own 
profile, the effects of the different drugs will 
be discussed separately below. 
The selective NMDA-antagonist AP-7 
(CoUingridge and Lester, 1989) dose-
dependently increased the frequency of cue-
directed behaviours (figure 3-20) as well as 
the ability to switch between cue-directed 
behaviours (figure 3-21). Furthermore the 
behaviour did not appear to be stereotyped; an 
observation which is illustrated by the 
increase in the number of different cue-
directed behaviours (figure 3-19). Overall, 
these data thus suggest that blockade of the 
NMDA-receptor enhanced the ability to switch 
to cue-directed behaviours. Accordingly one 
would predict that stimulation of the NMDA-
receptor leads to a decrease in the mentioned 
variables. However the NMDA-agonist NMA 
(CoUingridge and Lester, 1989) did not 
change the ability to switch to cue-directed 
behaviours. Thus, neither the frequency of 
cue-directed behaviours, the actual number of 
switches between cue-directed behaviours nor 
the number of different cue-directed 
behaviours was changed by the different 
doses of NMA (figures 3-19, 3-20 and 3-
21). A possible explanation for this 
phenomenon might be that the basal degree of 
stimulation of the NMDA-receptor was simply 
too high, leading to a low susceptibility for 
the agonist and a relatively high susceptibility 
for the antagonist (see Cools et al, 1990a and 
references therein). It is anyhow clear from 
the data that AP-7 was effective whereas 
NMA was devoid of producing significant 
effects in this respect in this test. Kynurenic 
acid too was ineffective in this paradigm. 
Although one might argue that the doses were 
too low to induce an effect, previous 
experiments have shown that these doses were 
behaviourally active (Cools and Peelers, 
1987). Kynurenic acid is known to block both 
the QA- and NMDA-receptor (CoUingridge 
and Lester, 1989). If one assumes that the 
QA-receptor and NMDA-receptor have 
opposite roles in the nucleus accumbens in 
the ability to switch to cue-directed 
behaviours, the effect of kynurenic acid may 
be explained as follows. It might actually 
block the effect resulting from the blockade 
of the NMDA-receptor, i.e. an increase in the 
ability to switch to cue-directed behaviours (cf 
AP-7 see above), by inhibiting the QA-
receptor at the same time. If so, one would 
predict that stimulation of the QA-receptor 
with AMPA asserts similar effects as 
blockade of the NMDA-receptor with AP-7. 
As shown in figures 3-19 to 3-21 this is 
indeed partly the case. Thus AMPA increased 
the number of different cue-directed 
behaviours (figure 3-19, panel A) as well as 
the actual number of switches between cue-
directed behaviours (figure 3-21, panel A). 
The analysis without 'scanning wall' showed 
that AMPA also increased the frequency of 
the remainder of cue-directed behaviours, i.e. 
'diving', scanning bottom' and 'crossing', 
although the frequency of cue-directed 
behaviours including 'scanning wall' was not 
enhanced (figure 3-20, panel A). Since the 
major bulk of cue-directed behaviours 
consisted of 'scanning wall' (paragraph 3.4.3; 
Π), these findings indicate that the behavioural 
changes were rather subtle. The observation 
that the actual number of switches between 
cue-directed behaviours did not increase 
anymore after the dose of 100 ng/0.5 ul 
(figure 3-21, panel A), might be due to the 
fact that the behaviour became stereotyped 
with increasing doses. Overall these data 
strongly suggest that the QA- and NMDA-
receptor subserve functionally opposite roles 
in the nucleus accumbens in the ability to 
switch to cue-directed behaviours. The finding 
that both AP-7 and AMPA affected the ability 
to switch to cue-directed behaviours fits in 
with the fact that the nucleus accumbens is 
known to play a role in this ability (paragraph 
3.4.3; ІД). Whether these two EAA receptor 
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Table 3-16: Effects of glutamatergic drugs on the detection of the rope, free escape and free+forced 
escape. Shown are percentages. 
DRUG DOSE DETECTION 
AD 
AMPA 
AMPA 
AMPA 
AP-7 
AP-7 
NMA 
NMA 
NMA 
KYN 
KYN 
-
10 
100 
250 
100 
500 
250 
750 
1500 
250 
500 
50.0 
0.0 
66.6 
44.4 
55.6 
77.8 
11.1 
25.0 
11.1 
12.5 
77.7 
For abbreviations see text; Ν: number 
* p<0.05 X-square two-tailed 
subtypes are directly or indirectly coupled 
remains to be established (see Cotman et al, 
1987). 
Surprisingly it was found that AMPA and 
NMA enhanced the actual number of switches 
between cue-directed behaviours and non cue-
directed behaviours. As shown in figure 3-
21, it turned out that NMA affected the 
number of switches from cue-directed 
behaviours to non cue-directed behaviours , 
and vice versa, without an effect on the 
number of switches between cue-directed 
behaviours. Also the doses of AMPA 
appeared to be selective in this respect: the 
highest dose solely enhanced the number of 
switches between cue-directed behavioun, 
whereas the lowest dose solely enhanced the 
number of switches from cue-directed 
behaviours to non cue-directed behaviours, 
and vice versa (figure 3-21). Finally AP-7 
enhanced only the number of switches 
between cue-directed behaviours (figure 3-
21). It might overall be concluded from these 
data that two different mechanisms are 
involved: one in the ability to switch between 
FREE FREE+FORCED N 
25.0 
0.0 
33.3 
0.0 
44.4 
55.6 
11.1 
25.0 
11.1 
0.0 
66.6 
87.5 
66.7 
41.6* 
11.1* 
77.8 
88.9 
11.1* 
75.0 
11.1* 
62.5 
100.0 
8 
9 
12 
9 
9 
9 
9 
β 
9 
8 
9 
of rats; dose: ng/0.5 ul 
cue-directed behaviours and one in the ability 
to switch between cue-directed behaviours and 
non cue-directed behaviours. This drug 
induced increase in mutual switches between 
cue-directed behaviours and non cue-directed 
behaviours might imply that the nucleus 
accumbens is involved in both types of 
switches despite the fact that previous 
experiments have shown that the (dorsal) 
striatum is involved in the ability to switch to 
non cue-directed behaviours (Cools, 1980; 
Vrijmoed-de Vries and Cools, 1986; section 
3-3). Although no fully satisfying explanation 
can be given as yet, the possibility might be 
considered that the increase in the mutual 
switches results from interfering with the 
neuronal flow from the nucleus accumbens to 
the (dorsal) striatum. The projection from the 
nucleus accumbens on the neurons of the 
nigrostriatal system (section 3-2; paragraph 
3.4.4) might be one pathway along which this 
may take place. A prerequisite for this would 
be that EAA-receptors affect this pathway 
either directly, or indirectly. Since no clear 
experimental data are available in this respect, 
this possibility remains highly speculative. 
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The data on the rope-directed behaviour 
showed that AMPA and AP-7 differed on this 
parameter. Whereas AMPA decreased the total 
number of rats that escaped, AP-7 had no 
effect on this parameter (table 3-16). In 
contrast NMA decreased the total number of 
rats that escaped. Kynurenic acid had no 
effect on any of the parameters concerning 
the rope. It would thus appear that AMPA 
and NMA have similar effects on escape. 
This direction of the effect seems thus to be 
similar to the direction of the effect of these 
drugs on the number of switches between 
cue-directed behaviours and non cue-directed 
behaviours. Overall the data on the rope-
directed behaviour support the notion that 
differences exist between the behavioural 
profiles of the different drugs. 
To what extent these results were related to 
changes in motor activity is at present not 
clear. Previous studies showed that AMPA 
increased motor activity in the dose-range of 
the present study (Amt, 1981; Shreve and 
Uretsky, 1988a). Although AMPA did not 
affect rearing during the first IO min after 
injection, preliminary data have shown that 
AMPA 250 ng/0.5 ul increased motor 
activity in non habituated rats only from 10 
min after injection onward (Charria Ortiz, Van 
den Bos and Cools, unpublished data) i.e. 
during the period in which the behavioural 
effects in the swimming test were found. One 
could thus argue that the observed effects in 
the swimming test were simply due to 
nonspecific increases in motor activity. The 
highest dose of AMPA, i.e. 250 ng/0.5 ul, 
however enhanced the number of switches 
between cue-directed behaviours without an 
effect on the number of switches from cue-
directed behaviours to non cue-directed 
behaviours, and vice versa. Moreover 
blockade of the NMDA-receptor enhanced the 
number of switches between cue-directed 
behaviours, whereas this had no effect on 
motor activity (Hamilton et al, 1986; table 3-
15). Furthermore the lowest dose of AMPA, 
i.e. 10 ng/0.5 ul, enhanced solely the number 
of switches between non cue-directed 
behaviours and cue-directed behaviours, 
whereas it had no effect on motor activity 
(Amt, 1981; table 3-15). The same applies to 
the lowest dose of NMA, i.e. 250 ng/O.5 ul: 
an enhancement of the number of switches 
between cue-directed behaviours and non cue-
directed behaviours without an increase in 
motor activity (Donzanti and Uretsky, 1983; 
Hamilton et al, 1986). In fact, although it has 
been shown that NMA enhanced motor 
activity in the dose range of the present study 
(Donzanti and Uretsky, 1983), only a decrease 
was found in the number of rearings in the 
present study (table 3-15). These latter 
findings appear however to be in line with 
those from O'Neill and coworkers who were 
unable to find profound changes in motor 
activity or rearing using NMDA in doses 
ranging from 0.4-4.0 ug/0.5 ul (O'Neill et 
al, 1989). These data overall thus show that 
the effects observed in the swimming test 
were not due to or accompanied by changes 
in motor activity per se. 
In conclusion the present study showed that 
EAA in the nucleus accumbens play a role in 
the ability to switch to cue-directed 
behaviours; differences may however exist as 
far as it concerns the contribution of the 
different EAA-receptor subtypes (cf Pulvirenti 
and Koob,1989; Pulvirenti et al, 1989). In 
section 3-5 these results will be discussed 
with respect to those obtained for dopamine. 
3-5 General discussion; towards a new 
concept on the role of the nucleus 
accumbens in behaviour 
3.5.1 General conclusions from the swimming 
test 
The main findings from the experiments 
presented in this chapter were that 
manipulation with the nucleus accumbens 
affected the ability of rats to display cue-
directed behaviours with little -if any- effect 
on the ability to display non cue-directed 
behaviours. Moreover these effects were not 
related to changes in general activity of the 
rats per se. Table 3-17 summarizes the data 
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for the different drugs. It is clear from this 
table that several drugs had properties in 
common with respect to their ability to affea 
the swimming behaviour of the rats. Thus, it 
may be suggested that these agents affected 
transmitter systems within the nucleus 
accumbens which may have directly or 
indirectly interacted with each other in the 
nucleus accumbens (see below). 
A number of questions can be put forward 
here: (i) what is the effect of the open field 
preceeding the swimming test on the 
subsequent swimming behaviour of the rats; a 
question of particular importance for 
understanding the nature of the effects of the 
drugs, i.e. an interaction of the drugs with the 
'novelty induced stress' of the open field may 
exist; (ii) what are the relationships between 
the different neurotransmitters, which were 
studied here, within the nucleus accumbens, 
and to what extent do these relate to the 
observed effects, i.e. what might be the 
underlying neuronal mechanisms for the 
observed effects; and finally (iii) what can 
be derived on the role of the nucleus 
accumbens in behaviour from these 
experiments, i.e. do these data support the 
original hypothesis on the role of the nucleus 
accumbens put forward in section 3-3. 
the open field 
Table 3-17: Summary of the results of the experiments presented in this chapter (see paragraphs 
3.4.3, 3.4.4 and 3.4.5). 
DRUG REC CDB CUE NOTE CUE ESCAPE 
different frequency CUE CUE NCUE 
AMP 
LY 
RAC 
SKF 
SCH 
D1/D2 
D2 
D2 
Dl 
Dl 
t 
ts 
n.d. 
u 
== 
dopaminergic 
t 
t 
n.d. 
I 
=1 = 
drugs 
=™ 
== 
n.d. 
-= 
== 
== 
== 
n.d. 
-= 
== 
t free 
t free 
(Ifree) 
(|free) 
\ free 
+forced 
DPI DAi n.d. n.d. n.d. n.d. 
PHE alphal \ 
CLO alpha2 -= (*) 
RAU alpha2 | 
n.d. 
n.d. 
n.d. 
noradrenergic 
n.d. 
n.d. 
n.d. 
drugs 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
J free 
t free 
== 
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Since the rats were placed into an open 
field, which was novel to them, for 10 
minutes it might be expected that this open 
field had an influence on the rat's behaviour 
in the swimming test. Pilot experiments 
showed that omitting the open field had a 
dramatic effect on the swimming behaviour: 
the number of different cue-directed 
behaviours was low in the first time-block, 
effect on the initial number of different cue-
directed behaviours or the profile of time-
curve of cue-directed behaviours (table 3-18). 
It would appear that the novelty of the open 
field in itself had no profound effect on the 
rat's subsequent ability to display cue-directed 
behaviours in the swimming test. Thus, it 
might be concluded that the 'novelty induced 
stress' had little effect on the subsequent 
behaviour of the rats (see further paragraph 
Table 3-17: continued 
DRUG REC CDB CUE NCUE CUE 
different frequency CUE CUE NCUE 
AMPA QA 
NMA NMDA 
glutamatergic drugs 
u t t t 
t t 
ESCAPE 
\ free 
+forced 
| free 
+forced 
AP-7 NMDA 
KYN QA/ 
NMDA 
(t free) 
For the abbreviations of the drugs see the respective paragraphs; 
RAC, SCH 23390, RAU, AP-7 and KYN are antagonists of the respective 
receptors; all other drugs are agonists; 
REC: receptor; CDB, CUE: cue-directed behaviour; NCUE: non cue-
directed behaviour; 
I,J: increase respectively decrease in the parameter; n.d.: not 
determined; S: effect on remainder of CDB; (*): increase in the 
number of different non cue-directed behaviours; between brackets: 
nearly significant effect; ==: no effect. 
i.e. 0-2 min, and increased in time (table 3-
18). This effect was the opposite of that in 
the situation with the open field. Accordingly 
on a statistical evaluation of these data (two-
way ANOVA; see paragraphs 3.4.3, 3.4.4 and 
3.4.5) an interaction term was found 
F(2,42)=44.36, p<0.01 (O min novel vs 10 
min novel open field; table 3-18). Other 
manipulations (60 minutes novel open field; 
10 minutes home-cage) had no significant 
3.5.3). Although it would go too far here to 
go into too much detail into a possible 
explanation for the reversed time-curve of 
cue-directed behaviours in the situation in 
which the open field was omitted, an 
interesting possibility for this effect might be 
that it reflects the so called 'warm up 
sequence', which rats normally display in the 
open field (Eilam and Golani, 1988; Golani et 
al, 1981; see further paragraph 3.5.3). 
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dopamine and switching 
It is generally believed that dopamine is the 
transmitter involved in switching between 
alternative strategies (Oades, 1985; Robbins 
and Everitt, 1982; Swerdlow and Koob, 
1987a). The data presented in this chapter 
suggest that other transmitters are also 
involved in the ability to switch behaviour. 
Similar effects were found for the dopamine 
D2-agonist LY 171 555 and the EAA 
NMDA-antagonist AP-7. Moreover similar 
effects were observed for the dopamine D2-
antagonist raclopride and the alphal-
noradrenergic agonist phenylephrine and the 
alpha2-noradrenergic antagonist rauwolscine 
(table 3-17). Dopamine may however still 
subserve the role put forward above if one 
considers the following. 
It has been shown that Clonidine decreases 
the K+-induced release of tritiated dopamine 
(Nurse et al, 1984, 1985; Russell et al, 1987). 
In contrast, the beta-noradrenergic agonist 
isoproterenol enhanced both the basal and K+-
induced release of dopamine (Nurse et al, 
1984, 1985). These data suggest that 
noradrenaline acts presynaptically from 
dopamine, which is supported by data 
obtained in the limbic part of the caudate 
nucleus of the cat (Cools et al, 1978). 
According-ly changes in the noradrenergic 
transmission might affect the dopaminergic 
system and thus indirectly the ability to 
switch to cue-directed behaviours (see further 
paragraph 3.5.3). 
The interaction between glutamate and 
dopamine is multiform and complex. It has 
been shown that lesions of structures, which 
send glutamatergic efferents to the nucleus 
accumbens have profound effects on the 
dopaminergic transmission within the nucleus 
accumbens. Thus, lesions of the prefrontal 
cortex (Louilot et al, 1989; Pycock et al, 
1980; Starkstein et al, 1988; see also Reibaud 
et al, 1984), and the amygdala (Deminiere et 
al, 1988; Louilot et al, 1985; 1987) enhanced 
the dopaminergic activity in the nucleus 
accumbens. In contrast, lesions of the 
hippocampus reduced the dopaminergic 
activity (Springer and Isaacson, 1982). In vivo 
micro-dialysis experiments have furthermore 
shown that the NMDA-agonist NMDA 
enhanced the release of dopamine in the 
nucleus accumbens of the rat (Payson and 
Donzanti, 1989), although in vitro experiments 
have not confirmed this (Hamil-ton et al, 
1986). 
Dopamine on the other hand has been found 
to affect the input from both the hippocampus 
(Yang and Mogenson, 1984) and amygdala 
(Yim and Mogenson, 1982; see paragraph 
3.5.2). 
The foregoing shows that a dual interaction 
between dopamine and glutamate exists, 
which makes it difficult to assess whether the 
effects of AP-7 and AMPA were mediated via 
dopamine. 
It would be tentative to conclude that the 
effects which were observed in the swimming 
test for the ability to switch to cue-directed 
behaviours with the non dopaminergic drugs 
were due to changes in the dopaminergic 
transmission despite the remarks made on the 
interaction between dopamine and glutamate. 
This would in turn support then the general 
notion that dopamine is involved in switching 
(Oades, 1985). A closer look at the anatomy 
of the nucleus accumbens, elaborated in the 
next paragraph might give a more conclusive 
answer though. 
3.5.2 Towards a new concept: a second look 
at the anatomy of the nucleus accumbens. 
(sub)cortical inputs 
As outlined in section 3-2 the accumbens 
receives afférents from the hippocampus 
(dorsal and ventral subiculum) the amygdala 
(basolateral nucleus), the prefrontal cortex, 
and several midline thalamic nuclei (see e.g. 
Groenewegen et al, 1987; McGeorge and 
Faull, 1989); inputs, which contain 1-glutamate 
and/or 1-aspanate as neurotransmitter (Christie 
et al, 1987; Fuller et al, 1987), The afférents 
from the subiculum seem to terminate on two 
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Table 3-18: Effects of manipulation with the open fíeld on the subsequent ability to display 
different cue-directed behaviours in the swimming test. Shown are means+sem's. 
treatment 
CUE-DIRECTED BEHAVIOURS 
0-2 2-4 4-6 
О min novel * 1.50+0.19 
IO min novel $ 3.37+0.30 
60 min novel $ 3.33+0.27 
10 min home cage $ 3.88+0.12 
2, 
2. 
1. 
1. 
.38+0. 
.12+0. 
.44+0. 
.75+0. 
.38 
.27 
.23 
.29 
4 
1. 
1 
1 
.oo+o. 
. 0 0 + 0 . 
. 2 2 + 0 . 
. 0 0 + 0 . 
.00 
.35 
.21 
.00 
8 
8 
9 
В 
novel open field: see materials and methods (paragraph 3.4.2); 
N: number of rats; all rats received 0.5 ul AD 
*: Van den Воз, R, A.C. Bergmans and A.R. Cools, unpublished data; 
$: Van den Bos, R, G.A. Charria Ortiz and A.R. Cools, unpublished 
data ; 
types of neurons: the medium-sized spiny 
neurons and the large aspiny neurons 
(Totterdell and Smith, 1989; DeFrance et al, 
1985a; see also Groenewegen et al, 1990; 
Meredith et al, 1990). Whereas the former 
are believed to contain GABA as 
neurotransmitter, the latter may use 
acetylcholine and constitute a population of 
intemeurons (paragraph 3.2.1). Totterdell and 
Smith showed that dopaminergic input (from 
the VTA-region) and hippocampal input 
converge on both types of neurons (Totterdell 
and Smith, 1989; see Groenewegen et al, 
1990). Although these authors suggested a 
convergence upon the neuron itself, others 
have suggested that an interaction between 
dopamine and glutamate might take place at 
the level of the afferent terminals of the 
hippocampus (Yang and Mogenson, 1986). 
The input from the hippocampus seems to use 
at least the QA-type of receptor since 
glutamic diethyl ester (GDEE), a QA-
antagonist (Collingridge and Lester, 1989), 
attenuated the excitation of accumbens 
neurons induced by ventral subiculum 
stimulation (Yang and Mogenson, 1984). 
Since this inhibition occurred in about 50% 
of the cells these data suggest that other 
types of receptor, i.e. the NMDA-type and 
ΚΑ-type may also be involved (see below). 
Electrophysiological experiments have 
shown that stimulation of the hippocampus 
excites and inhibits neurons in the nucleus 
accumbens (DeFrance et al, 1985a; Yang and 
Mogenson, 1984). This latter effect seemed to 
be due to activation of GABA-ergic 
mechanisms in the nucleus accumbens, since 
the GABA-antagonist bicuculline was able to 
block it (DeFrance et al, 1985a). As indicated 
above the hippocampal input terminates on 
medium-sized spiny neurons, which are 
believed to be GABA-ergic. This latter 
population of neurons serves both as output 
and as intemeurons. It has been shown that 
stimulation of the hippocampus inhibits 
neurons in the ventral pallidum via a 
monosynaptic pathway (Yang and Mogenson, 
1985), which suggests that the hippocampus 
output indeed terminates on accumbens output 
neurons. It appears however that the 
hippocampus output also terminates on the 
GABA-ergic intemeurons (see below). 
Electrophysiological experi-ments have 
moreover shown that dopamine is able to 
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attenuate the excitation of accumbens neurons 
induced by stimulation of the ventral 
subiculum of the hippocampus (DeFrance et 
al, 1981a, 1981b, 1985b; Yang and 
Mogenson, 1984). Subsequent experiments 
have shown that the mixed dopamine D1/D2 
antagonist haloperidol attenuated the inhibitory 
effect of repeated stimulation of the VTA-
region, which released dopamine in the 
accumbens (Yang and Mogenson, 1984). 
Moreover the D2-antagonist sulpiride 
attenuated the enhanced hippocampus terminal 
excitability induced by dopamine; the Dl-
antagonist SCH 23390 was ineffective in this 
set-up (Yang and Mogenson, 1986). The 
effects of dopamine on the incoming 
hippocampus signals appear therefore to be 
mediated via the dopamine D2-receptor. In 
line with this it was found that the selective 
D2-agonist LY 171 555 mimicked the effect 
of dopamine whereas the Dl-agonist SKF 
38393 was devoid of activity in this respect 
(Yang and Mogenson, 1986; see also Yang 
and Mogenson, 1987). Moreover other 
experiments have shown that the effects of 
dopamine were frequency dependent: at low 
frequencies (0.5 Hz) of subiculum stimulation 
dopamine was able to attenuate the excitatory 
effects on accumbens neurons, whereas at 
higher frequencies (6.0 Hz) dopamine was 
ineffective (DeFrance et al, 1981a, 1981b, 
1985b). The latter frequency is within the 
range of the theta-rhythm (see O'Keefe and 
Nadel, 1978; see further below). The series of 
experiments performed by Mogenson and 
coworkers were performed with low 
frequencies of stimulation (0.5-1.5 Hz; see 
e.g. Yang and Mogenson, 1984). Interestingly, 
DeFrance et al observed that cAMP attenuated 
both the excitatory effects of low and high 
frequency stimulation (DeFrance et al, 1985 b). 
This finding may be related to the data 
obtained by Takaori and coworkers. They 
showed that stimulation of the locus coeruleus 
(LC) as well as local application of 
noradrenaline attenuated the excitatory effects 
of ventro-dorsal subiculum stimulation on 
accumbens neurons (Unemoto et al, 1985) 
whereas stimulation of the VTA was 
ineffective in this respect (Akaike et al, 
1984). From their last paper it can be derived, 
that Takaori and coworkers used a high 
frequency of stimulation of the hippocampus 
(10-40 Hz). These data confirm thus the 
findings of DeFrance and collegues reported 
above. The fact that the beta-antagonist Sotalol 
was effective in antagonizing the effect of 
LC-stimulation, whereas the alpha-antagonist 
phentolamine was ineffective showed that the 
effect of noradrenaline was mediated via a 
beta-noradrenergic receptor (Unemoto et al, 
1985). These findings are interesting in view 
of the finding that beta noradrenergic 
receptors unlike alpha noradrenergic receptors 
are affected after manipulation with the LC 
(see e.g. Stone et al, 1987). Since beta-
receptors are coupled to an adenylate cyclase 
system (see e.g. Exton, 1985) this suggests 
that the effects of cAMP observed by the 
DeFrance and coworkers (see above) were due 
to a direct or indirect effect on this secondary 
messenger system. It would furthermore 
suggest that noradrenaline (via the beta-
receptor) in contrast to dopamine (via the D2-
receptor) is active over the whole spectre of 
subicular frequencies. 
The glutamatergic input from the 
(basolateral) amygdala (Christie et al, 1987; 
Fuller et al, 1987; Kelley et al, 1982) is less 
well characterized in terms of its terminal 
patterning in the nucleus accumbens, i.e. in 
terms of its interaction with specific neuronal 
cell-populations in the nucleus accumbens, 
than the (subiculum of the) hippocampus. 
Some authors however suggest that the 
efferents from the (basolateral) amygdala 
impinge upon the same neuronal population as 
the efferents from the (subiculum of the) 
hippocampus (see e.g. Groenewegen et al, 
1990). In favour of this possibility, it has 
been found that stimulation of the efferent 
pathways from the amygdala and from the 
hippocampus excite the same neurons in the 
nucleus accumbens (DeFrance et al, 1980). 
The input from the amygdala is also 
modulated by dopamine. Thus, Yim and 
Mogenson showed that repeated stimulation of 
the VTA as well as application of dopamine 
in the nucleus accumbens attenuated the 
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excitatory effects of amygdala stimulation on 
accumbens neurons (Yim and Mogenson, 
1982, 1986). Subsequently these authors 
showed that haloperidol attenuated this 
inhibitory effect of VTA-stimulation (Yim and 
Mogenson, 1982, 1986). Since haloperidol is 
both a dopamine D2- and Dl- antagonist, 
next to being an alpha-noradrenergic 
antagonist (Christensen, 1985), no unequivocal 
conclusion can be drawn from these data on 
the involvement of one of these types of 
receptors. Recently however behavioural 
experiments have shown that Dl-receptors are 
specifically involved in affecting secondary 
reinforcement (Wolterink et al, 1989; see 
further paragraph 3.5.4.4); a phenomenon, 
which is mediated via the amygdala-
accumbens pathway (Cador et al, 1989; 
Everitt et al, 1989). This would thus suggest 
that the effect of haloperidol (Yim and 
Mogenson, 1982, 1986) might be achieved via 
the Dl-receptor. Interestingly these data 
suggest that dopamine Dl-receptors and D2-
receptors are differentially located in the 
nucleus accumbens, i.e. on the amygdala-
accumbens pathway and the hippocampus-
accumbens pathway respectively. If so, this 
might explain why it has been observed that 
D2-agents do not affect the Dl-mediated 
increase in cAMP in the nucleus accumbens 
(Stoof and Verheijden, 1986; Stoof et al, 
1987a ; cf Kelly and Nahorski, 1987). 
The afférents from the prefrontal cortex 
terminate in the anterior-medial region of the 
nucleus accumbens (see paragraph 3.2.2.3). At 
present it is not known on which cell-
populations these afférents terminate or 
whether they are modulated by dopamine. 
The excitatory input from the parafascicular 
nucleus of the thalamus (pf-thal) seems to 
terminate on the cholinergic intemeurons and 
on an as yet unidentified population of 
neurons (see Groenewegen et al, 1990). The 
excitation of accumbens neurons after 
stimulation of the pf-thal was attenuated by 
repeated stimulation of the VTA region 
(Akaike et al, 1984), whereas LC-stimulation 
was ineffective in this respect (Unemoto et al, 
1985). Behavioural experiments have however 
shown that blockade of alpha-noradrenergic 
receptors in the nucleus accumbens attenuated 
the effects of pf-thal stimulation (Cools, 
1978). 
interrelationship between the 
different excitatory inputs 
Since the hippocampal input terminates both 
on output neurons and on intemeurons (see 
above) the hippocampus may thus not only 
directly affect the output of the nucleus 
accumbens (see chapter 4 section 4-2, and 
references therein) but also indirectly; the 
latter might be achieved through a local 
circuitry within the nucleus accumbens. As 
pointed out above the hippocampal afferent 
terminals impinge upon the cholinergic 
intemeurons. Interestingly it has been found 
that stimulation of the NMDA-receptor 
enhances the release of acetylcholine in the 
nucleus accumbens (Hamilton et al, 1986). 
The cholinergic agonist oxotremorine has been 
shown to enhance the K+-induced release of 
dopamine in the nucleus accumbens; an effect, 
which appeared to be mediated via the 
muscarinic type of receptor (De Belleroche 
and Gardiner, 1982). Some data suggest that 
muscarinic receptors might actually be located 
on terminals of the mesolimbic dopamine 
system in the nucleus accumbens (De 
Belleroche et al, 1982a). In support of this 
behavioural experiments have shown that both 
carbachol (Jones et al, 1981) and 
oxotremorine (De Belleroche et al, 1982b) -
muscarinic agonists (Watson et al, 1986)-
stimulated dopamine induced motor activity 
(see however also Costali et al, 1979). 
Furthermore haloperidol attenuated the 
enhanced motor activity induced by injections 
of carbachol into the nucleus accumbens 
(Austin and Kali vas, 1988). In the latter case 
the effect of carbachol appeared to be 
nicotinic in nature however (Austin and 
Kalivas, 1988). Finally a lesion of the 
dopaminergic system in the nucleus 
accumbens with 6-OHDA decreased the 
amplitude of tremorine induced tremor 
(Dickinson and Slater, 1981). Although this 
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suggests a stimulatory effect of acetylcholine 
on the dopaminergic transmission in the 
nucleus accumbens, others have found that -
the nicotinic antagonist- nicotine enhanced the 
release of dopamine in the nucleus accumbens 
after either systemic (Imperato et al, 1986; 
see also Lapin et al, 1989) or local (Mifsud 
et al, 1989) injections.In line with this 
nicotinic receptors have been found to exist 
on dopaminergic terminals within the nucleus 
accumbens (Clarke and Pert, 1985). These 
findings indicate an inverse relation between 
muscarinic and nicotinic receptors as far as it 
concerns the ability to affect the dopaminergic 
system (cf De Belleroche and Bradford, 1978 
for the striatum). 
As already outlined above NMDA has been 
found to stimulate the release of acetylcholine 
in the accumbens (Hamilton et al, 1986). This 
suggests that the glutamatergic input from the 
hippocampus might direct the release of 
acetylcholine, which in return might direct the 
release of dopamine. Since the hippocampus 
input is modulated by dopamine D2-receptors, 
it follows that D2-receptors might affect the 
release of acetylcholine. Indeed, it has been 
found that stimulation of dopamine D2-
receptors attenuates the stimulated release of 
acetylcholine; an effect, which was attenuated 
by the D2-antagonist 1-sulpiride (Stoof et al, 
1987a, 1987b; Wedzony et al, 1988; see 
however Consolo et al, 1977). Interestingly 
SKF 38393 was virtually devoid of activity 
(Wedzony et al, 1988). One might 
furthermore predict that stimulation or lesions 
of the hippocampus affect the dopaminergic 
transmission in the nucleus accumbens. In 
support of this it has been found that lesions 
of the hippocampus decrease the dopamine 
turnover in the nucleus accumbens (Springer 
and Isaacson, 1982). The behavioural changes 
which accompanied these lesions, like an 
increased locomotion, were partially 
antagonized by intra-accumbens injections of 
the DAi-agonist DPI (Reinstein et al, 1982). 
Since the DAi-receptor shares some 
characteristics with the Dl-receptor 
(Offermeier and Van Rooyen, 1982; paragraph 
3.4.3), and since the latter appears to be 
located at the level of the amygdala input 
(see above), this tentatively suggests that the 
behavioural changes due to the lesions of the 
hippocampus were antagonized by 
manipulation at a site beyond the actual 
hippocampus-accumbens input, i.e. at the level 
of the amygdala-accumbens pathway. The data 
suggest that the behavioural changes were the 
consequence of a relatively enhanced activity 
of the amygdala-accumbens pathway. 
If the foregoing interaction indeed exists, 
the following paradox in the data of 
Mogenson and coworkers might be resolved. 
Injection of carbachol in the dentate gyrus of 
the hippocampus enhanced motor activity in 
the open field which was attenuated at the 
level of the accumbens by injection of the 
QA-antagonist GDEE or the NMDA-
antagonist 2-amino-4-phosphobutyric acid 
(APB; Mogenson and Nielsen, 1984a). These 
latter findings suggested that the glutamatergic 
pathway from the hippocampus to the nucleus 
accumbens was activated (see above). Since 
stimulation of the hippocampus has been 
shown to inhibit the firing rate of cells within 
the subpallidal areas via the nucleus 
accumbens (Yang and Mogenson, 1985) 
through an activated GABA-ergic accumbens-
subpallidal pathway (chapter 4 section 4-2), 
one might predict that the effects induced by 
injections of carbachol into the hippocampus 
are attenuated at the subpallidal level by a 
GABA-antagonist. Instead however, it was 
found that GABA attenuated this effect 
(Mogenson and Nielsen, 1984a). An 
explanation for these findings might be that 
the carbachol-induced effect was funnelled via 
the intra-accumbens pathway outlined above. 
The enhanced hippocampus-accumbens 
activity, would lower indirectly the amygdala-
accumbens input according to the reasoning 
followed above. Electrophysiological 
experiments have shown that stimulation of 
the amygdala inhibits neuronal activity within 
the ventral pallidum/substantia innominata area 
via an amygdala-accumbens-pallidal pathway 
(Yim and Mogenson, 1983). Thus a decreased 
activity within the amygdala-accumbens 
pathway lowers the output to the subpallidal 
areas. With respect to the experiment 
performed by Mogenson and Nielsen, the 
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foregoing suggests that the GABA-
transmission within the subpallidal areas is 
reduced, which would explain why GABA 
was effective in attenuating the effects 
induced by carbachol in the hippocampus 
(Mogenson and Nielsen, 1984a). Similarly, 
this route could explain why the activity 
induced by injections of NMDA into the 
hippocampus was blocked by the GABA 
uptake inhibitor nipecotic acid in the 
subpallidal areas (Yang and Mogenson, 1987). 
It should however be kept in mind that an 
alternative route via GABA-ergic intemeurons 
might also account for these effects, if it is 
assumed that these GABA-ergic intemeurons 
terminate upon the output-neurons of the 
accumbens; for, stimulation of the 
hippocampus reduces the output of the 
accumbens neurons then. These data overall 
suggest that several hippocampus-accumbens 
channels might exist, which might be 
differentially activated upon manipulation with 
the hippocampus. 
6-OHDA Lesions of the basolateral part of 
the amygdala (Deminiere et al, 1988) or 
blockade of the dopaminergic transmission 
within this nucleus (Louilot et al, 1985, 1987) 
enhanced the dopamine turnover in the 
nucleus accumbens. Conversely enhancing the 
dopaminergic transmission within the 
basolateral amygdala decreased the 
dopaminergic transmission within the nucleus 
accumbens (Louilot et al, 1985; 1987). At 
present it is not known whether these effects 
are mediated via direct glutamatergic 
projections from the amygdala to the nucleus 
accumbens or via a -feedback- pathway from 
the amygdala to the VTA (see Louilot et al, 
1987). Injections of NMDA in this part of the 
amygdala decreased exploratory locomotion 
;an effect which was attenuated by intra-
accumbens injections of otherwise ineffective 
doses of dopamine (Yim and Mogenson, 
1989). If it is assumed that NMDA enhanced 
the output of the amygdala this effect can be 
explained by a direct effect on the output 
neurons of the nucleus accumbens. For, 
enhancing the GABA-output to the ventral 
pallidum blocks motor activity (chapter 4, 
section 4-3). The effect of dopamine could 
accordingly be explained via its effect on the 
incoming glutamatergic afférents from the 
amygdala (see above). Although no precise 
information on the synaptic contacts of the 
amygdala input onto accumbens neurons exist, 
it has been suggested that they may be 
similar as those from the hippocampus 
(Groenewegen et al, 1990). It may 
accordingly be speculated that manipulation 
with the amygdala has consequences for the 
incoming signals from e.g. the hippocampus. 
Thus, changes in the output of the amygdala 
to the nucleus accumbens may have 
(m)direct effects on the input from the 
hippocampus (, prefrontal cortex or pf-thal 
(see below)) to the nucleus accumbens. 
Lesions of the prefrontal cortex enhance the 
dopamine turnover in the nucleus accumbens 
(Pycock et al, 1980; Starkstein et al, 1988; 
see also Louilot et al, 1989). Furthermore the 
number of binding sites for tritiated ADTN (a 
dopamine Dl-agonist) and tritiated spiperone 
(a dopamine D2-antagonist) were enhanced 
(Pycock et al, 1980). Moreover the activity of 
the DA-sensitive adenylate cyclase was 
enhanced (Pycock et al, 1980; Reibaud et al, 
1984; see also Tassin et al, 1987). The latter 
observation suggests a decreased dopamine 
Dl-transmission, which would render the 
receptors supersensitive to stimulation (see 
Reibaud et al, 1984). Moreover the foregoing 
data suggest that the increase in dopamine 
D2-antagonist binding sites might reflect an 
increase in dopamine D2-activity (cf. Cools et 
al, 1990a and references cites therein; 
paragraph 3.4.4). 
Enhancing the dopaminergic transmission 
within the prefrontal cortex lowers the 
dopaminergic activity in the nucleus 
accumbens, whereas lowering the prefrontal 
activity has the opposite effect (Louilot et al, 
1989). Whether this effect occuis directly via 
the glutamatergic prefrontal-accumbens 
pathway or indirectly via a -feedback-
pathway from the prefrontal cortex to the 
VTA (see Oades and Halliday, 1987) is at 
present not clear (see Louilot et al, 1989). 
Although the precise anatomical connections 
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are not known it is tentative to suggest that 
changing the prefrontal activity has effects on 
the incoming signals from other structures. 
More specific, it would be tempting to 
speculate that via the Dl-receptor the 
amygdala input is affected, and via the D2-
receptor the hippocampus input. In fact, 
decreasing the prefrontal activity might 
enhance the amygdala-accumbens activity - a 
decreased Dl-activity- and decrease the 
hippocampal-accumbens activity -an increased 
D2-activity-. The mirror image holds true for 
increasing the prefrontal output 
Lesions of the parafascicular nucleus of the 
thalamus (pf-thal) with the neurotoxin ibotenic 
acid induced small but significant decreases in 
dopaminergic activity in the nucleus 
accumbens (Kilpatrick et al, 1986). Since an 
increase is found within the prefrontal cortex 
(Kilpatrick et al, 1986) it cannot be excluded 
that this effect in the nucleus accumbens was 
indirect, i.e. due to the increase in the 
prefrontal cortex the dopaminergic 
transmission in the accumbens may be 
enhanced (see above). Electrical stimulation of 
this nucleus had nearly no effects on 
dopaminergic activity in the accumbens -if 
anything a slight increase-, whereas the 
dopaminergic activity in the prefrontal cortex 
was profoundly decreased (Kilpatrick and 
Phillipson, 1986), suggesting some 
independence of the observed effects. 
Although the terminal patterning of this 
nucleus on neurons in the nucleus accumbens 
is not known (see above) it might be 
speculated that changes within the neuronal 
activity within this nucleus of the thalamus 
may have effects on the incoming signals 
from the hippocampus, amygdala or prefrontal 
cortex. 
In figure 3-22 the foregoing considerations 
are brought together and fit into a model on 
neuronal connections within the nucleus 
accumbens. This model is in part published 
earlier (Cools et al, 1990b) but extended here 
to include the excitatory input from the 
prefrontal cortex. Moreover an intrinsic 
circuitry is given for the possible interactions 
between different inputs. Furthermore in 
contrast to this previous concept the 
hippocampus input is suggested to be 
glutamatergic in nature. As can be seen in 
figure 3-22 an alphal-noradrenergic receptor 
is situated within the amygdala-accumbens 
channel, for which arguments are given in 
Cools et al (Cools et al, 1990b). However, 
unlike this previous model, no specific 
afferent pathway is given. Whereas in the 
previous concept the input was suggested to 
come from the medulla oblongata system via 
the ventral noradrenergic bundle, it is 
suggested here that the input may be provided 
by circulating noradrenaline from the 
adrenocortical system (Stone et al, 1987). It 
should be stressed however that the former 
innervation still has been shown to exist (see 
section 3-2). In order to avoid 
misunderstandings it should finally be stressed 
that the model is not meant to represent a 
'true' anatomical model of the nucleus 
accumbens; in essence it is a 'functional' 
model, which may hold true at an anatomical 
level though. Given the model depicted in 
figure 3-22 the data obtained in this chapter 
might be explained along the lines given in 
paragraph 3.5.3. 
3.5.3 Towards a new concept: a possible 
explanation of the results of the swimming 
test 
In the hippocampus of rats which explore a 
novel environment, a so called 'theta-rhythm' 
has been shown to exist (Whishaw and 
Vander- wolf, 1971, 1973; see also Bland and 
Vanderwolf, 1972; O'Keefe and Nadel, 1978, 
pl42). Since the swimming tank may be 
considered a novel environment, it might be 
assumed that this theta-rhythm is present in 
the hippocampus (see Whishaw and 
Vanderwolf, 1971, 1973 for data underlining 
this notion). In favour of this, it has been 
found that the lateral septum -which indirectly 
drives the theta-rhythm in the hippocampus-
showed a higher deoxyglucose uptake in rats 
which swam for 5 minutes in a 'novel' 
environment than in rats which were 
immobile in their home cages (Duncan et al, 
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Figure 3-22: Model based upon electrophysiological and behavioural findings presented in this 
chapter (adapted from Cools et al, 1990b with modifications). GLU: glutamate; ACH: acetylcholine; 
-: inhibition; +: excitation; ?: not known 
1989). The output from the hippocampus to 
the accumbens might thus be governed by this 
theta-rhythm. If so, dopamine in the nucleus 
accumbens might not attenuate the excitatory 
effects of the hippocampus on accumbens 
neurons. Instead as DeFrance and coworkers 
suggested dopamine might filter out the lower 
frequencies in this case and hence sharpen the 
hippocampal informational load (DeFrance et 
al, 1981b; see also Swerdlow and Koob, 
1987a). 
The effects of LY 171 555 and d-
amphetamine in the swimming test might be 
explained by this filtering function of 
dopamine. It may be suggested that they 
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enhanced the informational load from the 
hippocampus. In fact this may explain why 
these drags appeared to enhance the existing 
behaviour. Conversely, the D2-antagonist(s) 
raclopride (sulpiride and haloperidol) might 
have disrupted the incoming signal, by 
preventing dopamine from filtering out these 
lower frequencies. Consequently, they 
disrapted the ongoing behaviour of the rats. 
This explanation of the results would 
predict that beta-noradrenergic agonists show 
a dual effect: a LY 171 555-(D2-)like 
enhancing effect with low doses and a 
disruption with higher doses (see paragraph 
3.5.2). Since the LC-activity has been 
suggested to be enhanced by novelty, 
subserving a 'stand by and watch' function 
(see van Dongen, 1980), it might be assumed 
that the LC beta-noradrenergic activity is high 
upon entering the swimming test. This in turn 
might disrupt the incoming signal from the 
hippocampus and hence affect the ongoing 
behaviour. Interestingly upon entering the 
swimming test rats are 'immobile' for a 
period of 5-10 seconds, after which they start 
to display different cue-directed behaviours. In 
fact this immobility might be due to the 
initially hyperactive LC- system. This feature 
may also underlie the observed effect in the 
swimming test without the open field. 
Directly after injection of the rats ( a 
'stressftil' event) the LC beta-noradrenergic 
activity might be high, which in tum blocks 
the incoming hippocampus signal. This LC-
activity might then gradually decrease after 
which the hippocampus channel is 'opened' 
allowing rats to display cue-directed 
behaviours. Since the novelty of the open 
field did not affect the swimming behaviour 
of the rats, it is suggested that the injection 
procedure is the most important factor in this 
respect. In support of this, a similar pattern is 
in fact seen in the open field: upon entering 
the open field after injection, rats are initially 
motionless after which they gradually start 
to explore the environment. 
Mogenson and Nielsen showed that intra-
accumbens injections of the QA-antagonist 
GDEE attenuated spontaneous exploration in 
an open field (Mogenson and Nielsen, 1984b). 
Since they also observed that injections of 
GABA into the subpallidal areas decreased 
this activity (Mogenson and Nielsen, 1984b), 
these data suggest that the GABA-output from 
the accumbens is lowered. If one assumes that 
GDEE acted at the level of the hippocampus 
input in the nucleus accumbens (cf figure 3-
22) this moreover suggests that the 
hippocampus-accumbens pathway was active 
during exploration (cf Whishaw and 
Vanderwolf, 1971, 1973). Furthermore it 
might be speculated that the incoming signal 
from the hippocampus is not funnelled 
directly but indirectly to the subpallidal area 
(cf injections of carbachol and NM DA in the 
hippocampus; figure 3-22). Thus, if the 
hippocampus is similarly active in the 
swimming test (see above) it suggests that 
the cholinergic activity was high during this 
test (cf figure 3-22). Accordingly the 
dopamine Dl/DAi activity was also enhanced. 
The latter would explain why the Dl-
antagonist SCH 23390 decreased the number 
of different cue-directed behaviours. Moreover 
the data obtained with the partial Dl -agonist 
SKF 38393 become understandable in this 
context: due to the increased Dl-activity SKF 
38393 acted as antagonist. Alternatively the 
Dl-receptor might be in an unreceptive state 
for agonists (cf. Cools et al, 1990a and 
references therein). Furthermore since the 
DAl-receptor and the DAi-receptor share 
some properties it would explain why DPI 
was ineffective: the DAi-receptor was in an 
unreceptive state for agonists (cf. Cools et al, 
1990a and references therein). Finally the 
foregoing suggest that the amygdala-
accumbens activity was decreased at the level 
of the nucleus accumbens (figure 3-22). 
Hence the output from the nucleus accumbens 
to the subpallidal areas was lowered (Yim and 
Mogenson, 1983). Accordingly one would 
predict that the effects of injections of d-
amphetamine in the nucleus accumbens -
which enhance the information load from the 
hippocampus (see above)- are attenuated by a 
GABA-agonist at the level of the subpallidal 
areas. As will be shown in chapter 4, section 
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4-3 this appears to be indeed the case. 
It has been shown previously that the alpha-
noradrenergic activity and the dopamine DAi-
activity are functionally opposed in the limbic 
paît of the cat caudate nucleus (Cools et al, 
1978; cf Nurse et al, 1984, 1985; Russell et 
al, 1987). A decrease in the latter activity 
disrupts the flow of information from the 
hippocampus to the subpallida] areas by way 
of the nucleus accumbens (see figure 3-22). 
As pointed out in paragraph 3.4.4 the 
noradrenergic activity was low in the 
swimming test, rendering alphal-receptors 
sensitive to the agonist on the postsynaptic 
site, and alpha2-receptors sensitive to the 
antagonist on the presynaptic site (cf Cools et 
al, 1987). Thus phenylephrine might have 
lowered the number of different cue-directed 
behaviours by decreasing the DAi-activity. 
Conversely rauwolscine might have lowered 
the number of different cue-directed 
behaviours by interacting with the presynaptic 
receptor, which indirectly enhances the 
noradrenergic activity, and in return lowers 
the DAi-activity. 
Within this framework, the NMDA-
antagonist AP-7 might act either at the level 
of the prefrontal input, at the level of the 
amygdala-input, or at the level of the 
hippocampus input. To start with the former. 
If AP-7 blocked the prefrontal input one 
would predict a disruption of the ability to 
switch to cue-directed behaviours, for, 
according to the foregoing considerations 
blocking the prefrontal input lowers the 
dopamine Dl-activity (figure 3-22). Since an 
enhancement of the ability to switch to cue-
directed behaviours was observed it might be 
suggested that AP-7 did not act at this level. 
Since the AP-7 induced effects closely 
mimicked those of d-amphetamine and LY 
171 555, it might be speculated that it acted 
rather at the level of the hippocampus input. 
Following the assumption that the 
hippocampus-accumbens pathway is active in 
the swimming test (see above), the release of 
EAA is high. Consequently the NMDA-type 
of receptor might be receptive for the 
antagonist (see paragraph 3.4.5). In support of 
this possibility the data indeed showed that 
the NMDA-antagonist AP-7 was effective, 
whereas the NMDA-agonist NMA was 
ineffective in affecting the ability to switch to 
cue-directed behaviours. This would lead to 
the interesting possibility, that by blocking the 
NMDA-type of receptor the incoming 
hippocampal signal was enhanced within the 
nucleus accumbens. As pointed out in 
paragraph 3.4.5 the QA-receptor and NMDA-
receptor appeared to be in functional opposite 
states in the nucleus accumbens with respect 
to the ability to switch to cue-directed 
behaviours in the swimming test. Despite the 
enhanced activity of the hippocampus-
accumbens pathway the QA-agonist AMPA 
might act at the level of the hippocampus 
input to increase the number of switches to 
cue-directed behaviours. The possibility 
remains however that AP-7 and AMPA acted 
at the level of the accumbens-amygdala 
pathway. 
The underlying assumption in the foregoing 
explanation of the results is that the 
behaviours in themselves were not generated 
in the nucleus accumbens. The above given 
explanation in fact suggests that the cue-
directed behaviours i.e. behaviours with a 
spatial component, were generated within the 
hippocampus, which appears to be compatible 
with the suggested role of the hippocampus in 
spatial learning (O'Keefe and Nadel, 1978). 
The data presented in this chapter showed 
that d-amphetamine, LY 171 555 and AP-7 
did not interfere with the habituation of the 
rats to environmental aspects of the swimming 
test, for, a decrease in the number of switches 
to cue-directed behaviours in time was 
observed in these cases (figure 3-6; figure 3-
8; figure 3-20). Accordingly it appears that 
learning about the specific environment was 
not disrupted by these drugs. Previous 
experiments have shown that rats display a 
different behavioural pattern upon entering the 
swimming test for the second time: they show 
less 'crossing', 'diving' and 'scanning bottom' 
(Charria Ortiz, Van den Bos and Cools, 
unpublished data; Ploeger and Cools, 
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unpublished data; Scheenen and Cools, 
unpublished data). Moreover they spend more 
time on performing 'swimming free' (Ploeger 
and Cools, unpublished data; Scheenen and 
Cools, unpublished data). Furthermore it has 
been observed that rats display more 'planing' 
during the second exposure to the test, when 
they have shown this behaviour on the first 
exposure to the test (Cools, 1980). In fact, 
these observations were the major reason why 
rats were only used once in the swimming 
test. With respect to 'swimming free' 
(swimming in the middle of the tank; table 3-
1, figure 3-3) it is interesting to note that 
they showed this behaviour only when the 
rope, which appeared in the middle of the 
tank, had been offered to them on the first 
day. These observations indicate that the rats 
anticipated on the appearance of the rope on 
the second day. Overall these data suggest 
that the test itself had a strong impact on the 
rat's subsequent behaviour: the stimuli in the 
environment became 'conditioners' during the 
experiments on the first day and were able to 
direct the behaviour on the second day. Those 
behaviours which initially were not directed 
by overt stimuli in the environment, i.e. 
behaviours which could not be derived from 
or predicted by currently available sensory 
information on the first day, were directed by 
the stimuli inherent to the test on the second 
day: upon entering the swimming test, the rats 
were immediately able to display them (one-
trial learning). Two remarks should therefore 
be made on the terminology that has been 
used here: cue-directed and non cue-directed 
behaviours. First, the above given data show 
that the differentiation into behaviours which 
are directed by stimuli from the environment 
and behaviours which are not directed by the 
environment only holds in case rats are only 
used once, i.e. for the first exposure to the 
test. Second, the term 'cue' - as a synonym 
for 'stimulus'- was tacitly introduced in this 
chapter, following existing literature (see e.g. 
Morris et al, 1982). However the following 
considerations might force one to adopt 
another terminology in the future. The wall 
and the bottom of the tank were at fust 
stimuli which were present throughout the 
experiment. During the test, the rats learned 
about the environment, i.e. they 'explored' 
wall and bottom of the tank. This was shown 
by the decrease in the frequency and duration 
of wall- and bottom- directed behaviour, i.e. 
cue-directed behaviours. Since they showed 
less of these behaviours upon the second 
exposure to the test, the wall and the bottom 
may have become familiar at first sight, i.e. 
'known' to the rats in the sense that the rats 
immediately know that this is the same 
environment as in the first exposure. In fact, 
the test itself as a complex of stimuli may 
'tell' the rat that this was the same 
environment. In terms of learning about the 
specific environment, it might be better 
accordingly to use the term 'cue' to indicate 
a 'stimulus' or a complex of 'stimuli' which 
has gained the ability to direct the behaviour 
on the subsequent exposure to this 
environment. Thus a 'cue' in this sense has a 
higher level of complexity than a 'stimulus'. 
In fact in first instance the stimulus directs 
the behaviour, (stimulus-response). This 
stimulus may be transformed into a 'cue' in 
time depending on its importance, e.g. its 
surviving or reinforcing value. Several 
'stimuli' may group together to become a 
complex 'cue'. These 'cues' have accordingly 
the ability to elicit the whole set of responses. 
The experiments presented in this chapter 
showed that the nucleus accumbens was 
involved in the ability to switch to behaviours 
which were directed by stimuli from the 
environment -could be predicted from the 
stimuli in the environment-. The decrease in 
'stimulus'-directed behaviours in time may 
point to a transformation of these 'stimuli' 
into a 'cue' or 'cues'. It can not however 
unequivocally be concluded from these 
experiments that the nucleus accumbens was 
involved in the ability of 'cues' to switch to 
behaviour. A review of the literature described 
in the next paragraph however seems to allow 
for such a conclusion. 
3.5.4. Towards a new concept: a review of 
some experiments with respect to the nucleus 
accumbens 
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3.5.4.1 Environment specific conditioning 
Rats treated chronically with 
psychostimulants, e.g. d-amphetamine or 
cocaine, in a constant environment for days, 
show two interesting phenomena: (i) the 
motor response becomes stronger after each 
challenge (sensitisation), and (ii) a higher 
motor activity is found in rats, which received 
the drug than in rats which received vehicle, 
after replacement in the forementioned 
environment (environment specific 
conditioning; see e.g. Gold et al, 1988; Post 
et al, 1988). Thus, it appears that a 
conditioned response (CR) was elicited by 
cues that were previously neutral (conditioned 
stimuli; CS). Moreover it has been recently 
shown that the effect is mediated via the D2-
receptor, since the specific D2-agonist LY 171 
555 was able to induce a (weak) environment 
specific conditioning (Mazurski and Beninger, 
1988). In line with this the development of 
the d-amphetamine induced environment 
specific conditioning was blocked by 
concomitant treatment with the D2-antagonist 
pimozide (Beninger and Hahn, 1983). 
Furthermore 6-OHDA nucleus accumbens 
lesions were effective in attenuating the 
development of environment specific 
conditioning (Gold et al, 1988). The 
development of the cocaine-induced 
sensitisation was blocked by the D2-antagonist 
haloperidol, and electrolytic or 6-OHDA 
lesions of the nucleus accumbens (Post et al, 
1988). Interestingly it was found that 
pimozide was not able to block environment 
specific conditioning per se (Beninger and 
Hahn, 1983); nor was haloperidol able to 
attenuate the expression of cocaine- induced 
sensitisation (Post et al, 1988). Since the 
underlying mechanisms in these two 
paradigms appear to be the same, they are 
considered together in the following parts. 6-
OHDA Lesions of the nucleus accumbens 
have been found to be effective in 
suppressing environment specific conditioning 
(Gold et al, 1988). Although the latter finding 
was at variance with the foregoing 
observations the following observations may 
bridge these apparently contradictory results. 
First, in the Gold et al study the 
noradrenergic system was lesioned next to the 
dopaminergic system, since the authors did 
not use desmethylimipramine (DMI), which 
protects the noradrenergic terminals from the 
neurotoxic effects of 6-OHDA (Gold et al, 
1988). Second, Cools and coworkers showed 
that motor activity becomes under 
noradrenergic control after a challenge with d-
amphetamine (Cools et al, 1990b). Third, 
Post et al showed that treatment with the 
alpha2-agonist Clonidine attenuated the 
development and the expression of cocaine-
induced sensitisation (Post et al, 1988). Thus, 
it might be derived from these data that the 
noradrenergic system controls (the 
development and) the expression of cocaine-
induced sensitisation and environment specific 
conditioning, which makes it understandable 
why the dopaminergic antagonists pimozide 
and haloperidol were ineffective in this 
respect (see above), whereas lesions of the 
noradrenergic (and dopaminergic) system 
were. Post et al furthermore observed that 
electrolytic lesions of the amygdala were 
effective in attenuating the development of 
sensitisation whereas dorsal hippocampus 
lesions were not; both lesions were ineffective 
in affecting the acute motor effects of cocaine 
(Post et al, 1988). This would render the 
amygdala-accumbens pathway important for 
the development of sensitisation. Similarly this 
pathway may play a role in environment 
specific conditioning. Data from another -by 
itself not entirely convincing- experiment lend 
some support for this latter possibility. Rats 
with amygdala lesions were retarded in 
acquiring environment specific conditioned 
defecation whereas rats with fornix 
transsections -which blocks hippocampal 
function- were not (Vanderwolf et al, 1988). 
3.5.4.2 Conditioned place preference 
A set-up which is related to the paradigms 
described above is conditioned place 
preference. The principle of this paradigm is 
rather simple. It starts with observing the rat's 
initial preference for two clearly different 
environments. In the lesser preferred 
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environment the psychostimulants are injected, 
in the preferred environment the vehicle. After 
8-10 days of alternating psychostimulant-
environment and vehicle-environment pairing 
the rat's preference in an undrugged state is 
observed. Using this paradigm it has been 
shown that injections of d-amphetamine into 
the nucleus accumbens changed the initial 
preference of the rats, i.e. the rats spent more 
time in the amphetamine-paired environment -
the initially less preferred one- than in the 
vehicle-paired environment (Carr and White, 
1983). These effects appear to be accumbens-
specific since intrastriatal injections of d-
amphetamine were ineffective in eliciting this 
phenomenon (Carr and White, 1983). Thus, it 
seems that the nucleus accumbens plays a 
critical role in establishing a conditioned place 
preference. 
3.5.4.3 Secondary reinforcement 
Another paradigm which has been studied 
in relation to the nucleus accumbens is 
secondary reinforcement; a phenomenon, in 
which a conditioned stimulus (CS) elicits a 
conditioned response (CR) in the absence of 
the -initially present- primary reinforcer 
(unconditioned stimulus; US) to which this 
CS was paired. The paradigm is essentially as 
follows: in the training phase (phase I) a 
stimulus or a sequence of stimuli is paired 
with a primary reinforcer. In the studies 
reported below water was used as primary 
reinforcer in thirsty rats. After a stable base 
line of responding is obtained the second 
phase -the testing phase (phase II)- is 
initiated, in which two levers are introduced 
into the chamber in which the rats were 
trained. Responding on one lever results in 
the presentation of the CS (CR-lever), 
responding on the other lever has no 
programmed consequences (NCR-lever). Since 
the primary reinforcer is absent in this phase, 
this phase is by definition an extinction phase. 
In an alternative procedure the levers were 
already present in the training phase but 
responding on them had no programmed 
consequences. 
In 1976, Robbins showed that the 
psychostimulant drug pipradrol (15 mg/kg) 
enhanced the number of responses on the CR-
lever in the testing phase, whereas it had no 
effect on the number of responses on the 
NCR-lever (Robbins, 1976). Moreover, the 
effect was only obtained when the CS was 
explicitly combined with the primary 
reinforcer, random pairing of CS and reward 
did not induce specific responding (Robbins, 
1976). Interestingly he furthermore 
demonstrated that the rats were responding on 
the CR-lever in a highly stereotyped manner, 
which was shown by the fact that rats kept 
responding on the second component of a two 
lever sequence, which resulted in the CR if it 
was correctly performed, under pipradrol 
(Robbins, 1976). These results were replicated 
in another study, and extended to include 
other psychostimulants (Robbins, 1978). 
Whereas methylphenidate mimicked the effect 
of pipradrol, d-amphetamine did not (Robbins, 
1978). Yet, in another study a weak effect 
with the latter drug was obtained (Robbins 
and Everitt, 1982). The latter study also 
demonstrated that 6-OHDA lesions of the 
caudate nucleus -lesions were made prior to 
the testing phase- attenuated the enhanced 
responding on the CR-lever by pipradrol; an 
effect, which was ascribed to an attenuation 
of the stereotyped manner of responding of 
the rats (Robbins and Everitt, 1982). They 
were however still able to sample the 
contingency. This effect on the stereotyped 
character of the response seems to be in 
agreement with the role of the caudate 
nucleus in stereotypy (see e.g. Kelly et al, 
1975). 6-OHDA Lesions of the nucleus 
accumbens/olfactory tubercle also lowered the 
number of responses on the CR-lever, which 
was however primarily due to the fact that 
the rats remained at the spot where the water 
had been delivered previously; whenever the 
rat went to the CR-lever it was still able to 
sample the contingency (Robbins and Everitt, 
1982). Although it would thus appear that 
neither structure was specifically involved in 
secondary rein-forcement, subsequent 
experiments shed more light on this. Thus, 
Taylor and Robbins showed that injections of 
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d-amphetamine (10-30 ug/0.5 ui) into the 
nucleus accumbens increased the number of 
responses on the CR-lever, while they had no 
effect on the number of responses on the 
NCR-lever, injections into the caudate nucleus 
produced only weak effects (Taylor and 
Robbins, 1984). Moreover they showed that 
d-amphetamine elicited only an effect when 
the CS was positively coupled to the primary 
reinforcer, no effect was obtained when it was 
randomly or negatively coupled to the CS 
(Taylor and Robbins, 1984) confirming earlier 
findings (Robbins, 1976). It was subsequently 
shown that the effect of injections of d-
amphetamine into the nucleus accumbens was 
blocked by 6-0HDA lesions of the nucleus 
accumbens , whereas 6-0HDA lesions 
of the caudate nucleus were ineffective 
(Taylor and Robbins, 1986). Moreover a low 
-by itself ineffective- dose of apomoiphine 
enhanced responding on the CR-lever in 6-
OHDA accumbens lesioned rats but not in 6-
OHDA caudate nucleus lesioned rats (Taylor 
and Robbins, 1986). It was finally shown that 
the differential responding on the CR-lever 
and the NCR-lever was reduced (from a 
factor 4-5 to a factor 2-2.5) after NMDA 
lesions of the (basolateral) amygdala (Cador 
et al, 1989). This lowered difference was 
maintained under intra-accumbens d-
amphetamine injections (Cador et al, 1989; 
see also Everitt et al, 1989). Moreover 
lesioned and non-lesioned rats showed similar 
extinction rates (CS presented), and were 
equally capable in learning a new conditioned 
response, i.e the coupling between a stimulus 
and a primary reinforcer (Cador et al, 1989). 
Intra-accumbens injections of dopamine have 
been shown to mimic the effect of d-
amphetamine, whereas injections of 
noradrenaline were ineffective (Wolterink et 
al, 1989), showing that the effect of d-
amphetamine was mediated via the dopamine 
system. Moreover the effect appeared to be 
mediated via the dopamine Dl-receptor 
(Wolterink et al, 1989). 
Overall these data indicate that the 
amygdala-accumbens axis is important for 
secondary reinforcement. Whereas the 
amygdala appeared to play a role in the 
sampling of the contingency (difference 
between CR-lever and NCR-lever), (dopamine 
in) the nucleus accumbens seemed to be 
important for the expression of the existent 
association (increase in number of CR-lever 
responses). It is finally important to note that 
the amygdala-lesioned rats were still able to 
learn a new contingency in the presence of a 
primary reinforcer, indicating that this 
immediate learning per se and thus the 
coupling between a stimulus and a reward 
does not need an intact amygdala; the latter 
structure appears only to play a role in the 
absence of the primary reinforcer. 
3.5.4,4 Learning and memory 
Recently evidence has been obtained that 
the nucleus accumbens is involved in maze-
leaming tasks like the Olton radial maze and 
the Morris water maze. Taghzouti et al 
showed that the acquisition in both the Olton 
radial maze and the Morris water maze were 
retarded after intra-accumbens injections of 
haloperidol (Taghzouti et al, 1987). Moreover 
both the D2-antagonist sulpiride (10-50 ng) 
and the Dl-antagonist SCH 23390 (100-
500 ng) worsened the performance in the 
Morris water maze (Klimek et al, 1989; 
Scheel-Kruger et al, 1989). Both the retention 
in the Olton radial maze (Taghzouti et al, 
1987) and in the Morris water maze (Klimek 
et al, 1989; Scheel-Kruger et al, 1989) were 
unaffected by the above mentioned dopamine 
antagonists, suggesting a differential role for 
dopamine in the acquisition and retention of 
maze-learning. It was furthermore found that 
the NMDA-antagonist AP-7 retarded both the 
acquisition and retention in the Morris water 
maze (Klimek et al, 1989; Scheel-Kruger et 
al, 1989). 
Ploeger et al showed that intra-accumbens 
injections of the DAi-agonist DPI enhanced 
recognition of a previously (2 hours delay) 
presented juvenile by elder rats (1-1,5 years); 
an effect which was antagonized by the 
specific DAi-antagonist ergometrine (Ploeger 
et al, 1989, 1990). Since DPI was injected 
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directly into the nucleus accumbens of the 
elder rats after the first exposure to the 
juvenile, it appears that the drug interfered 
with the acquisition phase i.e. the ability to 
form a new memory. 
When cats were trained to withdraw their 
hindlimb after presentation of a stream of air 
(CS) to an unshaved part of their body 
immediately followed by a shock (US), intra-
accumbens injections of dopamine decreased 
the conditioned leg flexion (CS-presentation) 
whereas it had no effect on the unconditioned 
leg flexion (US; Wilson and Soltysik, 1985), 
indicating that dopamine blocked the retention 
of the response but not the renewed 
acquisition. The dopamine antagonist 
haloperidol and the glutamatergic QA-
antagonist GDEE were not effective in any 
phase (Wilson and Soltysik, 1985). 
3.5.4.5 Conclusions 
From the foregoing paradigms the following 
can be concluded. It appears that 
noradrenaline and dopamine (as well as 
glutamate) in the nucleus accumbens play a 
role in the acquisition phase of several tests: 
(i) in learning to find a platform in the 
Morris water maze or food in the Olton radial 
maze and (ii) in the development of 
environment specific conditioning. Especially 
the latter experiment showed that dopamine 
(and noradrenaline) in the nucleus accumbens 
play an essential role in transforming previous 
neutral stimuli into a 'cue' or a set of 'cues'. 
Since this occurs in the absence of any 
reward it truly shows that a previous neutral 
environment starts to direct behaviour in time. 
The observation that the amygdala-accumbens 
pathway is of particular importance in this 
latter phenomenon corresponds nicely to the 
observation that this pathway is also involved 
in secondary reinforcement. One might 
suggest that the amygdala-accumbens pathway 
is important in cue-directed behaviour. If so, 
it explains why AP-7 was able to attenuate 
the retention in the Morris water maze. 
Furthermore it explains why D2-antagonists 
were unable to affect the expression of 
cocaine-induced sensitisation or environment 
specific conditioning: as shown in figure 3-
22 the amygdala-accumbens pathway contains 
no D2-receptors. 
Although the increase in responding on the 
CR-lever after injections of d-amphetamine or 
dopamine into the nucleus accumbens was 
interpreted as evidence that dopamine in the 
nucleus accumbens strengthens the reward-
response relationships (Taylor and Robbins, 
1984, 1986), these results may also be 
interpreted in another way. The testing phase 
in this paradigm is by definition an extinction 
phase (see above). Thus, it might be expected 
that rats normally stop responding during the 
session, and regroup their behaviour according 
to the new demands of the task, i.e. the non-
presence of the previous reward (water) after 
the CS. Several stadia can be recognized in 
this testing phase: (i) pressing the lever and 
expecting reward, (ii) noting the absence of 
the reward, and (iii) reorganizing expectancies, 
i.e. suppress previously learned behaviour. 
Accordingly the d-amphetamine induced 
effects (Cador et al, 1989; Everitt et al, 1989; 
Taylor and Robbins, 1984, 1986) might be 
due to interference with one or more of these 
stadia. It is therefore a pity that in none of 
these studies time-curves are presented, for 
they could have given essential information 
on how d-amphetamine affects the pattern of 
responding in time. According to figure 3-22 
d-amphetamine and SKF 38393 might 
decrease the amygdala input. Since Robbins 
and coworkers did not observe a disruption of 
the responding of the CR-lever by these 
agents, i.e. their rats were still able to 
discriminate the CR-lever from the NCR-
lever after intra-accumbens injections of these 
agents, it follows that the signalling of the 
altered testsituation or the suppression of 
responding was disrupted. Thus, the ability to 
regroup behaviour may have been disrupted. 
At present is not clear however at which level 
this might have taken place. The data of 
Wilson and coworkers (Wilson and Soltysik, 
1985) may be explained along this line 
however: a disruption of the incoming 
amygdala-signal by dopamine in the nucleus 
accumbens. 
118 
Overall it can thus be concluded from these 
paradigms that the nucleus accumbens is 
important in both the acquisition and retention 
phases of several tasks. The amygdala-
accumbens pathway may be of particular 
importance for the establishment and 
expression of 'cue'-directed behaviour, 'cue', 
in the sense as outlined in paragraph 3.S.3. 
3.5.5. Towards a new concept: general 
conclusions 
Overall the data in this chapter and the 
review from the literature suggest the 
following role for the nucleus accumbens in 
behaviour: it is involved in the ability to 
switch to behaviours which are directed by 
stimuli from the environment, as well as in 
the transformation of these stimuli into 
cues and in the subsequent ability of cues 
to direct behaviour. The hippocampus-
accumbens may play a crucial role in ability 
to express stimulus-directed behaviour, 
whereas the amygdala-accumbens pathway 
may be important for the ability to express 
cue-directed behaviour. The transformation 
may be achieved through a delicate interplay 
of these inputs in the nucleus accumbens 
(Cools et al, 1990b). Moreover it appears that 
dopamine might play an important role in 
these processes. As pointed out in paragraph 
3.4.3. the data obtained with dopamine Dl-
agents in the swimming tests might be 
explained by assuming a dopamine Dl-
dynamicity. In fact, the foregoing 
considerations might support such a 
possibility, if one assumes that the 
hippocampus-accumbens activity decreases in 
time. According to figure 3-22 this would 
lead to a lower Dl -activity (and hence to an 
enhanced amygdala-accumbens activity). In 
fact, the 'switch' from an active hippocampus-
accumbens pathway to an active amygdala-
accumbens pathway might underlie the 
observed decrease in cue-(stimulus)-directed 
behaviour. 
The role of dopamine seems to be essential 
in the above mentioned role of the nucleus 
accumbens. In 1983, Richard Beninger wrote 
a review on the role of dopamine in learning 
(Beninger, 1983). In this review he started 
with the statement that two types of learning 
occur when food is presented to hungry rats: 
"One is s-s [stimulus-stimulus] learning 
involving the association of environmental 
stimuli with sensory aspects of the food such 
as taste, odor, texture, appearance and 
sound ; the other is incentive motivational 
learning that would involve a change in the 
ability of these environmental stimuli to elicit 
operant responses in the future.." (Beninger, 
1983 pl77; see also Bolles, 1972). He 
subsequently demonstrates that the former 
type of learning does not require dopamine, 
since rats responded to a tone which was 
previously used in a one-way avoidance 
procedure, in which these rats were drugged 
with DA-antagonists, with conditioned 
autonomic responses (Beninger, 1983; see 
also Beninger and Phillips, 1981). The 
incentive motivational learning however was 
critically dependent on the integrity of the 
dopaminergic system. Although he does not 
specify the dopaminergic system in question 
(Beninger, 1983), it might be concluded from 
the foregoing that this may be the 
dopaminergic pathway innervating the nucleus 
accumbens. 
The role of the nucleus accumbens in 
behaviour described in this chapter is broader 
than the roles previously proposed. It has 
been suggested that the nucleus accumbens 
plays a role as an interface between limbic 
and motor structures (Mogenson et al, 1980), 
in which locomotion plays a role in adaptive 
behaviours (Mogenson, 1984; 1987). Moreover 
the nucleus accumbens has been suggested to 
play a role in selective attention (Solomon 
and Staton, 1982; Swerdlow et al, 1986a, 
1990a, 1990b; see also Crider et al, 1982, 
1986) and reward-related processes 
(Broekkamp et al, 1975; Colle and Wise, 
1988; Hernandez and Hoebel, 1988a, 1988b; 
Kurumiya and Nakajima, 1988; Nakahara et 
al, 1989; Nakajima, 1989; Stellar and Corbett, 
1989; see Fibiger and Phillips, 1979, 1986 for 
reviews; see however Neill and Justice, 1981 
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for arguments against this role). It remains to 
be determined how these different roles might 
be compatible with each other. 
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3-6 Pilot studies on the role of the nucleus 
accumbens in tremor 
3.6.1 Introduction 
In sections 3-4 and 3-5 the role of the 
nucleus accumbens in the ability to switch to 
cue-directed behaviours, i.e. a role in 
programming a non motor aspect of 
behaviour, has been studied and discussed 
respectively. The nucleus accumbens however 
also plays a role in the regulation of 
electromyographic (EMG) activity in the 
triceps muscle of the forelimb of the rats 
(EUenbroek et al, 1988; chapter 4, section 4-
3), i.e. an example of a role in programming 
a motor aspect of behaviour. As pointed out 
in chapter 2, section 2-7, tremor might be 
associated with a dysbalance between the A9-
(nigrostriatal) and AIO- (meso-striatal 
(accumbens)) system. It may therefore be 
suggested that the nucleus accumbens is also 
involved in regulating tremor, i.e. another 
example of a role in programming a motor 
aspect of behaviour. Although it was not the 
aim of this thesis to provide full evidence for 
this hypothesis the following pilot studies are 
still worthwhile to be discussed within the 
scope of this thesis. 
Until now no good animal model exists for 
Parkinson tremor, although attempts have been 
made in monkeys (Waid et al, 1948), cats 
(Baker et al, 1976) and rats (Matthews and 
Chiou, 1978). Parkinson tremor is 
characterized by several features, e.g. (i) it 
occurs during periods of complete relaxation 
in fingers, limbs and tongue (rest tremor) and, 
(ii) it consists of rhythmically alternating 
contractions of agonist-antagonist muscles 
(reciprocal alternating tremor) with a 
frequency of 4-5 cycles per second (Rondot et 
al, 1978; Struppler et al, 1978). Clinically, it 
is observed that especially cholinolytics 
alleviate tremor, whereas 1-dopa is less 
effective (see Brimblecombe and Pinder, 
1972; Korten, 1984). It has been proposed 
that a dysbalance between dopamine and 
acetylcholine is responsible for the motor 
symptoms occurring in Parkinson's disease 
including tremor, i.e. the motor symptoms 
would be due to a decrease in dopaminergic 
and (consequently) an increase in 
acetylcholinergic activity (see Brimblecombe 
and Pinder, 1972). Since the nigrostriatal 
system is involved in the occurrence of motor 
symptoms in Parkinson's disease (Bemheimer 
et al, 1973; Fahn et al, 1971; Leenders et al, 
1986), it might be predicted that such a 
dysbalance exists at the level of the 
nigrostriatal system. At the biochemical level 
it has been shown that a balance between 
dopamine and actylcholine exists in striatal 
tissue (see e.g. Stoof et al, 1987b). Moreover 
at the behavioural level it has been shown 
that both a decrease in the dopaminergic 
activity and an increase in the 
acetylcholinergic activity in the striatum 
enhance tonic EMG- activity in the 
gastrocnemius soleus muscle in the hindlimb 
of the rat (EUenbroek et al, 1985a; EUenbroek 
et al, 1986). However such a balance does 
not seem to exist for the ability to switch to 
non cue-directed behaviours: dopamine and 
acetylcholine act in the same direction 
(Vrijmoed-de Vries, 1985; Vrijmoed-de Vries 
and Cools, 1986). As far as it concerned 
tremor, it has been shown that tremor does 
not correlate with parameters related to 
dopaminergic activity in the nigrostriatal 
system (paragraph 2.5.2.1). Indeed, animal 
experiments have shown that blocking the 
dopamine transmission in the caudate nucleus 
does not lead to tremor, but rather to an 
increase in tonic EMG-activity in the 
gastrocnemius soleus muscle in the hindlimb 
(EUenbroek et al, 1985a) and the inability to 
change forced postures (catalepsy; EUenbroek 
et al, 1985a; Fletcher and Starr, 1988). In 
contrast, cholinergic agonists injected into the 
caudate nucleus clearly induced tremor in the 
hindlimbs of cats (Connor et al, 1966a, 
1966b, 1967; see Baker et al, 1976 for a 
review) and in the forelimbs of rats (DUI et 
al, 1968a, 1968b; Matthews and Chiou, 1978, 
1979). Moreover it has been shown that they 
induce whole body tremor in rats (Cox and 
Potkonjak, 1969). The frequencies of these 
tremors were higher than those found in 
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Figure 3-23: Seríes of injection sites within the dorso-medial parts of the striatum (•) and nucleus 
accumbens ( · ) for rats receiving carbachol. 
Parkinson's disease (cat: 20 Hz Connor et al, 
1966b; rat: 8 Hz Dill et al, 1968a, 1968b; rat: 
28 Hz Matthews and Chiou, 1978, 1979). It 
is clear from these data that no balance 
between dopamine and acetylcholine in the 
caudate nucleus appears to exist for tremor. 
In an attempt to study whether stimulation 
of the cholinergic activity in the mesolimbic 
system might also lead to tremor and in order 
to study whether a balance between dopamine 
and acetylcholine might exist in the 
mesolimbic system, it was decided to study 
the effects of the muscarinic M1/M2 agonist 
carbachol (Watson et al, 1986) in the 
nucleus accumbens. For comparison with 
previous studies (see above) carbachol was 
injected within the dorsomedial part of the 
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striatum, i.e. an area innervated by A9-/A8-
fibres (Gerfen et al, 1987). 
3.6.2 Materials and methods 
The rats used in the present experiments 
were drug-naive (one week recovery 
from the operation) or previously used in the 
swimming test (section 3-4; one week drug 
free interval). They were randomly allocated 
to the different treatment groups. They were 
equipped with cannulae aimed at the nucleus 
accumbens (section 3-4) or the striatum (A9.4; 
L+/-2.0; H 1.0 mm). They were injected 
with carbachol (250-1000 ng/0.5 ul) or 
distilled water (AD; 0.5 ul). In case it was 
intended to antagonize drug-induced effects, a 
5-min interval was used between two 
injections; the antagonist was injected first. 
After injection the rats were observed in 
small glass cages (24*13.3*14.5) for 30 
minutes for the occurrence of forelimb tremor. 
Each time a rat displayed a burst of forelimb 
tremor (clearly visible rhythmical movement 
of the lower part ('hand') of the forelimb) 
this was denoted. Data were subsequently 
analysed according to the following methods. 
First, the number of rats per group was 
denoted that showed forelimb tremor (yes/no 
criterion; expressed as percentage of the total 
group). Second, the latency to the first burst 
was calculated as well as the duration of the 
occurrence of tremor (time of the last burst 
minus time of the first burst). Third, in order 
to obtain an impression of the dose-effect 
curve, the number of 15-second periods per 5 
minutes in which the rat showed a forelimb 
tremor (maxium=20), was scored. 
Finally in a number of rats electrodes 
(Cooner-Wire AS632-4ASS) were implanted 
in the triceps and biceps muscle of the 
forelimb according to methods 
described in chapter 4 section 4-3. The EMG-
activity was recorded as described in chapter 
4 section 4-3. However unlike the experiments 
described in the latter section the EMG-
activity was recorded on tape (AGFA РЕМ 
369, FRG) and analysed with a computer-
program (D. Heeren, Psychoneurophanm. Res. 
Unit, Catholic University Nijmegen). 
3.6.3 Results 
Figure 3-23 shows the extent of the 
injection sites within the dorsomedial parts of 
Table 3-19: Percentages of rats showing tremor after injection of carbachol in the dorsomedial parts 
of the striatum or the nucleus accumbens. Shown are percentages. 
Dose 
0 (AD) 
250 
500 
750 
1000 
1000 carb 
+5000 scop 
Striatum 
0.0 (8) 
25.0 (8) 
75.0* (8) 
100.0* (8) 
87.5* (8) 
14.4$ (7) 
N u c l e u s Accumbens 
0.0 
28.2 
00.0* 
87.5* 
OO.O* 
(8) 
(7) 
(7) 
(8) 
(8) 
0 . 0 $ (6) 
AD: distilled water; carb: carbachol; scop: scopolamine 
dose: ng/0.5 ul; 
between brackets: number of rats 
AD; $: p<0.05 vs lOOO ng/0.5 ul *: p<0.05 two-tailed X-square versus 
carbachol. 
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Figure 3-24: Dose-effect curves of carbachol in the doreomedial striatum (panel A) and 
nucleus accumbens (panel B). Y-axes: number of 'tremor periods' per 5 min; X-axes: time 
after injection; number of rats: see table 3-19; shown are means. 
the striatum and nucleus accumbens, whereas 
in table 3-19 the scores per dose of carbachol 
per area are depicted. .It is clear from this 
table that the number of rats that showed 
tremor is similar in both areas. It furthermore 
turned out that virtually no differences existed 
between the latency and duration of tremor in 
the different areas (not shown). Figure 3-24 
shows the dose-effect curves of the injections 
of carbachol in both areas. The maximal 
effect occurred after IO minutes. Moreover 
the effect lasted for 20-25 minutes. It is clear 
that virtually no differences existed between 
the two areas. In order to study whether the 
effects were muscarinic-specific the highest 
dose of carbachol (1000 ng) was in both 
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areas combined with the muscarinic antagonist 
scopolamine (5000 ng; Watson et al, 1986). 
In both cases scopolamine attenuated the 
carbachol induced effect (table 3-19). 
Interestingly the dopamine D2-antagonist 
sulpiride (20-100 ng) did not attenuate the 
carbachol (lOOO ng) induced tremor in these 
areas (not shown). It induced similar changes 
in both areas: a slight enhancement with the 
lowest dose of sulpiride (20 ng), and a slight 
decrease with the highest dose (100 ng). 
Examples of EMG activity in the triceps 
and biceps muscle after injection of carbachol 
in the dorsomedial part of the striatum are 
shown in figure 3-25. These activities were 
recorded during periods in which the rats 
showed tremor. It is clear that during this 
period a regular pattern of peaks occurred, 
which was most clear in the biceps muscle. 
From these recordings the frequency of tremor 
(number of peaks) can be estimated to be 8-
10 Hz. 
3.6.4 Discussion 
The data thus showed that tremor was 
elicited in the rat by injection of carbachol 
within several areas of the striatal system. It 
would appear that most notably the area 
innervated by the mesolimbic AIO- (A8-) 
neurons was involved in this activity 
(compare figure 3-23 with figures in Gerfen 
et al, 1987; Kelley et al, 1982; Oades and 
Halliday, 1987). More conclusive evidence for 
this may be obtained if carbachol is also 
injected within the most dorso-lateral part of 
the striatum, i.e. the area innervated by the 
dorsal part of the A9 cell-group (Gerfen et al, 
1987). These data however suggest that the 
AlO-system is involved in tremor in rats. 
As pointed out in section 3-5 cholinergic 
intemeurons modulate dopamine release in the 
nucleus accumbens; in fact, they modulate 
those dopaminergic terminals that modulate 
the input from the amygdala, which possess a 
subclass of dopamine receptors, i.e. the 
DAi/Dl receptor. Accordingly one might 
expect that the DAi-agonist DPI (Cools and 
Van Rossum, 1980) potentiates carbachol 
induced tremor. Preliminary data showed that 
DPI (1000 ng/0.5 ul) did not affect 
carbachol (375 ng/0.5 ul) induced tremor. 
Although this would argue against the 
foregoing, future experiments have to be 
awaited before a final conclusion can be 
drawn in this respect. It is finally interesting 
to note that nicotine has been found to induce 
tremor in rats (Yen and Day, 1965) and to 
release dopamine in the nucleus accumbens 
(seaion 3.5 paragraph 3.5.2). It would be of 
interest to study how these findings are 
related to each other. 
If the nucleus accumbens is involved in 
tremor, output stations may also be involved 
in this phenomenon. Although no studies exist 
in animals, in man it has been shown that the 
subthalamic nucleus (in combination with the 
ventro-Iateral thalamus; Nitmer, 1985) is the 
most effective site for ameloriating tremor by 
lesions. The subthalamic nucleus is innervated 
by the subpallidal areas (i.e. ventral pallidum; 
Berendse and Groenewegen, personal 
communication), which in tum are innervated 
by the nucleus accumbens (chapter 4, section 
4-2). These data would thus point to a role 
for the nucleus accumbens (ventral striatum) -
ventral pallidum circuitry in tremor. 
With respect to tremor two variables can be 
discriminated: frequency and amplitude. It has 
been shown that these parameters can be 
separately affected. First, it has been shown 
that adrenaline enhances the amplitude of 
tremor with little effect on the frequency of 
tremor (Constas, 1962; Owen and Marsden, 
1965). Funhermore beta-noradrenergic 
antagonists diminished the increase in 
amplitude of tremor induced by adrenaline in 
Parkinson patients (Owen and Marsden, 1965) 
as well as the amplitude of spontaneous 
tremor in Parkinson patients (Foster et al, 
1984; Owen and Marsden, 1965). Moreover 
alpha methyl dopa has been found to 
diminish the amplitude of tremor in Parkinson 
patients (Marsh et al, 1963). It has 
funhermore been shown that peripheral 
(Foster et al, 1984) and central (see e.g. 
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Constas, 1962) mechanisms are involved in 
the regulation of the amplitude of tremor. 
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Figure 3-25: EMG-recordings of triceps and 
biceps muscles of the forelimb during a 
period in which tremor was visually scored. 
Time (seconds) is indicated underneath the 
recordings. 
With respect to the latter it has been shown 
in rats that lesions of the dopaminergic 
system in the nucleus accumbens decreased 
the amplitude of tremorine-induced tremor 
without affecting the frequency (Dickinson 
and Slater, 1981). This suggests thus that at 
least the meso-accumbens system is involved 
in regulating the amplitude. These data might 
become understandable against the background 
of the circuitry depicted in figure 3-22 in 
section 3-5: if one assumes that tremorine 
induces tremor at the level of the nucleus 
accumbens (cf. carbachol see above), the 
lesions of the dopaminergic system prevent 
the effect of tremorine via the acetylcholine-
dopamine interaction within the nucleus 
accumbens. 
Although stress has been shown to 
aggreviate the amplitude of tremor, it has 
been suggested that this is only partly 
mediated via an increase in peripheral 
adrenaline (Owen and Marsden, 1965). In 
fact, it appeared that lesions of the frontal 
cortex were effective in ameloriating this 
effect of stress ('The emotional enhancement 
of the resting tremor can be suppressed by 
prefrontal lobotomy' Jung and Hassler, 1960 
p885). As pointed out in section 3-5 a lesion 
of the prefrontal cortex affects the 
dopaminergic transmission in the nucleus 
accumbens. It might be speculated that these 
lesions attenuated this stress induced effect 
via changes in the dopaminergic activity 
within the nucleus accumbens. In this respect 
the data of Dubois et al may be recalled 
(Dubois et al, 1983) from which it could be 
derived that the severity of tremor (amplitude 
!) was related to an increased cholinergic 
activity in the frontal cortex, and possibly an 
enhanced dopaminergic activity in the nucleus 
accumbens. Hence a decrease in dopamine 
Dl-activity after lesions in the prefrontal 
cortex (section 3-5) might have attenuated the 
enhancement of the amplitude of tremor after 
stress. It would thus appear that the amplitude 
of tremor may be regulated via the nucleus 
accumbens-ventral pallidal axis. 
With respea to frequency, it has been 
found that within certain thalamic nuclei, i.e. 
the caudal-ventral nucleus and the nucleus 
ventralis oralis posterior cells exist which fire 
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with the frequency of tremor (Lenz et al, 
1988). It was shown that this firing rate was 
not the consequence of peripheral feedback 
mechanism from tremorating muscles to these 
thalamic nuclei. Moreover lesions within these 
nuclei have been found to abolish the tremor 
(frequency) completely in Parkinson patients 
(Narabayashi and Ohye, 1978). Since these 
thalamic nuclei are situated within the output 
of the nigrostriatal system (striatum-substantia 
nigra-ventro-lateral thalamus), this would lead 
to the speculative possibility that the 
derangements in the nigrostriatal system 
determine the frequency of tremor. 
The foregoing considerations lead to the 
possibility that in Parkinson's disease the 
hypofunctioning nigrostriatal system 
determines the frequency of tremor, whereas 
the meso-accumbens system determines 
whether the tremor becomes visible or not, 
i.e. modulates the amplitude. Hence, a 
hypoactive meso-accumbens system would 
lead to a non observable tremor, whereas a 
normo-active or hyperactive meso-accumbens 
system would allow tremor to become visible. 
This hypothesis could explain why Rinne et 
al observed that with a decreasing number of 
neurons in the nigrostriatal system tremor 
disappears (Rinne et al, 1989a): in fact, 
tremor does not disappear as such, but as 
pointed out in chapter 2, due to concurrent 
lesions in the meso-accumbens system the 
amplitude is decreased, which allows tremor 
not be observed anymore. Accordingly the 
original hypothesis developed in section 2-7 
might be somewhat adjusted by stating that an 
intact AlO-system is necessary for the 
amplitude of tremor to become manifest. 
With respect to the present data the 
possibility exists that the carbachol induced 
tremor was in fact an expression of an 
existing tremor, i.e. a physiological tremor 
which became observable (enhanced 
amplitude), or due to a direct or indirect 
dysbalance between the striatum and 
accumbens system. These possibilities deserve 
further study. 

CHAPTER IV 
STUDIES ON THE ROLE OF 
THE SUBPALLIDAL AREAS 
IN BEHAVIOUR 
In which a major first-order output station of the nucleus accumbens is studied. Next 
to swimming rats, running rats are investigated. Moreover the triceps muscle of the 
forelimb is studied. Finally the interaction with the nucleus accumbens is being 
looked at. 
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4-1 Introduction 
In the preceeding chapter the role of the 
nucleus accumbens in behaviour was studied 
using the swimming test. Among others, the 
subpallidal areas, i.e.the ventral pallidum-
/substantia innominata (VP/SI) complex, are 
an important first-order output station of the 
nucleus accumbens (see e.g. Haber et al, 
1985; Nauta et al, 1978; chapter 3, section 3-
2). These area contain the cholinergic cells, 
which constitute the NBM in man, which is 
affected in Parkinson's and Alzheimer's 
disease (see chapter 2, section 2-5). These 
cells moreover appear to receive direct 
information from the nucleus accumbens 
(monkey: Mesulam and Mufson, 1984; rat: 
Haber et al, 1988). It has furthermore been 
shown that manipulation with the nucleus 
accumbens affects the neuronal activity of 
these cells (Blaker, 1985 and references cited 
therein). In an attempt to study how 
information from the nucleus accumbens is 
transmitted to lower structures, the role of the 
subpallidal areas is investigated in this 
chapter using inter alia the swimming test. 
First the anatomy of the subpallidal areas 
will be described in this chapter (section 4-
2), next the experiments (section 4-3). The 
chapter will end with a general discussion on 
the behavioural effects observed in these latter 
experiments. Furthermore the relationship with 
the nucleus accumbens will be discussed. 
4-2 A brief survey of the anatomy of the 
subpallidal areas 
4.2.1 Introduction 
In 1975 Heimer and Wilson introduced the 
term 'ventral pallidum' in analogy with the 
term 'ventral striatum' (Heimer and Wilson, 
1975; see also Heimer, 1978; Heimer et al, 
1982). In their study they observed two 
important features. First, it was observed that 
projections from the allocortex, which 
includes areas like the piriform cortex and 
hippocampus, terminated in a specific, 
circumscribed area of the striatal complex, i.e. 
the ventral part of the striatum, the nucleus 
accumbens and the olfactory tubercle. This 
area was labelled the 'ventral striatum'. 
Projections from the neocortex appeared to 
terminate in the more dorsal pan of the 
striatal complex, which was accordingly 
labelled 'dorsal striatum'. Second, when the 
nucleus accumbens or olfactory tubercle was 
electrolytically lesioned degenerating terminals 
were found in a certain well circumscribed 
area; an area, which seemed to be a ventral 
extension of the globus pallidus (Heimer and 
Wilson, 1975). Hence this area was labelled 
'ventral pallidum'. Since the dorsal striatum 
projects to the dorsal globus pallidus (see e.g. 
Haber et al, 1985) it seems that the 'dorsal-
ventral' axis at the level of the striatal 
complex is parallelled by such an axis at the 
level of the first-order output station, i.e. at 
the level of the pallidal complex (see Haber 
et al, 1985 and below). Furthermore it was 
noted that the area which was delineated by 
the degenerating terminals belonged to the so 
called 'substantia innominata' (Heimer and 
Wilson, 1975). The latter term was introduced 
by the German neuroanatomist Johann 
Christian Reil in the beginning of the 19th 
century to delineate a ventral forebrain area in 
man which extends laterally and caudally 
deep to the optic tract; an area, for which he 
could determine neither an organization nor a 
destination and accordingly called 'die 
ungenannte Marksubstanz' or 'substantia 
innominata' (see Alheid and Heimer, 1988). 
Unfortunately the two different terms 'ventral 
pallidum' and 'substantia innominata' indicate 
overlapping areas and are not consequently 
used in the literature. The initial boundaries 
of the ventral pallidum as defined by Heimer 
and Wilson have been subject to change 
through time due to the different specific 
techniques used to delineate the area (see 
paragraph 4.2.2). Moreover some authors 
prefer to use the term 'substantia innominata' 
solely; the latter is then subsequently 
subdivided into a subcommissural and a 
sublenticular part (see e.g. Mogenson et al, 
1983). The former part is often more or less 
equivalent to Heimer and Wilson's ventral 
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pallidum (see e.g. Mogenson et al, 1987). In 
this thesis the terms subpallidal areas and 
VP/SI complex will be used; the area is 
further subdivided into rostral (i.e. ventral 
pallidum according to the atlas of Paxinos and 
Watson, 1986) and caudal (i.e. substantia 
innominata according to the atlas of Paxinos 
and Watson, 1986) areas (figure 4-4). 
The ventral forebrain area in the rat is a 
highly complex structure consisting of several 
subareas. As outlined above the most rostral 
part constitutes the ventral pallidum described 
by Heimer and Wilson, whereas the caudal 
part is considered to be the substantia innomi-
nata. Moreover the medial and lateral preoptic 
area as well as the hypothalamic nuclei are 
found wthin the caudal areas (see the atlas of 
Paxinos and Watson, 1986). The deeper layers 
of the olfactory tubercle, which contain the 
large cells of this nucleus, are also considered 
to be part of the ventral pallidum (see Haber 
and Nauta, 1983). The cholinergic cells, i.e. 
the cells of the nucleus basalis 
magnocellularis, which constitutes the rat 
homologue of the human NBM, are scattered 
throughout the VP/SI complex (Mesulam et 
al, 1983a; see below). 
With respect to the boundaries between the 
ventral pallidum and the substantia 
innominata, the following may be noted. 
Grove delineated the substantia innominata 
from the ventral pallidum by the higher 
number of scattered cholinergic neurons 
within the former as well as by the axons of 
the ansa peduncularis which travers the 
substantia innominata (Grove, 1988a). 
Moreover the ventral pallidum seems to 
contain a higher density of enkephalinergic 
'wooly fibres' (Grove, 1988a; Buma, personal 
communication). With respect to the latter it 
should be mentioned that èie ventral pallidum 
shows a high substance Ρ (SP) immuno-
reactivity which clearly delineates it from the 
dorsal pallidum; the latter area hardly shows 
SP immuno-reactivity (Haber and Nauta, 
1983). Interestingly the same holds true for 
the immunoreactivity against dynorphin-beta 
(Buma, personal communication). Moreover 
the substantia innominata displays only little 
immunoreactivity against dynorphin-beta 
(Buma, personal communication). It should 
finally be noted that the area is neurotensin 
(NT) immunoreactive (Zahm, 1989). In fact as 
outlined by the latter author, two areas within 
the ventral pallidum exist. A ventromedial 
area, which stains strongly for an NT-antibody 
and a dorsolateral area, which hardly stains 
for an NT-antibody (Zahm, 1989). This 
immunoreactivity is complementary to the 
immunoreactivity against leu-enkephalin, i.e. 
the ventromedial area shows less 
immunoreactivity against leu-enkephalin than 
the dorsolateral area (Zahm, 1989). This latter 
area may be equivalent to the cat 
subcommissural part of the globus pallidus 
(Cools et al, 1989b; Spooren et al, 1989, 
1990). As shown in the next paragraphs 
(paragraphs 4.2.2 and 4.2.3) these areas might 
have differential inputs and outputs. It should 
finally be noted that based upon afferent and 
efferent pathways. Grove subdivided the 
substantia innominata in a dorsal and a 
ventral area (Grove, 1988a, 1988b). 
Recently Alheid and Heimer introduced a 
new perspective on the organization of the 
ventral forebrain (Alheid and Heimer, 1988). 
They subdivided this area into three systems: 
a ventral striatopallidal system, an extended 
amygdala and a magnocellular corticopetal 
system. Within the former the ventral striatum 
and ventral pallidum proposed by Heimer and 
coworkers are contained (see above). The 
extended amygdala compromises the 
centromedial amygdala and the bed nucleus of 
the stria terminalis together with a subpallidal 
corridor within the sublenticular substantia 
innominata which connects these two 
structures. Alheid and Heimer furthermore 
suggested that within the latter system the 
medial nucleus accumbens may be involved 
(Alheid and Heimer, 1988). Finally the 
cholinergic and GABAergic cell groups that 
project towards the different cortical areas 
compromise the corticopetal system (Alheid 
and Heimer, 1988). It remains to be proven 
whether this subdivision has value for 
understanding the behavioural role of these 
areas and hence in understanding the 
behavioural deficits due to dysfunction of 
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these areas. 
4.2.2. Some afferent pathways 
As outlined above the extent of the 
degenerating terminals after lesion of the 
nucleus accumbens and/or olfactory tubercle 
was used to delineate the area of the 'ventral 
pallidum', (Heimer and Wilson, 1975; Heimer, 
1978; Heimer et al, 1982). The latter area 
might accordingly be called more 
appropriately 'the ventral pallidum of Heimer 
and Wilson', since other authors have shown 
that terminal degeneration after lesions of the 
nucleus accumbens extends to much wider 
areas (Williams et al, 1977). Thus, it has been 
shown that also more caudal areas, e.g. as far 
as the hypothalamus contain degenerating 
terminals. The use of tritiated amino acids has 
in fact shown this even more convincingly. 
Nauta et al e.g. showed that radioactive 
labelling can be found throughout the ventral 
forebrain after injections of tritiated leucine 
and proline into the nucleus accumbens: from 
just ventral of the commissura anterior to as 
caudal as the hypothalamus (Nauta et al, 
1978). Other studies using essentially the 
same method have confirmed these 
observations (Conrad and Pfaff, 1976; 
Mogenson et al, 1983; Swanson and Cowan, 
1975). Newman and Winans using yet a 
different method -tract tracing with horse 
radish peroxidase- observed that also in the 
golden hamster labelling extends to somewhat 
more caudal areas (Newman and Winans, 
1980). Conversely injection of the retrograde 
tracer Fast Blue into the VP/SI complex 
heavily labelled the ventral striatum, including 
the nucleus accumbens, whereas injection of 
this tracer into the dorso-lateral part of the 
globus pallidus labelled the dorso-lateral part 
of the striatum (Mogenson et al, 1983). These 
latter results confirmed thus the pattern of the 
projections from the dorsal and ventral striatal 
areas: the dorsal and ventral pallidal areas 
respectively (e.g. Heimer and Wilson, 1975; 
see also Haber et al, 1985). 
Interestingly Nauta et al observed that the 
most intensely labelled area was the area 
delineated by Heimer and Wilson; less intense 
labelling was found in more caudal areas 
(Nauta et al, 1978). Accordingly this might 
indicate that the former area receives 
quantitatively more projections from the 
nucleus accumbens. Accordingly these 
projections might have thus been easier to 
detect by the method employed by Heimer 
and Wilson (Heimer and Wilson, 1975), 
which would account for their more restricted 
terminal patterning area. 
A certain medio-lateral topography in the 
projections from the nucleus accumbens to the 
VP/SI complex appears to exist; more lateral 
parts of the VP/SI complex receive 
projections from more lateral parts of the 
nucleus accumbens, whereas more medial 
pans of the VP/SI complex receive 
projections from more medial parts of the 
nucleus accumbens (Conrad and Pfaff, 1976; 
Mogenson et al, 1983; Swanson and Cowan, 
1975). Similarly, the dorsal-ventral axis in the 
nucleus accumbens is parallelled by such an 
axis in the VP/SI complex (Mogenson et al, 
1983). The latter authors were however unable 
to find a posterior-anterior topography (see 
also Yang and Mogenson, 1985). In addition, 
the nucleus accumbens and the underlying 
olfactory tubercle innervate different areas of 
the ventral pallidum: the lateral part is 
innervated by the olfactory tubercle whereas 
the nucleus accumbens innervates the medial 
parts (Heimer and Wilson, 1975; Heimer et 
al, 1987). The projections from the tubercle 
arise from the superficial layers of this 
nucleus. 
Both anatomical (Zahm et al, 1985, 1987), 
biochemical (Dray and Oakley, 1978; Walaas 
and Fonnum, 1979), electrophysiological 
(Dray and Oakley, 1978; Jones and 
Mogenson, 1980a; Mogenson et al, 1983; 
Yang and Mogenson, 1989) and behavioural 
(paragraph 4.3.3.1) experiments have 
suggested that the efferents from the nucleus 
accumbens to the subpallidal areas may use 
the neurotransmitter GABA. Moreover met-
enkephalin has been found to coexist with 
GABA in some neurons (Zahm et al, 1985). 
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Finally SP has been suggested to act as 
neurotransmitter in this pathway (Zahm et al, 
1985). 
It should be noted that electrical stimulation 
of the nucleus accumbens affects the firing 
rate of neurons throughout the VP/SI region 
with no clear topography with respect to 
excitatory or inhibitory responses (Mogenson 
et al, 1983). It was fiowever observed by the 
latter authors that certain neurons solely 
responded to stimulation of the lateral 
accumbens, whereas others solely responded 
to stimulation of the medial accumbens; some 
neurons responded to stimulation of both sites 
(Mogenson et al, 1983). In line with the 
anatomical data, which showed that the 
projection towards the rostral VP/SI region is 
heavier, i.e. the 'ventral pallidum of Heimer 
and Wilson', it was found that four times 
more neurons respond in the nucleus 
accumbens after antidrome stimulation of the 
VP than after stimulation of the SI region 
(Yang and Mogenson, 1985). Since the latter 
authors however considered only those 
neurons in the nucleus accumbens that 
responded to both antidrome stimulation of 
the VP or SI region, and orthodrome 
stimulation of the subiculum of the 
hippocampus, these data might alternatively 
indicate that hippocampal output has more 
access to ventral pallidum neurons than to 
substantia innominata neurons (Yang and 
Mogenson, 1985; section 4-4). 
It should finally be noted that the VP/SI 
complex receives afferent projections from 
several cortical areas, i.e the temporal cortex, 
prefrontal cortex and insular cortex as well as 
from the ( basolateral) amygdala (see e.g. 
Grove, 1988a; Irle and Markovitsch, 1986; 
Russchen et al, 1985). These projections may 
use the neurotransmitters 1-glutamate and/or 1-
aspartate (Davies et al, 1984; see also Tsai 
et al, 1989). Intra VP/SI injections of agents 
selective for EAA-receptors have been found 
to increase motor activity (Shreve and 
Uretsky, 1989). 
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Figure 4-1: Schematic drawing of some efferent pathways from the VP/SI complex (after Grove, 
1988b; Haber et al, 1985; Zahm, 1989). 
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4.2.3 Some efferent pathways 
A schematic drawing of some efferent 
pathways is given in figure 4-1. It can be 
seen from this figure that the efferents from 
this area reach widespread areas of the brain. 
In this paragraph weight will be put upon the 
projections towards the mediodorsal nucleus 
of the thalamus (MD-Thal) as well as upon 
the projections towards the (basolateral) 
amygdala and the nucleus tegmenti 
pedunculopontinis (Ntpp), since these 
pathways may be of particular importance for 
the experiments described in this chapter (see 
sections 4-3 and 4-4). 
The projections from the VP/SI complex to 
the MD-Thal emerge primarily from the 
ventral pallidal area, i.e. the rostral areas of 
the VP/SI complex (Haber et al, 1985; 
Mogenson et al, 1987; Parent et al, 1988; 
Zahm et al, 1987; Zahm and Heimer, 1987). 
However it should be noted that also 
projections from the substantia innominata to 
the MD-Thal exist (Grove, 1988b). 
Anatomical (Zahm et al, 1987) and 
electrophysiological (Mogenson et al, 1987; 
Vives and Mogenson, 1985) experiments have 
shown that these efferents contain both a 
GABA-ergic and a non GABA-ergic 
component. The latter may be cholinergic in 
nature (Hreib et al, 1988). It has nmhermore 
been shown that the projection neurons in the 
VP/SI complex are innervated by GABA-
ergic terminals (Zahm et al, 1987), which 
probably belong to the projections from the 
ventral striatum (see above). 
The projections towards the amygdala 
emerge from the ventral pallidum (Haber et 
al, 1985) and the substantia innominata 
(Grove, 1988b). They terminate inter alia in 
the basolateral nucleus of this structure. These 
projections may use the neurotransmitter 
acetylcholine (Carlsen et al, 1985; Zaborsky 
et al, 1986), arising from the cholinergic 
corticopetal system ( Mesulam et al, 
1983a,1983b) as well as another transmitter 
(Carlsen et al, 1985), which may be GAB A, 
arising from the GABA-ergic corticopetal 
system (Fisher et al, 1988). The former cells 
are innervated by GABA-containing terminals 
(Zaborsky et al, 1986), which belong probably 
to the projections from the ventral striatum 
(Haber et al, 1988; Mesulam and Mufson, 
1984; see also Grove et al, 1986). 
The projections to the Ntpp arise from both 
the ventral pallidum (Haber et al, 1985) and 
the substantia innominata (Grove, 1988b; see 
also Swanson et al, 1987). Several data 
suggest that the projection arises primarily 
from the latter area (Mogenson, 1987; 
Swanson et al, 1987; Yang and Mogenson, 
1987). 
4-3 Behavioural studies on the role of the 
subpallidal areas 
4.3.1 Introduction 
It might be derived from section 4-2 that 
the subpallidal areas are heterogeneous with 
respect to behaviour. In fact, the more caudal 
areas may be different from the more rostral 
areas. In the studies that will be described in 
this section these differences were taken into 
account. Thus rats were injected in the rostral 
and caudal areas in the experiments presented 
in this chapter. 
The nucleus accumbens is involved in the 
regulation of tonic electromyographic (EMG) 
activity in the triceps muscle of the forelimb 
of rats (Ellenbroek et al, 1988), in motor 
activity of rats (see e.g. Pijnenburg et al, 
1976; Cools, 1986; Г ), and in the ability to 
switch to cue-directed behaviours in the 
swimmimg test in rats (Ι,Π,ΙΠ). In order to 
study the role of the subpallidal areas, i.e. a 
first-order output station of the nucleus 
accumbens, in transmitting behavioural 
changes elicited by manipulation of the 
nucleus accumbens to lower brain structures 
these parameters were used. It will be shown 
that the rostral and caudal areas of the VP/SI 
complex are differentially involved in 
transmitting (and eliciting) the forementioned 
behaviours. 
4.3.2 Tonic electromyographic activity of the 
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triceps muscle of the forelimb of the rat; 
catalepsy 
4.3.2.1 Introduction 
Recent studies have shown that intra-
accumbens injections of haloperidol (500-
1000 ng/0.5 ul) increase tonic EMG-activity 
in the triceps muscle of the forelimb of the 
rat (Ellenbroek et al, 1988). No effects were 
found on tonic EMG-activity of the 
gastrocnemius soleus muscle of the hindlimb. 
Tonic EMG-activity from this latter muscle 
seems to be regulated by the dorsal striatum 
(Ellenbroek et al, 1985 a; Ellenbroek et al, 
1988). The effect of haloperidol was 
attenuated by the alphal-noradmergic agonist 
phenylephrine and only partly by the 
dopamine D2-agonist apomorphine (first 20 
minutes; Ellenbroek et al, 1988). In line with 
the latter finding the dopamine D2-antagonist 
dl-sulpiride in doses up to 100 ng/0.5 ul 
increased tonic EMG-activity of the triceps 
muscle only weakly when injected into the 
nucleus accumbens (from 10-25 minutes after 
injection; Ellenbroek, 1988). In contrast 
however the dopamine Dl-antagonist SCH 
23390 (500-1000 ng/0.5 ul) increased 
tonic EMG-activity of the triceps muscle 
throughout the observation period (10 to 60 
minutes); an effect, which was attenuated by 
the dopamine Dl-agonist SKF 38393 
(Ellenbroek, 1988). Accordingly both alphal-
noradrenergic and Dl-dopaminergic 
mechanisms in the nucleus accumbens appear 
to be involved in regulating forelimb triceps 
muscle tonic EMG-activity. To study the latter 
phenomenon further it was decided to 
investigate whether tonic EMG-activity of the 
triceps muscle of the forelimb is affected by 
manipulation with the neurotransmission in 
the VP/SI complex, since this complex is a 
major output station of the nucleus accumbens 
as shown in section 4-2. Since several 
behavioural studies have shown that an 
inverse relationship exists between accumbens 
dopamine and subpallidal GABA (paragraph 
4.3.3, 4.3.4) it was decided to use the specific 
GABAa-agonist muscimol (Bowery et al, 
1983; Simmonds, 1983) as the tool of choice 
to study the role of the subpallidal areas in 
forelimb triceps tonic EMG-activity. 
4.3.2.2 Materials and methods 
general 
Male Wistar rats (Central Animal 
Laboratory, Catholic University Nijmegen) 
weighing 180-210 grams at the time of 
surgery were anaesthetized with pentobarbital 
(60 mg/kg; Narcovet(R)) and secured in a 
stereotaxic frame. They were equipped with 
cannulae (5.0 mm in length, inner diameter 
0.2 mm; outer diameter 0.65 mm) aimed at 
either the rostral (stereotaxic coordinates: A7.4 
L+/-2.5 H-2.0 mm) or the caudal (stereotaxic 
coordinates: A6.6 L+/- 2.5 H-2.0 mm) areas 
of the VP/SI complex (coordinates according 
to König and Klippel, 1963). These cannulae 
were inserted under a lateral angle of 5 
degrees. They were secured onto the skull 
with stainless steel retaining screws and dental 
acrylic cement (Paladur(R)) using standard 
methods (see Pijnenburg et al, 1976). 
Furthermore each rat was equipped with a 
three pinned plug. The three pins of the plug 
were connected to teflon insulated stainless 
steel wires (Cooner Wire AS 632-4ASS) from 
which two were led subcutaneously to the 
triceps muscle of the forelimb and secured as 
previously described (Ellenbroek et al, 1988). 
The third wire served as grounding control. 
The placing of the electrode was checked by 
passing a current (10 uA) through the elec-
trodes and observing the extension of the 
forelimb. After surgery rats were individually 
housed in a temperature controlled room (-
T=21+/-l degrees Centigrade) on a standard 
day-night cycle (06:00-18:00 hrs lights on) 
and allowed to recover for one week before 
experiments started. Food and water were 
available as required. Injections were given in 
conscious unrestrained rats using a 5.0 ul 
Hamilton(R)-syringe extending 3.0 mm under 
the tip of the cannulae. A volume of 0.5 ul 
was delivered over a period of 5 seconds; 
hereafter the needle was kept in place for 10 
seconds. Experiments were performed between 
09:00 and 18:00 hrs., i.e. during the Ught 
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Figure 4-2: Schematic representation of the experimental setup for measuring tonic EMG-activity 
in the triceps muscle of the forelimb of the rat (see text for (explanation of) the several parts of 
this drawing). 
phase of the day-night cycle. In principle rats 
were used twice. They were divided over the 
different treatment groups in a random order. 
Muscimol (Serva, FRG) and bicuculline.met-
hiodide (Pierce, USA) were dissolved in 
distilled water (AD; PBNI, the Netherlands), 
which was used as control throughout the 
study. After completion of the experiments the 
rats were sacrificed by an overdose of pento­
barbital after which the brains were removed. 
These were stored on 4% formalin and secti­
oned into 30 urn slices by means of a 
fteezing microtome (Bright, UK). After 
staining with cresyl violet the injection sites 
were determined. 
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Figure 4-3: The upper tracings in each recording represent the integrated signal, the lower tracings 
the rectified EMG-signal.Phasic activity due to movements was present (A) and was corrected for 
by the dashed line in the integrated signal. 
procedure 
The EMG-recordings were performed in 
conscious freely moving rats (figure 4-2, 
panel I) by connecting their three pinned plug 
to a Polygraph (Grass Model 78D; figure 4-
2, panel Π A). The rats were habituated for 
30 minutes to the glass cages (24x13.3x14.5 
cm) in which the recordings took place 
(figure 4-2, panel I). They were subsequently 
injected with AD in the VP/SI complex, and 
EMG-activity was recorded for 50 minutes 
starting 10 minutes after injection. This 
recording served primarily as habituation to 
the experimental set up. Hereafter rats were 
injected with either AD or muscimol and 
EMG-activity was again recorded for 50 
minutes starting 10 minutes after injection 
(V). During the recording period the rats were 
observed for behavioural changes, like e.g. 
changes in motor activity. After 50 minutes 
of measuring EMG-activity the rats were 
tested for catalepsy. They were gently placed 
on a woodblock (9 cm high) with both 
forelimbs and the time was recorded for 
removing one forelimb; a cut-off point of 10 
seconds was used (Scheel-Kruger, 1983). 
EMG analysis 
The analysis of the EMG-recordings has 
been described in detail in another study 
(EUenbroek et al, 1988; see figure 4-3). In 
brief, the EMG-signal was amplified, band­
pass filtered (5 Hz to 10 kHz), rectified and 
fed into an integrator (figure 4-2, panel Π В), 
which was automatically reset after reaching 
a predetermined value (V). The EMG-activity 
was also displayed on an oscilloscope (Type 
502A dual beam; Tektronix, the Netherlands; 
figure 4-2, panel Π С) and printed on 
recording paper (Grass Chart (R); figure 4-2, 
panel Π D; panel Ш). The reciprocal of this 
reset time was a measure of the total EMG-
activity; the EMG-activity was calculated per 
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5 min period. Brief periods of phasic activity 
due to movements of the rat were discarded 
by subtracting them from the integrated acti-
vity (figure 4-3). Since the integrator could 
not be fully adjusted to zero, the integrated 
activity after short circuiting the electrodes 
was subtracted from the absolute integrated 
EMG-activity (V). The thus obtained relative 
values of tonic EMG-activity are displayed in 
the figures. In all figures means+sem's are 
shown. 
Statistical analysis 
For the parametric data, i.e. the relative 
values of tonic EMG-activity, statistics were 
performed using a two-way ANOVA with 
time and doses as factors and scores per rat 
as cell entries followed by a Student-
Newman-Keuls (SNK) test where appropriate 
(Ferguson, 1981). The non parametric data, 
i.e. the catalepsy and motor activity scores, 
were analysed with a Mann-Whitney U-test 
and X-square test whichever was appropriate 
(Ferguson, 1981; Siegel, 1956). Only rats with 
their injection sites within the boundaries of 
the intended areas were included in the 
statistical analyses. Rats in which the EMG-
signal was permanently changed after one 
injection were also discarded from the 
analyses. 
Final remarks 
To accustom the rats to the injection 
procedure in the experiments described in this 
part of the thesis, the stylets were removed 
from the cannulae and inserted again on the 
day preceeding the actual experiment. 
Moreover it was judged whether the animals 
could take part in the experiments by 
checking their physical health, i.e the outlook 
of their furs and their weights. A total of 70 
rats was included in the present experiments. 
The results described in this part can be 
found, in part, in paper V. 
4.3.2.3 Results 
In figure 4-4 representative series of 
injection sites in the rostral and the caudal 
areas of the VP/SI complex are shown. These 
injection sites were drawn on the planes of 
the atlas of Paxinos and Watson (Paxinos and 
Watson, 1986) since this atlas delineates the 
structures under discussion clearer than the 
atlas of König and Klippel (Konig and 
Klippel, 1963). 
Muscimol (10-25 ng/0.5 ul) had a 
differential effect in the rostral and caudal 
areas (table 4-1). In the rostral areas (A7.4) 
injections of muscimol enhanced motor 
activity during the one hour of measuring 
tonic EMG-activity, whereas they had no 
effect on motor activity in the caudal areas. 
The activity displayed by the rats was 
characterized as follows: it started with an 
increase in general activity, and developed 
from a rotation around the hindlimbs in a 
pattern in which the rats only showed 
repititive movements of the head and 
forelimbs (forepaw-treading). They continued 
with this latter behaviour after the one hour 
observation period. This activity prevented a 
reliable measurement of the tonic EMG-
activity. Accordingly only the effect of 
muscimol on tonic EMG-activity in the caudal 
area will be presented. It should however be 
noted that in those rats that did not display 
increases in motor activity in the rostral areas 
no changes in the tonic EMG-activity were 
found. Furthermore a lower dose of muscimol 
(1 ng/0.5 ul), which did not induce clear 
changes in motor activity, was also ineffective 
in affecting tonic EMG-activity (not shown). 
In the caudal areas, i.e. A6.6, however the 
rats appeared to be cataleptic (table 4-1). 
Since these rats did not display any motor 
activity tonic EMG-activity could be reliably 
measured (V). 
It turned out that all rats decreased their 
basal tonic EMG-activity during the one hour 
habituation period after the initial injection of 
AD in the caudal areas. When these baseline 
values of the different treatment groups (AD, 
10 ng and 25 ng muscimol; see below) were 
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Figure 4-4: Representative series of injection sites in the rostral (A7.4; panels A3.C and D) and 
caudal (A6.6; panels E,F and G) areas of the VP/SI complex. Planes were taken from the atlas of 
Paxinos and Watson (Paxinos and Watson, 1986). 
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Figure 4-4: continued 
analysed during the last 30 min preceeding 
the experimental injections of AD or 
muscimol no statistical differences were found 
(F(2,120)=2.60, p>0.05). 
In figure 4-5 (panel A) the EMG-activity 
after injection of AD or muscimol into the 
caudal areas of the VP/SI complex is shown. 
Muscimol (10-25 ng /0.5 ul) slightly but 
significantly increased tonic EMG-activity in 
the triceps muscle of the forelimb. 
(F(2,200)=8.48, p<0.01; V). A post hoc 
SNK- test showed that the dose of 25 ng 
differed significantly (p<0.01) from both AD 
and the dose of IO ng. In figure 4-5 (panel 
B) the effect of co-injection of muscimol (25 
ng) and the GABAa-antagonist bicuculline 
(50 ng; Bowery et al, 1983; Simmonds, 
1983) is shown. Bicuculline attenuated the 
effect of muscimol (two-way ANOVA: F-
(1,140)=40.34, p<0 01; V). 
The cataleptic effect of muscimol tended to 
be attenuated by this dose of bicuculline 
(muscimol vs muscimol+bicuculline (median 
value): 10.0 vs 3.0 seconds). 
4.3.2.4 Discussion 
The main finding from these studies was 
that the specific GABAa-agonist muscimol 
(Bowery et al, 1983; Simmonds, 1983) 
enhanced tonic EMG-activity of the triceps 
muscle of the forelimb of the rat in a 
circumscribed area of the VP/SI complex, i.e. 
the more caudal areas of the VP/SI complex; 
an effect, which was attenuated by the 
specific GABAa-antagonist bicuculline 
(Bowery et al, 1983; Simmonds, 1983; figure 
4-5; V). The latter suggests that the effect 
was GABAa-specific. From this area also 
catalepsy was elicited (table 4-1). Moreover 
muscimol increased motor activity in more 
rostral areas of the VP/SI complex; the latter 
phenomenon will be studied further in 
paragraph 4.3.3. 
The more rostral areas of the VP/SI 
complex were not involved in regulating tonic 
EMG-activity of the triceps muscle of the 
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forelimb of the rat although the effect of 
muscimol on motor activity per se interfered 
with the reliable measurement of tonic EMG-
activity. The latter precludes therefore to draw 
a firm conclusion. However, the fact that no 
changes in tonic EMG-activity were found in 
those rats that did not show an increase in 
motor activity support the notion that the 
effect was region-specific. This is furthermore 
underlined by the observation that a low dose 
of muscimol was ineffective in affecting tonic 
EMG-activity. It can overall be concluded that 
the areas were differentiaUy susceptible to 
the GABAa-agonist muscimol. 
It is unlikely that the results in the caudal 
area were due to spread of muscimol to the 
dorsal pallidum along the needle track, since 
others have found that muscimol injected into 
this area changed particularly hindlimb muscle 
tone (Ossowska et al, 1984). The caudal areas 
of the VP/SI complex, which is the SI proper 
according to the atlas of Paxinos and Watson 
(Paxinos and Watson, 1989), is a region 
known to receive projections from the nu-
cleus accumbens (see e.g. Mogenson et al, 
1983; Williams et al, 1977; section 4-2). This 
region also corresponds to the region from 
which muscimol (25 ng/0.5 ul) is known to 
induce catalepsy (Scheel-Kruger, 1983), a 
finding which was confirmed here. 
Previous studies have shown that the 
nucleus accumbens is involved in eliciting 
increases in tonic EMG-activity of the triceps 
muscle of the forelimb of the rat (Ellenbroek 
et al, 1988). The findings from the present 
study showed that a GABA-ergic pathway 
from the nucleus accumbens to the caudal 
areas of the VP/SI complex may play a role 
in transmitting this increase in tonic EMG-
activity to lower brain structures. To obtain 
more conclusive evidence in this respert, it 
was decided to study whether the increase in 
tonic EMG-activity induced by intra-
accumbens injections of haloperidol 
Table 4-1: Effects of muscimol (10-25 ng/0.5 ul) on motor activity and catalepsy in the rostral 
(A7.4) and caudal (A6.6) areas depicted in figure 4-4. 
A 7.4 A 6.6 
MOT. ACT.(%) CAT.(sec) MOT. ACT.(%) CAT.(sec) 
AD 0.0(8) 1.0(4) 
MSM 10 62.5(8)# 1.0(8) 
MSM 25 83.4(6)# 1.0(6) 
0.0(11) 1.0 (8) [1.0(7)] 
0.0(13) 2.0(13)* [1.5(6)] 
9.9(11) 10.0(11)*[10.0(7)*] 
MOT. ACT. 
CAT. : 
motor activity (muscimol-type of activity, 
rats; see text) 
catalepsy (9 cm woodblock; seconds) 
percentage of 
The values between brackets denote the number of rats tested. In case of the 
area A6.6 the values between square brackets denote the values for catalepsy 
for those rats displayed in figure 4-5, i.e. those rats that were included 
in the statistical analysis of tonic EMG-activity (see materials and 
methods). 
#: p<0.05 two-tailed X-square test 
*: p<0.05 two-tailed Mann-Whitney U-test 
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Figure 4-5: Effects of muscimol (msm; 10-25 ng/O.5 ul) in the caudal areas on triceps tonic EMG-
activity (panel A), and its antagonism by bicuculline (bic; panel B).DOAD ( N = 1 0 ) ; w l 0 ng msm 
(Ν=6);··25 ng msm (Ν=7);Οθ25 ng msm + 5 0 ng bic (N=9). 
(Ellenbroek et al, 1988) could be antagonized 
by injections of bicuculline in the caudal 
areas of the VP/SI complex; the results of 
this experiment are shown in the next 
paragraph. 
4.3.2.5 Interaction between the nucleus 
accumbens and the caudal areas of the VP/SI 
complex 
The general procedure was the same as that 
for the experiments described above. Rats 
(N=9) weighing 180-210 grams were 
however cannulated in this case with cannulae 
(5.0 nun in length) aimed at the nucleus 
accumbens (stereotaxic coordinates: A9.8 L+/-
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Figure 4-6: Injection sites into the nucleus accumbens (panel A) and caudal areas of the VP/SI 
complex (panel B) of the rats treated with intra-accumbens haloperidol, and AD or bicuculline (25 
ng/0.5 ul) into the caudal areas of the VP/SI complex. 
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1.2 H-0.6 mm) and with cannulae (3.0 mm 
in length) aimed at the caudal areas of the 
VP/SI complex (stereotaxic coordinates A6.6 
L+/-2.5 H-2.0 mm) according to the atlas of 
König and Klippel (Konig and Klippel, 1963). 
The rats were habituated to the glass cages 
for 30 minutes. Hereafter they were injected 
with AD (0.5 ul) in the nucleus accumbens 
followed 5-7 minutes later by an injection of 
AD (0.5 ul) into the VP/SI region. Tonic 
EMG-activity was recorded for 55 minutes 
starting 5 minutes after the latter injection. 
Again this recording served primarily as 
habituation to the experimental procedure. The 
rats were subsequently injected with a dose of 
haloperidol into the nucleus accumbens, which 
has previously been shown to enhance triceps 
tonic EMG-activity, i.e. 1000 ng/0.5 ul 
(Ellenbroek et al, 1988), followed 5-7 minutes 
later by an injection of AD (0.5 ul) or 
bicuculline (25 ng/0.5 ul) into the VP/SI 
region. 5 Minutes after the latter (i.e. 10 
minutes after injection of haloperidol into the 
nucleus accumbens) EMG-activity of the 
triceps muscle of the forelimb of the rat was 
recorded for 55 minutes. Rats were used 
twice in a counter-balanced design with a 
week interval between separate experiments 
(V). 
Since previous experiments showed that 
intra-accumbens injections of dl-sulpiride 
induced catalepsy after a latency of 60 
minutes, lasting hereafter for at least 5 hours 
(Ellenbroek, 1988), it was decided to test 
whether haloperidol could also induce 
catalepsy. For purely experimental reasons 
catalepsy was tested 150 minutes after 
injection of haloperidol, i.e. 90 minutes after 
ending to record EMG-activity using the 9 cm 
woodblock test as described above. The cut-
off point was 30 seconds (cf. Ellenbroek, 
1988). 
Two rats were discarded from the 
experiments since their injection sites were 
not within the intended region of the VP/SI 
complex (injection sites too rostral). The 
Figure 4-6: continued 
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injection sites of the other rats were within 
the caudal areas of the VP/SI complex as 
shown in figure 4-6, panel B; figure 4-6 also 
shows the injection-sites within the nucleus 
accumbens (panel A). 
The following procedures were used to 
analyse whether intra-accumbens injections of 
haloperidol induced an increase in tonic 
EMG-activity of the triceps muscle of the 
forelimb and whether intra VP/SI injections of 
bicuculline were able to attenuate this 
increase. The overall tonic EMG-activity of 
the rats injected with haloperidol (1000 
ng/0.5 ul) into the nucleus accumbens and 
AD into the caudal areas of the VP/SI 
complex was calculated and compared to the 
appropriate control value, i.e. the overall tonic 
EMG-activity of the 55 minutes prior to the 
actual testing (AD into the nucleus accumbens 
and AD into the caudal areas of the VP/SI 
complex). The former activity was 
significantly increased (haloperidol/AD vs 
AD/AD (mean+sem): 70.9+21.4 vs 52.7+17.1, 
t=2.430 df=6 p<0.05 two-tailed paired t-
test). In contrast the rats injected with 
haloperidol in the nucleus accumbens and 
bicuculline (25 ng/0.5 ul) into the caudal 
areas of the VP/SI complex showed no 
increase in tonic EMG-activity: 
haloperidol/bicuculline vs AD/AD 
(mean+sem): 79.1+37.5 vs 94.7+32.0, t=-
0.316 df=6 p>0.05 two-tailed paired t-test). 
These data thus showed that intra-accumbens 
injections of haloperidol increased tonic EMG-
activity (cf EUenbroek et al, 1988). This latter 
increase was not observed when intra-
accumbens injections of haloperidol were 
combined with injections of bicuculline into 
the caudal areas of the VP/SI complex (V). It 
cannot however be concluded unequivocally 
that bicuculUne attenuated the effect of 
haloperidol since baseline differences (see 
above) may have accounted for the observed 
effects. Therefore to compare the two 
experiments more properly the following 
procedure was followed. To equal out baseline 
differences between the two experiments the 
mean tonic EMG-activity per 5 minutes 
during the last 30 min before the injections 
of haloperidol into the nucleus accumbens 
was calculated per rat. The tonic EMG-
activity recorded after injection of haloperidol 
in the nucleus accumbens and AD or 
bicuculline into the caudal areas of the VP/SI 
complex was subsequently calculated as 
percentage of this mean EMG-activity per 5 
minutes per rat (V). The overall group 
percentages are shown in figure 4-7. It is 
clear from the data shown in this figure that 
injections of bicuculline (25 ng/0.5 ul) into 
the caudal areas of the VP/SI complex 
attenuated the increase in tonic EMG-activity 
induced by injections of haloperidol (1000 
ng/0.5 ul) into the nucleus accumbens (two-
way ANOVA for repeated measurements: 
(F(l,66)=30.36, p<0.01; Ferguson, 1981; 
SAS Institute Inc. USA; V). 
Injections of bicuculline (25 ng/0.5 ul) into 
the caudal areas of the VP/SI complex 
decreased the catalepsy scores of the rats 
injected with haloperidol (1000 ng/0.5 ul) 
into the nucleus accumbens measured 150 
minutes after injection: haloperidol/bicuculline 
vs haloperidol/AD, median values; 30.0 vs 
6.0 seconds, p<0.062 two-tailed sign test 
(N=5 rats). 
The present data confirmed the previous 
finding that injections of haloperidol into the 
nucleus accumbens enhanced tonic EMG-
activity of the triceps muscle of the forelimb 
of the rat (EUenbroek et al, 1988) and 
extended them by showing that this increase 
in tonic EMG-activity is transmitted from the 
nucleus accumbens to the caudal areas of the 
VP/SI complex via GABA-ergic mechanisms 
(figure 4-7). Although no appropriate controls 
were used, the data indicated that the rats 
were cataleptic after haloperidol, which was 
strengthened by the observation that 
bicuculline decreased this effect. Thus also 
catalepsy induced after injections of 
haloperidol into the nucleus accumbens, 
appears to be transmitted via the caudal areas 
of the VP/SI complex. Since dl-sulpiride has 
been shown to induce catalepsy upon injection 
into the nucleus accumbens, unlike SCH 
23390 (400-1000 ng/0.5 ul. Van den Bos, 
Bergmans and Cools, unpublished data; see 
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Figure 4-7: Tonic EMG-activity (means+sem's; N=7 rats) expressed as percen-tage (see text) before 
(panel A) and after (panel B) injection of haloperidol (1000 ng/0.5 ul), and AD (0.5 ul) or 
bicuculline (25 ng/0.5 ul). 
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however Fletcher and Starr, 1988), the effect 
of haloperidol on catalepsy may be asserted 
via a dopamine D2-receptor mechanism. 
4.3.2.6. Overall discussion and conclusions 
Table 4-2 summarizes the findings of the 
present experiments. It overall appears that the 
increase in tonic EMG-activity of the triceps 
muscle of the forelimb as well as the 
catalepsy elicited from the nucleus accumbens 
by haloperidol was transmitted to lower brain 
structures via the caudal areas of the VP/SI 
complex. The more rostral areas appeared not 
to be involved in regulating forelimb muscle 
tone and catalepsy. 
The more caudal areas appear to be the 
areas from which the projections to the 
midbrain Ntpp mainly originate (see section 
4-2; Mogenson, 1987; Swanson et al, 1987; 
Yang and Mogenson, 1987), suggesting that 
this may be the next station through which 
tonic EMG-activity is funnelled to the spinal 
cord. In this way parallel circuits may exist 
for the regulation of forelimb muscle and 
hindlimb muscle tone. In the latter case this 
has been traced from the striatum (Ellenbroek 
et al, 1985a) downstream to the substantia 
nigra pars reticulata (Ellenbroek et al, 1985b), 
and the deeper layers of the colliculus 
superior (Ellenbroek et al, 1984; 1985b) as 
well as the ventromedial nucleus of the 
thalamus (Klockgether et al, 1985). 
Since catalepsy was evoked from the same 
area as the increase in tonic EMG-activity it 
follows that these phenomena might be 
funnelled via the same route. The inability of 
SCH 23390 to elicit catalepsy (see previous 
paragraph) in a dose which elicited tonic 
EMG-activity (Ellenbroek, 1988) suggests that 
Table 4-2: Summary of the findings presented in this part of chapter 4. 
VARIABLE drug r-VP/SI C-VP/SI 
motor activity 
tonic EMG-activity 
catalepsy 
bic 
msm 
bic 
msm 
bic 
msm 
¡a, 
n.d. 
n.d./ == 
n.d. 
n.d. 
== 
n.d. 
t 
n.d. 
t 
(2) 
(2) 
r-VP/SI: rostral areas of the VP/SI complex (figure 4-4/panels A,B,C 
and D) ; c-VP/SI: caudal areas of the VP/SI complex (figure 4-4, 
panels E,F and G) 
bic: bicuculline; msm: muscimol 
I: increase in variable; ==: no effect; n.d.: not determined; 
(1) not shown (50 ng/0.5 ul); see paragraph 4.3.3 
(2) attenuated the increase in tonic EMG-activity and catalepsy 
respectively after infections of haloperidol into the nucleus 
accumbens 
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different mechanisms and/or pathways may 
however exist. 
Overall it can thus be concluded that the 
caudal areas of the VP/SI complex arc 
involved in regulating tonic EMG-activity in 
the tnceps muscle of the forelimb of the rat 
as well as in inducing catalepsy. 
153 
4.3.3 Motor activity 
4.3.3.1 Introduction 
Motor activity is traditionally inextricably 
bound up with the dopaminergic mesolimbic 
system: the nucleus accumbens and the 
olfactory tubercle. As outlined in section 4-
2 the nucleus accumbens and olfactory 
tubercle project towards the VP/SI complex. 
Thus it is not surprising that a number of 
behavioural studies have dealt with the 
question whether and how this motor activity 
is transmitted to lower brain structures via the 
VP/SI complex. Several studies have provided 
evidence that the projection from the nucleus 
accumbens to the VP/SI complex is GABA-
ergic (section 4-2). Hence, a number of 
studies have investigated the effects of 
GABA-ergic compounds on the motor activity 
elicited either directly or indirectly from the 
nucleus accumbens. Activity induced by intra-
accumbens injections of dopamine, which 
give a reliable short-term activity (see e.g. 
Pijnenburg et al, 1976; see however Cools, 
1986), or ADTN (2-amino-6,7-dihydroxy-
1,2,3,4-tetra-hydronaphtalene), which give a 
reliable long-term activity (Elkhawad and 
Woodruff,1975), was attenuated at the level 
of the VP/SI complex by (i) injections of 
GAB A (Jones and Mogenson, 1980b; 
Mogenson and Nielsen, 1983), (ii) injections 
of the GABAa-agonist muscimol (Patel and 
Slater, 1985, 1988; Slater et al, 1982), and 
(iii) injections of GABAb-agonist baclofen 
(Slater et al, 1982). Since in the latter study 
both (+)- and (-)-baclofen attenuated the 
ADTN induced activity the specificity of this 
effect may however be questioned. Moreover 
intra VP/SI application of ethanolamine-O-
sulphate (EOS), an inhibitor of the GABA 
metabolizing enzyme GABA-transaminase, 
attenuated the stimulatory effects of injections 
of dopamine into the nucleus accumbens 
(Pycock and Horton, 1976). In this latter 
study the injection sites in the VP/SI complex 
appeared to be located in the (dorsal) globus 
pallidus however, which makes the results 
equivocal. In fact the authors stated that the 
rats were akinetic after injections of EOS 
(Pycock and Horton, 1976) which thus 
questions the specificity of the blockade, 
although it should be noted that Jones and 
Mogenson showed that injections of GABA in 
the dorsal pallidum were unable to block 
motor activity induced by injections of 
dopamine in the nucleus accumbens (Jones 
and Mogenson, 1980b). Furthermore motor 
activity induced by d-amphetamine or heroin, 
compounds which are presumed to act via the 
nucleus accumbens, was attenuated at the 
level of the VP/SI complex by injections of 
muscimol (Swerdlow and Koob, 1985). 
Finally electrolytic lesions of the VP/SI 
complex were effective in attenuating the 
activity induced by injections of dopamine in 
the nucleus accumbens (Patel and Slater, 
1985; Pycock and Horton, 1976). 
The motor activity obtained after systemic 
injections of an otherwise ineffective dose of 
apomorphine in rats with 6-0HDA lesions of 
the nucleus accumbens -so called 
'supersensitive' motor response- was 
attenuated by intra VP/SI injections of 
muscimol (Swerdlow and Koob, 1984; 
Swerdlow et al, 1986b). Furthermore both 
electrolytic lesions (Swerdlow et al, 1984a) 
and chemical lesions (ibotenic acid; Swerdlow 
et al, 1984b) of the VP/SI complex were 
effective in attenuating this type of motor 
activity. 
Motor activity induced by intra-accumbens 
injections of (i) the GABA-antagonist 
Picrotoxin, (ii) EAA-agonists (Shreve and 
Uretsky, 1988b) and (iii) the cholinergic 
agonist carbachol (Austin and Kalivas, 1988) 
into the nucleus accumbens was also 
anenuated at the level of the VP/SI complex 
by injections of muscimol. 
The indirect GABA-antagonist Picrotoxin 
and the GABAa-antagonist bicucuUine were 
without an effect on the ADTN induced 
activity (Patel and Slater, 1988). Picrotoxin 
however has been found to potentiate motor 
activity induced by injections of dopamine 
into the nucleus accumbens upon injection 
into the ventral globus pallidus (Jones and 
Mogenson, 1980b). 
Several studies thus show that an inverse 
relation exists between dopamine in the 
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nucleus accumbens and GABA in the VP/SI 
complex with respect to motor activity. It has 
been shown that the nonspecific GABA-
antagonist Picrotoxin (Austin and Kalivas, 
1990; Scheel-Kruger, 1983; Swerdlow and 
Koob, 1987b; see also Jones and Mogenson, 
1980b) and the specific GABAa-antagonist 
bicucuUine (Austin and Kalivas, 1990) 
enhance motor activity. Accordingly it might 
be expected that the GABAa-agonist 
muscimol decreases spontaneous motor 
activity. No studies have thusfar shown this 
however explicitly (see however figure 1 
Baud et al, 1988). In fact, it has rather been 
shown that this drug enhanced motor activity 
(Baud et al, 1988; Scheel-Kruger, 1983; 
Swerdlow and Koob, 1984; Swerdlow et al, 
1986b). Although this is a rather controversial 
finding relatively little attention has been paid 
to these observations. As shown in the 
previous section this activity may even be 
limited to a specific subarea of the VP/SI 
complex; a finding which confirmed the initial 
observations of Scheel-Kruger (Scheel-Kruger, 
1983). 
From the foregoing it was decided to study 
whether the GABA-antagonist bicucuUine also 
induced a regional specific effect. It was 
furthermore decided to study whether the 
muscimol induced activity was GABAa-
specific by combining it with the specific 
GABAa-antagonist bicucuUine (Bowery et al, 
1983; Simmonds, 1983; VI). Finally, it was 
decided to study the effects of cholinergic 
drugs on motor activity in the rostral areas 
of the VP/SI complex. It was decided to use 
the muscarinic agonist carbachol (Spencer et 
al, 1988; Watson et al, 1986), since this agent 
has been found to be effective in eliciting 
behavioural changes in the rostral VP/SI 
complex, i.e. the scGP (section 4-2) in cats 
(Spooren, Cuypers, Bezemer and Cools, 
unpublished data; Spooren et al, 1989). 
4.3.3.2 Materials and methods 
General 
Male Wistar rats, weighing 180-200 grams 
at the time of operation, were anaesthetized 
with pentobarbital (60 mg/kg; Narcovet (R)) 
and equipped with cannulae (4.0 mm in 
length; inner diameter: 0.2 mm; outer 
diameter 0.65 mm) aimed at different areas 
of the VP/SI complex (stereotaxic coor-
dinates: A7.4 and A6.6; L +/-2.5, H3.1 mm; 
according to König and Klippel, 1963; see 
paragraph 4.3.2.2). The cannulae were inserted 
under a lateral angle of 5 degrees and secured 
onto the skull with dental acrylic cement 
(Paladur(R)) and stainless steel retaining 
screws. After surgery the rats were 
individually housed in macrolon(R)-cages in 
a temperature-controlled room (T=21+/-l 
degrees Centigrade) on a standard day-night 
cycle (18:00-06:00 hrs lights off). Water 
and food were available as required. Rats 
were given at least one week of recovery 
from the operation before the experiments 
started. Conscious, non restrained rats 
were injected with the solvent or the 
appropriate drugs with a 5.0 ul Hamilton(R)-
syringe extending 4.0 mm under the tip of 
the cannulae. A volume of 0.5 ul was 
delivered over a 5 second-period after which 
the needle was kept in place for 10 seconds. 
Experiments were performed between 09:00 
and 16:00 hrs, i.e. during the light phase of 
the day-night cycle. 
Distilled water (AD; PBNI, the Netherlands) 
was used as solvent for the drugs and as 
control throughout the study. Muscimol 
(Serva, FRG), bicucuUine.methiodide (Sigma, 
USA) and carbachol (carbamyl-
choline.chloride; Sigma, USA) were dissolved 
in AD. The solutions of bicucuUine and 
carbachol were freshly prepared each time. 
Muscimol was dissolved and stored in smaU 
aliquots (lOOO ul) at -20 degrees 
Centigrade. Solutions were not stored for 
longer than 4-5 months. After thawing they 
were dUuted to the appropriate concentrations 
with AD just before the experiment. During 
the experiments the solutions were kept on 
ice. In case it was intended to antagonize 
drug-induced effects, the drugs were mixed 
and injected in one solution. 
After the experiments the rats were 
sacrificed by an overdose of pentobarbital and 
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transcaidially perfused with 4% formalin. The 
brains were stored on 4% formalin until 
sectioning. Brain slices (20-30 urn) were cut 
on a freezing microtome (Bright, UK). 
Injection sites were determined according to 
the atlas of Paxinos and Watson (Paxinos and 
Watson, 1986). 
Procedure 
part I: regional selectivity 
The rats used in these experiments had 
already taken part in the swimming test 
(paragraph 4.3.4). They were randomly 
allocated to the different experimental groups. 
At least two days of recovery between the 
swimming test and the experiments described 
in this part were given. After injection with 
the appropriate drugs the rats were placed in 
a smaU open field (38*26*28 cm) as part of 
the swimming-test procedure (see chapter 3, 
section 3-4 and paragraph 4.3.4). Hereafter 
they were transferred to the motor cages (see 
below) in which their activity was measured 
for 60 minutes. It should be noted that the 
rats were not habituated to these cages. 
part Π: muscimol 
induced effect 
The rats used in these experiments were 
drug and experiment naive. They were 
habituated to the motor cages for 60 minutes 
after which AD was injected in all the rats 
used in this experiment. Activity was 
measured for 180 minutes. On the day after, 
i.e. on the experimental day, the rats were 
rehabituated to the motor cages for 60 
minutes and subsequently injected with AD 
or the appropriate drugs or their combination. 
Activity was measured again for 180 minutes. 
In this paradigm the rats were thus habituated 
to both the injection-procedure and the 
experimental cages (VI). 
part Ш: Carbachol 
induced activity 
In an attempt to study the effect of 
cholinergic drugs on motor activity in the 
VP/SI complex, the rats, which had been used 
in the muscimol and bicuculline experiment, 
were randomly allocated to the different 
experimental groups. At least three drug and 
experiment free days were allowed between 
the two sets of experiments. After habituation 
to the motor cages (60 minutes) they were 
injected with AD or the appropriate dose of 
carbachol. Activity was measured for 180 
minutes. 
Apparatus 
Motor activity was measured in motor cages 
(36x24x25 cm) equipped with three photo­
electric cells; two along the long, and one 
along the short end of the cages, 2 cm above 
the grid-floor (see Cools, 1986). The motor 
cages were individually situated in diffusely 
illuminated sound-proof boxes. A maximum 
of nine rats could be measured at the same 
time. The number of beam interruptions was 
automatically measured and scored per 2 
minutes. After these data were transferred 
from a temporary buffer to a micro PDP-11 
computer (Digital, the Netherlands) they were 
pooled to obtain scores per block of 10 
minutes. Means+sem's, which are displayed in 
the graphs, were subsequently calculated (VI). 
Statistics 
All statistics were performed using a two-
way analysis of variance (ANOVA) with 
doses or drags and time (unit=10 min) as 
factors (Ferguson, 1981). Cell-entries were the 
scores per rat per block of 10 minutes. Only 
rats with their injection sites within the 
boundaries of the appropriate area of the 
VP/SI complex were included in the statistical 
analyses. 
Final remarks 
The rats (N=140) included in these 
experiments were treated in the same way as 
described in paragraph 4.3.2. i.e. they were 
handled (see above) and their physical health 
was checked. The results presented in this 
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part of the thesis can, in part, be found in 
paper VI. 4.3.3.3 Results 
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Figure 4-8: Motor activity after injection of bicuculline in the rostral (panel A) or caudal (panel 
B) areas of the VP/SI complex. Y-axis: counts/10 min; X-axis: time after entering the motor cages 
(+10 min after injection); N=8-9 rats per group. 
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Figure 4-9: Effects of bicuculline (25-100 ng/0.5 ul; panel A) and muscimol (25 ng/O.5 ul; panel 
B) on motor activity. In panel С the effect of bicuculline (25-100 ng) on the muscimol (25 ng) 
induced motor activity is shown. 
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paît I: regional selectivity 
Injection sites within the two areas i.e. the 
rostral and caudal areas of the VP/SI complex 
were comparable to those shown in figure 4-
4. Figure 4-8 shows the differential effects of 
bicuculline (25 ng/0.5 ul) on motor activity 
in the two different areas. Bicuculline 
enhanced motor activity (F(l,84)=13.11, 
p<0.01) in the rostral areas; furthermore an 
interaction-term was found: F(5,84)=3.97, 
p<0.01 (figure 4-8, panel A). A lower dose 
of bicuculline (10 ng/0.5 ul) was ineffective 
(not shown). In the caudal areas bicuculline 
failed to significantly (F(l,90)=1.45, p<0.23) 
affect motor activity. It should be mentioned 
that significant differences (F(l,90)=5.27, 
p<0.05) between the control-groups of these 
different areas existed. A SNK-test pointed 
out that the rats in the caudal areas had a 
higher level of spontaneous activity than those 
in the rostral areas (p<0.05). No significant 
differences (F(l,84)=0.06, p<0.80) between 
ts/10 mm 
150 1Θ0 
Time (mm) 
o-o: msm 25 ng/0.5 ul 
· · · : msm + bic 25+ 25 ng/0.5 ul 
ft-Δ: msm + bic 25+ 50 ng/0.5 ul 
l-k: msm + bic 25+100 ng/0.5 ul 
Figure 4-9: continued; shown are means+sem's of N=7-9 rats per group; Y-axes: counts/10 min; 
X-axes: time after injection. 
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the groups injected with 25 ng bicuculline 
were however found. Towards more rostral 
areas, i.e. just ventral of the nucleus 
accumbens, bicuculline failed to alter motor 
activity. 
part Π: muscimol 
induced effect 
Since bicuculline showed its effect only in 
the rostral areas (see above) like muscimol 
(see paragraph 4.3.2), the following studies 
were only conducted in this area. Bicuculline 
increased motor activity in habituated rats 
(figure 4-9, panel A; F(3,558)=37.04, 
p<0.01; VI). As can be seen in panel A a 
bell-shaped curve appeared to exist: the doses 
of 25 and 50 ng enhanced activity whereas 
the dose of 100 ng had nearly no effect, 
which was confirmed by a post hoc SNK-
test: this latter dose was not significantly 
different from AD, whereas the doses of 25 
and 50 ng were (p<0.05; VI). A lower dose 
of bicuculline (10 ng/0.5 ul) also enhanced 
motor activity (not shown). As expected 
muscimol (25 ng/0.5 ul) increased motor 
activity (F(l,270)=240.34, p<0.01; figure 4-
9, panel B; VI). A higher dose, i.e. 50 ng, 
also increased motor activity (not shown). The 
above mentioned doses of bicuculline dose-
dependently attenuated the muscimol (25 ng) 
induced activity (F(3,486)=4.98, p<0.01; 
figure 4-9, panel C; VI). It is clear that the 
effect was most prominent in the first 60 
min, which appears to agree with the short-
term effect of bicuculline as shown in figure 
4-9, panel A. Analysing accordingly the first 
60 min it turned out that bicuculline dose-
dependently attenuated the muscimol induced 
activity (F(3,162)=7.98, P<0.01). Both the 
dose of 50 ng and the dose of 100 ng were 
significantly different (p<0.05 SNK-test; VI) 
from the control, i.e. muscimol 25 ng alone. 
The curves showed a nice parallel shift, 
which was statistically confirmed by the fact 
that no significant interaction-term in the two-
way ANOVA (F(15,162)=1.49> p<0.11; VI) 
was found. When the remainder of the time-
period was analysed , i.e. 70-180 min after 
injection, it turned out that the motor activity 
of the combination of muscimol 25 ng and 
bicuculline 100 ng was significantly 
(p<0.05, SNK-test) higher than the motor 
activity of the other groups (F(3,324)=4.20, 
p<0.01). 
The dose of 25 ng muscimol (msm) was 
also able to attenuate the bicuculline (bic) 
induced activity in the first IO min period, 
i.e. 0-10 min after injection (compare in 
figure 4-9 panel С with panel A): msm 25+ 
bic 25 vs bic 25 (mean+sem): 111.1+96.0 vs 
521.5+79.0, t=3.300 df=15 p<0.01; msm 
25+bic 50 vs bic 50: 78.0+9.7 vs 
819.0+147.8, t=5.001 df=14 p<0.01 (two-
tailed t-tests; figure 4-9; VI). Muscimol also 
antagonized the bicuculline induced activity 
in the second 10 min period, i.e. 10-20 min 
after injection: msm 25+bic 50 vs bic 50: 
178.0+135.0 vs 836.1+182.4, t=2.900 df=14 
p<0.05 two-tailed t-test; figure 4-9; VI. 
part Ш; carbachol 
induced activity 
Carbachol (100-1000 ng/0.5 ul) enhanced 
motor activity in the rostral areas of the VP/SI 
complex (figure 4-10; F(4,702)=9.32, 
p<0.01). It is clear from this figure that the 
motor activity appeared only after a latency of 
20 minutes. Accordingly statistical analysis of 
the first 20 minutes revealed no differences 
between the groups (F(4,78)=1.83, p<0.13), 
whereas a significant effect was found in the 
period 30-180 minutes (F(4,624)=22.40, 
p<0.01). A post hoc SNK-test showed that 
the doses of 1000 and 50O ng carbachol 
were significantly different from 250 ng, 
100 ng and AD, whereas the dose of 250 
ng was different from 100 ng and AD; the 
dose of 100 ng was not different from AD. 
4.3.3.4 Discussion 
general 
The main findings of these studies were 
(i) that a regional selectivity for the GABAa-
antagonist bicuculline existed, i.e. injections 
of bicuculline into the rostral areas of the 
VP/SI complex increased motor activity, 
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whereas similar injections into the caudal 
areas of the VP/SI complex were ineffective 
(part I), (ii) that bicuculline and muscimol 
induced motor activity after injection into the 
rostral areas of the VP/SI complex, which 
was attenuated by co-injection of muscimol 
and bicuculline respectively (part П), and (iii) 
that the cholinergic agonist carbachol 
enhanced motor activity after injection into 
the rostral areas of the VP/SI complex (pan 
Ш). 
part I: regional selectivity 
The data from this study showed that the 
specific GABAa-antagonist bicuculline 
(Bowery et al, 1983; Simmonds, 1983) 
enhanced motor activity in the rostral areas 
of the VP/SI complex, whereas it had no 
effect in the caudal areas (figure 4-8). Until 
now only one study has concentrated on the 
question whether the subpallidal areas are 
homogeneous with respect to their 
susceptibility for GABA-ergic drugs (Scheel-
Kruger, 1983). Scheel-Kruger observed that 
the behavioural effects of the indirect GABA-
antagonist Picrotoxin and the GABAa-agonist 
muscimol were dependent on the region in 
which these drugs were injected (Scheel-
Kruger, 1983). In fact, he found that these 
drugs only affected motor activity in the 
rostral areas. The findings of the present 
study together with those from the previous 
paragraph (4.3.2) confirmed these initial 
results and extended them by including more 
caudal areas than Scheel-Kruger studied 
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(Scheel-Kruger, 1983). In the general 
discussion following the experimental part of 
this chapter (section 4-4) the functional 
implications of these findings will be 
discussed. 
pan Π: muscimol 
and bicuculline 
induced activity 
The main findings of this part were that 
both bicuculline and muscimol enhanced 
motor activity after injection in the rostral 
areas of the VP/SI complex. This increase in 
motor activity was attenuated by co-injection 
of muscimol and bicuculline respectively 
(figure 4-9; VI). This study thus not only 
confirmed the findings of previous 
experiments that muscimol (Baud et al, 1988; 
Scheel-Kruger, 1983; Swerdlow and Koob, 
1984; Swerdlow et al, 1986b) and bicuculline 
(Austin and Kalivas, 1990) enhance motor 
activity but also actually extended them (VI). 
Since muscimol and bicuculline are a 
GABAa-specific agonist and antagonist 
respectively (Bowery et al, 1983; Simmonds, 
1983) this strongly suggests that the effects of 
these drugs were mediated via the GABAa-
receptor. 
Bicuculline dose-dependently enhanced 
motor activity (figure 4-9; cf Austin and 
Kalivas, 1990); an effect, which was 
attenuated by the GABAa-agonist muscimol 
(Bowery et al, 1983; Simmonds, 1983) 
suggesting that the effect was mediated via 
the GABAa-receptor (VI).A new finding was 
the observation that bicuculline had a dual 
effect: at lower doses it enhanced motor 
activity whereas at higher dose it produced 
only a weak effect. Although the effect of 
bicucculline on motor activity has been 
studied by others using a similar dose-range 
(10-100 ng), such a phenomenon was not 
observed (Austin and Kalivas, 1990). Since 
these authors used another strain of rats, the 
sensitivity for such a phenomenon might 
differ across strains of rats (cf. Cools et al, 
1990a). The possibility remains therefore that 
Austin and Kalivas would also have observed 
a bell-shaped curve if they had studied higher 
doses. 
Muscimol enhanced motor activity (figure 
4-9; cf Baud et al, 1988; Scheel-Kruger, 
1983; Swerdlow and Koob, 1984; Swerdlow 
et al, 1986b). The GABAa-antagonist 
bicuculline (Bowery et al, 1983; Simmonds, 
1983) dose-dependently attenuated this 
muscimol induced activity. Since a nice dose-
dependent effect was found, with the 
muscimol induced activity returning to 
baseline levels at the moment that the effect 
of bicuculline began to wear off, it strongly 
suggests that the muscimol induced activity 
was mediated via the GABAa-receptor. 
From these data it would appear that both 
stimulation of the GABAa-receptor and 
blockade of the GABAa-receptor lead to an 
increase in motor activity. At this stage it 
cannot be discriminated whether these effects 
are mediated via GABAa-receptors located on 
the same population of neurons or via 
GABAa-receptors on different (surpopulations 
of neurons. In the latter case, the basal 
GABA activity within each subpopulation may 
determine the differential sensitivity to the 
agonist and antagonist respectively (cf. Cools 
et al, 1990a and references cited therein). 
Although Scheel-Kruger observed that the area 
from which muscimol induced activity differs 
slightly from the area from which the indirect 
GABAa-antagonist Picrotoxin induced motor 
activity (Scheel-Kiuger, 1983), such a 
distinction was not found in the present study: 
the injection sites for bicuculline and 
muscimol were located in the same area (see 
figure 4-4). It should be noted however that 
Scheel-Kruger observed that Picrotoxin 
induced activity in the lateral part of the 
ventral pallidum, whereas muscimol induced 
activity in the medial part (Scheel-Kruger, 
1983). As indicated in the previous section 
(section 4-2) the olfactory tubercle innervates 
the ventrolateral part of the ventral pallidum, 
whereas the nucleus accumbens innervates the 
mediodorsal part (Heimer and Wilson, 1975; 
Heimer et al, 1987). This would thus suggest 
that the Picrotoxin induced activity is related 
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to the olfactory tubercle, whereas the 
muscimol induced activity is related to the 
nucleus accumbens. With respect to the 
present experiments, it should be stressed that 
the injection sites were situated in both 
(sub)areas, thus probably affecting the input 
from both olfactory tubercle and nucleus 
accumbens. Future experiments should be 
directed at investigating whether the 
bicuculline and muscimol induced activity are 
indeed related to the olfactory tubercle and 
nucleus accumbens respectively (see further 
section 4-4). 
It is clear that by simply measuring the 
disruption of photocell beams little can be 
said on the differences between the two types 
of activity. From the graphs it is however 
already clear that differences existed. First, 
the bicuculline induced motor 
activity was short-lasting in contrast to the 
long-lasting muscimol induced activity (figure 
4-9). Second, the onset of the bicuculline 
induced activity was faster than that of the 
muscimol induced activity (figure 4-9). 
Although the rats were not observed for their 
behaviour in the motor cages, this already 
suggests that they may have had different 
underlying behavioural profiles. Behavioural 
observations in the EMG-experiments 
described in paragraph 4.3.2 already 
confirmed this. As outlined in the latter 
paragraph rats treated with muscimol (10-25 
ng/O.5 ul) showed repititive head movements, 
forepaw treading and circling. Preliminary 
experiments showed that rats treated with 
bicuculline (50 ng/0.5 ul) in the rostral areas 
displayed a motor activity pattern that 
resembled that of d-amphetamine in the 
nucleus accumbens: an increase in sniffing, 
forward locomotion and rearing (cf. IV). 
Experiments run in cats in an area comparable 
to that in the present experiments, i.e. the 
scGP, also showed that muscimol induced 
circling behaviour (Spooren, Cuypers and 
Cools, unpublished data). Until now no clear 
counterpart for a muscimol type of activity 
has been found in the nucleus accumbens. 
Since the motor activity induced by intra-
accumbens ergometrine (Cools, 1986) or 
ADTN (Elkhawad and Woodruff, 1975) is 
also long-lasting and starts after an initial 
immobility period, the possibility exists that 
this may be the accumbens counterpart of the 
motor activity induced by injections of 
muscimol in the VP/SI complex. 
At present it is not clear whether the 
differences in the behavioural profiles between 
muscimol and bicuculline were due to 
differences in pharmacokinetic or 
physicochemical properties of the drugs, 
differences in interaction with the GABAa-
receptor or whether they reflect different 
interactions with differentially localized 
GABAa-receptors (see above; VI). Future 
experiments should thus be directed at 
elucidating the behavioural differences 
between the motor activity induced by 
muscimol and bicuculline (VI). 
part ΠΙ: carbachol 
induced activity 
Injections of the muscarinic agonist 
carbachol (Spencer et al, 1988; Watson et al, 
1986) enhanced motor activity upon injection 
into the rostral areas of the VP/SI complex 
(figure 4-10). The activity appeared biphasic 
in nature: first a decrease subsequently a 
weak increase in motor activity. 
Recent experiments have shown that 
carbachol injections within the caudal areas 
of the ventral forebrain area decrease the 
turnover rate of acetylcholine in the cortex 
(Robinson et al, 1988). Although carbachol 
has an affinity for both the muscarinic Ml-
and M2-receptor (Spencer et al, 1988; Watson 
et al, 1986) Robinson and collegues did not 
determine via which of these receptors the 
effect was mediated. Both types of muscarinic 
receptors are present in the VP/SI complex 
(Cortes et al, 1986, 1987; Mash and Potter, 
1986). In this respect it is interesting to note 
that blockade of the Ml-type of receptor has 
been shown to enhance the release of 
acetylcholine within the ventral forebrain 
(Suzuki et al, 1988). One might infer from 
these data that stimulation of the Ml-receptor 
decreases the release of acetylcholine. It might 
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thus be speculated, that carbachol decreased 
the release of acetylcholine in the ventral 
forebrain, which in tum might have lowered 
the activity of the cholinergic cells that 
project to cortex (via autoreceptors) and 
accordingly decreased the turnover rate of 
acetylcholine in the cortex. Although no data 
for the rostral areas exist in this respect, this 
decrease in the cortical acetylcholinergic 
activity might have underlied the observed 
effect in the present experiments. If so, it 
might be predicted that other treatments, 
which also lower the cortical acetylcholinergic 
activity also enhance motor activity. Injections 
of muscimol in high (lOO ng) doses in the 
more caudal VP/SI complex (Wood and 
Richard, 1982) and low (1-2 ng) doses in 
more rostral areas of the VP/SI complex 
(Robbins et al, 1990) decrease the turnover 
rate of acetylcholine in the cortex. Moreover 
behavioural experiments have shown that 
systemic injections of the muscarinic M1/M2 
antagonist scopolamine, -which induces 
activity by itself (like atropine; Whishaw et 
al, 1985)- potentiate the motor activity 
induced by injections of muscimol into the 
VP/SI complex (Baud et al, 1988). 
Furthermore electrolytic or chemical lesions 
of the VP/SI complex, which inter alia 
destroy the cholinergic projections to the 
cortex, also enhanced motor activity (Dubois 
et al, 1985; Dunnet et al, 1987; Kepler and 
Lerer, 1986; Whishaw et al, 1985). Dunnet 
and coworkers were however unable to find 
a significant correlation between the changes 
in overnight activity and the changes in 
choline-acetyltransferase activities in the 
cortex (Dunnet et al, 1987). Moreover as 
indicated above only high doses of muscimol 
(>10 ng) within the rostral areas of the VP/SI 
complex enhanced motor activity, whereas 
also low doses decreased acetylcholine 
turnover in the cortex (Robbins et al, 1990). 
These findings would thus suggest that no 
absolute correlation between the enhanced 
motor activity and the decreased turnover rate 
of acetylcholine in the cortex exists. Although 
the results presented in this paragraph do not 
allow for such a conclusion it is tempting to 
suggest that carbachol and muscimol share 
some features with respect to inducing motor 
activity (note e.g. that both drugs only 
induced an increase in motor activity after a 
certain latency). 
In cats injections of carbachol (lOO-lOOO 
ng) into the scGP (section 4-2) increased the 
number of postural changes (Spooren, 
Bezemer, Cuypers and Cools, unpublished 
data), which was attenuated by the cholinergic 
antagonist scopolamine (Spooren, Bezemer 
and Cools, unpublished data). This increase in 
general activity may be comparable with the 
increase in motor activity observed in the 
present study. Moreover the injections of 
carbachol in the scGP elicited tongue 
protrusions, which were also attenuated by 
scopolamine (Spooren et al, 1989). Although 
the rats were not thoroughly observed in the 
motor cages in the present study, pilot open 
field experiments showed that injections of 
carbachol (600-800 ng/0.5 ul) into the 
rostral areas of the VP/SI complex in rats 
also elicited tongue protrusions. Although 
these data were only preliminary they show 
that the same type of syndrome may be 
elicited in the rat as in the cat after injections 
of carbachol. 
overall conclusions 
In conclusion the present studies showed 
that differences between the different regions 
of the VP/SI complex existed as far as it 
concerned their susceptibility to GABA(a)-
ergic drugs. These differences might be 
related to different in- and outputs of these 
regions (see section 4-4). Moreover it was 
shown that both bicuculline and muscimol 
induced activity via the GABAa-receptor. At 
present it is not clear whether they induced 
this activity via receptors on different or on 
the same population of neurons. These 
findings have implications for understanding 
the role of the GABA-ergic input into the 
VP/SI complex. Finally, it was found that 
carbachol increased motor activity in the 
rostral areas of the VP/SI complex. It is 
suggested that it may do this by decreasing 
cortical acetylcholine turnover. 
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Figure 4-11: Injection sites in the striatal area:-*, striatal-pallidal area:© and rostral VP/SI 
complex: · . 
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4.3.4 The swimming test 
4.3.4.1 Studies on the role of the VP/SI 
complex 
4.3.4.1.1 Introduction 
As outlined in section 4-2 the nucleus 
accumbens projects to the subpallidal 
areas. Furthermore the type of motor 
activity induced by injections of d-
amphetamine into the nucleus accumbens 
and the type of motor activity induced by 
injections of bicuculline into the 
subpallidal areas appeared to be the same 
at first glance (latency, duration, 
behavioural pattern). Since clear changes 
in the ability to switch to cue-directed 
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Figure 4-12: Number of different cue-directed and non cue-directed behaviours (Y-axes) after 
manipulation with the areas depicted in figure 4-11. X-axes: time-blocks; the number of rats 
is indicated in the figure; shown are means+sem's. 
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behaviours were obtained with intra-
accumbens injections of d-amphetamine in 
the swimming test, it was decided to use 
this test to study the behavioural effects of 
bicuculline into the subpallidal areas in 
more detail. As shown in chapter 3, 
section 3-4, the swimming test is a very 
sensitive test for detecting small, subtle 
changes in ongoing behaviour. In order to 
study the behavioural effect of injections 
into the subpallidal areas per se, it was 
also decided to investigate to what extent 
injections through the overlying areas (i.e. 
the globus pallidus) affected the behaviour 
of the rats in the swimming test. In first 
instance it was decided to investigate the 
effects in the rostral areas of the VP/SI 
complex (A7.4) since bicuculline was 
behaviourally active in this area as shown 
in paragraph 4.3.3., i.e elicited changes in 
motor activity in the rostral areas of the 
VP/SI complex. 
4.3.4.1.2 Materials and methods 
Rats were prepared as described in 
paragraph 4.3.3. In brief, rats weighing 
180-210 grams, were equipped with 
cannulae (length 4.0 mm) aimed at the 
rostral areas of the VP/SI complex 
(stereotaxic coordinates A7.4 L+/-2.5 H-
3.1, according to the atlas of König and 
Klippel, 1963), and allowed to recover 
from the operation for at least one week. 
In principle the swimming paradigm as 
described in chapter 3, section 3-4 was 
used. Thus, rats were injected with the 
appropriate drugs and observed in an open 
field (38*26*28 cm) for 10 minutes. The 
number of rearings was scored as a 
measure of general activity. Hereafter the 
rats were subjected to the swimming test 
and their behaviour was analysed in terms 
of the number of different cue-directed 
and non cue-directed behaviours. The term 
'cue' is used here in the sense of 
'stimulus' (see discussion chapter 3, 
section 3-5). After 6 minutes a rope was 
lowered into the middle of the tank for 2 
minutes. If the rope was not detected 
within 2 minutes, it was offered to the 
rats for a period of 3 minutes; it was kept 
in front of the rats, after which they were 
allowed to grasp it. Rats were considered 
to have escaped succesfully when their 
hindlimbs were clearly visible above the 
water surface. 
After the experiments the rats were 
sacrificed by an overdose of pentobarbital 
after which the brains were removed. The 
brains were cut into 30 urn slices on a 
freezing microtome (Bright, UK). After 
staining the slices with cresyl violet, the 
injection sites were determined and drawn 
on the planes of the atlas of Paxinos and 
Watson (Paxinos and Watson, 1986). Only 
rats with their injection sites within the 
appropriate areas were included in the 
statistical analysis. Data were analysed 
with a two way ANOVA and X-square 
test as described in section 3-4, chapter 3. 
The rats were taken care of as described 
in chapter 3, section 3-4. A total of 68 
rats was included in these experiments. 
4.3.4.1.3 Results: part I 
part A: variable 
needle lengths 
In the first experiment distilled water 
(AD) was injected at different depths 
(needle-lengths 11.0 and 13.0 mm, i.e. 
2.0 and 4.0 mm below the tip of the 
cannulae respectively) within the brain, i.e. 
within the striatal/pallidal (SP) area and 
the VP/SI complex respectively. 
Furthermore the effect of the cannulae per 
se was investigated. These rats were not 
injected, but the stylets were removed 
from the cannulae and inserted again in 
order to compensate for the stress of 
handling the rats. 
In figure 4-11 the injection sites within 
the (rostral areas of the) VP/SI complex 
and the SP are shown, as well as the 
location of tips of the cannulae in the 
experiment in which no injections were 
made, i.e. the (dorsal) striatal area. 
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Table 4-4: Effect of variable needle-lengths on detection of the rope, free escape, and free + 
forced escape. Shown are percentages. 
Length detect ion free escape free+forced escape N 
0 . 0 
2 . 0 
4 . 0 
33.3 
37.5 
0 . 0 
33.3 
25.0 
0 . 0 
100.0 
62.5 * 
12.5 * * , # 
9 
β 
8 
Length: d i s t a n c e (mm) below t h e t i p of t h e cannulae; N: 
i n t h e case of 0.0 mm no needle was i n s e r t e d . 
*: p<0.05; * * : p < 0 . 0 1 < X-square t w o - t a i l e d vs 0.0 mm 
#: p<0.05, X-square t w o - t a i l e d vs 2.0 mm 
number of r a t s ; 
Table 4-3: Effects of different needle-
lengths on the rearing behaviour in the 
open field. Shown are means+sem's. 
time 
length 
0-5 5-10 
0.0 27.0+3.4 10.0+2.1 9 
2.0 16.0+3.3 28.6+4.3 8 
4.0 5.5+1.8 16.6+5.1 8 
length: distance (mm) below 
the tip of the cannulae; in 
the case of 0.0 mm no needle 
was inserted; N: number of 
rats. 
Table 4-3 shows the effect on rearing in 
the open field. From this table it is clear 
that two effects existed. First, the overall 
number of rearings of the rats injected 
within the VP/SI complex was lower than 
the number of rearings of the rats injected 
within the SP area or of the rats that were 
not injected at all (p<0.05 SNK-test 
following a significant group effect: 
F(2,44)=4.98, p < 0 . 0 1 ) . Second, 
differences existed between the different 
groups with respect to the number of 
rearings across the two time-periods: the 
rats that were not injected showed a 
decrease in the number of rearings in time 
whereas the other two groups, i.e. the rats 
that were injected within the SP area and 
the rats that were injected within the 
VP/SI complex, showed an increase in the 
number of rearings in time. This was 
reflected by the significant interaction 
term (F(2,44)=11.41, p<0.01) in the two-
way ANOVA. 
In figure 4-12 the number of different 
cue-directed and non cue-directed 
behaviours are shown. From this figure it 
is clear that no differences existed with 
respect to the number of different cue-
directed behaviours (F(2,66)=1.68, 
p<0.19). A difference however existed as 
far as it concerned the number of different 
non cue-directed behaviours (F(2,66)=7.19, 
p<0.01). A post hoc SNK-test showed 
that the rats injected within the VP/SI 
complex had a lower number of different 
non cue-directed behaviours than the rats 
that received no injections at all (p<0.05 
SNK-test). 
It was finally found that the total 
number of rats that escaped after injection 
168 
Table 4-6: Effects of bicuculline on detection, free escape and free+forced escape. Shown 
are percentages. 
drug dose d e t e c t i o n free escape free+forced escape N 
AD 
BIC 
BIC 
10 
25 
0 . 0 
25.0 
0 . 0 
0 . 0 
12.5 
0 . 0 
12.5 
25.0 
22.2 
8 
β 
9 
AD: d i s t i l l e d water; BIC: b icucu l l ine 
dose: ng/0.5 u l ; N: number of rats 
of AD in the SP area was lower than that 
of the rats that were not injected (table 4-
4). Moreover the total number of rats that 
escaped after injection of AD in the VP/SI 
complex was lower than that of the rats 
that were not injected or that were 
injected with AD in the SP area. 
Furthermore a nearly significant decrease 
was found in the number of rats that 
detected the rope and showed free escape 
in the latter case (p<0.10 X-square two-
tailed 4.0 vs 0.0 mm). 
part B: effects 
of bicuculline 
Table 4-5: Effects of bicuculline on the 
number of rearings in the open field 
preceeding the swimming test. Shown are 
means+sem's. 
time o-S 
drug 
5-10 
AD (8) 5.5+1.8 16.6+5.1 
B10(B) 8.5+2.2 19.3+3.5 
B25(9) 5.2+1.7 16.7+5.0 
AD: d i s t i l l e d water; BIO, B25: 
b icucu l l ine 10 and 25 ng/0.5 
ul r e s p e c t i v e l y 
Between brackets the number of 
rats i s shown per group. 
The injection sites of the rats treated 
with AD or bicuculline 10-25 ng/O.5 ul 
are essentially the same as those depicted 
in figure 4-4 and figure 4-11. Bicuculline 
(10-25 ng/0.5 ul) had no effect on the 
number of rearings during the IO min 
open field session (F(2,44)=0.40, p<0.67; 
table 4-5). Moreover no effects were found 
on the number of different cue-directed 
(F(2,66)=0.02. p<0.97) or non cue-
directed (F(2,66)=1.02, p<0.37) 
behaviours (figure 4-13). Furthermore no 
effects were found on any of the 
parameters concerning the rope (table 4-
6). 
4.3.4.1.4 Discussion: part I 
The main findings from the first part of 
these studies were-that injections of AD in 
the rostral areas of the VP/SI complex had 
profound effects (i) on the ability to 
display different non cue-directed 
behaviours (figure 4-12), (ii) on the 
number of rats that escaped (table 4-4), 
and (iii) on the number of as well as on 
the pattern of rearings in the open field 
(table 4-3). With respect to the latter, the 
rats that were injected with AD in the 
VP/SI complex had a lower overall 
number of rearings than the rats that were 
injected with AD in the overlying SP area 
or the rats that were not injected, but in 
which the stylets were removed from the 
cannulae and inserted again in order to 
compensate for the stress of handling the 
rats. Since these latter two groups did not 
differ from each other, the data show that 
this effect on the number of rearings was 
not due to injection of AD per se, i.e. due 
to e.g osmotic effects or the like. It 
appeared therefore to be due to the 
injections aimed at the area itself. In 
support of this, it should be noted that rats 
injected with AD into the most rostral part 
of the VP/SI region, i.e. just ventrally of 
the nucleus accumbens, had a higher 
number of rearings than the rats that were 
injected within the rostral areas depicted in 
figure 4-11 (mean+sem: 50.3+5.6 (N=4) 
vs 22.1+6.8 (N=8), t=3.201 df=10 
p<0.01, two-tailed t-test). However rats 
injected within the most caudal part of the 
VP/SI complex, i.e. the caudal areas of the 
VP/SI complex depicted in figure 4-4, 
showed even a lower number of rearings 
although this effect did not yet reach 
significance (mean+sem: 8.2+2.6 (N=5) vs 
22.1+6.8 (N=8), t=1.909 df=ll p<0.10, 
two-tailed t-test). Three possibilities exist 
to explain these data. First, the effect may 
be due to a -temporary ?- disturbance of 
the integrity of the neuronal network 
within the rostral areas of the VP/SI 
complex themselves. Second, the effect 
may be due to a similar phenomenon in 
the overlying globus pallidus ; three, the 
effect may be due to a combination of the 
former two. It has recently been shown 
that bicuculline enhances rearing upon 
injection in an area in between two of the 
injection areas of the present experiments, 
i.e. the SP area and the VP/SI complex 
(Vrijmoed-de Vries, 1985; Vrijmoed-de 
Vries et al, 1987). Thus it appears that 
this area of the globus pallidus is involved 
in the expression of rearing behaviour. 
These data together suggest that the lower 
number of rearings may thus be due to 
disturbances in the overlying globus 
pallidus and/or the rostral areas of the 
VP/SI complex. 
The groups injected with AD in the SP 
area or the VP/SI complex showed an 
increase in the number of rearings across 
the two time periods in contrast to the 
group of rats that was not injected at all 
(table 4-3). These patterns are similar to 
those observed after injections of AD into 
the nucleus accumbens (chapter 3, section 
3-4; not shown). The change in the time-
curves may therefore reflect an injection 
stress related phenomenon, i.e. insertion of 
the needle in brain-tissue (chapter 3, 
section 3-5). The increase in mobility may 
reflect a 'recovery' from this phenomenon. 
No differences were found between the 
different groups as far as it concerned the 
number of different cue-directed 
behaviours. These data thus suggest that 
inserting the needle into the VP/SI 
complex had no effect on the ability to 
display different cue-directed behaviours 
(figure 4-12). In contrast, the injections of 
AD into the rostral areas of the VP/SI 
complex decreased the number of different 
non cue-directed behaviours compared to 
the situation in which no injections were 
made (figure 4-12). As outlined in chapter 
3, section 3-3, the (dorsal) striatum 
mediates the ability to switch to non cue-
directed behaviours. Until now it has only 
been studied whether the ability to switch 
to non cue-directed behaviours is funnelled 
via the striatal-nigra-collicular pathway 
(Gelissen, 1987). This latter study has 
shown that this pathway is involved in 
transmitting the ability to switch to non 
cue-directed behaviours. Extensive 
projections however exist from the (dorsal) 
striatum to the globus pallidus (see e.g. 
Haber et al, 1985). The possibility, that 
the globus pallidus is involved in 
transmitting the ability to switch to non 
cue-directed behaviours, has not been 
investigated yet. The findings from the 
present study suggest that the globus 
pallidus -through which the needle travels 
to reach the VP/SI region- may be also a 
station through which the ability to switch 
to non cue-directed behaviours is funnelled 
from the (dorsal) striatum to lower brain 
structures. In this respect it is interesting 
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Figure 4-13: Effects of bicuculline (bic) on the number of different cue-directed and non 
cue-directed behaviours (Y-axes). X-axes: time-blocks; the number of rats is indicated in the 
figure; shown are means+sem's. 
to note that 'swimming' rats had a higher 
2-deoxyglucose uptake in the rostral 
globus pallidus, i.e. the area through 
which the needle travels to reach the 
rostral VP/SI complex, than 'resting' rats 
(Duncan et al, 1989). 
Free escape was slightly decreased after 
injection of AD in the rostral areas of the 
VP/SI complex; interestingly however the 
total number of rats that escaped after 
injection of AD in the SP area or the 
VP/SI complex was decreased (table 4-4). 
As shown in chapter 3 these parameters 
are affected by manipulation with the 
nucleus accumbens (chapter 3, section 3-
4). Moreover it has been shown that the 
(dorsal) striatum is involved in rope-
directed behaviour (Vrijmoed-de Vries and 
Cools, 1986; Cools and Peeters, 1987). 
These findings thus suggest that the 
observed effects may be due to -temporary 
?- disturbances in the output of the 
nucleus accumbens (rostral areas of the 
VP/SI complex) and/or -temporary ?-
disturbances in the output of the (dorsal) 
striatum (globus pallidus). 
The main findings from the second part 
were that injections of bicuculline into the 
rostral areas of the VP/SI complex had (i) 
no significant effect on the number of 
rearings (table 4-5), (ii) the number of 
different cue-directed or non cue-directed 
behaviours (figure 4-13), and (iii) the 
number of rats which detected the rope or 
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escaped (table 4-6). Since an inverse 
relationship has been shown to exist 
for DA in the nucleus accumbens and 
GABA in the subpallidal areas at the level 
of behaviour or electrophysiological 
responses (see paragraphs 4.3.2 and 4.3.3), 
and since the ability to switch to cue-
directed behaviours is mediated via the 
dopaminergic system within the nucleus 
accumbens (chapter 3, section 3-4), it was 
predicted that the GABAa-antagonist 
bicuculline (Bowery et al, 1983: 
Simmonds, 1983) would enhance the 
ability to twitch to cue-directed 
behaviours. The fact that bicuculline did 
not affect the number of different cue-
directed behaviours, thus suggests that the 
ability to switch to cue-directed behaviours 
is a feature specific for the nucleus 
accumbens. The fact that bicuculline did 
not increase motor activity casts however 
shadows on this suggestion, for these data 
stand in sharp contrast with the 
observation that 25 ng/0.5 ul bicuculline 
exerted an immediate, and strong, motor 
enhancing effect in non habituated and 
habituated rats (paragraph 4.3.3). It should 
be noted that in the present experiments 
even a higher dose of bicuculline, i.e. 50 
ng/0.5 ul, was ineffective in inducing an 
increase in motor activity (not shown). As 
already pointed out above injections into 
the VP/SI complex affected the total 
number of rearings. These data thus 
furthermore underline the notion that a -
temporary ?- 'lesion' was made within the 
VP/SI complex and/or overlying globus 
pallidus, which -in this case- prevents 
bicuculline from showing its stimulatory 
effect. In fact it might be speculated that 
the area became insensitive to the GABA-
antagonist. Accordingly one might suggest 
that the area was still sensitive to the 
effects of an agonist. In favour of this it 
was found that the GABAa-agonist 
muscimol (Bowery et al, 1983; Simmonds, 
1983) in a dose of 10 ng/0.5 ul 
decreased rearing in the open field 
(muscimol versus AD (mean+sem): 
1.3+0.8 (N=9) vs 22.1+6.8, t=3.038 
df=15 p<0.01, two-tailed t-test), which 
appeared to agree 'with earlier published 
data (see figure 1 Baud et al, 1988). 
These data however do net allow to draw 
a conclusion on the effects of injections of 
bicuculline in the rostral areas of the 
VP/SI complex on the ability to switch to 
cue-directed behaviours. Since in the 
experiments described in paragraph 4.3.3, 
in which bicuculline induced a strong, 
immediate, increase in motor activity, the 
rats had been pretreated with AD 24 hrs 
before the actual experiments were 
performed, it was decided to follow this 
paradigm to study the swimming 
behaviour of the rats further. Furthermore 
in order to study whether muscimol might 
affect the ability to switch to cue-directed 
behaviours a low dose of muscimol (1 
ng/0.5 ul) was injected into the rostral 
areas of the VP/SI complex. 
4.3.4.1.5 Results: part Π 
The paradigm for the swimming test was 
similar to that used above. The sole 
difference was that the rats were pretreated 
with an injection of AD (0.5 ul) 24 hrs 
before the actual experiment. 36 Rats were 
included in these experiments. 
The injection sites were within the 
rostral areas of the VP/SI complex (cf. 
figure 4-4). Table 4-7 shows the number 
of rearings in the open field. It is clear 
that bicuculline dose-dependently enhanced 
the number of rearings in the open field 
(F(2,50)=26.12, p<0.01). The dose of 25 
ng was significantly (p<0.05 SNK-test) 
different from both the dose of 10 ng and 
AD; the dose of IO ng was significantly 
(p<0.05 SNK-test) different from AD. 1 
ng Muscimol decreased the number of 
rearings as can be seen in table 4-7 
(F(l,36)=8.81, p<0.01). 
The number of different cue-directed 
behaviours was significantly affected after 
injection of 10-25 ng/0.5 ul bicuculline 
(F(2,75)=4.26, p<0.02; figure 4-14, panel 
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Table 4-7: Effects of bicuculline and muscimol on the number of rearings in the open field. 
Shown are means+sem's. 
drug dose 0 - 5 5-10 
AD 
BIC 
BIC 
MSM 
10 
25 
1 
12 
8 
8 
8 
9.6+2.4 
19.6+5.5 
33.4+4.8 
2.0+0.9 
5.9+1.0 
19.1+4.6 
35.4+3.5 
3.4+1.0 
AD: distilled water; BIC: bicuculline; 
MSM: muscimol; N: number of rats 
dose: ng/0.5 ul; 0-5, 5-10 time-blocks 
A). A post hoc SNK-test showed that the 
dose of 10 ng was significantly different 
from the dose of 25 ng. None of the 
doses themselves were different from the 
control, i.e. AD. Also a significant group 
effect for the non cue-directed behaviours 
was found (F(2,75)=4.18, p<0.02). As can 
be seen in figure 4-14, panel B, the dose 
of 25 ng decreased the number of different 
non cue-directed behaviours, which was 
confirmed by a post hoc SNK-test 
(p<0.05 from AD). Muscimol had no 
effect on either the number of different 
cue-directed behaviours (F(1.54)=0.0, 
p<1.0; figure 4-14, panel jC) or the 
number of different non cue-directed 
behaviours (F(l,54)=1.80, p<0.19; figure 
4-14, panel D) 
None of the parameters on the rope-
directed behaviour was affected by the 
treatment with bicuculline or muscimol 
(table 4-8). 
4.3.4.1.6 Discussion: part Π 
Table 4-8: Effects of bicuculline and muscimol on detection of the rope, free escape, and 
free+forced escape. Shown are percentages. 
drug dose detect ion free escape free+forced escape N 
AD 
BIC 
BIC 
MSM 
10 
25 
1 
33.3 
37.5 
37.5 
12.5 
25.0 
25.0 
25.0 
12.5 
66.7 
62.5 
75.0 
50.0 
12 
8 
8 
8 
AD: d i s t i l l e d water; BIC: b icucu l l ine; MSM: muscimol; 
N: number of rats 
dose: ng/0.5 ul 
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Figure 4-14: Effect of bicuculline (bic; panel A and B) and muscimol (msm; panel С and 
D) on the number of different cue-directed and non cue-directed behaviours (Y-axes). X-
axes: time-blocks; shown are means+sem's. 
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The major findings from this second part 
were that bicuculline enhanced rearing 
after a priming injection of AD (table 4-
7), while it had no effect on the number 
of different cue-directed behaviours (figure 
4-14). Bicuculline however decreased the 
number of different non cue-directed 
behaviours (figure 4-14). Moreover a low 
dose of muscimol decreased rearing (table 
4-7) whereas it did not affect the number 
of different cue-directed or non cue-
directed behaviours (figure 4-14). Finally 
none of the drugs had an effect on rope-
directed behaviour (table 4-8). 
In contrast to the experiments in the 
previous paragraph injections of 
bicuculline into the rostral areas of the 
VP/SI complex dose-dependently enhanced 
the number of rearings (table 4-7). 
Behavioural observations revealed that the 
overall motor activity was clearly 
enhanced, which is in agreement with the 
data presented in paragraph 4.3.3. As 
already indicated in paragraph 4.3.4.1.4 a 
disturbance of the integrity of the neuronal 
network within the rostral areas of the 
VP/SI complex (and/or overlying globus 
pallidus) might have prevented bicuculline 
from showing its stimulatory effect in 
these experiments; apparently the rats 
recover from these disturbances in time, 
showing that these disturbances are only 
temporary (see paragraph 4.3.4.1.4). 
Although the open field behaviour after 
injections of bicuculline into the rostral 
areas of the VP/SI complex resembled that 
of injections of d-amphetamine in the 
nucleus accumbens, the effects on the 
swimming behaviour were different after 
these different treatments. None of the 
doses of bicuculline was significantly 
different from the control with respect to 
the number of different cue-directed 
behaviours, although the dose of 10 ng 
differed significantly from the dose of 23 
ng (figure 4-14). In the latter case the 
behaviour appeared to become stereotyped 
however, i.e. within the category of cue-
directed behaviours the behaviour was 
reduced to nearly only 'scanning wall'. 
This latter dose also decreased the number 
of different non cue-directed behaviours. 
In this case the behaviour was reduced to 
nearly only 'sinking'. These two 
behaviours accordingly dominated the 
behavioural repertoire of the rats. Thus the 
effects of this dose of bicuculline appeared 
to be rather nonspecific (in a sense). 
In contrast to injections of d-
amphetamine into the nucleus accumbens, 
injections of bicuculline into the rostral 
areas of the VP/SI complex had no effects 
on rope-directed behaviour (table 4-8). The 
percentage of rats that detected the rope, 
that showed free escape, or that escaped at 
all (free+forced escape), after injections of 
AD or bicuculline was in these 
experiments however higher than the 
respective percentages presented in table 4-
6 (rats which did not receive a prior 
injection of AD; compare table 4-8 and 
table 4-6). This again suggests that the 
rats may have recovered from the initial -
temporary- 'lesion' (paragraph 4.3.4.1.4) 
Despite the fact that injections of 
muscimol into the rostral areas of the 
VP/SI complex decreased the number of 
rearings (table 4-7 and general activity as 
judged from the open field behaviour, cf. 
figure 1 Baud et al, 1988), they had no 
effect on the ability to display different 
cue-directed or non cue-directed 
behaviours (figure 4-14) or on the ability 
to escape (table 4-8). These data underline 
previous notions that the level of motor 
activity and the ability to display different 
cue-directed behaviours or non cue-
directed behaviours are not necessarily 
related to each other (chapter 3, section 3-
4; see also above). 
These data thus showed that the ability 
to switch to cue-directed behaviours was 
not affected by the present manipulations 
with the rostral VP/SI. In order to study 
whether this ability is still transmitted 
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from the nucleus accumbens to lower 
brain structures via the rostral VP/SI 
complex, it was finally decided to study 
the interaction between the nucleus 
accumbens and the rostral VP/SI complex. 
4.3.4.2 Interaction between the nucleus 
accumbens and the VP/SI complex 
Rats were equipped with cannulae -10 
mm in length- aimed at the nucleus 
accumbens (A9.8 L+/-1.2 H2.7 mm, lateral 
angle 10 degrees; chapter 3, section 3-4) 
and the rostral areas of the VP/SI complex 
(A7.4 L+/-2.5 H3.1 mm; lateral angle 5 
degrees; paragraph 4.3.2; 4.3.3). The 
cannulae were inserted 5.0 and 4.0 mm 
below the surface of the skull respectively 
and needle-lengths were adjusted as 
required. The rats were pretreated with 
injections of AD (0.5 ul) in the VP/SI 
complex 24 hrs before the actual 
experiment (see paragraph 4.3.4.1.5). Rats 
received no prior injections in the nucleus 
accumbens (cf experiments described in 
chapter 3, section 3-4), A dose of 10 
ug/0.5 ul d-amphetamine was injected into 
the nucleus accumbens, since this dose has 
been found to enhance the number of 
different cue-directed behaviours (chapter 3 
section 3-4). A dose of 1 ng/0.5 ul 
muscimol was injected into the rostral 
areas of the VP/SI complex to study the 
interaction, since this dose was found to 
be ineffective in affecting the ability to 
display different cue-directed behaviours 
by itself in the previous experiments 
(paragraph 4.3.4.1.5). AD Or d-
amphetamine was injected into the nucleus 
accumbens 5-6 minutes after injection of 
AD or muscimol into the VP/SI complex. 
After injection of the latter the rats were 
put in their home-cages, whereas after 
injection of the former the rats were put 
into the open field (38*26*28 cm) and 
observed for the occurrence of motor 
deficits (chapter 3, section 3-4). Moreover 
the number of rearings was counted. 19 
Rats were included in these experiments. 
In figure 4-15 the injection sites within 
the nucleus accumbens (panel A) and the 
Figure 4-15: Injection sites into the nucleus accumbens (panel A) and the rostral areas of 
the VP/SI complex (panel B). 
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Figure 4-15: continued. 
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rostral areas of the VP/SI complex (panel 
B) are shown. The injections sites were 
comparable to those shown in figure 3-4 
and figures 4-4 and 4-11. 
d-Amphetamine enhanced the number of 
rearings in the open field (d-
amphetamine/AD vs AD/AD (mean+sem): 
115.8+16.2 (N=6) vs 22.5+1.3 (N=4), 
t=5.741 df=8 p<0.01, two-tailed t-test), 
which was attenuated by injections of 
muscimol into the VP/SI complex (d-
a m p h e t a m i n e / A D v s d -
amphetamine/muscimol (mean+sem): 
115.8+16.2 (N=6) vs 4.0+1.1 (N=5), 
t=6.885 df=9 p<0.01, two-taUed t-test). It 
should be noted that the number of 
rearings after the combination of d-
amphetamine and muscimol was lower 
than that of the AD/AD control values 
(p<0.01). Muscimol by itself decreased 
the number of rearings (AD/muscimol vs 
AD/AD (mean+sem): 9.3+2.2 (N=4) vs 
22.5+1.3 (N=4), t=5.166 df=6 p<0.01, 
two-tailed t-test). 
d-Amphetamine enhanced the number of 
different cue-directed behaviours 
(F(l,24)=10.54, p<0.01; figure 4-16, 
panel A). Furthermore it changed the 
profile of the control curve; hence a 
significant interaction-term was found in 
the two-way ANOVA (F(2,24)=6.23, 
p<0.01). d-Amphetamine had no effect on 
the number of different non cue-directed 
behaviours (F(l,24)=0.23, p<0.64; figure 
4-16, panel B). Muscimol attenuated the 
increase in the number of different cue-
directed behaviours (F(l,27)=9.74, 
p<0.01; figure 4-16, panel A). No 
significant interaction term was found 
(F(2,27)=1.23, p<0.31). Furthermore no 
effect was found on the number of 
different non cue-directed behaviours 
Number/2 mm 
1A 
из ш Ш Ш 
ACC AD AD AMP AMP 
UPtSl AD MSM AD MSM 
N = ( ( 6 5 
2 -
B non CUE-directed 
0-2 2-4 4-6 Time (mm) 
Figure 4-16: Effect of intra VP/SI muscimol (msm) on the intra-accumbens d-amphetamine 
(amp) induced effect on the number of different cue-directed and non cue-directed behaviours 
(Y-axes). X-axes: time blocks; shown are means+sem's. 
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(F(l,27)=0.85, p<0.37). Muscimol did not 
affect the number of different cue-directed 
behaviours (F(l,18)=0.09, p<0.77) by 
itself but enhanced slightly the number of 
different non cue-directed behaviours 
(F(l,18)=8.07 p<0.05). 
Injections of d-amphetamine into the 
nucleus accumbens enhanced the number 
of rats that detected the rope and escaped; 
an effect, which was attenuated by 
injections of muscimol into the rostraJ 
areas of the VP/SI complex (table 4-9). 
Muscimol had no effect by itself on rope-
directed behaviour. 
The main findings from these 
experiments were that injections of 
muscimol into the rostral areas of the 
VP/SI complex attenuated (i) the increase 
in the number of rearings, (ii) the increase 
in the number of different cue-directed 
behaviours (figure 4-16), and (iii) the 
increase in the number of rats that 
detected the rope (table 4-9), after 
injections of d-amphetamine into the 
nucleus accumbens. These data thus 
suggest that the ability to switch to cue-
directed behaviours was transmitted from 
the nucleus accumbens to lower brain 
structures via GABA-ergic mechanisms in 
the rostral areas of the VP/SI complex. 
As expected d-amphetamine enhanced 
the number of rearings in the open field 
(chapter 3, section 3-4). The fact that 
muscimol attenuated this increase at the 
level of the rostral areas of the VP/SI 
complex suggests that this effect is 
transmitted via the rostral areas of the 
VP/SI complex (cf. expectancies from 
paragraph 4.3.3). Muscimol however 
decreased the number of rearings by itself. 
Therefore no conclusion can be drawn on 
the specificity of this effect. 
Intra-accumbens injections of d-
amphetamine enhanced the number of 
different cue-directed behaviours without 
an effect on the number of different non 
cue-directed behaviours (figure 4-16). 
These results confirm the findings of 
chapter 3 (figure 3-5). The fact that this 
increase was attenuated at the level of the 
rostral areas of the VP/SI complex by an 
ineffective dose of the GABAa-agonist 
muscimol (Bowery et al, 1983; Simmonds, 
1983; cf. figure 4-14) strongly suggests 
that the ability to switch to cue-directed 
behaviours is transmitted via GABA-ergic 
mechanisms in the rostral areas of the 
VP/SI complex. One could however argue 
that the lower motor activity observed in 
these rats was responsible for the decrease 
in the number of different cue-directed 
behaviours. As pointed out in chapter 3 
section 3-4, and in the foregoing 
paragraphs, rearing in the open field and 
the ability to display different cue-directed 
behaviours in the swimming test are not 
related to each other. Hence the 
antagonism is -probably- not due to an 
effect of muscimol on motor activity per 
se. 
As shown in chapter 3 (table 3-2) intra-
accumbens injections of d-amphetamine 
enhanced the number of rats that detected 
the rope and escaped. The present data 
confirm these findings and extend them by 
showing that this increase was attenuated 
at the level of the rostral areas of the 
VP/SI complex by injections of muscimol 
(table 4-9). These data moreover underline 
the notion that the ability to switch to 
cue-directed behaviours was transmitted to 
lower brain structures via GABA-ergic 
mechanisms in the rostral areas of the 
VP/SI complex. 
In conclusion, the data from this study 
showed that the ability to switch to cue-
directed behaviouis is transmitted from the 
nucleus accumbens to lower brain 
structures via GABA-ergic mechanisms in 
the rostral areas of the VP/SI complex. 
4.3.4.3 Conclusions 
The present studies revealed a number 
of findings (see also table 4-10). 
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First, injections of AD into the rostral 
areas of the VP/SI complex had profound 
effects (i) on the expression of rearing 
behaviour (table 4-3), (ii) the ability to 
switch to non cue-directed behavioure 
(figure 4-12), and (iii) the total number of 
rats that escaped (table 4-4). It appeared 
that injections of AD 24 hrs before the 
actual experiment enhanced the number of 
rats that escaped (table 4-8), while they 
had no effect on the changes in the other 
parameters. This indicates that the rats 
recover in time from disturbances of the 
integrity of the neuronal network either in 
the rostral areas of the VP/SI complex or 
in the overlying globus pallidus (paragraph 
4.3.4.1.4). It moreover turned out that 
bicuculline was only able to enhance 
motor activity after at least one prior 
injection of AD (compare table 4-7 with 
table 4-5). This suggests that these rats 
also recovered from the initial disturbances 
(see above) which prevented them from 
showing an enhancement of motor activity 
after injections of bicuculline. 
Second, the fact that injections of 
bicuculline into the rostral areas of the 
VP/SI complex had no effect on the 
number of different cue-directed 
behaviours while they strongly enhanced 
motor activity (figure 4-14 and table 4-7) 
underlined previous notions (chapter 3, 
section 3-4) that these phenomena were 
not related. Together with the observation 
that the increase in motor activity after 
injections of d-amphetamine into the 
nucleus accumbens and the increase in the 
ability to switch to cue-directed behaviours 
were attenuated at the level of the rostral 
areas of the VP/SI complex by injections 
of the GABAa-agonist muscimol (figure 4-
16; Bowery et al, 1983; Simmonds, 1983; 
cf. paragraph 4.3.3), it strongly suggests 
that the nucleus accumbens is specifically 
involved in the ability to switch to cue-
directed behaviours, while it is not 
critically involved in the expression of 
motor activity. In fact it moreover 
suggests that the increase in motor activity 
induced after injections of bicuculline into 
the rostral areas of the VP/SI complex, 
and the increase in motor activity after 
injections of d-amphetamine into the 
nucleus accumbens may 
be different with' respect to their 
behavioural profiles, although it should be 
noted that visual observation of these 
Table 4-9: Effect of intra VP/SI muscimol intra-accumbens d-amphetamine induced effects 
on detection, free escape and free+forced escape. Shown are percentages. 
ACC VP/SI det. free еэс. free+forced esc. N 
AD AD 25.0 25.0 75.0 4 
AD MSM 25.0 25.0 50.0 4 
AMP AD 8 3 . 4 * 6 6 . 7 8 3 . 4 6 
AMP MSM 20.0# 20.0 80.0 5 
ACC: nucleus accumbens; AD: d i s t i l l e d water; AMP: d-amphetamine (10 
ug/0.5 ul) ; MSM: muscimol (1 ng/0.5 ul) ; N: number of r a t s ; det : 
detect ion; esc: escape 
* : p<0.05, X-square one-tailed vs AD-AD 
#: p<0.025, X-square one-tailed vs AMP-AD 
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increases in motor activity suggests that 
the forementioned injections induce similar 
types of increases in motor activity. 
As outlined in paragraph 4.3.3, 
subregions can be found within the rostral 
areas of the VP/SI complex, which are 
differentially susceptible to GABA-drugs 
and which appear to have different inputs: 
the ventrolateral area is innervated by the 
olfactory tubercle and susceptible to 
bicuculline whereas the dorsomedial area 
is innervated by the nucleus accumbens 
and susceptible to muscimol. This suggests 
different GABA-tones: a high GABA-tone 
from the olfactory tubercle with a 
susceptibility for GABA-antagonists (cf. 
Cools et al, 1990a and references cited 
therein), and a low GABA-tone from the 
nucleus accumbens with a susceptibility 
for GABA-agonists (cf. Cools et al, 1990a 
and references cited therein). Cools 
suggested that the enhanced motor activity 
observed after intra-accumbens injections 
of dopamine (or d-amphetamine) is 
actually due to an effect on the olfactory 
tubercle via diffusion of this (these) 
drug(s) from the nucleus accumbens to the 
olfactory tubercle (Cools, 1986). With 
respect to the ability to switch to cue-
directed behaviours one may suggest that 
this is related to the nucleus accumbens 
(chapter 3, section 3-4), although it should 
be noted that the olfactory tubercle has 
not yet been studied in this respect. If this 
differentiation between motor activity and 
the ability to switch to cue-directed 
behaviours indeed exists however the 
present data suggest that the inability of 
bicuculline to affect the ability to switch 
to cue-directed behaviours, in contrast to 
the ability to affect motor activity, is due 
to its differential effects on subregions in 
the rostral areas of the VP/SI complex as 
indicated above: the mediodorsal and 
ventrolateral areas respectively (see further 
section 4-4). This highly speculative 
possibility clearly needs to be investigated. 
4-4 General discussion 
The studies in this chapter clearly 
showed that differences existed between 
the rostral and caudal areas of the VP/SI 
complex. The main findings are 
summarized in table 4-10. From this table 
it is clear that the rostral areas were 
involved in motor activity and in 
transmitting the ability to switch to cue-
directed behaviours from the nucleus 
accumbens to lower brain structures, 
whereas the caudal areas were involved in 
mediating tonic EMG-activity of the 
triceps muscle of the forelimb, and in 
transmitting changes in tonic EMG-activity 
from the nucleus accumbens to lower 
brain structures. This separation confirms 
and extends previous notions on the 
differential involvement of these areas in 
behaviour (Scheel-Kruger, 1983). 
The rostral and caudal areas of the 
VP/SI complex have been found to differ 
in terms of their firing rates and firing 
patterns of their neurons: in more rostral 
areas these neurons fire slow and irregular, 
whereas in more caudal areas they fire fast 
and regular (Yang and Mogenson, 1989). 
Interestingly the former neurons responded 
to dopamine injections into the nucleus 
accumbens with an increase in firing rate, 
whereas no effect was found in the latter 
neurons (Yang and Mogenson, 1989). 
Since the former neurons were susceptible 
to the indirect GABA-antagonist Picrotoxin 
(Yang and Mogenson, 1989), this suggests 
a difference in GABA tone for these 
neurons: a high tone in more rostral areas 
and a low tone in more caudal areas, with 
receptors susceptible for GABA-
antagonists and GABA-agonists 
respectively (see Cools et al, 1990a and 
references cited therein). In this context it 
is worth noting that it has been found that 
bicuculline injected within the caudal areas 
of the VP/SI complex is ineffective in 
altering acetylcholine turnover in the 
cortex (Blaker, 1985; see also Wood and 
Richard, 1982), whereas muscimol is 
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effective in this respect (Wood and 
Richard, 1982). Moreover kainic acid 
lesions of the nucleus accumbens were 
ineffective in this respect (Blaker, 1985). 
These findings suggest that the basal level 
of stimulation of the cholinergic cells was 
low (Blaker, 1985). Indeed electrical 
not shown 
stimulation of the nucleus accumbens, 
which enhances the GABA-output to the 
subpaUidal areas (see e.g. Mogenson et al, 
1983) has been found to decrease 
acetylcholine turnover in the cortex (Wood 
and McQuade , 1985; cited in Blaker, 
1985). The foregoing supports thus the 
above given notion that the GABA-activity 
might be low in the caudal areas of the 
VP/SI complex. Overall the foregoing 
might explain then why bicuculline was 
ineffective in eliciting behavioural chnages 
in the caudal areas in the present 
experiments, whereas muscimol was 
effective in this respect. Although this 
could also explain why injections of 
bicuculline were behaviourally active in 
the rostral areas, the situation appears to 
be more complex within this area as 
outlined in paragraph 4.3.4.3 (see further 
below). 
Table 4-10: Summary of the findings presented in this chapter. 
VARIABLE 
motor activ 
CDB 
tonic EMG 
activity 
catalepsy 
•ity 
drug 
BIC 
BIC 
MSM 
CARS 
BIC 
MSM 
BIC 
MSM 
BIC 
MSM 
r-VP/SI 
•Til) 
t(2) 
low(l) 
(2) 
=-(1) 
==(2) 
-=<1*,2( 
n.d. 
==/n.d. 
n.d. 
" 
th: 
,3) 
igh<2) 
C-VP/SI 
— (1,*) 
"(2) 
=-(2) 
n.d. 
--(1,*) 
n.d. 
n.d. 
n.d. (4) 
n.d,(4) 
r -VP/SI : r o s t r a l a r ea s of the VP/SI complex ( f igure 4-4; pane l s 
A,B,C and D) ; c-VP/SI: caudal a reas of the VP/SI complex ( f igure 
4-4 ; pane l s E,F and G); 
BIC: b i c u c u l l i n e ; MSM: muscimol; CARB: ca rbacho l ; CDB: cue-
d i r e c t e d behaviour 
l , | : i n c r e a s e r e s p e c t i v e l y decrease in v a r i a b l e ; - » : no e f f e c t ; 
n . d . : not determined 
(1) no p r i o r i n j e c t i o n s ; 
(2) a f t e r a t l e a s t one p r i o r i n j e c t i o n ; 
(3) a t t e n u a t e d intra-accumbens induced i n c r e a s e ; 
(4) a t t e n u a t e d intra-accumbens induced i n c r e a s e ; 
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Electrophysiological and anatomical data 
have suggested a difference between the 
rostral and caudal areas of the VP/SI 
complex with respect to their afferent and 
efferent connections. Thus, it has been 
shown that the hippocampus has more 
direct access to the rostral areas by way 
of the nucleus accumbens than to the 
caudal areas (Yang and Mogenson, 1985). 
Furthermore the projections to the 
mediodorsal nucleus of the thalamus seem 
to originate from the more rostral areas 
(section 4-2), whereas the projections to 
the Ntpp seem to originate from the more 
caudal areas (section 4-2). This suggests 
that two pathways might originate from 
the nucleus accumbens: (i) a nucleus 
accumbens-ventral pallidum (rostral areas 
of the VP/SI complex)-mediodorsal 
thalamus pathway, with a high accumbens-
subpallidal GABA-tone, and (ii) a nucleus 
accumbens-substantia innominata (caudal 
areas of the VP/SI complex)-Ntpp 
pathway, with a low accumbens-subpallidal 
GABA-tone. As indicated above the 
hippocampus has probably a differential 
access to these pathways. 
The olfactory tubercle projects to the 
rostral areas and might play a role in the 
expression of behaviours in the rostral 
areas of the VP/SI complex. In fact, 
following earlier suggestions (see 
paragraphs 4.3.3 and 4.3.4) it might even 
be speculated that an olfactory tubercle-
ventral pallidum (rostral areas of the 
VP/SI complex)-mediodorsal thalamus 
pathway with a high tubercle-subpallidal 
GABA-tone, and a nucleus accumbens-
ventral pallidum (rostral areas of the 
VP/SI complex)-mediodorsal thalamus 
pathway with a low-GABA tone exist. 
Recent experiments have suggested that 
the forementioned channels may subserve 
different functions. Thus food-hoarding has 
been shown to be attenuated at the level 
of the nucleus accumbens, the subpallida] 
areas and the mediodorsal thalamus, but 
not the Ntpp (Mogenson and Wu, 1988a). 
In contrast spontaneous activity has been 
shown to be attenuated by procaine 
injections into the Ntpp but not the 
mediodorsal thalamus (Mogenson et al, 
1989). This seems to be in line with the 
fact that the increase in motor activity 
induced by injections of Picrotoxin into 
the VP/SI complex was attenuated by 
procaine-injections into the Ntpp but not 
the mediodorsal thalamus (Mogenson and 
Wu, 1988b; see also Brudzynski and 
Mogenson, 1985). These latter findings 
however contrast with the data of 
Swerdlow et al, who showed that activity 
induced indirectly from the nucleus 
accumbens (Swerdlow et al, 1986b; 
Swerdlow and Koob, 1987b) or directly 
from the VP/SI complex (Swerdlow and 
Koob, 1987b) was attenuated by lesions of 
the mediodorsal thalamus. Ntpp lesions 
were ineffective in this respect (Swerdlow 
et al, 1986b; Swerdlow and Koob, 1987b). 
Although it is at present not clear why 
these data are in contrast with each other, 
methodological differences might underlie 
these different results (see Swerdlow and 
Koob, 1987b). It is clear that specific 
experiments may be designed for 
investigating the hypothesis that different 
channels exist with differential roles in the 
regulation of behaviour. 
It should finally be noted that numerous 
studies have investigated the behavioural 
effects of electrolytic or neurotoxic lesions 
of the VP/SI complex in several 
experimental paradigms (see Collerton, 
1986 for a review). Initially these studies 
were conducted in an attempt to study the 
behavioural deficits of cholinergic 
forebrain lesions as a model for 
Alzheimer's disease (Archer and Fowler, 
1985; Gower, 1986). It has become more 
and more clear however that lesions within 
this area have widespread effects on the 
integrity of the area in toto. Hence the 
specificity of such lesions is doubtful (see 
e.g. Dunnet et al, 1987). Accordingly it is 
not surprising that for a number of tests 
no correlations were found between the 
behavioural changes and cortical measures 
of acetylcholine activity (see Dunnet et al, 
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1987). Recent experiments using local 
injection techniques or electro-
physiological techniques have indicated 
that the VP/SI complex may be involved 
in reward-related processes (Holzhauer-
Oitzl et al, 1988; Richardson and DeLong, 
1986; Rigdon and Pirch, 1986; Robinson 
et al, 1988). Future experiments may be 
direaed at further investigating the 
foregoing role of the rostral and caudal 
areas of the VP/SI complex in behaviour. 
In conclusion the experiments presented 
in this chapter clearly showed that 
differences existed between the rostral and 
caudal areas with respect to their role in 
behaviour. Future experiments should be 
directed at further elucidating the 
differences between the rostral and caudal 
areas of the VP/SI complex in relation to 
their possible differential afferent and 
efferent connections. At present it is not 
clear how these behavioural differences 
are related to the concept introduced by 
Alheid and Heimer (see section 4-2; 
Alheid and Heimer, 1988). 
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OVERALL DISCUSSION 
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CLINICAL IMPACT 
OF ANIMAL RESEARCH 
In which the experimental findings of chapter 3 and 4 are used to predict the 
cognitive and behavioural disturbances of Parkinson patients with and without 
dementia, i.e. the patients mentioned in chapter 2. Also, some directions for future 
research are given. 
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5-1 Introduction 
As pointed out in the last pages of chapter 
2 (chapter 2, section 2-7) studying of the 
nucleus accumbens-subpallidal axis may give 
insight in some of the symptoms associated 
with the dementia in Parkinson's and 
Alzheimer's disease. This final chapter deals 
with the clinical picture of the patients 
mentioned in chapter 2, i.e. non-demented and 
demented Parkinson patients as well as 
Alzheimer patients, in relation to the data 
obtained in the previous chapters, i.e. chapter 
3 (nucleus accumbens) and chapter 4 
(subpallidal areas). First, a model is discussed 
which offers a framework for predicting and 
understanding certain cognitive and 
behavioural disturbances of patients suffering 
from Parkinson's disease with and without 
dementia and patients suffering from 
Alzheimer's disease. The chapter will end 
with some prospects for future research. 
5-2 A framework to predict some of the 
cognitive and behavioural deficits in 
patients suffering from Parkinson's (and 
Alzheimer's) disease 
Frith, while developing a model to 
understand the disturbances inherent to 
schizophrenia, suggested that in Parkinson 
patients 'intentions of will are formed...but 
these intentions fail to be transformed into 
action* (Frith, 1987, p643). Moreover he 
stated that Parkinson patients are still able to 
use stimulus intentions to guide behaviour 
(Frith, 1987; Frith and Done, 1988). His 
model, shown in figure 5-1, panel A, is in 
essence a model in which man's actions are 
considered to be the result of 'free will' 
(willed intention) or the result of stimuli in 
the environment (stimulus intention). He 
suggested that the frontal cortex and the 
caudate nucleus play a role in willed intention 
(Frith, 1987; Frith and Done 1988); no 
suggestions were given for structures that play 
a role in stimulus intention. The findings 
presented in chapter 3 and 4 offer the 
possibility to extend the model of Frith by 
including structures, which are involved in 
stimulus intention. Thus the nucleus 
accumbens- subpallidal circuitry may play 
a role in stimulus intention. However Frith's 
'stimulus intention' is a phenomenon which 
occurs at a low level within the hierarchy 
(Frith, 1987). As will be discussed below the 
complexity of (external) information increases 
if one reaches higher levels in the hierarchy, 
i.e. higher order structures take care of more 
complex information. Frith's model will 
therefore be adopted here according to this 
insight. Frith considers two possible pathways 
along which intentions lead to actions: one, 
starting from willed intention, and one, 
starting from stimulus intention (figure 5-1, 
panel A). Two separate channels thus exist. In 
this thesis however this model is altered in 
the sense that it is described in terms of how 
'willed intention' is transformed into action 
via two possible modes, i.e. an 'internal' and 
an 'external' mode (figure 5-1, panel B; see 
below). In this way Frith's 'stimulus 
intention' is incorporated in the 'external 
mode' (levels of complexity; figure 5-1, panel 
B). It should be noted that in figure 5-1, 
panel B, only the essential elements for the 
present discussion are depicted. The omission 
of a number of elements of the original 
model depicted in panel A does not mean to 
imply that they are not important. Two 
channels thus exist: (i) a channel through 
which 'willed intention' is transformed into 
'action' by 'internal mechanisms', mediated 
via the frontal cortex-dorsal striatum-subtantia 
nigra pars reticulata-colliculus superior (Cools 
et al, 1984a, 1989c; Cools, 1985; 1990), and 
(ii) a channel through which 'willed intention' 
is transformed into 'action' by using 'external 
mechanisms'. The data presented in this thesis 
show that the latter may be mediated via the 
frontal cortex-nucleus accumbens-subpallidal 
areas circuitry. It is clear that tight 
interactions must exist between these two 
possible modes. In this way a framework is 
obtained in which some of the behavioural 
and cognitive disturbances in patients 
suffering from Parkinson's disease with or 
without dementia as well as in patients 
suffering from the dementia inherent to 
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Figure 5-1: In panel A the model according to Frith (Frith, 1987; Frith and Done, 1988) 
is shown; in panel В a modincation of this model; see text for explanation. 
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Alzheimer's disease may be understood. 
In both channels the complexity of 
information decreases from the frontal cortex 
to lower brain structures (Cools et al, 1984a, 
1989c; Cools, 1985, 1990; cf figure 5-1, 
panel B; see below). A flow from changes in 
programming non motor aspects of behaviour 
to changes in programming motor aspects of 
behaviour has been shown to exist within the 
dorsal striatal channel. Thus a small 
neurochemical change in the striatum 
decreases the ability to switch to non cue-
directed behaviours (non motor aspects; Cools, 
1980; Vrijmoed-de Vries and Cools, 1986) 
whereas large(r) neurochemical changes 
increase tonic EMG-activity of the 
gastrocnemius soleus muscle of the hindlimb 
(motor aspects; Ellenbroek et al, 1985a). 
It might be expected that a flow from 
disturbances characteristic for the subsequent 
dysfunction of hierarchically lower ordered 
Table 5-1: Behavioural effects of manipulation with structures studied in this thesis in several 
paradigms. 
Var H ICC AMY ACC VP/SI 
CDB not studied not studied d-aipp t (1) bic no m
LY t(2) effect (4) 
SCH,hal i (2,3) 
EMG not studied not studied SCH 
ha 
 t (5) 
1 t ( 5 , 6 , 7 ) 
rosm t (6) 
MA c a r b ( ( 8 , 9 ) NMDA J (11) d-amp t ( 1 2 , 1 3 ) b i e t ( 1 4 , 1 5 ) 
NMDA 1(10) DA 1(13) p t x 1(15) 
PPI c a r b \ (16) n o t s t u d i e d DA J ( 1 6 , 1 7 ) p t x J (16) 
V a r : v a r i a b l e ; HICC: h i p p o c a m p u s ; AMY: ( b a s o l a t e r a l ) a m y g d a l a ; ACC: 
n u c l e u s a c c u m b e n s ; V P / S I : v e n t r a l p a l l i d u m / s u b s t a n t i a i n n o m i n a t a 
complex ( s u b p a l l i d a l a r e a s ) 
CDB: c u e - d i r e c t e d b e h a v i o u r ; EMG: e l e c t r o m y o g r a p h i c a c t i v i t y ; P P I : 
p r e - p u l s e i n h i b i t i o n ; MA: m o t o r a c t i v i t y 
c a r b : c a r b a c h o l ; d - a m p : d - a m p h e t a m i n e ; b i c : b i c u c u l l i n e ; p t x : 
P i c r o t o x i n ; DA: d o p a m i n e ; h a l : h a l o p e r i d o l ; LY: LY 171 5 5 5 ; SCH: SCH 
2 3 3 9 0 ; msm: musc imo l 
t , i i n c r e a s e i n ( enhancement of ) 
( d i s r u p t i o n of ) r e s p e c t i v e v a r i a b l e 
r e s p e c t i v e l y d e c r e a s e i n 
(1) I ; t h i s t h e s i s : chap t e r 3 , s e c t i o n 3-4 ; (2) I I ; t h i s t h e s i s : c h a p t e r 
3 , s e c t i o n 3-4 ; (3) t h i s t h e s i s : chap t e r 3 , s e c t i o n 3-4; (4) t h i s t h e s i s : 
chap te r 4, s e c t i o n 4 - 3 ; (5) El lenbroek, 1988; (6) V; t h i s t h e s i s : c h a p t e r 
4 , s e c t i o n 4 - 3 ; (7) El lenbroek e t a l , 1988 (8) Mogenson and Nie l s en , 1984a; 
(9) F l i c k e r and Geyer, 1982; (10) Yang and Mogenson, 1987; (11) Yltn and 
Mogenson, 1989; (12) t h i s t h e s i s : c h a p t e r 3 , s e c t i o n 3-4; IV; (13) e . g . 
P i jnenburg e t a l ,1976; (14) VI; t h i s t h e s i s : c h a p t e r 4 , s e c t i o n 4 - 3 ; (15) 
e . g . Aust in and K a l i v a s , 1990; (16) Geyer e t a l , 1990; (17) Swerdlow e t a l , 
1990a 
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structures exists. For the striatal axis this has 
convincingly been shown to be the case. For 
example, in cats manipulation with the 
caudate nucleus elicited a series of 
behavioural changes in time characteristic for 
the -successive involvement of the-substantia 
nigra pars reticulata and deeper layers of the 
colliculus superior (Jaspers, 1991). In fact 
these behavioural changes correlated well with 
neurochemical changes in these structures 
(Jaspers, 1991). Similarly as pointed out 
earlier increases in tonic EMG-activity of the 
gastrocnemius soleus muscle of the hindlimb 
of the rat were elicited in the striatum 
(Ellenbroek et al, 1985a), the substantia nigra 
pars reticulata (Havemann et al, 1983) and the 
deeper layers of the colliculus superior 
(Ellenbroek et al, 1984), suggesting that these 
changes in tonic EMG-activity were due to a 
dysfunction of a lower order output station of 
the striatum (cf. Cools, 1990). 
Until now similar phenomena as described 
above have not been systematically studied in 
the nucleus accumbens channel. The studies 
presented in this thesis provide some insight 
in this respect however. 
In chapter 3, section 3-4 it was shown that 
SCH 23390 (100-400 ng) decreased the 
ability to switch to cue-directed behaviours, 
i.e affected programming non motor aspects 
of behaviour (table 5-1). Interestingly 
Ellenbroek and coworkers observed that 
slightly higher doses (500-1000 ng) of this 
drug enhanced tonic EMG-activity of the 
triceps muscle of the forelimb of the rat 
(Ellenbroek, 1988; table 5-1), i.e. elicited 
changes in programming motor aspects of 
behaviour. Although lower doses of this drug 
were not studied, the effect of the lowest dose 
on tonic EMG-activity was already rather 
weak. This thus suggests, that an increasing 
pathology might exist with increasing doses of 
this drug leading to successive disturbances in 
the programming of non motor and motor 
aspects of behaviour. The same seems to 
apply to haloperidol (compare the data 
presented in chapter 3, paragraph 3.4.3.2 with 
the data of Ellenbroek et al, 1988). 
In chapter 4, paragraph 4.3.2 it was shown 
that neurochemical changes in both the 
nucleus accumbens and the subpallidal areas 
elicited an increase in tonic EMG-activity of 
the triceps muscle of the forelimb of the rat 
Table 5-2: Summary of findings presented in table 5-1 
CDB tonic EMG PPI MA 
cortex 
(incl. AMY) 
I 
ACC 
I 
VP/SI 
n.d. n.d. 
CDB: cue-directed behaviour; EMG: electromyographic activity; PPI: 
pre-pulse inhibition; MA: motor activity 
AMY: (basolateral) amygdala; ACC: nucleus accumbens; VP/SI: ventral 
pallidum/substantia innominata complex (subpallidal areas) 
+: structure from which changes in parameter can be elicited; *: 
hierarchically lowest order station from which changes can be 
elicited or have been elicited thusfar; -: no effect; n.d.: not 
determined 
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(table 5-1). These data suggest that these 
changes are due to a dysfunction of lower 
order output stations of the nucleus 
accumbens (see below). 
In table 5-2 the foregoing data are 
summarized in terms of effects in a series of 
hierarchically ordered structures. As shown in 
chapters 3 and 4, the ability to switch to cue-
directed behaviours appears to be specific for 
the nucleus accumbens. This suggests that any 
effect on the ability to switch to cue-directed 
behaviours, observed after manipulations with 
higher ordered structures, i.e. the basolateral 
amygdala, the hippocampus or the prefrontal 
cortex, is only an expression of how these 
structures modulate the function of the 
nucleus accumbens. Thus the nucleus 
accumbens mediates the ability to switch to 
cue-directed behaviours. 
In contrast, changes in tonic EMG-activity, 
which are found after manipulation with the 
nucleus accumbens, are not due to a 
dysfunction of the nucleus accumbens per se, 
but due to a dysfunction of one of its output 
stations, i.e. (the caudal areas of) the VP/SI 
complex. In fact the nucleus accumbens 
modulates the function of the latter structure 
in this respect. Since no output stations of the 
caudal areas of the VP/SI complex were 
investigated no conclusions can be drawn on 
the involvement of lower order output stations 
in the regulation of tonic EMG- activity of 
the triceps muscle of the forelimb. 
The results of the studies conducted with 
pre-pulse inhibition (PPI) underline the 
foregoing notions. As shown in tables 5-1 and 
5-2 PPI has been found to be disrupted in 
several structures including the nucleus 
accumbens and its output station the VP/SI 
complex. Since no output stations of VP/SI 
complex were studied, the VP/SI complex is 
at present the lowest structure within the 
hierarchy from which this phenomenon can be 
affected. The data in table 5-1 show 
accordingly that the hippocampus and nucleus 
accumbens only modulate the function of the 
VP/SI complex in this respect. 
With respect to the data presented in tables 
5-1 and 5-2 the following two remarks have 
to be made. First, the difference between the 
level, from which the ability to switch to cue-
directed behaviours and PPI are specifically 
affected, probably reflects a difference in 
stimulus-complexity in which these levels, i.e. 
brain structures presented in tables 5-1 and 5-
2 are involved. Second, the treatments shown 
in table 5-1 disrupt pre-pulse inhibition, i.e. 
disrupt so called 'sensorimotor gating' 
(Swerdlow et al, 1990a). In fact, disruption 
of pre-pulse inhibition is thought to be an 
animal model for the proposed disrupted 
sensorimotor gating function in schizophrenic 
patients (Geyer and Braff, 1987; see 
Ellenbroek and Cools, 1990 for a review). 
Given the similarities between the disruption 
of pre-pulse inhibition, and induction of motor 
activity with respect to their pharmacological 
profiles in several structures, one might come 
to the provocative suggestion that motor 
activity is also an expression of a disrupted 
sensorimotor gating. Accordingly an increase 
in motor activity would not reflect an 
enhancement of the normal function of the 
system, but rather a disruption of the normal 
function of this system. The foregoing 
suggestion would challenge current ideas on 
the function of the accumbens and its output 
stations in motor activity (see e.g. Mogenson, 
1987). It is clear that this deserves further 
study. 
The foregoing framework (figure 5-1) will 
serve as a guide through the literature on the 
clinical picture of Parkinson's (and 
Alzheimer's) disease. It should be noted that 
Frith's suggestions on schizophrenia and the 
frontal lobe syndrome still appear to hold true 
despite the changes in the original model 
(figure 5-1; not elaborated here). 
5-3 Clinical picture of patients suffering 
from Parkinson's disease with and without 
dementia in relation to the preclinical 
findings presented in this thesis 
5.3.1 Introduction 
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In this section it is attempted to integrate 
the clinical picture of patients suffering from 
Parkinson's disease with or without dementia 
and the preclinical knowledge obtained in this 
thesis and other studies. Moreover the 
relationship to Alzheimer's disease will be 
touched upon. 
5.3.2 Temporal organization 
It has been shown that patients suffering 
from Parkinson's disease have difficulties in 
recency discrimination, i.e. in the ability to 
date events or the order of events (Sagar et 
al, 1988a, 1988b). Furthermore they are 
impaired on verbal serial order learning 
(Weingartner et al, 1984). It has been 
observed that Parkinson patients are able to 
leam three-gesture sequences (Canavan et al, 
1989). This latter task may however be too 
simple to unravel any deficit in serial order 
learning. Sagar and coworkers found that 
Parkinson patients are not impaired in the 
recognition of the stimuli per se (Sagar et al, 
1988a, 1988b). They furthermore found that 
the deficit is larger in patients with a higher 
score on the Blessed Dementia Scale, i.e the 
more demented patients (Sagar et al, 1988a; 
1988b). They suggested that this deficit is due 
to a dysfunction of the frontal cortex (Sagar 
et al, 1988a). While reviewing the literature 
on the function of the frontal cortex Kolb 
suggests that the frontal cortex might indeed 
play a role in the temporal organization of 
behaviour (Kolb, 1984). As mentioned in 
chapter 2 Parkinson patients have disturbances 
within the frontal cortex, which might thus 
account for the abovementioned results. 
Moreover demented patients have a more 
severe dysfunction of the frontal cortex, which 
would explain why they perform even worse 
on this test. 
This deficit might furthermore account for 
the decreased ability of set formation in 
Parkinson patients (see next paragraph), i.e. in 
the ability to establish a rule 'initially'. For 
establishing such a rule continuous monitoring 
of what has already been done and what 
needs to be done is necessary, i.e. a temporal 
organization of behaviour. 
5.3.3. Shifting aptitude 
It has been shown in several studies that 
patients suffering from Parkinson's disease 
perform poor on the Wisconsin Card Sorting 
Test (WCST; Brown and Marsden, 1988b; 
Lees and Smith, 1983; Lichter et al, 1988; 
Pillon et al, 1986; Taylor et al, 1986, 1987); 
a test, in which 'hidden' strategies have to be 
searched for via yes/no feedback from the 
experimentator. It was found that patients 
need more trials in selecting the first strategy 
(Taylor et al, 1986) as well as are less able 
to select different strategies (Brown and 
Marsden, 1988b; Lees and Smith, 1983; Pillon 
et al, 1986; Taylor et al, 1986, 1987). These 
data suggest that these patients have a 
disturbed ability to switch between sets. 
Several remarks should be made however. 
First, the larger number of trials needed to 
achieve the criterion for the first category 
suggests that the patients have difficulties in 
forming a set per se, which may in turn 
hamper achieving a second criterion. 
Somewhat in line with this, others have 
observed that Parkinson patients have 
difficulties in establishing a rule in series of 
colours that are presented (Caltagirone et al, 
1985). One could thus argue that the 
decreased number of different categories is 
not due to an inability to regroup behaviour 
according to the demands of the task 
(switching sets) but simply due to a 
decreased ability to form a set per se (see 
above). Several data argue however in favour 
of a decreased ability to shift. First, Parkinson 
patients respond more to the previously 
correct category (more perservative errors 
according to Milner's classification) on new 
trials (Lees and Smith, 1983), suggesting that 
they are less able to regroup their behaviour 
according to the new demands of the task, 
once they have selected a strategy. Second, 
Cools and coworkers found in a basically 
similar task that Parkinson patients still need 
more trials than the controls to detect the 
change of criterion after correcting the scores 
in the second phase with the scores from the 
first phase (Cools et al, 1984c). From this test 
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it might thus be concluded that Parkinson 
patients have a decreased ability to regroup 
behaviour compared to controls. Interestingly 
Taylor et al observed that the performance on 
the WCST test is poor in Parkinson patients 
regardless of whether the patients are 
responding bad or good to 1-dopa-treatment, 
or whether they are treated or not (Taylor et 
al, 1987), suggesting thus that a fundamental 
disturbance in Parkinson's disease is tested. 
The WCST does not provide external 
information which would give a direction for 
the shiñ to make. Accordingly patients have 
to rely upon internal mechanims in selecting 
a strategy. It has been concluded from this 
and related experiments that the patients have 
'a loss of internally guided behaviour' (Taylor 
et al, 1986; see also Cools et al, 1984c; see 
also Downes et al, 1989). 
This deficit in Parkinson patients does not 
limit itself to the cognitive level, for it has 
been shown that Parkinson patients have 
similar deficits in the ability to shift between 
motor sequences (see e.g. Cools et al, 1984c). 
In fact this suggests that in Parkinson patients 
deficits occur both in the programming of non 
motor and motor aspects of behaviour (see 
Cools, 1984; in Korten 1984). 
The WCST has been considered to be a test 
of frontal lobe function, for patients with 
frontal lobe damage perform poor on this test 
(see e.g. Milner and Petrides, 1984). As 
shown in chapter 2, section 2-5, non-
demented Parkinson patients have indeed 
some neurochemical changes in the frontal 
cortex, which might suggest that the 
disturbances observed in the WCST are due 
to frontal lesions. Animal experiments have 
however shown that the (dorsal) striatum 
specifically mediates the ability to switch 
behaviours without the help of external 
information, which would give a direction for 
a shift to be made; lower order output 
stations of the (dorsal) striatum are not 
involved in this phenomenon (chapter 3, 
section 3-3; see Cools et al, 1984a, 1989c; 
Cools, 1990 for reviews). Since the frontal 
cortex projects upon the (dorsal) striatum (see 
Kolb, 1984 for a review) it follows then that 
in analogy with the ability to switch to cue-
directed behaviours (see section 5-2) the 
frontal cortex can only modulate the function 
of the (dorsal) striatum. Accordingly it might 
be argued that the decreased ability to switch 
in the WCST is due to disturbances inherent 
to the dorsal striatum. It should finally be 
noted that the dopamine antagonist haloperidol 
has been found to decrease the ability to shift 
arbitrarily using similar tests as employed in 
the Parkinson patients (Berger et al, 1989) 
suggesting that at least dopamine plays a role 
in this ability to shift behaviour without 
external information (cf. expectancy chapter 3, 
section 3-3; cf. animal experiments: Cools, 
1980). 
It may be clear that Parkinson patients have 
a lower ability to use 'self-generated' 
strategies to solve problems. Hence, according 
to the model presented in figure 5-1, they 
may have retained the capacity to use external 
information inherent to tasks to solve 
problems. Although little research has been 
conducted with respect to this possibility, it 
has been shown by Cools and coworkers that 
the number of trials to detect the last criterion 
in their shifting paradigm is not different 
between controls and Parkinson patients, i.e. 
a shift which can be derived from the 
'external information' of the task (Cools et al, 
1990c). Moreover it has been shown that 
Parkinson patients have less difficulties in 
performing a cued-version than a non-cued 
version of the Stroop-colour-word task (Brown 
and Marsden, 1988b). In fact, these latter 
authors showed that no differences exist 
between the Parkinson group and the control 
group on the cued-version. Finally in the 
initiation phase of a reaction-time task 
Parkinson patients profit more from the cues 
in the task than controls (Lichter et al, 1988). 
This implies that the frontal cortex-nucleus 
accumbens - ventral pallidum circuitry is 
intact to the extent to which external 
information can be used in these tasks to 
regroup behaviour according to the demands 
of the task. This might explain why non-
demented Parkinson patients are able to learn 
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spatial alternation as well as the reversal of 
tactile discrimination: they are still able to use 
the external cues of the test (Freedman and 
Oscar-Berman, 1986; 1987). In this respect 
the possibilty may be considered that the poor 
performance of demented Parkinson patients 
in these tasks (Freedman and Oscar-Berman, 
1986; 1987) is due to a decreased ability to 
use external cues. This would be compatible 
with the fact that they have large disturbances 
within the circuitry involved with the use of 
external information (chapter 2, section 2-5). 
It may be wondered whether the deficits 
described in this paragraph also manifest 
themselves in the overt behaviour. This issue 
will be dealt with in the next paragraph. 
5.3.4 Overt behaviour 
Korten describes in his book on Parkinson's 
disease some characteristics of the premorbid 
personality structure of patients suffering from 
Parkinson's disease (Korten, 1984). It appears 
that these patients show little initiative of 
their own and are environment- and person-
dependent (Korten, 1984; see also Prichard et 
al, 1951). The question of course arises 
whether this premorbid personality structure 
predisposes them for the disease, i.e. whether 
a person with a specific personality structure 
is at a higher risk or deemed to develop 
Parkinson's disease (Dakof and Mendelsohn, 
1986; see also Prichard et al, 1951), or 
whether it is a personality structure inherent 
to the disease itself, i.e. reflecting an 
expression of disturbances in non motor 
aspects of the disease process itself (see 
below). In line with the foregoing others have 
stated that Parkinson patients lack the ability 
to induce behavioural changes by themselves 
(Frith and Done, 1988; Frith, 1987). 
It may also in this case be expected that 
Parkinson patients have retained the capacity 
to use external information to guide 
behaviour. Indeed, it has been described that 
the Parkinson patient is stimulus-driven, e.g. 
its gait is improved by regular external 
information (martial music or regular spaced 
lines on the floor) and worsened by irregular 
stimulation (Frith and Done, 1988; see also 
Frith, 1987). Some further anecdotal events 
support the above given ideas: severe akinetic 
Parkinson patients have been found to display 
'normal behaviour' in life-threatening 
situations (kinesia paradoxa; see e.g. Schwab 
and Zieper, 1965). 
5.3.5 General conclusion 
Table 5-3 summarizes the major conclusions 
of this discussion. It may be clear from this 
table that several disturbances are present in 
Parkinson's disease, which may be due to the 
pathological and neurochemical changes 
pointed out in chapter 2. 
Disturbances in the frontal cortex may lead 
to the disturbances found in recency 
discrimination. The fact that demented patients 
have larger disturbances in the frontal cortex 
may account for the larger deficit observed 
in these patients in this respect. The caudate 
nucleus lesions may be responsible for the 
deficits found in switching without the help of 
currently available external stimuli. It has not 
been studied yet whether differences exist 
between non-demented Parkinson and 
demented Parkinson patients in this respect. It 
might however be predicted that demented 
patients perform poorer on tests in which the 
ability to arbitrary switch behaviour has to be 
used (chapter 2, section 2-5, 2-7). Indirect 
evidence for this is obtained in a free recall 
memory task, in which information has to be 
retrieved without the help of currently 
available external information, i.e. demented 
Parkinson patients perform poorer on this test 
than non-demented Parkinson patients 
(Caltagirone et al, 1985; Heindel et al, 1989; 
Sagar et al, 1988b). An increasing pathology 
in the striatum may moreover be responsible 
for the deficits observed in shifting motor 
sequences, i.e. programming motor aspects of 
behaviour (Cools, 1984; in Korten 1984). 
With respect to the nucleus accumbens-
subpallidal axis the following may be noted. 
It would appear that non-demented Parkinson 
patients have a spared ability to use external 
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Table 5-3: Summary of some behavioural and cognitive deficits in Parkinson patients without and 
with dementia. 
non demented 
internal external 
overt • ~-
shift i 
recency ? \ 
J: decrease;^-: no change; ?: not 
information to guide behaviour, i.e. their 
nucleus accumbens-subpallidal axis appears to 
be still intact to the extent to which external 
information can be used to guide behaviour. 
Relatively little research has been conducted 
on the difference between demented and non-
demented Parkinson patients in this respect. 
One might infer from the larger pathology in 
this system in demented Parkinson patients 
than in non-demented Parkinson patients that 
demented Parkinson patients have larger 
distubances in the ability to use stimuli and/or 
cues to guide behaviour than non-demented 
Parkinson patients. Although no hard evidence 
is available in this respect, data from a 
number of memory-tasks in which external 
information has to be used suggest that this 
may be the case indeed (Heindel et al, 1989; 
Huber et al, 1986; Sagar et al, 1988b). 
As pointed out in chapter 2 Alzheimer 
patients share some features with respect to 
pathology with patients suffering from 
Parkinson's disease. The pathology in the 
mesolimbic system appears to be larger in 
Alzheimer patients than in Parkinson patients. 
Accordingly it may be predicted that 
Alzheimer patients not only show disturbances 
in tasks in which the mesolimbic system is 
involved, i.e. the ability to use external 
information to guide behaviour, but also that 
they perform poorer than demented Parkinson 
demented 
internal external 
? ? 
known; #: зее text 
patients. It has been shown that Alzheimer 
patients are indeed impaired on tasks in which 
they have to rely on external information 
(Heindel et al, 1989; Freedman and Oscar-
Berman, 1987; Sagar et al, 1988a, 1988b; 
Sahakian et al, 1988). Moreover their 
performance appears to be poorer than that of 
demented Parkinson patients. Furthermore 
Alzheimer patients have been found to be 
impaired on tasks in which they have to rely 
on internal information (Heindel et al, 1989), 
which is in agreement with their nigrostriatal 
deficits (cf. chapter 2, section 2-6). 
Finally Alzheimer patients develop 
inappropriate, 'out of context', behaviour in 
the course of the disease process (Jolles, 
1986). In fact the impression is obtained that 
the Alzheimer patient becomes more and 
more locked within itself, i.e. unattached to 
his environment. It would be of interest to 
know whether the latter may be due to 
extensive lesions within the (meso)limbic 
system, and hence whether the patient is 
deprived of his way to interact with the 
environment. It should be stressed however 
that Alzheimer patients have also disturbances, 
like aphasia, apraxia and agnosia which they 
do not share with Parkinson patients, and 
which are -probably- due to disturbances in 
other structures than the ones that have been 
studied here. 
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5-4 Some final remarks 
With respect to the original hypothesis on 
the involvement of the mesolimbic dopamine 
system the following may finally be noted. 
The data presented in this thesis showed that 
a decreased dopaminergic activity in the 
nucleus accumbens decreases the ability to 
switch to cue-directed behaviours, whereas an 
increased dopaminergic activity enhances the 
ability to switch to cue-directed behaviours 
(chapter 3, section 3-4). This ability is 
transmitted via the rostral areas of the VP/SI 
complex (chapter 4, section 4-3). An inverse 
relationship appears to exist between the 
dopaminergic activity in the nucleus 
accumbens and the GABA-ergic activity in 
the VP/SI complex, i.e. an increase in the 
dopaminergic activity in the nucleus 
accumbens is accompanied by a decrease in 
the GABA-ergic activity in the VP/SI 
complex. As shown in chapter 4, section 4-
2 efferents from the nucleus accumbens, 
which contain inter alia GABA as 
neurotransmitter, impinge upon cholinergic 
neurons in the VP/SI complex (Haber et al, 
1988; Mesulam and Mufson, 1984). 
Accordingly, an enhanced dopaminergic 
activity in the nucleus accumbens will be 
accompanied by an enhanced NBM-cortical 
cholinergic activity. Conversely, a decreased 
dopaminergic activity in the nucleus 
accumbens will be accompanied by a 
decreased NBM-cortical cholinergic activity. 
Thus, in Parkinson patients, that suffer from 
dementia the extensive decrease in cholinergic 
activity may, in part, be due to a secondary 
phenomenon, i.e. due to an increased 
pathology in the nucleus accumbens the NBM 
starts to dysfunction (cf. Cools et al, 1989b; 
cf. Candy et al, 1983). Accordingly the 
cognitive and behavioural deficits may 
become increasingly larger in time, which 
may finally lead to a clinical state 
warranting the diagnosis of 'dementia'. 
Conversely tremor may be an expression of 
a dysfunction of lower brain structures due to 
an increased dopaminergic (Dl?, see section 
3-6, chapter 3) activity in the nucleus 
accumbens. With respect to the latter the 
following might finally be noted. In cats, it 
has been shown that an oro-facial syndrome 
(OFD) is elicited in the limbic part of the 
caudate nucleus by dopamine (DAi) agonists; 
a syndrome, which resembles that induced by 
1-dopa in Parkinson patients in its morphology 
(Cools et al, 1976; Spooren et al, 1990). This 
syndrome is attenuated at the level of the 
subpallidal areas (scGP) by the GABA-agonist 
muscimol (Spooren et al, 1990). Moreover it 
is elicited from the latter area by either a 
GABA-antagonist or a cholinergic agonist 
(Cools et al, 1989b; Spooren et al, 1989). 
These data suggest that the 1-dopa induced 
oro-facial syndrome in Parkinson patients is 
the consequence of a dysfunction of a lower 
order output station of the limbic part of the 
caudate nucleus, i.e. the scGP, and provide 
further evidence for the interaction between 
(meso)limbic striatal areas and subpallidal 
areas. Since demented Parkinson patients have 
a lower dopaminergic activity in the limbic 
part of the striatum, i.e. the ventral striatum, 
than non-demented Parkinson patients 
(chapter 2, section 2-5 and 2-7) it may be 
expected that demented patients are less 
sensitive for developing an oro-facial 
syndrome after 1-dopa treatment than non-
demented Parkinson patients. In support of 
this notion it has been found that the 
percentage of demented Parkinson patients 
which develop 1-dopa induced abnormal 
involuntary movements is lower than of non-
demented patients (Elizan et al, 1986; 
Lieberman et al, 1979; see however Ransmayr 
et al, 1986). 
5-5 Some suggestions for future research 
Overall this final chapter suggests that by 
following the approach presented in this thesis 
insight may be obtained in (i) the nature of 
the structures involved at a certain time-point 
in the disease, (ii) the progression of the 
disease and its underlying pathology as such, 
and (iii) differences between diseases. 
Therefore two lines of research may be 
pursued in the near future for understanding 
the behavioural deficits inherent to 
Parkinson's disease and Alzheimer's disease. 
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It should be stressed that these lines do not 
solve the problem of the underlying 
fundamental cellular deficits per se, but solely 
deal with the question how a pathology might 
spread through the brain on a macro-level. 
The first -preclinical- line may encompass to 
study how neurochemical changes within 
cortical areas affect the function of subcortical 
areas. Thus, it may be of interest to study the 
short- and long-term behavioural and 
neurochemical changes after lesions in the 
frontal cortex, and structures like the 
hippocampus and basolateral amygdala, in 
order to obtain insight into the order in which 
subcortical areas, like the nucleus accumbens 
and/or VP/SI complex are affected. A second 
-clinical- line, may be the development of 
specific neuropsychological tests which test 
specific deficits in Parkinson's and 
Alzheimer's disease. Thus, tests may be 
developed which specifically lean on the 
ability to use stimuli or cues in several 
modalities. It may be clear that after the work 
of Weingartner et al (Weingartner et al, 1984) 
the complexity of these tasks may be varied 
in order to understand and to unravel the 
extent of the cognitive deficits. In this way 
these cognitive deficits may be mapped in a 
systematic way. Accordingly insight may be 
obtained in the extent of the pathology, and 
in connection with the preclinical research in 
the extent to which the pathological process 
progresses in the brain. As a corollary of this 
kind of testing it may become possible to 
activate those capacities that are still retained; 
something which unfortunately is still too 
little done. 
It is hoped that this thesis may offer some 
contributions for future research in this 
respect. 
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SUMMARY 
The present thesis in a nutshell. 

In chapter 1 the purpose of this thesis is indicated: to study a number of brain structures 
involved in the dementia associated with Parkinson's disease and Alzheimer's disease. This thesis 
is not a textbook on dementia but a fundamental study on the role of a number of brain structures 
involved in the forementioned dementias. It consists of three parts. The first paît encompasses a 
literature study in which the occurrence of dementia in Parkinson's disease is investigated. In the 
second part the animal research is described. In the third part finally the clinical implication of the 
results of the second pan for the dementia associated with Parkinson's and Alzheimer's disease is 
discussed. 
In chapter 2 the relationship between Parkinson's disease and dementia is analysed on basis of 
existing literature. First attention is being paid to the definition of dementia. Dementia is not a 
unitary disease. It occurs in several diseases, among them Alzheimer's disease and Parkinson's 
disease. Since the DSM-Ш and the 'Mini-Mental State examination' are often used in dementia 
research these scales are somewhat highlighted. Based upon literature it is concluded, that a 
subpopulation of Parkinson patients exists, which develops dementia. Despite the fact that the 
criteria, on which the diagnosis of dementia is made, are sometimes vague, it is concluded, in part 
on basis of a number of studies which have used more specific criteria (DSM-Ш), that Parkinson 
patients still have a higher chance for developing dementia than might be expected on the basis of 
a population of elderly people. Next to the fact that the occurrence of dementia is correlated with 
age, other factore also correlate. The occurrence of dementia is e.g. positively correlated with the 
motor symptom akinesia. In contrast, tremor correlates negatively with the occurrence of dementia. 
Based upon these and other results it is suggested that more than one type of Parkinson patient 
exists. Subsequently attention is being paid to the pathology that might underlie the occurrence of 
dementia. Several neurotransmitter systems are involved. The occurrence of dementia is correlated 
with a decrease in the activity of the dopaminergic mesolimbic system and the cholinergic nucleus 
basalis of Meynert (NBM)-cortical system: non- demented Parkinson patients have small to no 
changes in the activity of these systems, whereas demented Parkinson patients have large decreases 
in the activity of these systems. The NBM is situated within the ventral pallidum/substantia 
innominata complex (VP/SI complex; subpallidal areas) and receives projections from the nucleus 
accumbens, which occupies a central role in the mesolimbic dopamine system. The symptoms 
akinesia and rigidity are correlated with a decrease in the activity of the nigrostriatal system, 
whereas tremor is not. Tremor seems to be correlated with an active cholinergic NBM-cortical 
system. Based upon literature it can be concluded that an active NBM cholinergic system is 
correlated with an active mesolimbic dopamine system. In patients suffering from the dementia of 
the Alzheimer type the forementioned systems are also involved, i.e. both the mesolimbic dopamine 
system and the cholinergic NBM-cortical system show a decreased activity. Moreover a 
subpopulation can be recognized which has Parkinson(-like) symptoms. Especially akinesia and 
rigidity are found within this group. From the foregoing the hypothesis is developed that the 
pathology in the nigro-striatal and mesolimbic dopamine system are interrelated. On the one end 
of the spectre Parkinson patients can be found with cognitive and motor disturbances characteristic 
for a hypoactive nigrostriatal and a normoactive (or hyperactive) mesolimbic system (tremor). On 
the other end patients suffering from the dementia of the Alzheimer-type can be found with an 
intact nigrostriatal system and a hypoactive mesolimbic dopamine system. In between, patients 
suffering from Parkinson's disease with cognitive and motor (akinesia and rigidity) deficits inherent 
to a hypoactive nigrostriatal system, and with dementia characteristic for a hypoactive mesolimbic 
dopamine system exist. The pathology might spread from the nigrostriatal to the mesolimbic system 
in the course of the disease process. 
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In order to obtain moie insight into aspects of the dementia associated with Parkinson's and 
Alzheimer's disease, the nucleus accumbens which occupies a central role in the mesolimbic 
dopamine system is studied. The subpallidal areas, in which the NBM lies and which receive 
projections from the nucleus accumbens are studied next, in order to obtain insight into the way 
the pathology in the mesolimbic system progresses. 
In chapters 3 and 4 the experiments are described, which are carried out in this investigation. 
In chapter 3 the role of the nucleus accumbens in programming a non motor and a motor aspect 
of behaviour is studied. As a working hypothesis for the former it is hypothesized that the nucleus 
accumbens is involved in the ability to switch to behaviours which are directed by stimuli from the 
environment In order to investigate this hypothesis a swimming test is used in which the ability 
of rats to switch to cue-directed behaviours and non cue-directed behaviours is tested. To study the 
role of the nucleus accumbens in programming a motor aspect of behaviour tremor is studied, 
since on basis of the literature presented in chapter 2, this is associated with (changes in) the 
mesolimbic dopamine system. 
Since dopamine is in general suggested to be the neurotransmitter involved in switching between 
strategies the role of this neurotransmitter is studied first. The general stimulant d-amphetamine 
enhanced the ability to switch to cue-directed behaviours upon injection into the nucleus accumbens 
without an effect on the ability to switch to non cue-directed behaviours. The specific dopamine 
D2-agonist LY 171 SS5 also enhanced the former. Since this effe« was attenuated by the specific 
dopamine D2-antagonist raclopride, this effect appears to be mediated via the dopamine D2-
receptor. With respect to the dopamine Dl-receptor no firm conclusion could be drawn, since the 
effects of the Dl-selective drugs were equivocal: both the dopamine Dl-agonist SKF 38393 and 
the dopamine Dl-antagonist SCH 23390 decreased the ability to switch to cue-directed behaviours. 
Since noradrenaline has been found to regulate dopaminergic activity in the nucleus accumbens 
via alpha-noradrenergic receptors, it was decided to study the effects of alpha-noradrenergic drugs 
on the ability to switch to cue-directed behaviours. The alpha 1-agonist phenylephrine and the 
alpha2-antagonist rauwolscine decreased the ability to switch to cue-directed behaviours without an 
effect on the ability to switch to non cue-directed behaviours. In contrast the alpha2-agonist 
Clonidine had no effect upon the ability to switch to cue-directed behaviours. It enhanced however 
the ability to switch to non cue-directed behaviours. The latter data lead to the suggestion that the 
nucleus accumbens may have affected the function of the striatum, which mediates the ability to 
switch to non cue-directed behaviours. Moreover on basis of these data it is suggested that two 
alpha-noradrenergic systems may exist in the nucleus accumbens. It is discussed that the effects of 
these alpha-noradrenergic drugs on the ability to switch to cue-directed behaviours may be funnelled 
via the dopamine system. 
Several projections to the nucleus accumbens use excitatory amino acids (EAA) as 
neurotransmitter, among them, the frontal cortex, the hippocampus and the (basolateral) amygdala, 
structures which are involved in the dementias associated with Parkinson's and Alzheimer's disease. 
Since it is known that these EAA have functional interactions with dopamine in the nucleus 
accumbens, it was decided to study the effects of drugs selective for EAA-receptors in the nucleus 
accumbens on the ability to switch to cue-directed behaviours. The N-methyl-d-aspanate (NMDA) 
antagonist AP-7 enhanced the ability to switch to cue-directed behaviours, whereas the NMDA -
agonist NMA was ineffective. The quisqualate (QA) agonist AMPA also enhanced the ability to 
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switch to cue-directed behaviours. The nonspecific QA/NMDA-antagonist kynurenic acid was 
ineffective in producing an effect on the ability to switch to cue-directed behaviours. These data 
have overall led to the suggestion that the NMDA- and QA-receptor have opposite roles in 
mediating the ability to switch to cue-directed behaviours. It was finally observed that the NMDA-
agonist and the QA-agonist mentioned above in low doses enhanced the number of switches from 
cue-directed to non cue-directed behaviours, and vice versa. It is concluded from these data that a 
second interaction between the QA- and NMDA-receptor in the nucleus accumbens probably exists. 
One of these interactions affects the function of the striatum. 
Based upon the results of the experiments presented in this chapter and on a review of some 
literature with respect to the nucleus accumbens, it is suggested that the nucleus accumbens plays 
a role in the ability to switch to cue-directed behaviours. The results of the forementioned 
experiments are explained using a model developed on basis of existing literature, in which several 
afferent projections of the nucleus accumbens play a role. The starting point of the model is the 
balance between the input from the (subiculum of the) hippocampus and the (basolateral) amygdala. 
The results are explained in terms of interfering with one of these inputs. Subsequently the term 
'cue' is explained on basis of literature. It is discussed in the sense of a stimulus or a complex of 
stimuli which has gained the property of directing behaviour on future exposures. In fact, these 
'cues' are abstracted stimuli at a higher level of complexity. With respect to the swimming test the 
present experiments investigated -in first instance- the ability to switch to stimulus-directed 
behaviours. The decrease in stimulus-directed behaviours during the test might be the consequence 
of a transformation of these stimuli into cues (learning ?). Based upon literature it is suggested that 
the hippocampus-accumbens and amygdala-accumbens pathway might be differentially involved in 
regulating behaviour: the former is involved in stimulus-directed behaviours whereas the latter is 
involved in cue-directed behaviours. The transformation of stimuli into cues is thus the result of 
a delicate balance between these pathways. Dopamine in the nucleus accumbens plays a role in 
regulating the activity of these pathways at the level of the nucleus accumbens, and in regulating 
the balance between these two pathways at the level of the nucleus accumbens. The nucleus 
accumbens is thus involved in the ability to switch to stimulus-directed behaviours and cue-directed 
behaviours, and in the transformation of stimuli into cues. 
Chapter 3 ends with a short study on the role of the nucleus accumbens in tremor, i.e. a role in 
programming a motor aspect of behaviour. Tremor in the forelimb of the rat could be elicited by 
injections of the cholinergic muscarinic agonist carbachol in the nucleus accumbens and the 
dorsomedial part of the striatum. Based upon the model discussed in this chapter it suggested that 
the effect of carbachol is mediated via the dopamine Dl -system. Moreover the hypothesis is 
discussed that the nucleus accumbens is involved in regulating the amplitude of tremor whereas the 
striatum is involved in regulating the frequency of tremor. 
In chapter 4 the role of the subpallida] areas (VP/SI complex) in behaviour was investigated. 
This chapter is mainly concerned with the interaction between the subpallidal areas and the nucleus 
accumbens. 
It is known that tonic electromyographic (EMG)-activity of the triceps muscle of the forelimb of 
the rat increases after injections of haloperidol in the nucleus accumbens. These results were 
replicated here. Injections of the gamma-aminobutyric acid (GABA) agonist muscimol in the caudal 
areas of the VP/SI complex mimicked this effect, i.e. enhanced tonic EMG-activity of the triceps 
muscle. Moreover the increase in tonic EMG-activity of the triceps muscle induced by injection of 
haloperidol in the nucleus accumbens was attenuated at the level of the caudal areas of the VP/SI 
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complex by injeaions of the GABA-antagonist bicuculline. No changes in tonic EMG-activity were 
observed after injections of muscimol in the rostral areas of the VP/SI complex; instead, these 
injections increased motor activity in a specific way. From these data it is concluded that increases 
in tonic EMG-activity elicited from the nucleus accumbens are transmitted to lower brain structures 
via the caudal areas of the VP/SI complex. Moreover these data showed that the subpallidal areas 
are heterogeneous with respect to their sensitivity for the GABA-agonist muscimol. 
The role of the rostral areas of the VP/SI complex in motor activity was subsequently studied. 
It was shown that both the GABA-agonist muscimol and the GABA-antagonist bicuculline enhanced 
motor activity in this area. Moreover it was shown that these drugs antagonized each others effects. 
These data led to the suggestion that muscimol and bicuculline elicited their effect via GABA-
receptors on different populations of neurons. Furthermore it appeared that bicuculline was 
ineffective in enhancing motor activity in the caudal areas of the VP/SI complex. It was finally 
observed that the muscarinic agonist carbachol enhanced motor activity. Since it is known that 
muscimol and Picrotoxin (an indirect GABA-antagonist) elicit activity from slightly different areas 
of the rostral areas of the VP/SI complex, which overlap to some extent the projection areas from 
the nucleus accumbens and olfactory tubercle -structures involved in regulating motor activity- to 
the rostral areas of the VP/SI complex respectively, it is speculated that the differential effects of 
the forementioned drugs are due to their differential effects on these projections. 
Given the fact that intra-accumbens injections of d-amphetamine elicit a clear increase in the 
ability to switch to cue-directed behaviours (via dopamine D2-receptors; chapter 3), it was decided 
to study whether this ability is transmitted to lower brain structures via the subpallidal areas. Since 
previous studies showed that an inverse relationship between dopamine in the nucleus accumbens 
and GABA in the subpallidal areas with respect to the regulation of behaviour exists, the 
behavioural effects of the GABA-antagonist bicuculline are studied. Especially the effects of this 
drug in the rostral areas of the VP/SI complex are investigated. In the first set of experiments it 
was found that injections of distilled water in the rostral areas of the VP/SI complex had profound 
effects on the ability to display different non cue-directed behaviours. The latter effect was probably 
due to an effect on the globus pallidus, which overlies the rostral areas of the VP/SI complex, i.e. 
an output station of the striatum, which is involved in the ability to switch to non cue-directed 
behaviours. Moreover it was found that injections of the GABA-antagonist bicuculline were 
ineffective in affecting the ability to switch to cue-directed behaviours. It was finally found that the 
enhanced ability to switch to cue-directed behaviours induced by intra-accumbens injections of d-
amphetamine was attenuated by injections of the GABA-agonist muscimol in the rostral areas of 
the VP/SI complex. Overall these data showed that the rostral areas of the VP/SI complex were 
involved in transmitting the ability to switch to cue-directed behaviours. Moreover these data have 
led to the conclusion that this ability is specific for the nucleus accumbens. 
In chapter 5 the findings of the experiments described in chapters 3 and 4 are discussed in view 
of the hypothesis outlined in chapter 2. The nucleus accumbens plays a role in the ability to switch 
to stimulus-directed and cue-directed behaviour as well as in the transformation of stimuli into cues. 
The nucleus accumbens transmits these effects to lower brain structures via the subpallidal areas. 
It appears thus that the function of the nucleus accumbens is the opposite of that of the striatum, 
which mediates the ability to switch to non cue-directed behaviours. 
Based upon the data of the animal research it is tried to predict the behavioural and cognitive 
changes in patients suffering from Parkinson's disease and patients suffering from Alzheimer's 
disease. Since non-demented Parkinson patients have pathological changes in the nigrostriatal 
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system, it may be expected that they have a decreased ability to switch behaviour without the help 
of external information. A survey of the literature shows that this is indeed the case. Fuithermore 
it may be expected that they have retained the ability to use external information to switch 
behaviour since the pathological changes are relatively small in the mesolimbic system. A survey 
of the literature shows that this appears to be the case. 
Since Parkinson patients with dementia and patients suffering from the dementia of the Alzheimer-
type show pathological changes in the mesolimbic system, it may be expected that they have a 
decreased ability to switch behaviour with the help of external information. Existing literature shows 
that -in some cases- these patients have indeed difficulties to switch behaviour with the help of 
external information. 
The data presented in this thesis may have implications for understanding some of the behavioural 
deficits in Parkinson patients with and without dementia. Moreover these data may have implications 
for understanding the relationship between Parkinson's and Alzheimer's disease. 
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SAMENVATTING 
Dit proefschriñ in een notedop 

In hooFdstuk 1 wordt uiteengezet wat het doel van dit proefschrift is: het bestuderen van een 
aantal hersenstructuren die betrokken zijn bij de dementie geassocieerd met de ziekte van Parkinson 
en de ziekte van Alzheimer. Dit proefschrift is geen tekstboek over dementie, maar een 
fundamentele studie naar de functie van een aantal hersenstructuren die betrokken zijn bij de 
bovengenoemde dementieen. Het is opgebouwd uit drie delen. Het eerste deel beslaat een 
literatuurstudie waarin het optreden van dementie in de ziekte van Parkinson bestudeerd wordt. In 
het tweede deel worden dierexperimenten beschreven. Het derde deel tenslotte beslaat de klinische 
implicatie van de resultaten, die in het tweede deel gevonden zijn, voor de ziekte van Parkinson 
en de dementie van het Alzheimer type. 
In hoofdstuk 2 wordt de relatie tussen de ziekte van Parkinson en dementie geanalyseerd aan de 
hand van de literatuur. Eerst wordt er aandacht besteed aan de definitie van dementie. Dementie 
is geen nosologische eenheid. Het komt voor bij een aantal ziektebeelden, zoals de ziekte van 
Alzheimer en de ziekte van Parkinson. Aangezien de DSM-Ш en de 'Mini-Mental State 
examination', veelgebruikte 'tools' zijn voor het diagnostiseren van dementie, wordt vervolgens 
daaraan aandacht besteed. Op basis van de bestaande literatuur wordt de conclusie getrokken, dat 
er een subpopulatie van Parkinson patiënten bestaat die dementie ontwikkelt. Ondanks het feit dat 
de criteria, waarmee de diagnose van dementie gesteld is, soms niet duidelijk zijn, wordt mede op 
basis van studies waarin meer specifieke criteria (DSM-Ш) gebruikt zijn, toch de conclusie 
getrokken dat Parkinson patiënten een grotere kans hebben om dementie te ontwikkelen dan op 
basis van populatie-onderzoek van gezonde ouderen verwacht mag worden. Naast het gegeven dat 
leeftijd correleert met het voorkomen van dementie, correleren ook andere factoren ermee. Het 
optreden van dementie is bijvoorbeeld positief gecorreleerd met het motor symptoom akinesie. In 
tegenstelling hiermee is het optreden van dementie negatief gecorreleerd met tremor. Op basis van 
deze en andere gegevens wordt gesuggereerd dat er meer typen Parkinson patiënten zijn. Vervolgens 
wordt aandacht besteed aan de pathologie, die ten grondslag kan liggen aan het optreden van 
dementie. Verschillende neurotransmitter systemen blijken hierbij betrokken te zijn. Het optreden 
van dementie is gecorreleerd met verlagingen in de activiteit van het mesolimbische dopamine 
systeem en het cholinerge nucleus basalis van Meyneit (NBM)-corticale systeem: niet-demente 
Parkinson patiënten hebben geen (of kleine) pathologische veranderingen in het mesolimbische 
dopamine systeem en het cholinerge NBM-corticale systeem, terwijl demente Parkinson patiënten 
grote veranderingen in deze systemen hebben. De NBM ligt in het ventrale pallidum/substantia 
innominata complex (VP/SI complex; subpallidale gebieden), en ontvangt projecties van de nucleus 
accumbens, die een centrale rol inneemt in het mesolimbische dopamine systeem. De symptomen 
akinesie en rigiditeit zijn gecorreleerd met verlagingen van de dopaminerge activiteit in het 
nigrostnatale systeem, terwijl tremor dat niet is. Tremor lijkt gecorreleerd te zijn met een actief 
cholinerg NBM-corticaal systeem. Op basis van literatuur kan geconcludeerd worden dat een actief 
NBM-corticaal systeem gecorreleerd is met een actief mesolimbisch dopamine systeem. In patiënten 
lijdend aan de dementie van het Alzheimer-type vertonen de voornoemde systemen eveneens 
pathologische veranderingen, dat wil zeggen:zowel het mesolimbische dopamine systeem als het 
cholinerge NBM-corticale systeem is hypoactief in dit ziektebeeld. Verder is er een subpopulatie 
te onderkennen die Parkinson-<achtige) symptomen heeft. Met name akinesie en rigiditeit worden 
hierbij gevonden. Uit het voorafgaande wordt de hypothese afgeleid dat de pathologie in het 
nigrostnatale en het mesolimbische dopamine systeem met elkaar verbonden zijn. Aan het ene eind 
van het spectrum staan patiënten lijdend aan de ziekte van Parkinson met cognitieve en motorische 
verstoringen kenmerkend voor een hypoactief nigrostriataal systeem en een normaal actief (of 
overactief) mesolimbisch systeem (tremor). Aan het andere eind van het spectrum staan patiënten 
lijdend aan de dementie van het Alzheimer-type met een intact nigrostriataal systeem en een 
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hypofunctionerend mesolimbisch systeem. Hiertussen bevinden zich patiënten lijdend aan de ziekte 
van Parkinson met cognitieve en motorische (akinesie en rigiditeit) verstoringen representatief voor 
een hypoactief nigrostriataal systeem, en met dementie kenmerkend voor een hypoactief 
mesolimbisch dopamine systeem. De pathologie verspreidt zich mogelijkerwijs hierbij van het 
nigrostriatale naar het mesolimbische systeem in de loop van de ziekte. 
Teneinde meer inzicht te verkrijgen in aspecten van de dementie geassocieerd met de ziekte van 
Parkinson en ziekte van Alzheimer, wordt de nucleus accumbens, die een centrale rol inneemt in 
het mesolimbische dopamine systeem, bestudeerd. De subpallidale gebieden, waarin de NB M ligt 
en die informatie ontvangen van de nucleus accumbens, worden vervolgens onderzocht om inzicht 
te krijgen in de wijze waarop een toenemende mate van pathologie binnen het mesolimbische 
systeem voortschrijdt. 
In hoofdstukken 3 en 4 worden de experimenten beschreven, die in het kader van dit onderzoek 
uitgevoerd zijn. 
Hoofdstuk 3 betreft onderzoek naar de rol van de nucleus accumbens in de programmering van 
een niet-motorisch en een motorisch aspect van het gedrag. Voor de eerstgenoemde wordt als werk-
hypothese gesteld, dat de nucleus accumbens betrokken is bij het vermogen om van gedrag te 
wisselen met behulp van momentaan aanwezige prikkels. Om deze hypothese te testen is een 
zwemtest gebruikt, die het mogelijk maakt het gedrag van ratten te bestuderen in termen van het 
wisselen naar 'cue-directed' en niet 'cue-directed' gedragingen. Voor de rol van de nucleus 
accumbens in de programmering van het motorische aspect van gedrag is tremor bestudeerd, omdat 
dit op basis van de literatuur weergegeven in hoofdstuk 2 met (veranderingen in) het mesolimbische 
dopamine systeem geassocieerd kan worden. 
Dopamine wordt in het algemeen gezien als de neurotransmitter die betrokken is bij het vermogen 
om van gedrag te wisselen. Derhalve is deze neurotransmitter eerst bestudeerd. Injecties van de 
stimulant d-amphetamine in de nucleus accumbens verhoogden het vermogen om te wisselen naar 
'cue-directed' gedragingen, terwijl ze geen effect hadden op het vennogen te wisselen naar niet 
'cue-directed* gedragingen. De specifieke dopamine D2-agonist LY 171 555 verhoogde het 
eemgenoemde vermogen eveneens. Aangezien dit effect geremd kon worden door de D2-antagonist 
raclopride lijkt het vermogen om te wisselen naar 'cue-directed' gedragingen via de dopamine D2-
receptor te worden gemedieerd. Met betrekking tot de rol van de dopamine Dl-receptor kon geen 
eenduidige conclusie getrokken worden, aangezien de effecten van dopamine Dl-pharmaca niet 
eenduidig waren: zowel de dopamine Dl-agonist SKF 38393 als de dopamine Dl-antagonist SCH 
23390 verlaagde het vermogen te wisselen naar 'cue-directed' gedragingen. 
Het is bekend dat noradrenaline via alpha-noradrenerge receptoren de dopaminerge activiteit in 
de nucleus accumbens reguleert. Derhalve is besloten de rol van noradrenaline in het vermogen om 
te wisselen naar 'cue-directed' gedragingen te bestuderen. De alphal-agonist phenylephrine en de 
alpha2-antagonist rauwolscine verlaagden het aantal verschillende 'cue-directed' gedragingen zonder 
dat ze een effect hadden op het aantal verschillende niet 'cue-directed' gedragingen. De alpha2-
agonist Clonidine daarentegen had geen effect op het vermogen verschillende 'cue-directed' 
gedragingen te laten zien, terwijl het het aantal niet 'cue-directed' gedragingen verhoogde. Deze 
laatste data hebben geleid tot de suggestie dat de nucleus accumbens de functie van het (dorsale) 
striatum, die het laatstgenoemde vennogen medieert, beïnvloedt. Tevens is gesuggereerd dat er meer 
noradreneige systemen in de nucleus accumbens aanwezig zijn. De effecten van de genoemde alpha-
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noradrenerge pharmaca worden vermoedelijk via het dopamine systeem in de nucleus accumbens 
gemedieerd. 
Velschillende projecties naar de nucleus accumbens gebruiken exciterende amino zuren (EAA) als 
neurotransmitter, zoals de projecties van de hippocampus, de basolaterale amygdala, de prefrontale 
cortex, en de projecties van een aantal thalamische kernen. Een aantal van deze stiucteren is 
betrokken bij de dementie geassocieerd met de ziekte van Parkinson en de ziekte van Alzheimer. 
Aangezien het bekend is, dat er een functionele interactie tussen deze EAA en dopamine in de 
nucleus accumbens bestaat, werd besloten de rol van EAA te bestuderen in het vermogen om 'cue-
directed' gedragingen te wisselen. De N-methyl-d-aspartaat (NMDA) antagonist AP-7 verhoogde het 
aantal wisselingen naar 'cue-directed' gedragingen, terwijl de NMDA-agonist NMA ineffectief was. 
De quisqualaat (QA) agonist AMPA verhoogde eveneens het aantal wisselingen naar 'cue-directed' 
gedragingen. De aspecifieke NMDA/QA-antagonist kynurine zuur was ineffectief in dit opzicht. 
Deze data hebben geleid tot de suggestie dat de NMDA-receptor en de QA-receptor 
tegenovergestelde rollen hebben in het vermogen om te wisselen naar 'cue-directed' gedragingen. 
Er werd tenslotte gevonden dat stimulering van de NMDA-receptor en stimulering van de QA-
receptor met de bovengenoemde stoffen een effect hadden op het aantal wisselingen van 'cue-
directed' naar niet 'cue-directed' gedragingen, en vice versa. Hieruit wordt afgeleid dat er twee 
verschillende interacties tussen de NMDA- en de QA-receptor in de nucleus accumbens bestaan, 
waarvan er een de functie van het striatum beïnvloedt. 
Op basis van de resultaten van de experimenten beschreven in dit hoofdstuk en op basis van een 
overzicht van de literatuur met betrekking tot de nucleus accumbens wordt gesuggereerd, dat de 
nucleus accumbens een rol speelt in het vermogen om te wisselen naar 'cue-directed' gedragingen. 
De resultaten van de hiervoor beschreven serie van experimenten worden verklaard met een model, 
dat op basis van bestaande literatuur ontwikkeld is en waarin verschillende afferente projecties van 
de nucleus accumbens een rol spelen. Het model gaat uit van een balans tussen de input van de 
hippocampus en de amygdala. Binnen dit model worden de resultaten verklaard in termen van het 
interfereren met een van de genoemde inputs. Vervolgens wordt het begrip 'cue' nader uitgewerkt 
op basis van literatuur studies. Het begrip 'cue' is in deze context bediscussieerd als een stimulus 
of een set stimuli die het vermogen gekregen heeft om gedrag te sturen in toekomstige situaties. 
In feite gaat het hierbij om een geabstraheerde stimulus of set van stimuli op een hoger niveau van 
complexiteit Met betrekking tot de zwemtest is -in eerste instantie- het vermogen om te wisselen 
naar stimulus-gestuurde gedragingen bestudeerd. Er wordt gesuggereerd dat de geobserveerde 
verlaging van dit aantal gedragingen gedurende de test de consequentie is van het transformeren van 
deze stimuli in cues (leren ?). Op basis hiervan en van bestaande literatuur is gesuggereerd dat de 
hippocampus-accumbens en de amygdala-accumbens projecties onderscheiden betrokken zijn bij het 
sturen van gedrag: terwijl het eerste kanaal betrokken is bij stimulus-gestuurd gedrag is het tweede 
kanaal betrokken bij cue-gestuurd gedrag. De transformatie van stimuli naar cues is met andere 
woorden het resultaat van een subtiele balans tussen deze twee kanalen. Dopamine in de nucleus 
accumbens vervult een belangrijke rol in het reguleren van de activiteit van de afzonderlijke kanalen 
op het niveau van de nucleus accumbens, en in het reguleren van de balans tussen deze kanalen 
op het niveau van de nucleus accumbens. De nucleus accumbens speelt dus een rol in het vermogen 
om te wisselen naar stimulus-gestuurde gedragingen en cue-gestuurde gedragingen, en in de 
transformatie van stimuli in cues. 
Hoofdstuk 3 eindigt tenslotte met een korte studie naar de rol van de nucleus accumbens in 
tremor, dat wil zeggen een rol in de programmering van een motorisch aspect van gedrag. Tremor 
in de voorpoot van de rat kon worden opgeroepen door injecties van de cholinerge muscarine 
agonist carbachol in de nucleus accumbens en het dorsomediale deel van het striatum. Op basis van 
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het model dat in dit hoofdstuk is beschreven, wordt gesuggereerd dat het effect van carbachol via 
het dopamine Dl-systeem gemedieerd wordt Op basis van de literatuur wordt de hypothese 
besproken dat de nucleus accumbens betrokken is bij de regulering van de amplitude van tremor 
terwijl het striatum betrokken is bij de regulering van de frequentie van tremor. 
Hoofdstuk 4 betreft onderzoek naar de rol van de subpallidale gebieden (VP/SI complex) in 
gedrag. In dit hoofdstuk staat met name de interactie tussen de subpallidale gebieden en de nucleus 
accumbens centraal. 
Het is bekend dat injecties van haloperidol in de nucleus accumbens tonische 
electromyographische (EMG-) activiteit in de triceps spier van de voorpoot van de rat verhogen. 
Deze resultaten werden hier gerepliceerd. Injecties van een gamma-amino boter zuur (GABA) 
agonist, muscimol, in de caudale gebieden van het VP/SI complex gaven eenzelfde resultaat te zien, 
dat wil zeggen, ze verhoogden de tonische EMG-activiteit van de triceps spier van de voorpoot. 
Verder konden injecties van een GABA-antagonist, bicuculline, in de caudale delen van het VP/SI 
complex de effecten van injecties van haloperidol in de nucleus accumbens remmen. Injecties van 
muscimol in rostrale gebieden van het VP/SI complex hadden geen effect op tonische EMG-
activiteit van de triceps spier van de voorpoot, maar verhoogden daarentegen motor activiteit op een 
specifieke manier. Deze data leiden tot de conclusie dat verhogingen in tonische EMG-activiteit 
opgeroepen vanuit de nucleus accumbens via de caudale gebieden van het VP/SI complex naar 
lagere structuren worden doorgegeven. Verder lieten deze data zien dat de subpallidale gebieden 
heterogeen zijn, voor zover het hun gevoeligheid voor de GABA-agonist muscimol betreft. 
De rol van de rostrale gebieden van het VP/SI complex in motor activiteit werd eveneens 
bestudeerd. Er werd aangetoond dat zowel de GABA-antagonist bicuculline als de GABA-agonist 
muscimol motor activiteit verhoogden. Bovendien werd aangetoond dat deze phannaca elkaars effect 
remden. Deze data hebben geleid tot de suggestie dat muscimol en bicuculline hun effect oproepen 
via GABA-receptoren op verschillende populaties van neuronen. Verder werd er gevonden dat 
bicuculline ineffectief was in het oproepen van motor activiteit in de caudale gebieden van het 
VP/SI complex. Tenslotte verhoogden mjecties van de cholinerge agonist carbachol in de rostrale 
delen van het VP/SI complex eveneens motor activiteit. Aangezien het bekend is dat muscimol en 
Picrotoxine (een indirecte GABA-antagonist) in verschillende delen van het rostrale gebied van het 
VP/SI complex, die overeen lijken te komen met de projectie gebieden van de nucleus accumbens 
en het tuberculum olfactorium -structuren betrokken bij de regulering van motor activiteit -
respectievelijk, motor activiteit oproepen, is er gespeculeerd dat de onderscheiden effecten van deze 
pharmaca het gevolg zijn van hun onderscheiden effecten op deze projecties. 
Gegeven het feit dat injecties van d-amphetamine in de nucleus accumbens het vermogen om te 
wisselen naar 'cue-directed' gedragingen verhogen (via de dopamine D2-receptor, hoofdstuk 3), is 
besloten te bestuderen of dit vermogen via de subpallidale gebieden wordt doorgegeven naar lagere 
structuren. Aangezien er voorheen aangetoond is dat er een inverse relatie bestaat tussen dopamine 
in de nucleus accumbens en GABA in de subpallidale gebieden wat het reguleren van gedrag betreft 
zijn eerst de effecten van de GABA- antagonist bicuculline bestudeerd. In het bijzonder zijn de 
rostrale gebieden van het VP/SI complex bestudeerd. In de eerste serie van experimenten werd 
gevonden dat mjecties van gedestilleerd water in de rostrale gebieden van het VP/SI complex onder 
meer effecten hadden op het vermogen om niet 'cue-directed' gedragingen te wisselen. Dit laatste 
was mogelijk het gevolg van een effect van deze injecties op de globus pallidus, die boven de 
rostrale gebieden van het VP/SI complex ligt en die een output station is van het striatum, die een 
rol speelt in het medieren van het vermogen om te wisselen naar niet 'cue-directed' gedragingen. 
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Verder werd aangetoond dat injecties van de GABA-antagonist bicuculline geen effect hadden op 
het vermogen 'cue-directed' gedragingen te wisselen. Tenslotte werd er gevonden dat het verhoogde 
vermogen om te wisselen naar 'cue-directed' gedragingen geïnduceerd door injecties van d-
amphetamine in de nucleus accumbens geremd kon worden door injecties van de GABA-agonist 
muscimol in de rostrale gebieden van het VP/SI complex. Overall hebben deze data aangetoond dat 
het vermogen om te wisselen naar 'cue-directed' gedragingen van de nucleus accumbens via de 
rostrale gebieden van het VP/SI complex naar lagere structuren wordt doorgegeven. Deze data 
hebben tot de conclusie geleid dat dit vermogen specifiek is voor de nucleus accumbens. 
In hoofdstuk 5 tenslotte zijn de resultaten van de experimenten beschreven in de hoofdstukken 
3 en 4, bediscussieerd in het licht van de hypothese die in hoofdstuk 2 gesteld is. De nucleus 
accumbens speelt een rol in het vermogen om te wisselen naar stimulus-gestuurde en cue-gestuurde 
gedragingen alsmede in de transformatie van stimuli in cues. De nucleus accumbens blijkt deze 
informatie via de subpallidale gebieden naar lagere stations te sturen. Het is dus gebleken dat de 
nucleus accumbens een functie heeft die tegengesteld is aan die van het (dorsale) striatum, die 
betrokken is bij het vermogen om niet 'cue-directed' gedragingen te wisselen. 
Op basis van deze dierexperimentele gegevens is een poging gedaan te voorspellen wat de 
cognitieve veranderingen in patiënten lijdend aan de ziekte van Parkinson of patiënten lijdend aan 
de ziekte van Alzheimer zijn. Aangezien niet-demente Parkinson patiënten pathologische 
veranderingen hebben in het nigrostriatale systeem mag verwacht worden dat ze een verlaagd 
vermogen hebben eigenmachtig van gedrag te veranderen. Een overzicht van de literatuur geeft aan 
dat dit inderdaad het geval is. Verder mag verwacht worden dat ze het vermogen behouden hebben 
om exteme informatie te gebruiken om van gedrag te veranderen aangezien de pathologische 
veranderingen in het mesolimbische circuit relatief klein zijn. Een overzicht van de literatuur geeft 
aan dat dit het geval is. 
Aangezien Parkinson patiënten met dementie en patiënten lijdend aan dementie van het Alzheimer-
type pathologische veranderingen in het mesolimbische systeem hebben, mag verwacht worden dat 
ze een verlaagd vermogen hebben om te veranderen van gedrag met behulp van exteme informatie. 
Een overzicht van de literatuur geeft aan dat deze patiënten -in sommige gevallen- inderdaad 
problemen hebben met het gebruik van exteme informatie om van gedrag te veranderen. 
De data die in dit proefschrift gepresenteerd zijn kunnen implicaties hebben voor het begrijpen 
van de gedragsmatige veranderingen in patiënten met de ziekte van Parkinson die al dan niet aan 
dementie lijden. Verder kunnen ze implicaties hebben voor het bestuderen van de overeenkomst 
tussen patiënten lijdend aan de ziekte van Parkinson en patiënten lijdend aan de ziekte van 
Alzheimer. 
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Er is veel gebeurd de afgelopen jaren. Wanneer ik terugkijk trekt een reeks gebeurtenissen 
aan mijn oog voorbij; sommige leuk, andere minder leuk. Wanneer ik terugkijk trekt een stoet 
van mensen aan mijn oog voorbij; sommigen zijn dichtby, anderen zijn ver weg. Aan velen van 
hen heb ik wat te danken. Niet dat ik zonder hen dit werk niet gedaan zou hebben, of dat ik 
dit werk niet geschreven zou hebben. Nee, het zou alleen gedaan zijn door iemand 'andere'. Ik 
wil die mensen bedanken voor datgene wat ze voor me gedaan of betekend hebben de afgelopen 
jaren. 
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bedanken voor de discussies over het werk. Daarnaast echter wil ik hen met name bedanken 
voor de tijd buiten het werk. In dit opzicht wil ik ook Luuk Lubbers bedanken. Ik hoop dat ik 
jullie nog vaak zal zien. Bart, bedankt voor het gevraagde en ongevraagde gebruik van je 
'papieren' en 'geestelijke' literatuur systeem. Will, bedankt voor het becommentariëren van 
hoofdstuk 4. Daarnaast wil ik de oudgedienden, dr(s) Rob Jaspers en dr. Marian Gelissen, 
bedanken voor hun belangstelling voor het werk gedurende de tijd dat ze op de afdeling waren. 
Annette Bergmans wil ik bedanken voor het vele werk dat ze gedaan heeft in het kader van 
haar hoofdvak Neuro-pharmacologie. Annette, zonder jou zou hoofdstuk 3 substantieel korter 
zijn geweest. Ik wil je verder bedanken voor het maken van en het mij laten gebruiken van de 
tekeningen die in figuur 3-3 staan. Het spijt me dat ik af en toe een ramp voor je geweest ben. 
I would like to thank Gustavo Charria Ortiz from Cali, Colombia, for the work he has done, 
which is found in chapter 3. Gustavo, I owe you a lot; not only for some of the ideas on the 
swimming test, but also for the many hours of discussions during the time that you were here. 
Our friendship meant and still means a lot to me; one day amigo, I am sure that we will meet 
again, have a few drinks and talk about the things that make life interesting and sorrowful. 
Harry van Aanholt, Mia Smeekens, Walter Hoeboer en Dick Heeren wil ik verder bedanken 
voor al het werk dat ze op de een of andere manier voor mij gedaan hebben. Wiel Honig wil ik 
tenslotte bedanken voor het mij aanleren van alle praktische vaardigheden betreffende het 
dierexperimentele werk. 
Hoe zou ik mijn experimenten ooit gedaan kunnen hebben als mijn ratten niet in de goede 
handen van de dierverzorgers van het Centrale Dierenlaboratorium terecht waren gekomen. In 
dit opzicht wil ik speciaal Henny en Helma bedanken. 
Cees en Nol van de Tekenkamer van de Medische Faculteit bedank ik voor de perfecte 
verzorging van de tekeningen en posters. De mensen van Medische Fotografíe verzorgden al het 
foto materiaal op tijd. In dit opzicht wil ik met name Mary bedanken. De bibliotheek van de 
Medische Faculteit liet mij in al die jaren nooit in de steek, bedankt Tinus, Henk, Hans, 
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Dit proefschrift is opgedragen aan mijn moeder en geschreven ter gedachtenis aan mijn 
vader. Hen wil ik bedanken voor de steun die ze me door de jaren heen gegeven hebben. Pa, 
jouw dood heeft veel veranderd in mijn leven. Er zijn dagen dat ik wilde dat we wat konden 
praten. Als er een leven na de dood is, en God ik weet het niet, dan hoop ik dat we elkaar nog 
eens ontmoeten. 
Dit proefschrift zou niet tot stand zijn gekomen zonder de steun en belangstelling van mijn 
dierbare vrienden. Het is niet nodig op deze plaats expliciet hun namen te noemen; goede wijn 
behoeft immers geen krans. Tbch wil ik de volgende mensen hier vermelden. Ik vind het een 
eer dat jullie, Hans en Joost, mijn paranymphen wilden zijn. Jose, jij stapte in mijn leven aan 
het begin van de jaren tachtig, ik stapte uit het jouwe aan het eind ervan. Voor de 
tussenliggende tijd wil ik je, ondanks allee wat er gebeurd is, oprecht bedanken. Je hebt me 
een aantal keren daadwerkelijk bijgestaan in moeilijke tijden. 
Lieve Marion, zonder jou zouden de afgelopen maanden donker geweest zijn. Ik denk, nee, ik 
weet zeker, dat we het wel zullen redden in de toekomst "have a little faith in me'. 
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Het diploma ongedeeld VWO werd daar behaald in mei 1979. Vervolgens begon hij in 
september van 1979 met zijn studie Chemie aan de Katholieke Universiteit te Nijmegen. Het 
kandidaats examen Chemie (S2) werd behaald in november 1982; het doctoraal examen in 
januari 1986. Voor het behalen van het laatstgenoemde examen werden als bijvakken 
Biochemie (Dr. GAM. Berbers; Dr. W.W. de Jong), en Milieukunde (Dr. D.J.W. Schoof), en als 
hoofdvak Pharmacologie (Psychoneuropharmacologie: Prof. Dr. A.R. Coole) gedaan. Binnen zijn 
studietijd heeft hij diverse practica geassisteerd en is hij studiebegeleider van eerste jaars 
studenten Chemie geweest. Van februari 1986 tot en met juni 1986 heeft hij gewerkt op het 
Astra Research Centre in Sodertalje Zweden binnen de afdeling Neuropharmacologie (Prof. Dr. 
S-O. Ogren; Prof. Dr. T. Archer). Van juni 1986 tot juni 1990 heeft hij onder leiding van Prof. 
Dr. A.R. Cools met een subsidie van de "Janivo" stichting binnen de werkgroep 
Psychoneuropharmacologie (afdeling Pharmacologie) het onderzoek, dat in dit proefschrift 
beschreven is, verricht. 
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STELLINGEN 
behorend bij het proefschrift getiteld: 
THE NUCLEUS ACCUMBENS AND SUBPALLIDAL AREAS: 
A STUDY ON THEIR ROLE IN BEHAVIOUR IN RATS 
Implications for some human diseases with emphasis on dementia 
I De nucleus accumbens speelt een rol in het vermogen om te wisselen naar 
gedragingen die door stimuli in de omgeving gestuurd worden of die op basis 
van stimuli uit de omgeving voorspeld kunnen worden. 
dit proefschrift 
Π De innervatie van de nucleus accumbens door de hippocampus speelt 
waarschijnlijk een andere rol in het sturen van het gedrag dan de innervatie 
van de nucleus accumbens door de amygdala: de eerstgenoemde is betrokken 
bij het sturen van het gedrag op basis van 'stimuli' uit de omgeving, de 
laatstgenoemde is betrokken bij het sturen van het gedrag op basis van 'cues' 
(een complexe abstracte set van getransformeerde 'stimuli'). 
dit proefschrift 
Ш Het subpallidale gebied is heterogeen voor zover het het sturen van gedrag 
betreft alsmede voor zover het het doorgeven van informatie uit de nucleus 
accumbens naar uitgangsstructuren betreft. 
dit proefschrift 
IV Het type dementie dat voorkomt bij de ziekte van Parkinson kan 
verschillende aspecten op het niveau van gedragsmatig of cognitief 
functioneren gemeen hebben met het type dementie dat optreedt bij de ziekte 
van Alzheimer. 
dit proefschrift 
V Ondanks het feit dat de multivariabele benadering van gedrag waarschijnlijk 
meer recht doet aan de complexiteit van het gedrag zelf, leidt de uitwerking 
ervan in termen van statistiek tot een multivariabele verwarring. 
Lars Stahle, proefschrift Karolinska 
Instituut Stockholm, 1987 
VI De integratie van het milieubeleid in Nederland wordt geremd door het 
sectorale patroon van bevoegdheden waar het de voorbereiding, de uitvoering 
en de handhaving van de regelgeving betreft; het ware beter regionale 
milieudiensten in te stellen voor met name een effectievere uitvoering en 
handhaving van de milieuregelgeving. 
DJ.W. Schoof, Integratie in het 
milieubeleid, proefschrift K.U. Nijmegen, 
1988; DJ.W. Schoof et al, Lucht en 
Omgeving 1: 63-68, 1985 
П Het niet meer verplicht stellen van het maken van stellingen behorend bij een 
proefschrift is een uiting van een phenomeen dat al langer in Nederland 
gaande is: Wie staat nog waarvoor? 
Ш Helaas moet geconcludeerd wOrden dat in Nederland een samenhangende 
inhoudelijke visie over het (academische) onderwijs als zodanig ontbreekt. 
IX Het verdient aanbeveling de mogelijkheid te onderzoeken om op basis van 
de hoeveelheid gegevens die bekend zijn over de physisch-chemische 
eigenschappen van bepaalde klassen van verbindingen alsmede over de 
effecten van deze klassen van verbindingen in een aantal testmodellen bij 
ratten, 'computer ratten' te ontwikkelen voor het vaststellen van de effecten 
van nieuwe verbindingen in deze testmodellen met behulp van "Hansch-
rekenmethoden" ten einde het gebruik van het aantal proefdieren in met name 
de pharmaceutische industrie terug te dringen. 
X Helaas is het beoefenen van wetenschap meer en meer een bezigheid in de 
'engte' in plaats van in de 'breedte' geworden; hierdoor zijn echte 
wetenschappers schaars geworden. 
^ і ш / pan den 'Bos 
Qfijmeßen, 7 maan 1991 



